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Zusammenfassung
Die Protein Phosphorylierung stellt  eine wichtige posttranslationale Modifikation dar,  die eine Vielzahl
biologischer Prozesse reguliert. Um die dynamischen Kontrollmechanismen besser verstehen zu können, ist es
wichtig  phosphorylierte  Proteine  identifizieren  und  quantifizieren  zu  können.  Die  Anwendung  isobarer
Derivatisierungsstrategien  (z.B.  iTRAQ)  zur  quantitativen  Phosphopeptid-Analyse  erfordert  (i)  optimal
eingestellte  Peptid-Fragmentierungsbedingungen und (ii)  speziell  angepasste  Algorithmen zur  Identifizierung
iTRAQ  derivatisierter  (phosphorylierter)  Peptide.  Weiterhin  (iii)  wird  eine  Vielzahl  an  Peptide-Spectrum-
Matches bzw. Phosphopeptid spezifischer Sequenzen für eine akkurate Quantifizierung benötigt.
Diese drei Anforderungen wurden in einer Plattform vereinigt, um iTRAQ derivatisierte (Phospho)Proteine
relativ  zueinander quantifizieren  zu können.  So werden  optimale Fragmentierungsbedingungen benötigt,  um
iTRAQ derivatiserte Phosphopeptide identifizieren und quantifizieren zu können. Dies schließt die Detektion
von Peptid-Rückgrat  Fragment-Ionen,  spezifischer  Phosphopeptid-Signale (z.B.  Neutralverlust  der  Phosphat-
Gruppe) und iTRAQ Reporter Ionen mit ein. Unterschiedliche Tandem MS Fragmentierungstechniken der LTQ
Orbitrap Velos (collision induced dissociation (CID), CID plus multistage activation, and higher energy collision
dissociation (HCD)) und ihre Fähigkeit diese Ionen zu erzeugen wurden untersucht. Hierbei ist anzumerken,
dass die Identifizierung und Quantifizierung gegenläufige Ansprüche an die normalisierte Kollisionsenergie bei
der  (Phospho)Peptid-Fragmentierung stellen.  Daher  muss  ein  Kompromiss  eingegangen  werden,  der  beiden
Anforderungen  (Identifizierung  und  Quantifizierung)  gerecht  wird.  Dafür  wurde  eine  angepasste  MS/MS
Methode  entwickelt.  Diese  verwendet  CID  ausschließlich  zur  Peptid-Identifizierung,  währenddessen  HCD
sowohl zur Identifizierung als auch Quantifizierung angewandt wird. Trotz der dualen Fragmentierung eines
Vorläufer-Iones ist die benötigte Messdauer mit LC-ESI MS/MS Experimenten vereinbar.
Zusätzlich zu den optimierten Fragmentierungsbedingungen werden auch speziell angepasste Algorithmen
in der computergestützten Peptid-Identifizierung (z.B. mittels Datenbanksuchen) benötigt.  Um z.B. die nicht
genau  berechnete  Masse  der  Vorläufer-Ionen  nach  iTRAQ-4Plex Derivatisierung  zu  korrigieren,  wurde  ein
Algorithmus entwickelt, der die Intensitäten der verschiedenen Reporter Ionen in die Berechnung miteinbezieht.
Hierdurch konnte die berechnete Masse der Vorläufer-Ionen (im Mittel) um 4 ppm verbessert werden, wenn die
verwendeten MS/MS Spektren ein sehr intensives iTRAQ114 Reporter Ion aufweisen. Eigenhändig geschriebene
Programme  wurden  auch  verwendet,  um  die  korrekte  Peptid-Identifizierung  iTRAQ  derivatisierter  Proben
sicherzustellen. Hierfür wurde Nebenreaktion bei der iTRAQ Derivatisierung, die Modifizierung von Tyrosin mit
iTRAQ,  genauer  untersucht.  Es  wurden  zwei  bisher  nicht  beschriebene  Immonium-Ionen  bei  m/z  280.17
(iTRAQ-4Plex)  und  440.28  (iTRAQ-8Plex)  entdeckt,  die  aufgrund  ihres  spezifischen  Charakters  auch  als
zusätzliche Merkmale in der automatisierten Peptide-Identifizierung genutzt werden können.
Um die Plattform zur relativen Quantifizierung iTRAQ derivatisierter Peptide zu komplettieren, wurde ein
neues Verfahren etabliert,  welches sowohl die Identifizierung als auch Quantifizierung von Phosphopeptiden
verbessert.  Dies  wurde  durch  das  Zusammenführen  eines  Multi-Protease-Verdaus  mit  der  iTRAQ-8Plex
Derivatisierung erreicht.  Hierdurch konnte die  Anzahl  quantifizierbarer  Phosphopeptid relevanter  Sequenzen
x
signifikant gesteigert werden. So wurden z.B. 16 (Multi-Protease Ansatz) statt nur vier (Trypsin) Phosphopeptid
spezifische Sequenzen von β-Casein korrekt quantifiziert. Gleichzeitig war die Vereinbarkeit des Multi-Protease-
Verdaus mit der SDS-PAGE, der iTRAQ Derivatisierung sowie der Phosphopeptid-Aufreinigung mittels TiO 2
gewährleistet. 
Im zweiten Abschnitt dieser Dissertation lag der Fokus auf der Entwicklung von Computerprogrammen für
zwei  (voneinander  unabhängigen)  Projekten,  um  eine  schnelle  und  reproduzierbare  Auswertung
massenspektrometrischer Daten zu gewährleisten. 
Das Ziel des ersten Projektes war es die Protein-Identifizierungen mehrerer Datenbanksuchen (SEQUEST,
Mascot,  OMSSA und  X!Tandem)  zu  vereinen.  Es  stellte  sich  heraus,  dass  X!Tandem  exzellent  für  die
Auswertung massenspektrometrischer Daten einer 3500 Jahre alten Eis-Mumie (Ötzi) geeignet ist. Weiterhin
wurde durch den kombinierten Ansatz von vier Datenbanksuchen nicht nur die Anzahl identifizierter Proteine
erhöht, sondern es konnten auch 87% der identifizierten Proteine mit mehr als einer Datenbanksuche identifiziert
werden. 
In dem zweiten Projekt lag der Fokus auf der Entwicklung zweier Programme für die Auswertung von Q-
PICS  Daten  im  Vordergrund,  um  die  Schnittstellenspezifität  uncharakterisierter  Proteasen  identifizieren  zu
können. Die Programme beinhalten Funktionen zur Datenfilterung und zum Export  der P1 – P5 Position in
Relation zum neuen N-Terminus. Die entwickelten Programme wurden in einer Studie eingesetzt, um die zuvor
berichtete Schnittstellenspezifität der Proteasen ADAM10 und ADAM17 zu bestätigen.  
Schlussendlich kombinierte diese Dissertation unterschiedliche Bereiche der Proteomforschung, um neue
Techniken zu entwickeln oder bereits bestehende massenspektrometrische Mess- oder Auswerte-Methoden zu
verbessern. Es konnten beiden Ziele, (i) Etablierung einer Plattform zur relativen Quantifizierung und (ii) der
Entwicklung neuer Computerprogramme zur automatisierten Datenanalyse, erfolgreich abgeschlossen werden. 
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Abstract
Protein phosphorylation is an important posttranslational modification that plays a regulatory role within
numerous  biological  processes.  The  simultaneous  identification,  localization,  and  quantification  of
phosphorylated proteins is vital for understanding this dynamic control mechanism. The application of isobaric
labeling  strategies,  e.g.,  iTRAQ,  for  quantitative  phosphopeptide  analysis  requires  (i)  optimal  peptide
fragmentation conditions, (ii) sophisticated computational proteomics algorithms to identify (phosphorylated)
iTRAQ labeled peptides, and (iii) the ability to use more than one Peptide-Spectra-Match and phosphopeptide
sequence to guarantee accurate phosphorylation specific quantification. 
These  three  demands  were  combined  into  a  platform  to  relatively  quantify  iTRAQ-4Plex  labeled
(phospho)proteins  on  a  LTQ  Orbitrap  Velos.  Optimal  fragmentation  conditions  for  identification  and
quantification of  iTRAQ labeled  phosphopeptides  requires  parallel  monitoring of  specific  ions arising from
peptide backbone fragmentation, neutral  losses  of  phospho moieties,  and cleaved iTRAQ tags.  Tandem MS
fragmentation techniques available in the LTQ Orbitrap Velos (collision induced dissociation (CID), CID plus
multistage  activation,  and  higher  energy  collision  dissociation (HCD))  were  examined  for  their  ability  to
generate these ions. The optimal Normalized Collision Energy for quantification and identification of iTRAQ
labeled  (phospho)peptides  show inverse  demands,  and  a  compromise  between  optimal  parameters  for  each
aspect is necessary. A MS/MS measurement protocol was established that involves CID measurement in ion trap
for identification followed by HCD measurement in Orbitrap for parallel identification and quantification that
satisfies the time requirements for LC-ESI MS/MS experiments.
In addition to optimize fragmentation conditions, automated peptide identification techniques via database
search engines require computational, proteomics specific, algorithms. To avoid an imprecise in-silico precursor
mass  calculation  after  iTRAQ-4Plex  labeling,  an  algorithm  was  compiled  which  factors  in  the  intensity
distribution  of  all  four  iTRAQ  reporter  ions  in  tandem  MS  spectra  to  calculate  the  precursor  mass  more
accurately. The benefit of this algorithm was shown by significantly improving the mass accuracy (up to 4 ppm)
for Peptide-Spectrum-Matches (PSMs) which were dominated by iTRAQ114 reporter ions.  In-house compiled
computational proteomics tools were also used to enhance the validity of peptide identification after iTRAQ
labeling. Here, the iTRAQ tyrosine modification, a frequently occurring side-reaction of iTRAQ labeling, was
under special  investigation. Two novel immonium ions,  at m/z 280.17 (iTRAQ-4Plex) and 440.28 (iTRAQ-
8Plex),  were  observed  which  are  highly  typical  for  this  modification.  These  ions  can  serve  as  additional
identification  features in search algorithms to enhance the identification confidence.   
To complement the platform to relatively quantify phosphopeptides by isobaric labeling, a new  procedure
was established to improve phosphopeptide identification and quantification simultaneously. This was achieved
by combining a multi-protease digest  with iTRAQ-8Plex labeling, which significantly raised the number of
quantifiable  (phospho)peptide  sequences  (e.g.,  from 4  (trypsin  only)  to  16  (multi-protease)  phosphopeptide
related sequences for β-casein). In addition, the compatibility of the multi-protease approach with SDS-PAGE,
iTRAQ labeling and phosphopeptide enrichment using TiO2 was achieved successfully.
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In  the  second part  of  this  dissertation the development  of  computational  proteomics  tools  to  assist  in
reproducible and fasts data-analysis was performed across two independent projects. 
The aim of the first project was to develop and establish a computational workflow to combine protein
identification results obtained from multi-database searches of  SEQUEST, Mascot,  OMSSA and X!Tandem.
Among these, X!Tandem was found to perform excellent to identify proteins from the 3,500 years old Tyrolean
iceman Oetzi. By combining the four search engines, the number of proteins identified increased significantly;
additionally, it could be demonstrated that more than 87% of the proteins could be identified by more than one
search engine. 
For the second project, two computational proteomics tools for the Q-PICS approach were developed to
identify cleavage site motifs of uncharacterized proteases. These tools covered the functions to filter peptide list
and export the P1 – P5 position in relation to the new N-Terminus. The developed tools were used in a study to
confirm the previously reported cleavage site specificities of the proteases ADAM10 and ADAM17.   
In conclusion, this dissertation has combined various distinct aspects within proteomics to develop novel,
or enhance already established, measurement and data processing procedures. To this end, the initial aims of (i)
providing a platform for relative quantification and (ii) the development of computational tool set to assist data
analysis, were successfully achieved.
xiii
Abbreviations
(p)AGC (predicted) automated gain control
[M-80 or [M-80/z] precursor ion with neutral loss fragmentation of HPO3
[M-98] or [M-98/z] or [M-P] precursor ion with neutral loss fragmentation of H3PO4
[M] precursor
[P] phospho
1024-A; 1025-A sample 1024 and 1025 analyzed by in-gel digestion
1024-B; 1025-B sample 1024 and 1025 analyzed by in-solution digestion
AA amino acid
AB antibodies
AC alternating current
ACN acetonitrile
AP alkaline phosphatase
APCI atmospheric pressure ionization
APS ammonium persulfate
AQUA absolute quantification
BEMAD β-elimination michael addition
bF big FASTA file
CE collision energy
CETG in-silico combined sample of chymotrypsin, elastase, GluC and trypsin
CF combined fraction; non-phosphorylated + wash fraction  + phosphorylated fraction  
Ch chymotrypsin
CID collision induced dissociation
CID-IT collision induced dissociation with analysis in ion trap
CIT-MSA(-IT) collision induced dissociation with multi stage activation & analysis in ion trap
CLI command line input
Da Dalton
DC direct current
DHB dihydroxybenzoic acid
DIGE differential gel electrophoresis
DNA deoxyribonucleic acid
é electron
ECD electron capture dissociation
EDTA ethylenediaminetetraacetic acid
El elastase
ESI electro spray ionization
Et-OH ethanol
ETD electron transfer dissociation
eV electron volt
FA formic acid
xiv
FAB fast atom bombardment
FDR false discovery rate
FT fourier transformation
GA glycolic acid
GAMBAS GAMBAS almost means basic
GC gas chromatography
Gl; GluC Staphylococcus aureus V-8 Protease
GPC gel permeations chromatography
GUI graphical user interface
HCD higher collision induced dissociation
HE-CID high energy collision induced dissociation
HEPES 4-(2-hydroxyethyl)-1-piperazineethansulfonic acid
HIC hydrophobic chromatography
HILIC hydrophilic interaction chromatography
HPC high pressure cell
HPLC high performance liquid chromatography
IAA iodoacetamide
ICAT isotope coded affinity tags
ICPL isotope-coded protein label
ICR ion cyclotron resonance
ID identification
IDi isotope dilution
IEC ion exchange chromatography
IEF isoelectric focusing
IMAC immobilized metal affinity chromatography
IP immuno precipitation
iPeptidei n-terminal and c-terminal iTRAQ labeled peptide
IT ion trap
iTRAQ isobaric tags for relative and absolute quantitation
iX immonium ion of X; X = any amino acid (including modifications)
LC liquid chromatography
LE-CID low energy collision induced dissociation
LIT linear ion trap
LPC low pressure cell
MA mascot
MALDI matrix assisted laser desorption/ionization
MCP multi channel plate
Me-OH methanol
MECi multi enzyme combined iTRAQ labeling
xv
min minute
MOAC metal oxide affinity chromatography
MOPS 3-(n-morpholine)propanesulfonic acid 
MS mass spectrometry
ms milli seconds
MSA multi stage activation
M. tuberculosis Mycobacterium tuberculosis
MudPIT multidimensional protein identification technology
m/z mass-to-charge ratio
nanoLC nano liquid chromatography
NCE Normalized Collision Energy
NHS n-hydroxysuccinimide
NI normalized intensity
NP non-phosphorylated fraction
NSAF normalized spectral abundance factors
OM OMSSA (Open Mass Spectrometry Search Algorithm) 
P; P' prime; non-prime (only chapter 3.2)
PA phosphoric acid
PC phosphoamidate chemistry
PD proteome discoverer
PeptidepS c-terminal phosphorylated serine
PF phosphopeptide fraction
PICS proteome-derived, database-searchable peptide libraries for identifying protease cleavage sites
PLP myelin proteolipid protein 
PMF peptide mass finger print
ppm parts per million
PQD pulsed q collision dissociation
pS phosphoserine
PSD post source decay
PSM(s) Peptide-Spectrum-Match(es)
pT phosphothreonine
PTM posttranslational modifications
pXNumber phosphorylation at amino acid X at the numbers position within the peptide
pY phosphotyrosine
Q quadrupole
Q-PICS quantitative protease cleavage site profiling using tandem-mass-tag labeling
QconCAT quantification concatamer
Qq double quadrupole
QqQ triple quadrupole
xvi
RF radio frequency
RGB red green blue
RI relative intensity
RP reversed phase
rpm rounds per minute
RT retention time
RT room temperature
S-Lens/ SRIG stacked ring ion guide
s; sec seconds
S/N signal to noise ration
sample D; sample P dephosphorylated and phosphorylated sample, respectively
SAX strong anion exchange
SCX strong cation exchange
SDS-PAGE sodiumdodecylsulfate polyacrylamid gel elecrophorese
SE SEQUEST
SEM secondary electron multiplier
sF small FASTA file
SFB Sonderforschungsbereich 
SILAC stable isotope labeling by/with amino acids in cell culture
SISCAPA table isotope standard capture with anti-peptide antibodies
SPC spectral counting 
TCEP tris-2-(carboxyethyl)phosphine
TEAB triethylammonium bicarbonate
TEMED tetramethylethylenediamine
TFA trifluoroacetic acid
TIC total ion chromatogram
TiO2 titanium dioxide
TMT tandem mass tag
TOF time of flight
Tr trypsin
u unit
UV ultra violet
v/v volume/volume
VB(A) visual basic for applications
WF wash fraction
XIC extracted ion chromatogram
XT X!Tandem
z charge
xvii
Table Of Contents
 Eidenstattliche Erklärung .........................................................................................................................................i
 Zitat .........................................................................................................................................................................ii
 Danksagung ............................................................................................................................................................iii
 Widmung ................................................................................................................................................................iv
 Lebenslauf ...............................................................................................................................................................v
 Veröffentlichungen .................................................................................................................................................vi
 Zusammenfassung ...................................................................................................................................................x
 Abstract .................................................................................................................................................................xii
 Abbreviations .......................................................................................................................................................xiv
 Table Of Contents ..............................................................................................................................................xviii
 1 Introduction ..........................................................................................................................................................1
1.1 Proteomics.....................................................................................................................................................1
1.1.1 Qualitative Proteomics..........................................................................................................................1
1.1.2 Quantitative Proteomics........................................................................................................................3
1.1.2.1 MS based Quantification Strategies.............................................................................................4
1.1.2.2 MS/MS based Quantification Strategies......................................................................................6
1.1.3 Phosphoproteomics.............................................................................................................................12
1.2 Mass Spectrometry......................................................................................................................................14
1.2.1 Soft Ionization Techniques..................................................................................................................15
1.2.2 Peptide Fragmentation Techniques.....................................................................................................17
1.2.2.1 Peptide Fragmentation................................................................................................................17
1.2.2.2 Fragmentation Techniques..........................................................................................................18
1.2.3 Mass Analyzers...................................................................................................................................21
1.2.4 Data-Processing and Automated Data-Analysis.................................................................................24
1.2.4.1 Identifying Peptides using the Search Engine SEQUEST.........................................................24
1.2.4.2 Alternative Peptide Identification Techniques............................................................................26
1.2.5 Phosphoproteomics by Mass Spectrometry........................................................................................27
1.2.5.1 Phosphopeptide Identification by Mass Spectrometry...............................................................27
1.2.5.2 Phosphopeptide Quantification by Mass Spectrometry.............................................................29
1.3 Aim of this Study.........................................................................................................................................31
 2 Developing a Platform for relative Quantification using iTRAQ ......................................................................33
2.1 iEM – iTRAQ Evaluation Method..............................................................................................................33
2.1.1 Introduction.........................................................................................................................................33
2.1.2 Material and Methods.........................................................................................................................35
2.1.2.1 Sample Preparation.....................................................................................................................35
2.1.2.2 Mass Spectrometry.....................................................................................................................40
xviii
2.1.2.3 Database Searches and Feature-Detection..................................................................................41
2.1.3 Results.................................................................................................................................................46
2.1.3.1 Phosphopeptide Standard...........................................................................................................46
2.1.3.2 Ten Protein-mix..........................................................................................................................61
2.1.3.3 Biological Sample......................................................................................................................66
2.1.4 Conclusion..........................................................................................................................................73
2.2 n-iTRAQ – Handling of Nominal Isobaric Labelings.................................................................................75
2.2.1 Introduction.........................................................................................................................................75
2.2.2 Material and Methods.........................................................................................................................76
2.2.2.1 Chemicals...................................................................................................................................76
2.2.2.2 Sample Preparation.....................................................................................................................76
2.2.2.3 Mass Spectrometry and Database Searches...............................................................................76
2.2.3 Results and Discussion........................................................................................................................79
2.2.3.1 Monitoring ppm Deviations Introduced by Different iTRAQ Ratios........................................79
2.2.3.2 Variations of Precursor Mass Accuracy Window.......................................................................82
2.2.3.3 Post Database Search Re-Calculation of Precursor Masses.......................................................83
2.2.4 Conclusion..........................................................................................................................................88
2.3 Y-iTRAQ – Accurate Identification of iTRAQ Tyrosine Labeled Peptides................................................89
2.3.1 Introduction.........................................................................................................................................89
2.3.2 Material and Methods.........................................................................................................................90
2.3.2.1 Chemicals...................................................................................................................................90
2.3.2.2 Sample Preparation and iTRAQ Labeling..................................................................................90
2.3.2.3 Mass Spectrometry, Database Searches and Data Analysis.......................................................91
2.3.3 Results.................................................................................................................................................95
2.3.3.1 Detection of iY-iTRAQ-4Plex Specific Immonium Ions...........................................................95
2.3.3.2 Y-iTRAQ Immonium Ion Formation in Dependance of Collision Energy..............................103
2.3.3.3 Detection of iY-iTRAQ-8Plex specific Immonium Ions..........................................................104
2.3.3.4 Influence of iTRAQ tyrosine Labeling on the LC Retention Time..........................................107
2.3.3.5 N-terminal Tyrosine as a Special Variant of Y-iTRAQ Modifications.....................................112
2.3.4 Conclusion.........................................................................................................................................116
2.4 MECi – Targeted Phosphoprotein Quantification......................................................................................117
2.4.1 Introduction.......................................................................................................................................117
2.4.2 Material and Methods........................................................................................................................118
2.4.2.1 Chemicals.................................................................................................................................119
2.4.2.2 Sample Preparation and Analytical Workflow.........................................................................119
2.4.2.3 Mass Spectrometry...................................................................................................................121
2.4.3 Results...............................................................................................................................................125
2.4.3.1 Percolator and FDR Analysis to Identify iTRAQ-8Plex Labeled Peptides..............................125
2.4.3.2 The Advantage of a Multi-Protease Approach.........................................................................128
xix
2.4.3.3 Enrichment of iTRAQ-8Plex labeled Phosphopeptides...........................................................134
2.4.3.4 Phosphoprotein Quantification using iTRAQ-4x2Plex............................................................136
2.4.4 Conclusion........................................................................................................................................148
2.5 Discussion and Outlook.............................................................................................................................149
 3 Development of Computational Proteomics Pipelines for Automated Data Processing ..................................153
3.1 Paleoproteomics – Studying the Iceman's Brain Tissue............................................................................153
3.1.1 Material and Methods.......................................................................................................................154
3.1.1.1 Sample Preparation...................................................................................................................154
3.1.1.2 Mass Spectrometry...................................................................................................................155
3.1.1.3 Database Searches....................................................................................................................156
3.1.2 Results and Discussion......................................................................................................................157
3.1.2.1 Protein Identification Using a Multi-Database Search Engine Approach................................157
3.1.2.2 Protein Aging Processes...........................................................................................................160
3.1.3 Conclusion........................................................................................................................................166
3.2 PCSP – Computational Proteomics Tools for Protease Cleavage Site Determination..............................167
3.2.1 Implementation of PeptideMerger....................................................................................................168
3.2.2 Implementation of AminoAcidFinder...............................................................................................169
3.2.3 Conclusion........................................................................................................................................172
3.3 Discussion and Outlook.............................................................................................................................173
 4 Appendix ...............................................................................................................................................................I
4.1 Chemicals and Instrumentation.....................................................................................................................II
4.2 Amino Acids................................................................................................................................................VI
4.3 cRAP FASTA File......................................................................................................................................VII
4.4 Supplemental Tables for Chapter 2.4...........................................................................................................IX
4.5 Figure Index..............................................................................................................................................XXI
4.6 Equation Index....................................................................................................................................XXVIII
4.7 Table Index.............................................................................................................................................XXIX
4.8 Copyright...............................................................................................................................................XXXI
4.8.1 Journal of Proteome Research.......................................................................................................XXXI
4.8.2 Cellular and Molecular Life Sciences........................................................................................XXXIII
4.9 References.........................................................................................................................................XXXVII
xx
1 Introduction
1 Introduction
1.1 Proteomics
The human genome contains about 2.85 billion nucleotides interrupted by 341 gaps, which contain about
20 – 25,000 gene-coding proteins (1). The entire set of proteins expressed by a genome at a point in time and
under specific conditions is termed the  proteome. This term was coined by Marc Wilkins who described the
proteome as “The entire PROTEin complement expressed by a genOME”  (2).  The analysis of proteomes is
complicated by alterations and protein splicing events. For example, up to 500,000 different protein species are
thought to exist in humans (3). Moreover, in contrast to the static genome, the proteome changes dynamically by
re-synthesis, degradation or posttranslational modifications of proteins (4,5).
The technique  to  identify  proteins  of  a  cell  or  tissue  and  research  their  sequences,  modifications and
quantity is  defined as  proteomics (2,6).  Since the introduction of  soft-ionization techniques namely Matrix-
assisted  Laser  Desorption/Ionization (MALDI;  (7–9))  and  Electrospray  Ionization (ESI;  (10)), the  term
proteomics is often used as a synonym for the analysis of proteins by mass spectrometry (MS).  
1.1.1 Qualitative Proteomics
Qualitative proteomics by mass spectrometry plays an important role in identifying proteins and can be
classified into two categories:  top-down and  bottom-up. Top-down proteomics involves the analysis of intact
proteins  (11),  whereas  peptides  released  from proteins  by  proteolytic  digestion  are  measured  in  bottom-up
approaches (12–15). The bottom-up process is also referred to as shotgun proteomics if a mixture of proteins is
digested (15).
To confidently identify proteins, these or their respective digests are often chromatographically separated
prior MS-analysis to reduce the number of co-ionizing analytes  (16). This technology is referred to as  Liquid
Chromatography Mass Spectrometry (LC MS; (17)). In LC MS, the LC can be coupled online (e.g., for LC-ESI
MS) or offline (e.g., for LC-MALDI MS). Combining two complementary LC separation techniques is referred
to as Two Dimensional Liquid Chromatography Mass Spectrometry (2D-LC MS (18)). Strong Cation-Exchange
(SCX) chromatography in the first and Reversed Phase (RP) chromatography in the second dimension are often
combined (19). Alternatively, two RP separation (first high pH, second low pH) can also be connected (20,21).
The technology, using more than one LC dimension and combining the peptides identified from the different
dimensions  to  identify  their  respective  proteins,  is  referred  to  as  Multi-Dimensional  Protein  Identification
Technology (MudPIT; (22)).  
An alternative technique to identify proteins is GeLC-MS/MS. Here, intact proteins are first separated using
SDS-PAGE (Sodium Dodecylsulfate Polyacrylamide Gel Electrophoresis). Afterwards, each gel lane is cut into
slices (e.g., 10 pieces) and each gel slice is subjected to in-gel digestion followed by LC MS. The advantage of
GeLC-MS/MS is to reduce the sample complexity on the protein level and peptides, of a protein, are (ideally)
retained in a single fraction. Moreover, interfering substances (e.g., for protein resolubilization) are removed
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prior in-gel digestion (23–25). 
Another  gel-based  technique  is  Two-Dimensional  Gel  Electrophoresis (2-DE)  which  combines  the
isoelectric focusing of intact proteins in the first dimension and SDS-PAGE in the second dimension. After the
stained protein spots are excised, these are in-gel digested and analyzed by mass spectrometry (26,27). Usually,
peptides obtained from proteolytic digest of 2-DE spots are directly measured by MS (direct infusion for ESI MS
or spot based MALDI MS) without further LC separation. 
One technique to identify proteins (e.g., obtained from 2-DE) is by Peptide-Mass-Fingerprint(ing) (PMF;
(28)). In this technique, the unknown protein of interest is digested by endopeptidases into smaller peptides,
whose  masses  are  measured  by  mass  spectrometry  (MS full  scan).  The measured  peptide  masses  are  then
compared  to  theoretical  peptide  masses  from known proteins.  The  higher  the  number  of  matching  peptide
masses,  the more confident is the protein identification. Identifying proteins by PMF does well with 2D-gel
electrophoresis where the protein purity is high. Here, a high number of specific and unique peptides can be
detected, which is required to accurately identify proteins (29). However, protein samples of low purity generate
to complex MS full scans, in which protein specific signals might be suppressed and not be detected. Nowadays,
PMF is almost replaced by a technique referred to as  Peptide-Spectrum-Match (PSM), which is used for LC
separated protein digests as well as 2-DE gel spots of higher complexity. 
Contrary to PMF, Peptide-Spectrum-Matching uses the information of MS (peptide mass) and MS/MS
spectra (peptide sequence specific tags) to identify peptides and their respective proteins. To generate MS/MS
spectra, which are also referred to as tandem MS spectra, precursor ions of interest are isolated and induced to
dissociation (see upper section in Figure 1-1). The resulting fragment ions (including non-dissociated precursor
ions if still present) are then analyzed and recorded as tandem MS spectra (see upper right spectrum in Figure 1-
1). 
Figure 1-1: Mass spectrometry workflow describing the principle steps to obtain an experimental (upper) and
theoretical (lower) spectrum. Both spectra are used for peptide identification by a search engine. Protein images
used were published under the CC-BY-SA-3.0 and GNU Free Documentation License, respectively (30,31).
To finally identify peptide sequences by Peptide-Spectrum-Matching, the precursor masses and the specific
fragmentation  tag  of  each  peptide  is  used  in  combination  to  their  in-silico analogs.  Independently  of  the
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identification method (either by manual or computer assisted interpretation), the protein sequence is obtained by
gene decoding. Afterwards, the protein is  in-silico digested into smaller peptides (see Figure 1-1, Peptide List;
MS analogs), and the corresponding peptides are in-silico fragmented; forming theoretical tandem MS spectra
(see Figure 1-1, Fragment Ion List; MS/MS analogs). These theoretical tandem MS spectra are compared to the
experimental MS/MS spectra, and a score is calculated based on the homology of both spectra. This scoring
process is usually performed by so called database search engines, whose mode of operation will be described in
chapter  1.2.4. Generating sequence specific fragment ions, which are necessary for peptide identification by
PSM, and the different techniques commonly applied to induce peptide dissociation are explained in chapter
1.2.2. 
1.1.2 Quantitative Proteomics
Quantitative  proteomics  offers  tools  to  evaluate  proteome wide  changes  of  protein  abundances  under
different biological conditions  (32). Either the absolute amount of a protein species is determined or relative
differences between two states are compared. At its starting point, quantitative proteomics was performed on 2D-
gels by comparing spot sizes, shapes and intensities after staining. To compensate for experimental errors, a high
number  of  multiple  gels  was  required  which  increased  the  number  of  experiments  performed  (33,34).  To
overcome some experimental  errors,  Differential  Gel Electrophoresis (DIGE) was introduced  (35). In DIGE
experiments,  up  to  three  biological  states  are  labeled  with  unique  amine  reactive  fluorescent  dyes  (36).
Afterwards,  the  samples  are  combined  and  separated  together  on  the  same  2D-gel.  Differences  in  protein
abundances  are  visualized  by  different  intensities  of  the  fluorescent  dyes  after  superimposing  them.  This
information  is  used  to  identify  differentially  regulated  proteins.  As  for  all  gel  based  techniques,  there  are
limitations regarding the protein species that can be observed (e.g., very acidic or basic proteins are frequently
lost during sample loading or separation). Although reference gels can be created by merging multiple gels, each
protein (or spot) of interest needs to be extracted and identified separately by mass spectrometry (37). 
Alternative gel-free techniques were developed which combine the identification and quantification process
of  proteins  in  a  single  workflow.  These  MS  based  techniques  can  be  grouped  into  absolute  and  relative
quantification, as illustrated in  Figure 1-2. Absolute quantification involves the measurement of representative
proteolytic peptides and stable-isotope labeled analogs in a single LC MS run  (38) to determine the protein
concentration and amount.  In  contrast  to absolute quantification methods,  signal  intensities  of  two or more
biological states are compared in relative quantification methods to recognize differentially regulated proteins.
Comparing signal intensities can be performed on the MS or MS/MS level, either without the utilization of tags,
by  introducing  (labeled)  tags,  or  the  addition  of  (labeled)  internal  standard  peptides  (39).  Only  relative
quantification methods will be described in the next section, as absolute quantification was note performed in
this dissertation.
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Figure  1-2: Summary of absolute (yellow) and relative (orange) quantification methods commonly applied in
mass spectrometry based proteome research. Relative quantification can be further subdivided into MS (blue)
and  MS/MS (green)  methods  depending  at  which  level  relative  quantification  is  performed.  Abbreviations:
AQUA (Absolute Quantification); SISCAPA (Stable Isotope Standard Capture with Anti-Peptide Antibodies);
QconCAT (Quantification Concatamer); IDi (Isotope Dilution); SILAC (Stable Isotope Labeling by/with Amino
Acids  in  Cell  Culture);  ICPL  (Isotope-Coded  Protein  Label);  ICAT  (Isotope-Coded  Affinity  Tag);  iTRAQ
(Isobaric Tags for Relative and Absolute Quantitation); TMT (Tandem Mass Tags). 
1.1.2.1 MS based Quantification Strategies
Relative MS based quantification strategies can be grouped into isotope labeling approaches or methods
which do not require any labeling. Incorporation of stable isotopes  in-vivo and  in-vitro has  frequently been
utilized to quantify proteins from cell or tissue cultures or, from pull-down experiments from cell compartments
(40).
Protein Metabolic Labeling  (41) utilizes  15N labeled inorganic salts which are added as substrates to the
growth medium for cell, bacterial or yeast cultures. By excluding all other nitrogen sources, all nitrogen atoms
within the culture contain the  15N isotope (referred to as heavy sample). A second biological sample is feed
exclusively with 14N (referred to as light sample). After combining both samples, different protein abundances
are determined by comparing precursor ion signals on the MS level. 
Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) involves the  in-vivo incorporation of
specific amino acids into proteins (42). The cell culture media lacks one or more essential amino acids, which are
replaced  by a  non-radioactive,  isotopically  labeled  form.  Similar  to  protein  metabolic  labeling,  up to  three
different samples are commonly compared in a quantitative proteomics workflow. 
Another MS based quantification techniques is Isotope-Coded Protein Label (ICPL; (43)), which  uses an
-4-
1.1 Proteomics
N-hydroxysuccinimide coupling reaction to bind differentially isotope-coded reagents to the amino group of N-
termini and lysine side chains. After endopeptidase digestion, up to four different samples can be labeled, which
appear as quadruplets in the acquired MS spectrum (44). 
Isotope Coded Affinity Tags (ICAT;  (45)) consist of three essential parts: a biotin affinity tag to isolate
ICAT-labeled peptides, a linker which includes the stable isotopes and a reactive group with a specific activity to
thiol-groups.  Only peptides  containing a  labeled  thiol-group can  be  used  for  quantification.  This  limits  the
application of ICAT in quantitative proteomics experiments. 
All MS based quantification methods using stable isotope labeling increase the sample complexity on the
MS level. This not only influences the ionization efficiency of peptides, but also requires specialized software
tools  for  automated (data-dependent)  precursor  ion selection to exclude the repeating selection of  the same
precursor pair  (46).  Additionally,  the identification of  peptides is  complex if  only one isotope (e.g.,  15N) is
present in the MS spectra. 
Some of these obstacles can be overcome by using relative quantification techniques which do not involve
peptide  labeling.  One  such  technique  is  Spectral  Counting (SPC;  (47)).  This  semiquantitative  technique
measures the protein abundance based on the total number of identified MS/MS spectra (PSMs) for a particular
protein. This technique is accepted as a practical approach for relative quantification. Although various statistical
frameworks are required to improve abundance estimations (48). For example, larger proteins tend to contribute
more spectra and peptides than smaller proteins do. To compensate for this effect,  the  Normalized Spectral
Abundance Factors (NSAFs) can be calculated to correct this. Other major challenges for SPC are co-eluting
peptides while precursor ion selection, the application of dynamic exclusion to increase the number of different
precursor ions being selected and the FDR filtering of peptide identification (49).  
Another  quantitative  method for  relative quantification relies  on the  assumption that,  under controlled
conditions, peptides can be compared directly across different LC-ESI or LC-MALDI MS measurements. This is
assisted by more robust chromatographic separation techniques and an increased scanning speed, resolution and
mass accuracy of mass spectrometers (46). For quantification purposes, the Extracted Ion Chromatogram (XIC)
of  unique  and  razor  peptides  is  calculated  and  used  to  explore  differentially  regulated  proteins  (50).  This
technique is referred to as Label-Free Quantification. 
This approach is rather flexible as data-dependent or data-independent fragmentation techniques (e.g., MSe)
can be applied (51,52). The major advantage is that no extra experimental steps (labeling and sample clean-up)
are required. Moreover, quantification can be performed across a multiple of samples simultaneously. 
As co-eluting peptides might influence the ionization efficiency or column aging processes might change
the retention time of peptides, sophisticated computational approaches are required for data alignment of label-
free experiments. Usually, these software tools also include data reduction algorithms (e.g., baseline removal,
denoising and centroiding (53)). Software suites such as MaxQuant (54) integrate these processing features and
directly links the quantification process to identified peptide and proteins. 
An important factor for label-free quantification is that samples are measured independently of each other.
This increases its flexibility but makes great demands on the LC MS instrumentation. For LC-ESI MS, changes
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in the Total Ion Chromatogram (TIC) intensities need to be compensated mathematically (55). This is a complex
task if spray instabilities (the main factor for TIC changes) are observed. For LC-MALDI MS, laser adjustments
during instrument  calibration can  influence  the ionization efficiency of  peptides,  which  in  turns  affects  the
observed intensity of peptides. Moreover,  the analyte needs to be dried uniformly with the matrix to ensure
reproducible ionization processes (56). Ideally for LC-MALDI MS, a peptide would only be present in exactly
one fraction. As this is usually not observed, grouping of several MS spectra from different fractions is required
to balance-out this effect (57). Due to the online-coupling of LC and analyte ionization, this correction procedure
is not required for LC-ESI MS which facilitates the application of LC-ESI for label-free quantification. 
All label-free experiments require a well designed experimental plan. This can include a measurement of
samples  in  triplicates  in  tandem repeats  ([A1,B1,C1],  [A2,B2,C2],  [A3,B3,C3])  or  to  shuffle  samples  randomly
(46,58,59).  
1.1.2.2 MS/MS based Quantification Strategies
The quantitative information of different (relative) protein abundances can not only be obtained from MS
spectra, but also from MS/MS spectra. Predominantly two different, but chemically very similar, reagents are
used: (i) iTRAQ which is an acronym for isobaric tags for relative and absolute quantification (60) and (ii) TMT
(tandem mass tag; (61)). Both rely on isobaric labeling of peptides or proteins each with a specific tag. 
TMT is  available  in  a  duplex,  sixplex  and  tenplex  form,  whereas  iTRAQ is  available  in  a  four-  and
eightplex form. The count correlates to the number of samples, which can be compared in a single experiment.
Each of the reagents shares a basic structure in which by variation of isotopes, isobaric structures are gained. The
basic  structure  of  iTRAQ-4Plex,  TMT-6plex  and  iTRAQ-8Plex,  which  are  most  frequently  employed  in
quantitative proteomics (62), are shown in Figure 1-3.   
Figure  1-3: Chemical structure of iTRAQ-4Plex (upper), TMT-6Plex (middle) and iTRAQ-8Plex (lower) and
their corresponding isotopes being used and their resulting masses, respectively (right side). Cleavage sites after
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MS/MS fragmentation are coded red and green for iTRAQ liberation and iTRAQ + balancer group dissociations
which are also observable, respectively. The blue line indicates the leaving group while iTRAQ labeling. The
exact structure for iTRAQ-8Plex is not published. Illustration is adapted by (63).
iTRAQ and TMT consist of an amine-reactive group, a mass-normalization spacer and a reporter ion group
(44,64),  as  illustrated in  Figure 1-3.  The purpose of  the amine-reactive group is to  bind  iTRAQ and TMT
reagents to the α- (peptide N-terminus) and ε-amino (lysine side chain) group of peptides. This amine-reactive
group employs N-hydroxysuccinimide (NHS) chemistry (63), which is a relatively specific reaction that cannot
be  reversed  and  permits  an  almost  complete  labeling of  primary  amines  with the  amine-reactive  group.  In
addition  to  primary  amino  groups,  side  reactions  can  be  observed  for  serine,  threonine  and  tyrosine  (65).
Especially the phenolic hydroxyl group of tyrosine is frequently derivatized at high pH values with up to 3% of
total reactions (60). In contrast to primary amino groups, this reaction is reversible by hydrolysis (66). 
The different reporter ion groups contain the quantitative information, whereas the mass normalizer group
out-balances the peptide masses after isobaric labeling. Due to varying number of isotopes ( 13C, 15N, 18O) in the
reporter and mass normalizer group, the isobaric labeled peptides are indistinguishable on the MS level (isobaric
mass) and appear as a single peak in MS scans (MS Spectrum in Figure 1-4).
Figure 1-4: Representative MS (left) and MS/MS (right) spectrum showing the combinatorial effect of iTRAQ-
4Plex multiplexing. The four samples are non-distinguishable in MS spectra (same precursor m/z due to iTRAQ
reporter  ion  and  balancer  group).  Upon  fragmentation,  the  four  iTRAQ  labelings  liberate  unique  iTRAQ
reporter ions in the low m/z region (demonstrated by orange, blue, green and gray signals).
Yet upon precursor ion fragmentation of isobaric labeled peptides, the reporter ions are readily formed by
cleavage at the carbonyl group of the piperazine ring (indicated with a red line in  Figure 1-3;  (63)) and are
detected in the low m/z region in MS/MS spectra. As each reporter ions contains a different number of isotopes,
which are out-balanced by the mass normalizer group in the undissociated precursor ion, the reporter ions are
detected at different m/z values mostly separated by 1 Da (see MS/MS Spectrum in Figure 1-4). 
Multiplexed peptides can be relatively quantified based on the reporter ion intensities (or areas), which
correlate to the quantities of the differentially labeled peptides (Figure 1-4) and by extension, their corresponding
proteins. For iTRAQ-4Plex, these reporter ions are detected at m/z 114.1, 115.1, 116.1 and 117.1 for the reagents
iTRAQ-114 to iTRAQ-117 (see MS/MS Spectrum in  Figure 1-4). The balancer group is usually cleaved as a
neutral fragment (cleavage between red and blue line in  Figure 1-3) and is not detected  (44). Fragmentation
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pathways  leading  to  non  informative  fragment  ions  are  suppressed  for  iTRAQ  labeled  peptides,  and
predominantly sequence specific signals are observed (65). 
The Fundamental Steps of Isobaric Labeling Workflows 
Every iTRAQ and TMT labeling workflow is composed of nine different sample preparation steps. These
are schematically illustrated in  Figure 1-5: After cell lysis, protein extraction and concentration determination
(summarized as  “Protein Extraction”  step),  the biological  samples  are  reduced and  alkylated (being  part  of
Protein Digestion step), as it is done for other quantitative proteomics techniques (e.g., label-free quantification).
During these steps,  primary amine free reagents have to be used in order  to avoid cross-reactions with the
iTRAQ reagents, such as tris-2(-carboxyethyl)phosphine (TCEP) for reduction and methyl methanethiosulfonate
(MMTS) or iodoacetamid (IAA) for alkylation (65).
Typically, digestion is performed with trypsin, which cleaves almost exclusively after arginine and lysine
(67).  Digestion  can  be  performed  in  buffers  such  as  triethyl  ammonium  bicarbonate  (TEAB),  4-(2-
hydroxyethyl)-1-piperazineethansulfonic  (HEPES),  3-(N-morpholine)propanesulfonic  acid  (MOPS)  or
phosphate buffers as these are compatible with iTRAQ labeling (free of primary amines). 
For isobaric labeling (step 4),  the protein digests of each sample are incubated with a unique isobaric
reagent,  e.g.,  iTRAQ-114,  iTRAQ-115,  iTRAQ-116 and  iTRAQ-117 for  iTRAQ-4Plex  labeling.  Either  one
(arginine)  or  two  (lysine)  isobaric  labelings  are  attached  to  a  tryptic  peptide.  Tyrosine  labeling  or  missed
cleavages after trypsin digestion can results in more than two isobaric labelings. However, this is less commonly
observed than single or double isobaric labeling.  To prevent cross-labeling of peptides with different isobaric
labeling reagents prior sample multiplexing, pure water can be added to quench remaining isobaric reagents (68).
After the labeling reaction is completed, samples are mixed together (step 5) and can be used for further
processing, such as peptide fractionation by LC and subsequent analysis by mass spectrometry (step 6 & 7).
Upon precursor fragmentation, reporter ion signals are formed alongside peptide sequence specific signals in
MS/MS spectra (as demonstrated in the combined schematic of Peptide Fractionation and Tandem MS Analysis
(right side) in Figure 1-5). It is noteworthy, that a single MS/MS spectra contains qualitative (sequence specific
fragment ions) and quantitative (reporter ions) information. 
After data acquisition, peak areas (or intensity values depending on the applied scan mode) of the reporter
ions are extracted, corrected for impurities (69), and peptide ratios are grouped into protein ratios (Data Analysis,
step 8, Figure 1-5). ANOVA or students t-test are frequently used to validate the results (70). 
The quantitative proteomics data can finally be used to highlight differentially regulated networks (Results,
step 9, lower right section in Figure 1-5) or be used in combination to other techniques like metabolomics.    
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Figure 1-5: From iTRAQ labeled samples to biological pathways. In iTRAQ-4Plex experiments, the four samples
are first  reduced, alkylated and digested (usually trypsin),  followed by iTRAQ labeling, each with a unique
iTRAQ labeling reagent. After labeling, samples are combined and analyzed by 1D- or 2D-LC ESI or MALDI
MS. Upon precursor ion fragmentation, reporter ion are formed together with sequence specific fragment ions.
Intensities (or areas) of the iTRAQ reporter ions are extracted from MS/MS spectra. Protein identification and
quantification results from database search are combined to calculate the significance of differentially abundant
proteins.  For  visualization,  protein  networks  are  a  common  approach  to  highlight  differentially  regulated
pathways (string-db;  (71)). Worflow was adapted by  (69) and further modified, images used were published
under the CC-BY-SA-3.0 License (31). 
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The Benefit and Drawback of Isobaric Labeling
An advantage of iTRAQ and TMT labeling is the reduced impact of handling errors due to the early stage
of  sample  combination  compared  to  label-free  approaches,  which  are  only  in-silico combined.  Moreover,
isobaric  labeled  protein  digests  can  be  pre-fractionated  or  enriched  for  specific  peptides  (such  as
phosphopeptides), which is a critical step for label-free quantification (72). Further, all peptides are labeled (if
the N-terminus is unmodified) and can be used to quantify proteins. This improves quantitative reproducibility as
all identified peptides are used to calculate the protein ratio rather than only a subset of peptides (e.g., cysteine
labeled peptides in ICAT; (69,73)). iTRAQ can be performed on the peptide and protein level, which increases
its  flexibility of use  (74).  Moreover,  iTRAQ and TMT do not show a significant retention time shift  using
reversed phase chromatography (75) due to the application of carbon, nitrogen and oxygen isotopes. In contrast
to deuterium isotopes (2H), these isotopes do not influence the retention time (76,77). 
iTRAQ and TMT quantification is exclusively performed on MS/MS level (Figure 1-4). Consequently, the
sample  complexity  remains  constant  on  MS  level  (MS  Spectrum in  Figure  1-4),  which  induces  a  signal
amplification and increases the sensitivity of analyte ions  (69). Theoretically, chemical noise is also reduced
upon precursor fragmentation, offering a higher quantification accuracy compared to MS based quantification
techniques (44,66).  
A drawback of isobaric labeling using iTRAQ or TMT is that every precursor ion needs to be selected for
fragmentation to receive iTRAQ reporter ion intensities. This increases the number of MS/MS spectra to be
recorded compared to  the  re-match between runs feature for  label-free approaches  (78).  Consequently,  pre-
fractionation  of  isobaric  labeled  peptides  has  to  be  performed,  which  reduces  the  advantage  of  sample
multiplexing, as a higher number of fractions have to be measured (20,79,80). 
Another drawback of isobaric labeling is that frequently only a single MS/MS spectrum is detected for a
peptide species. This increases the need to measure technical replicas and makes demands on robust LC MS
techniques. However, the overlap of identified proteins varies between technical and biological replicas. In a
recently  published  study,  only  35.4% of  identified  proteins  have  been  found in  each  of  the  nine  technical
replicates being measured  (81). This is  often referred to as missing values and is prominently observed for
peptides in low abundances and in data-dependent acquisition methods (81–83). 
Beside low precursor ion intensities, also extreme ratios of protein abundances, diverse fragmentation upon
precursor excitation and different ionization efficiencies of peptides can result in less robust quantification (77).
Further, the MS instruments sensitivity and resolution in MS/MS mode directly affect the relative quantification,
due to reporter ion detection in MS/MS spectra (70,83). 
As MS/MS spectra contain qualitative and quantitative information, interfering substances in the low m/z
region of reporter ions have to be avoided and must be excluded. Several interfering signals are known. Some of
these are, the phenylalanine immonium ion´s M+1 isotope (m/z 120.0 +1) which can interfere with iTRAQ121 at
m/z 121.1 (low resolution MS/MS; (73)); the immonium ion of arginine (m/z 115.0), which shows an m/z value
close to iTRAQ115 (m/z 115.1)  (74) and the  y1 fragment ion from C-terminal proline (at 116.1 Da;  (84)) that
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shares the m/z value with the iTRAQ116 reporter ion. However, using high resolution and high mass accuracy
instruments  (e.g.,  equipped  with  an  Orbitrap  mass  analyzer  (85)),  it  is  possible  to  distinguish  between
interferences  and  reporter  ions.  The  application  of  higher  collision  energies  upon  fragmentation  assists  to
generate higher intensive reporter ion signals, while the signal intensity of interfering signals (e.g., contaminants)
does not increase  (69). Contaminant signals can have a dramatic impact on peptide and protein quantification
regarding accuracy, precision and reproducibility, which can lead to miss-interpretation of data.   
Co-eluting peptides, which have similar m/z values close to the target precursor (≤ 3Da), can be co-isolated
during precursor isolation. These ions will be co-fragmented (alongside the precursor ion of interest) and will
also contribute to the iTRAQ reporter ion signals. This introduces a bias towards 1:1 ratios, a process often
referred to  as  underestimation (73) and is,  in  particularly,  observed for  precursor  ions with lower  intensity
(59,77). To avoid these co-isolations, sample complexity has to be decreased, e.g., by two-dimensional liquid
chromatography. However, this does not always lead to improved precursor selection and different techniques
have been developed to overcome this problem. For example, proton transfer ion-ion reaction (PRT) can be used
by which the charge of the precursor is reduced. This removes interfering substance at the observed m/z value.
Consequently,  the  accuracy  and  precision  of  protein  quantification  increases.  However,  less  peptides  are
identified as the sensitivity decreases (86). An alternative technique isolates the most intense ions of the MS/MS
spectra  and  subsequently  fragments  them  (MS/MS/MS  analysis).  The  MS/MS  spectrum  is  used  for
identification,  whereas  the  MS3 spectrum is  used  for  quantification.  Again,  protein  quantification  accuracy
increases,  but  less peptide are identified due to the prolonged cycle time. Moreover,  specialized software is
needed for data-analysis (87). 
Overall, customized software is required for each MS and MS/MS quantitative workflow (e.g., SILAC,
label-free or iTRAQ). Usually, a single software package cannot focus on all kind of quantification techniques,
leading to a variety of different tools being published. More problematically, each quantification method requires
its own algorithm (adapted to different artifacts created  (64)), which needs to be developed individually  (66).
This is usually performed by different research groups, increasing the level of complexity (software language,
cross-platform compatibility,  statistical  tests,  noise and data filtering methods).  In many cases,  this hampers
inter-lab comparison of results. To facilitate data sharing, defined data processing workflows (e.g., statistical
tests) and standard formats (e.g., mzQuantML (88)) are required. A systematic overview, which compares the
different quantification techniques, is shown in Table 1-1.
Table  1-1:  Overview  of  the  main  groups  used  to  relatively  quantify  proteins.  Metabolic  labeling  includes
techniques such as SILAC. Chemical labeling on protein or peptide level cover techniques like iTRAQ, TMT or
ICAT. For SPC, the number of  identified spectra is summarized (MS/MS*).   
Method LabelingLevel
Quantification
Level Application Accuracy
Proteome
Coverage
Linear Dynamic
Range (logs)
Metabolic Labeling Protein MS 2-3 entitiescell culture systems +++ ++ 1-2
Chemical Labeling Protein MS or MS/MS 2-3 entitiescell culture systems +++ ++ 1-2
Chemical Labeling Peptide MS or MS/MS 2-8 entitiescell culture systems ++ ++ 2
Label-Free - MS multiple + +++ 2-3
SPC - MS/MS* multiple + +++ 2-3
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1.1.3 Phosphoproteomics
Posttranslational Modifications (PTMs) are a fast method for cells to adapt to internal or external stimuli.
In contrast to regulations at the genome and transcriptome level, the modification of proteins is a fast (within
milliseconds to seconds) and more dynamically regulated mechanism (89). 
Beside glycolization, ubiquitination and acetylation, phosphorylation is one of the most prominent PTMs,
which can be grouped into four categories: (i) O-phosphomonoesters on the hydroxyl-group (predominantly:
serine,  threonine  and  tyrosine;  rare:  hydroxyproline  (90)),  (ii)  N-phosphoramidates  (arginine,  lysine  and
histidine), (iii) S-phosphothioesters (cysteine) and (iv) phosphoanhydrides (glutamic and aspartic acid; (91,92).
Reversible protein phosphorylation is an important post translational modification in both eukaryotic and
prokaryotic  biological  systems  involved  in  various  regulation  mechanisms,  e.g.,  catalytic  activity  changes,
protein-protein  and  protein-DNA interactions,  protein  synthesis,  gene  expression,  apoptosis;  and  survival,
metabolism, division, growth and differentiation of cells (92–96). Upon phosphorylation, not only a negatively
charged group is introduced: it can alter a protein's biochemical properties and cause conformational changes
(94,97). Protein phosphorylation - dephosphorylation events are important for medical research, as a variety of
diseases (e.g.,  liver cirrhosis or insulin resistance  (98–102)) are a consequence of dysregulation in signaling
networks. 
The formation of phosphoproteins is catalyzed by kinases using high-energy cofactors (e.g., ATP and GTP).
The dephosphorylation is catalyzed by phosphatases releasing orthophosphate (75,103). About 3% of the human
gene coding regions are responsible for kinases and phosphatases  (104).  517 kinases have been categorized
based on public and proprietary genomic, complementary DNA, and expressed sequence tag (EST) sequences of
the human genome (105).
Primarily  serine  (~90%,  pS),  threonine  (~10%,  pT)  and  tyrosine  (<1%,  pY)  are  phosphorylated  in
eukaryonts  (106–110). These O-phosphomonoesters are acid-stable,  making them (pS, pT and pY) the most
commonly studied phosphorylations by mass spectrometry as they are compatible with treatments commonly
used in proteomics  (111,112). Newer studies  using MS-based methods have revealed the importance of  pY,
changing the distribution to 86.4% (pS), 11.8% (pT) and 1.8% (pY), respectively (113,114). 
Phosphorylation events occur in many cases in the sub stoichiometry level, making their detection and
analysis in the presence of non-phosphorylated peptides challenging (92,115,116). To circumvent this problem,
mass  spectrometry  compatible  methods  were  established  to  enrich  phosphopeptides,  including  antibody
precipitation  (IP;  (117)),  immobilized  metal  ion  chromatography  (IMAC;  (118)),  metal  oxide  affinity
chromatography (MOAC; (119,120)) and HPLC based fractionation techniques. IP is a technique optimal for pY-
peptides. IMAC and MOAC are also capable of enriching pS- and pT- peptides. The IMAC method is based on
the selective affinity of trivalent ions, such as  Fe3+or Ga3+ to phosphate groups (118). The presence of highly
acidic non-phosphorylated peptides decrease the specificity of enrichment, as these tend to bind to the IMAC
material. However, lowering the pH below 1.9 neutralizes the acidic amino acids and improves the selectivity of
IMAC towards phosphopeptides (121). 
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TiO2, the most prominent material for MOAC, is often applied in offline enrichment strategies either in a
batch mode or via pre-packed columns (122,123). The addition of dihydroxybenzoic acid (DHB) or similar acids
increases the selectivity of this phosphopeptide enrichment technique  (124). As for IMAC, lowering the pH-
value reduces co-purification of non-phosphorylated (highly acidic) peptides during enrichment.  It  has been
shown that TiO2 is tolerant to a variety of buffers and salts used during sample preparation, thereby increasing its
application possibilities (125). The elution of phosphopeptides is typically performed under basic conditions (pH
9 to 11) using ammonia solutions. For singly phosphorylated peptides, the elution is reproducible. However, it is
speculated that the elution of multi-phosphorylated peptides is difficult and less reproducible due to their high
affinity towards TiO2 (122). 
Alternative strategies to analyze phosphopeptides involves the replacement of the phosphorylation into a
different chemical group (β-elimination with michael addition, BEMAD; phosphoamidate chemistry, PC). To
overcome some of the limitations observed for phosphopeptide enrichment technique (Table 1-2), combination
of these can be applied to increase the number of identified phosphopeptides. A common method employs SCX
fractionation  prior  IMAC  or  MOAC  phosphopeptide  enrichment  (126–128).  Recently,  7,000  unique
phosphopeptides were identified using a 3D-LC-MS setup (high-pH RP, SAX and low-pH separation; (129)). 
Table  1-2:  Overview  of  phosphopeptide  enrichment  techniques  commonly  applied  in  proteomics  (130).
Abbreviation: [P] phospho. 
Enrichment
Technique Function/ Interaction Advantages Disadvantages
Antibodies (AB) selective enrichment by specific regions for the AB and antigen
✔ Efficient for pY-peptides (more 
electron rich results in stronger 
binding)
✗ Expensive
✗ limited by number of AB available
✗ less specific for pS- and pT- 
peptides
IMAC
Affinity of [P] for transition metal ions
(Cu2+, Ni2+, Zn2+, Fe2+, Co2+, and other) 
based on coordinative bonds between 
electron donor (oxygen of [P]) and 
metal ion 
✔ Variation of metal ion influences 
specificity
✗ Variation of metal ion influences 
specificity
✗ nitrogen & sulfur (especially 
histidine) is enriched
✗ co-purification of acidic peptides
✗ pH dependent
✗ loss of mono[P] at 0.1% TFA
✗ bias towards multi[P]
MOAC Affinity of phosphate group for metal oxides
✔ High selectivity
✔ High robust towards a variety of 
buffers
✔ Compatible with organic solvents
✔ TA/ TFA minimizes acidic peptide 
isolation
✗ Acidic peptides are co-enriched
✗ excluder (organic solvents) required 
✗ DHB induces high background 
signal & ionization is suppressed
✗ bias towards mono[P]
✗ multi[P] bind to strong; 
✗ high pH required 
Precipitation Addition of calcium salts forms insoluble calcium phosphate deposits
✔ Efficiency comparable with IMAC
✔ Less biased towards multi[P]
✗ Sample loss
✗ Reproducibility
Chemical 
derivatization
Removal of [P] by β-elimination and 
addition of a suitable chemical group 
(michael-addition)
✔ Removal of [P] circumvents neutral
loss effects and increases ionization
efficiency
✔ Incorporation of label for 
quantification possible
✗ Sample loss
✗ Side reactions
SCX/ SAX
Retains cations (SCX) or anions 
(SAX) by interaction with stationary 
phase
✔ [P]peptides elute earlier (SCX) or 
later (SAX) than non-[P] peptides 
✗ Highly hydrophobic [P]peptides can
be retained (SCX) leading to co-
elution
✗ Highly acidic non-[P]peptides co-
elute
✗ Miss cleavages lead to co-elution
HILIC
[P] have a higher hydrophilicity and 
elute later than non-[P]peptides based 
on interactions with stationary phase   
✔ Compatible with most buffers used ✗ Low efficiency
✗ Co-elution
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1.2 Mass Spectrometry
Mass spectrometry (MS) has become the method of choice for identifying, quantifying and characterizing
proteins  at  the  molecular  level.  The  MS instruments  were  built  in-house and  have  evolved  since  the  first
commercial variant introduced in 1943 (Consolidated Engineering Corporation) into instruments which can be
referred  to  as  black  boxes (131) due  to  their  complexity and inter-disciplinary  aspects  (physics,  electronic,
informatics & related fields like chemistry and biology).  Pioneer work has been done by Wien and Sir J.J.
Thomson in the beginning of the twentieth century (132–134). In the 1940s and 1950s, the fundamental work of
introducing  Time  of  Flight  (TOF;  (135))  ion  cyclotron  resonance  (ICR;  (136))  and  ion  traps  (IT;  (137))
revolutionized MS. By coupling gas-chromatography to MS (GC-MS; (138,139)), analytes are separated prior to
ionization. This significantly improves the analysis of complex samples. 25 years later, the introduction of soft
ionization  techniques  [Fast  Atom Bombardment  (FAB;  (140)),  Electrospray  Ionization  (ESI;  (10,141))  and
Matrix-assisted Laser  Desorption/ Ionization (MALDI;  (7–9))]  allowed researches to also study biologically
complex samples, e.g., proteins and peptides. Here, tandem MS technique using fragmentation of precursor ions
with a collision gas (introduced 1960s;  (142)), in combination with the intact ionization of biological samples,
has allowed researches to study a variety of scientific questions, e.g., measuring precisely the molecular mass
(m/z value) of intact compounds, molecular structures like disulfide-linkages, reaction dynamics like enzyme
kinetics and gas-phase reactions to name a few (131). 
In the 21st century, the Orbitrap (Makarov, year 2000;  (143)) and linear quadrupole ion trap (LIT; Hager,
year 2002 (144)) were introduced. These, in combination to atmospheric pressure ionization sources (ESI, APCI)
and commercialization allowed LC-ESI MS to become the method routinely applied to analyze protein samples
(131). However, LC-MALDI MS is still a widely applied method. Due to its complementary nature to LC-ESI
MS, an increasing number of identified peptides and proteins are observed by combining both techniques (145–
147). In principle, all mass spectrometers are made up of five parts: (i) inlet system, (ii) ion source, (iii) mass
analyzer, (iv) detector, and (v) data storage (external system), as it is outlined in Figure 1-6. 
Figure  1-6: Schematic diagram of the fundamental  parts of a mass spectrometer with the ion source, mass
analyzer and detector being part of the instrument and the inlet system and data storage system which are
attached by interfaces.
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The inlet system (i) can be either under vacuum or under atmospheric pressure  (148). Its purpose is to
transfer samples into the gas phase and further into the mass spectrometer. Within the ion source (ii), analytes are
ionized and further transfered into the mass analyzer (iii), where they are separated according to their mass to
charge ratio (m/z). Each separated ion is detected (e.g., by electron multiplier) which is recorded by the detector
(iv) and stored in a data system (v).
1.2.1 Soft Ionization Techniques
Two soft ionization techniques (MALDI and ESI) paved the way for modern mass spectrometers  (6). In
MALDI experiments, the sample to be analyzed is firstly co-crystallized with a matrix compound (e.g., 2,5-
dihydroxybenzoic acid).  Due to its  structure,  this weak organic acids  serves  as  proton donator  and absorbs
ultraviolet (UV) laser energy  (149). By rapid laser heating, matrix molecules carrying analytes are transferred
into the gas phase  (6). As weak organic acids function as proton donators the analyte is positively ionized. If
weak bases are used, the matrix accepts protons from the analyte leading to a negative sample ionization (149).
By direct and efficient energy transfer from the matrix to the analyte molecule, the analyte ions can be measured
intact. Further, measurements with a high mass accuracy and up to the sub-picomole concentration are possible
(150–152). 
During ionization, mostly singly charged precursor ions are observed  (153).  By changing the classical
MALDI  sample  preparation  methods,  multiply  charged  precursor  ions  can  also  be  detected  (154–156).  To
receive stable and high signal-to-noise ratios, several MS spectra have to be accumulated. This is one of the
major drawbacks for MALDI. Other factors negatively affecting MALDI MS are the shot-to-shot and sample-to-
sample reproducibility, that is more critical for complex rather than simplified (pre-fractionated) samples (157). 
For electrospray ionization (ESI), analytes are directly injected as liquids via the inlet system into the ion
source. The application of voltage differences between a capillary and the ionization source of MS allows the
solvent to assimilate charges. With increasing charge state, the droplet at the end of the tip becomes unstable,
forming a so called Taylor cone (see Figure 1-7). This conical shape turns into a jet, which further fragments into
a stream of highly charged droplets with a diameter of two to three µm. By attraction forces and evaporation of
solvents, the size of each droplet shrinks and the charge to volume ratio increases. At a certain point, the surface
tension  cannot  be  hold  (Rayleigh  limit)  and  smaller  droplets  are  formed  (Coulomb explosion).  By further
evaporation of solvent, the Rayleigh limit is reached again and additional Coulomb explosions are observed.
This process is repeated until solvent free analyte ions are formed. These ions are attracted to and introduced into
the mass spectrometer (158,159). Upon analyte ionization, the formation of multiply charged ions is a common
observation for  ESI (in contrast  to MALDI),  and there are several  theories  and hypotheses  to explain this,
although the the process in not understood entirely (160–165). 
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Figure 1-7: Ion formation during the ESI process. According to the polarity of the capillary, either positively or
negatively charged analyte ions are obtained. Typically, molecules > 1000 Da are observed as multiple charged
ions. Image is adapted by (158,159) and further modified. 
Precursor Ion Transfer in LTQ Orbitrap Velos
The LTQ Orbitrap Velos is one of the most used mass spectrometers worldwide (166). It is a hybrid LC-ESI
MS instrument introduced in 2010 by Thermo Fisher Scientific that combines two different mass analyzers, that
is the linear quadrupole ion trap and Orbitrap. This instrument was used in particular for MS measurement in this
dissertation and some aspects of this instrument will be described in the following section.
To transfer ions from the inlet system via the ion source to the mass analyzers (Figure 1-8), an ion transfer
tube is used to pass the barrier of atmospheric pressure (760 Torr, API side) to the stacked ring ion guide (SRIG,
also known as S-lens) region with approx. 1 Torr  (167,168). The S-lens captures and focuses ions into a tight
beam, by applying a radio frequency (RF) which eliminates mass discrimination. The S-lens is made of 18 rings.
Each rings diameter is smaller than the previous one in order to capture as many ions as possible, focus them
simultaneously and transfer the ion beam into the multipole regime. Three multipoles are used to filter for or
select all ions to be transferred into the ion trap (High Pressure Cell; HPC): 1st bent square quadrupole (to
remove neutral ions increasing detector noise), 2nd square quadrupole (transfer and further focusing) and 3rd
round octapole (transfer into ion trap mass analyzer). The High Pressure Cell is used for ion trapping, isolation
(if required) and excitation (fragmentation of precursor ions), whereas the Low Pressure Cell (LPC) is used for
ion ejection towards the electron multiplier for detection, or towards the Orbitrap part of the hybrid nano-LC-ESI
MS instrument. 
One unique feature of this hybrid instrument is its capability to isolate and accumulate precursor ions for a
specific time frame. This accumulation time is inversely linear to the precursor ion intensity. Its maximal value
(in time scale) can be user defined. However, if a sufficient number of ions are isolated, the time regime for
trapping is dynamically adjusted. This process is referred to as Automatic Gain Control (AGC). This prevents the
Orbitrap mass analyzer to be overfilled with ions, which can cause detector blindness. The AGC also decreases
the cycle time for MS/MS events. Moreover, a higher number of low abundant precursor ions of a specific m/z
value  can be accumulated  for  fragmentation.  The reproducibility  and robustness  of  tandem MS spectra  are
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increased due to accumulation of (approximately) the same number of ions for fragmentation. 
Figure 1-8: Schematic diagram of the LTQ Orbitrap Velos equipped with ETD. ©2009 Thermo Fisher Scientific
1.2.2 Peptide Fragmentation Techniques
Identifying peptides and proteins by Peptide-Spectrum-Matching (PSM) has evolved into the technique
commonly applied in proteomics. In contrast to Peptide-Mass-Fingerprint (PMF), sequence specific signals upon
precursor fragmentation are used to match tandem MS spectra and peptide sequences. To reveal the advantages
and  disadvantages  of  each  fragmentation  techniques  commonly  applied  in  proteomics,  it  is  important  to
understand how peptides tend to fragment during precursor ion excitation.   
1.2.2.1 Peptide Fragmentation
Ionized peptides in the gas phase, exposed to an external stimulus (mostly by collision with gas molecules),
tend to dissociate in a controlled manner by cleaving the peptide between amino acid residues. This cleavage
leads to predominantly six ion series (a-, b-, c- and x-, y-, z-ions), which are related to only three possible
cleavage points within the peptide backbone; forming three ion-series pairs (a/x, b/y and c/z, respectively; see
Figure 1-9;  (84,169)). The fragment ions are termed a-, b-, c-ions if the charge remains at the N-terminal site
during peptide dissociation. Contrary, if the charge remains at the C-terminal site, the ions are termed  x-, y-, z-
ions (see Figure 1-10). 
Figure  1-9: Nomenclature to describe peptide backbone fragmentation leading to a-, b-, c- and x-, y-, z-ions
depending on the charge remaining N- or C-terminal. Illustration is adapted by (84,169).
The cleaving position in the peptide is indicated by lowercase numbering in right position of the peptide
specific ions (e.g., a3-ion). If hydrogens are transferred to (or lost from) a fragment ion, this is indicated with an
apostrophe in right (or left) position (not shown in Figure 1-10). Additional side chain fragmentation of peptides
can be observed, to which the letters d, w and v are assigned (169). Other fragmentation pathways, caused by
double backbone cleavage, are referred to as amino acylium, amino immonium and immonium ion, respectively
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(170–172). The former is usually a product of b- and y-type ion, the latter of a- and y-type cleavage. If the
internal fragment only carries one amino acid, formed by a combination of a- and y-type cleavage, the resulting
immonium ion is labeled with its corresponding one letter amino acid code. All or just a subset of the fragment
ions described above are used for manual or automated peptide identification (see chapter 1.2.4). 
The relative distribution of peptide sequence specific ions (e.g., b-, y- or immonium ions) in tandem MS
spectra depends on several factors, such as the primary peptide sequence, the energy introduced while precursor
fragmentation or the type of fragmentation applied (see chapter 1.2.2.2). 
Figure 1-10: Structure of the commonly observed a-, b-, c- and x-, y- and z-ions after peptide fragmentation.
1.2.2.2 Fragmentation Techniques
Peptide fragmentation techniques are applied to obtain sequence specific signals which are used to identify
peptides by Peptide-Spectrum-Matching. Presently,  Collision Induced Dissociation (CID;  (173)) is one of the
most commonly applied fragmentation techniques in bottom-up proteomics. 
CID can be further sub-grouped into high- and low-energy CID (HE-CID and LE-CID, respectively). HE-
CID applies energy regimes of hundreds to several thousands eV and is more often used in sector field TOF-TOF
instruments (166,174). The advantage of HE-CID is to monitor b- and y- beside a-, x- and immonium ions (175).
These and the presence of specific  indicator ions help to distinguished isobaric  amino acids in tandem MS
sequence  ladders  (e.g.,  leucine  and  isoleucine;  (176)).  Low-energy  CID (<  200  eV)  is  the  fragmentation
techniques predominantly applied in proteomics experiments and can be further sub-grouped into (166,174,177–
181):
• Resonant-excitation CID (CID-IT; 1 – 20 eV; performed in ion trap devices) 
• Beam-type CID (1 – 200 eV; triple quadrupole (QqQ) or hybrid double quadrupole – Time of Flight
instruments (QqTOF)) and 
• Pulsed q collision dissociation (PQD; performed in ion trap devices)
Fragmentation  of  the  peptide  precursor  ion  is  most  commonly  obtained  by  precursor  isolation,  its
acceleration to a higher kinetic energy state allows it to collide with an inert gas (helium, nitrogen or argon;
(181)).  This inelastic collision converts the kinetic into internal  vibrational  energy. If the vibrational  energy
reaches a specific point, covalent bonds might dissociate. However, as the dissociation rate is slower compared
to the redistribution of energy, the weakest bond in a peptide is favored to break first (referred to as low-energy
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pathway). This phenomena is especially observed for CID-IT (resonant-excitation). 
CID fragmentation of peptides follows the mobile proton model (171,182,183) in which a proton attached
to a basic side (R or K) is mobilized after activation and transferred to a backbone heteroatom (e.g., terminal
amino groups,  amide oxygens,  carbonyl  oxygens,  amide nitrogens or  side chain groups)  leading to charge-
directed fragmentation (182,184). As more than one protonated species exists after activation, several position
for peptide backbone cleavage are available. This process is monitored as a fragment ion series (sequence tag
ladders) in the MS/MS spectra. For certain amino acids (e.g., proline) or modifications (e.g., phosphorylation
and oxidation) a significant influence in peptide backbone fragmentation is reported. Beside peptide backbone
cleavage, water or ammonia losses are frequently observed as competing fragmentation pathways (181). 
If activation and deactivation processes are in competition (time scale based), this is referred to as  slow-
heating and typical for resonant excitation CID (CID-IT; (185)). B- and y-ions are mainly observed for CID-IT,
as this represents the lowest energy pathway (CO-N bond cleavage of peptides). Low m/z b- and y-ions cannot
be detected due to the low mass cut-off rule of ion traps (175,184,186,187). 
As the energy introduced is inversely proportional to the mass of the precursor, less energy is used for
conversion to internal energy with increasing mass. This can be overcome by changing the gas mass (using
nitrogen instead of helium), or using CID fragmentation techniques applying higher energy such as beam type
CID  (e.g.,  in  QqQ  or  QqTOF  instruments;  (188).  As  the  kinetic  energy  is  retained,  multiple  (sequential)
fragmentation  processes  are  more  likely  to  be  observed  by  further  energetic  collisions  (166,189,190).  The
fragmentation process is faster than the CID-IT in circumventing the problem of internal energy distribution to
(predominantly) break the weakest bond available in sequence. 
The advantage of monitoring the low m/z region led to a further beam-type CID fragmentation technique,
Higher Collision induced Dissociation (HCD), being available for Orbitrap hybrid MS instruments. During the
development  of  HCD, beam-type  like  fragmentation has  been  induced in  the C-trap  by changing the  radio
frequency voltages (2,500 instead of 1,500 Volts). This has allowed to retain a maximal number of ions. It has
been observed that the energy required for fragmentation scales linearly with m/z values. This has lead to a
normalized value (Normalized Collision Energy, NCE) at m/z 1,000 (190)). HCD fragmentation has been further
optimized by the integration of a dedicated octopole collision cell, which is located at the end of C-trap (HCD
Collision Cell in Figure 1-8). A variety of collision gases (nitrogen, helium or argon) can be used. This increases
the flexibility of HCD fragmentation, as different amounts of energy can be introduced. Recently, the limitation
of  acquiring  fragment  ions  only  in  the  Orbitrap  mass  analyzer  has  been  overcome,  allowing  detection  of
fragment ions also in the low resolution ion traps after HCD activation  (191,192). However,  this is not  the
commonly applied method, as fragmentation processes outside the ion trap (octopole collision cell; (188)). 
A further CID like fragment technique is the so-called Pulsed Q Dissociation (PQD), which overcomes the
problem of ion detection in the low m/z region with ion traps (e.g., iTRAQ reporter ions (see chapter  1.1.2)).
This is achieved by precursor activation with a high q value (0.6 – 0.8) for a short period of time using high
amplitude resonance excitation pulse (~ 100 µs).  Only ions resonant  to  this excitation pulse are kinetically
excited by absorption of energy. Before significant dissociation processes occur, the high value is kept constant
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(~ 100 µs) allowing for conversion of kinetic into internal energy. Then, the q value is lowered by dropping RF
amplitude, while activated ions undergo fragmentation. Due to the low q values, low mass ions are trapped, as
well (177,193). 
The pattern of tandem MS spectra of CID activated peptide precursor ions are influence by several factors,
such as amino acid composition, mass and charge state of the precursor ion and the time and energy introduced
upon  fragmentation.  A disadvantage  of  CID  is  that  labile  peptide  modifications  can  be  lost.  This  can  be
overcome by applying other fragmentation techniques (194): Electron Capture Dissociation (ECD) and Electron
Transfer Dissociation (ETD). 
Both techniques allow peptide backbone fragmentation breaking (N-Cα bond), which leads to the formation
of c- and z-ions (see Figure 1-10; (188)). Due to their nature, ECD and ETD are complementary techniques to
CID  (195).  Recently,  it  has  been  reported  that  the  sequence  coverage  is  higher  for  ECD than  for  CID-IT
(196,197). However, an intense signal originated from charge-reduced precursor ions limits its use, as sequence
specific signals are suppressed and cannot (or barely) be used for peptide identification (198).   
ECD  is  predominantly  applied  in  Fourier  Transform  Ion  Cyclotron  Resonance (FTICR)  mass
spectrometers. In the initial process of ECD, protonated peptides assimilate an electron. The formed peptide
cation then undergoes rearrangement processes and dissociates (Equation 1-1; (175,199)). 
[M+ nH]n++e -→[[M+ nH]n-1+ ]*→fragment ions Equation 1-1
ETD  is  more  commonly  applied  in  ion  traps.  An  electron  is  transferred  from  a  radical  anion  (e.g.,
fluoranthene for the LTQ Orbitrap Velos) to the protonated peptide precursor ion. This results in fragmentation
along the peptide backbone forming c- and z- ions (Equation 1-2; (199)). The ETD process is most effective for
highly charged peptide precursor  ions.  Similar  to ECD, a charge-reduced precursor ion often dominates the
tandem  MS  spectra.  To  induce  further  fragmentation,  a  coupled  ETD-CID  event  can  be  triggered  on  the
precursor ions, which increases the peptide sequence coverage significantly (200). This combined fragmentation
process is referred to as ETD with supplemental activation (ETD-sa)
[M+ nH]n++A-→[[M+ nH]n-1+]*+A→fragment ions Equation 1-2
The LTQ Orbitrap Velos (equipped with ETD support) offers the feature to create data-dependent decision-
trees to use CID for low charged ions (z < 3+) and ETD for higher charged ions (z > 2+). Although this improves
the  sequence  coverage,  the  total  number  of  identified  peptides  does  not  increase  significantly,  and  is  less
effective than double measurement using CID only (201,202). Similar results are reported for the combination of
CID and HCD (177), although the search algorithms and their settings have an impact on the number of peptides
identified (203). This is often not taken into account for fragmentation comparison.
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1.2.3 Mass Analyzers
To separate  and  isolate  precursor  or  fragment  ions  from surrounding  ions,  two basic  classes  of  mass
analyzers exist: (i) scanning and ion-beam devices (Time-of-Flight (TOF) and quadrupole (Q)), which are often
coupled to the pulsed ionization technique MALDI and (ii) trapping devices, (IT, Orbitrap and FT-ICR) coupled
online via continuous ESI (6). 
TOF analyzers determine the flight time of ions through a free flight tube. This flight time is proportional to
the m/z values.  Principally after ionizing analytes,  these are accelerated by an electric  voltage to a specific
kinetic energy Ekin. If the acceleration voltage and the flight length are known, the m/z value can be calculated by
measuring the flight time:
Ekin=
1
2
×mv2=z×e×U Equation 1-3
Ekin: kinetic energy
m : mass of analyte ion
v : ion velocity after acceleration
z : charge state
e : elementary charge
U : acceleration voltage
The speed is linearly corrected with the flight length and time, respectively.
v= L
t
Equation 1-4
L : length of drift tube
t : total flight time
By combination, the m/z value can be calculated as:
m
z
= 2×e×U×t
2
L2
Equation 1-5
Typically, the flight time ranges from µs to several 100 µs with flight length from one to four meters (204).
One of the main limitations of TOF instruments is the inability to measure tandem MS. Here, techniques like
PSD and prompt fragmentation are applied, but the fragmentation and selection capabilities of ions are limited
(205). This can be overcome if an other mass analyzer (e.g., quadrupole or TOF) is integrated, which functions
as a precursor ion filter. Only ions of a specific m/z are then subjected to fragmentation. Upon fragmentation, the
ions are accelerated towards the TOF analyzer and the drift time of each ion is measured. Often Multi Channel
Plates (MCP) and Secondary Emission Multiplier (SEM) are used for ion detection, respectively (206). 
In contrast to other mass analyzers, no increase in speed is observed for tandem MS. The only exception is
if a large number of ions are created, transferred and detected. MALDI TOF/TOF creates reproducible spectra,
but to obtain a high signal-to-noise ratio, several spectra have to be merged (205).
Quadrupole mass analyzers are build up of four rods with a parallel alignment and a hyperbolic profile. A
combination of  audio frequency (AC) and  direct  current  (DC) voltage is  applied to  stabilize ions over  the
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complete lengths (158). At counterpart rods, the same polarity (DC voltage) and phase (AC) are applied, whereas
side-by-side rods have reverse polarity (DC) and a phase (AC), which is shifted by 180 degrees. While scanning,
the DC and amplitude of alternating electrical field are increased and ions, passing the rods axially, begin to
oscillate. As the ratio of DC and amplitude is kept constant, only ions of a specific m/z are stabilized; while other
ions do not pass the complete length of the quadrupole and are filtered out. This also represents the biggest
disadvantage of quadrupoles: the loss of ions generated.
 Ion traps are often made up of three-dimensional (3D) quadrupole fields. Ions are trapped in the center and
scanned out in two directions. Although the cycle time for trap filling and spectrum generation is short  (207)
their small volume limits the trapping efficiency of externally generated ions to 1-10% and the overall number of
ions that can be trapped. Also, the dynamic range is limited as space-charging effects decrease spectra quality
and the mass accuracy and resolution is limited even if only a small m/z window is monitored.  
The development  of  Linear Ion  Traps (LITs)  has  allowed the  storage  of  a  up  to  10 times  more  ions
compared to ITs (187). This has lead to improved ion statistic and injection efficiency, respectively (205). The
injection is performed through an end cap and ejected from it as well  (187) towards two detectors allowing to
double the current detected. One disadvantage of ion traps operated in classical mode (non PQD, as described
previously in chapter 1.2.2.2) is its low mass cut-off at approximately 1/3rd of the precursors ion mass. 
LITs are versatile and fast mass analyzers, have the capability to perform MS n experiments (tandem in-
time),  have  high-duty  cycles  and  a  high  sensitivity.  These  features  make  LITs  best  suited  for  bottom-up
approaches. In hybrid mass spectrometers (e.g., LITs and Orbitrap mass analyzers combined), the linear ion trap
is used for trapping, ion selection and ion reactions (6). While tandem MS experiments are performed in the LIT,
ions can be further analyzed in the Orbitrap mass analyzer to improve spectra quality (208). 
Orbitrap mass analyzers are a further development of the Kindon trap (209). It applies trapping of ions in a
electrostatic field by an orbital motion around the spindle, as illustrated by the red arrows in Figure 1-11 (210).
By subsequent Fast Fourier Transformation, time-domain signals are converted into mass-to-charge spectra. 
Figure 1-11: Cross section of the Orbitrap mass analyzer. ©2009 Thermo Fisher Scientific
The Orbitrap mass analyzer has some unique features such as high mass resolution (up to 150,000) and
accuracy (2 ppm and 5 ppm for internal and external calibration, respectively), an m/z range of 6,000, a high
space-charging, a dynamic range of four order of magnitude (210) and no relevant mass cut-off, as observed for
ion trap devices (177,190,211,212).
The LTQ Orbitrap Velos combines a linear ion trap and an Orbitrap (Figure 1-12). To benefit from this
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hybrid configuration, a MS snapshot is performed at a reduced resolution in the Orbitrap mass analyzer (R =
7,500) to obtain a list of precursor ions (m/z value and signal intensity). While the full scan completes in the
Orbitrap, precursor ions of interest are isolated, trapped and fragmented in the Low Pressure Cell of the linear
ion trap. Afterwards, ions are transferred to the High Pressure Cell and scanned out from low to high m/z values.
This is referred to as the high-low strategy, because MS spectra are recorded at high resolution and MS/MS
spectra at low resolution in the LIT with a higher scanning speed and sensitivity compared to the Orbitrap mass
analyzer (6). 
Figure 1-12: Schematic overview of a dual fragmentation method utilizing CID-FT and HCD. After a prescan,
the five most intense precursor ions are being fragmented by CID and analyzed in the ion trap mass analyzer. In
parallel, the full scan is completed in the Orbitrap. After both processes have finished, the same precursor ions
are fragmented using HCD and subsequently analyzed in the Orbitrap mass analyzer. 
To prevent overfilling of the linear ion trap and the Orbitrap mass analyzer,  the number of ions to be
selected for scanning or fragmentation are predicted from the full scan. This method is referred to as predictive
Automatic Gain Control (pAGC). It is important to limit the number of ions to 106 (Orbitrap) and 105 (linear ion
trap), respectively, as a higher number of ions causes space-charging effects by which the mass accuracy and
resolution decreases (213). 
The Orbitrap mass analyzer of the LTQ Orbitrap Velos can be operated in five different resolution modes:
7,500; 15,000; 30,000; 60,000 and 100,000. The different resolutions are obtained by varying the acquisition
time for a full or tandem MS scan. The time scale for an MS scan ranges from 0.25 sec (R = 7,500) to 1.9 sec (R
= 100,000).  The acquisition of MS full  scans with a resolution of 60,000 has  become the gold-standard in
proteomics and requires approximately 1 sec per scan (210). 
The high mass accuracy of the Orbitrap mass analyzer has improved peptide identification upon database
searches due to a higher specificity, and hence lowering the number of false positive identifications for the same
number of true positives. Identifying modified or unexpected peptides is greatly facilitated due to the higher
resolution and mass accuracy to exclude wrong annotations (214). 
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1.2.4 Data-Processing and Automated Data-Analysis
The application of different fragmentation techniques (e.g., CID, HCD, PQD and ETD) generates spectra
typically containing a high degree of redundant and or complementary information. Despite this, the various
fragmentation  techniques  produce  spectra  with  highly  typical  characteristics  in  terms  of  the  presence  and
intensities of various sequence specific ions (e.g., a-ions). Manual interpretation and validation of these complex
data is a very time consuming and error-prone process. To circumvent this, so called database search engines
were  developed.  SEQUEST  (215) and  Mascot  (216) are  commercially  distributed  search  engines,  whereas
OMSSA (217) and X!Tandem (218) are available as open-source software, which are developed by the National
Center for Biotechnology Information (NCBI) and Global Proteome Machine Organization (219), respectively. 
In contrast to Peptide-Mass-Fingerprint approaches (see chapter 1.1.1), which only use the precursor mass
for  identification rather  than the MS/MS spectrum  (28,220–222),  database search algorithms are capable of
identifying peptides also from complex peptide digests (shotgun proteomics) due to the incorporation of peptide
sequence specific signals (e.g., b- and y-ions; see chapter 1.2.2.2)) of tandem MS spectra (223) . 
 These fragment ions signals can also be predicted  in-silico.  By supplying a FASTA file, in which the
protein sequence is encoded, and using a specific set of features to digestion a protein  in-silico (e.g., enzyme
specificity), a list of peptide candidates including their specific fragment ions can be calculated. The compilation
of such a list is a common approach for all database search engines. However, each search engine uses a different
algorithm (also referred to as model) to identify and match peptides from tandem MS spectra. These algorithms
can be sub-grouped into four groups (223):
(i) descriptive models use a mechanistic prediction of peptide fragmentation, which is scored against the
experimental spectrum.
(ii) interpretative models are based on the assumption, that sequence ladders are generated. These,  in
combination to  divide the spectra  into three regions (unknown,  sequence tag and  other)  are  used  to
compute probabilities or correlation scores.
(iii) stochastic models use a training set to evaluate the likelihood of measurement and fragmentation for
peptide matching.
(iv)  statistical  and  probability  models  create  relationships  between  sequences  ( in-silico created)  and
MS/MS spectra (experimental). Both are used to derive the probability and significance for a peptide
identification.
1.2.4.1 Identifying Peptides using the Search Engine SEQUEST 
The search engine SEQUEST, a member of the descriptive model group, is the algorithm (predominantly)
applied for data analysis in this dissertation. SEQUEST (215) has been designed to identify peptide from low-
energy CID spectra (LE-CID; see chapter 1.2.2.2), which generates mainly b- and y-ions. Several pre-steps need
to be taken before using this engines. This includes to calculate the corresponding a-, b- and y-fragment ions
from the peptide precursor ion. 
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The first step that is directly performed by the search engine SEQUEST is to simplify the experimental
MS/MS data (m/z values and intensities) by removing background signals. This is performed by eliminating all
but the 200 – 500 most intensive signals. Additionally, within a 10 Da window around the precursor, signals are
removed to circumvent wrong annotations. A pre-search (Sp-Score calculation) to obtain peptide candidates by
linear sequence combination is performed using only b- and y-ions. The masses of b- and y-ions are calculated
according to Equation 1-6 and 1-7. 
bn=∑ an+1 Equation 1-6
yn=MW−∑ an Equation 1-7
an : mass of amino acid
bn : type-b ion
yn: type-y ion
The number of matched fragments ions (ni) and their intensities (im) are summed. As peptides fragment
ideally randomly by forming sequence letters, this can be interpreted as a  positive hit indicator (β), which is
increased by 0.075 with each consecutive hit. The presence of immonium ions are scored with the addition of
0.15 points for each immonium ion present (ρ). The sequence length (exactly: the number of predicted sequences
in terms of b- and y-ions) is also taken into account to compensate for biases introduced.
S p=(∑ im)ni (1+β)(1+ρ)/nt Equation 1-8
Sp :score
ni :number of matched fragment ions
im : abundances of matched fragment ions
β : component of score (continuity of an ion series)
ρ : presence of immonium ions
nt : predicted number of sequence ions
For the Top 500 candidates obtained by Sp-Score calculation, a cross correlation is performed between the
experimental  (normalized)  spectrum and the  theoretically  calculated  spectra.  To  normalize  the  experimental
spectrum, the precursor is removed and the spectrum is divided into 10 equally distributed parts. Within each
part, the signals are normalized to a value of 50. The theoretically calculated spectrum is created by integration
of b- and y-ions and magnified them to a value of 50. In addition to each b- and y-ion, two signals at ± 1 Da are
inserted, respectively, and magnified to 25. Type a-ions, loss of water or ammonia are magnified to 10. Finally,
by Fourier Transformation (FT), the cross-correlation is calculated and the obtained scores are normalized to 1. 
Principally,  the  XCorr  represents  the  sum of  ions  observed  for  both,  the  theoretically  calculated  and
experimentally (but modified) MS/MS spectrum. For a detailed explanation of the cross-correlation, its dis- and
advantages by using continuous fragment series for score calculation, the phenomenon to receive higher XCorrs
for peptides with a higher number of amino acids, the assignment problem of charge states or spectra quality
handling problems (background removing),  please refer  to these publications  (224–227);  as these topics  are
outside the scope of this work.     
Mascot, X!Tandem or OMSSA are also widely applied database search engines. It is noteworthy, that each
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has  its  own  and  characteristic  scoring  system,  but  results  of  each  search  engine  have  to  be  validated  to
distinguish between true and false positive peptide identifications. This process is usually performed by a False
Discovery Rate (FDR) calculation (228,229). 
To calculate a FDR, a  decoy database is created by reversing or randomly shuffle the original peptide
sequences  (230). Both databases (decoy & original) are then supplied for peptide identification by database
search engines. The FDR validation is based on the assumption that PSMs  from the decoy database are  false
positive results, and results from the original database are only true positive hits. Moreover, the number of false
(true) positive PSMs is assumed to be equal to the number of decoy (original) PSMs. The FDR is then calculated
by dividing the number of decoy hits (false positives) by the number of target hits (false and true positive hits). A
detailed description about the FDR approaches can be found elsewhere (229).
An alternative method to validate peptide hits represent Semi-Supervised Machine Learning Algorithms
(e.g., Percolator; (231)), which have been shown to increase the number of peptide identifications compared to
FDR approaches  (231). For PSM validation, they use a higher (but fixed) number of identification features
instead of only one feature used in FDR approaches. For SEQUEST, 20 instead of one feature (XCorr) are used
for peptide validation by the Percolator. This includes for example the Sp-Score, the precursor mass deviation,
the  peptide  lengths  or  the  fraction  of  matched  by  b-  and  y-ions  (231).  Further  improvements  and  critical
comparisons of the different validation approaches can be found elsewhere (232–236). 
1.2.4.2 Alternative Peptide Identification Techniques
A newly upcoming approach for database searching is to supply a spectra library instead of a FASTA file.
These library files are published by organizations such as  The Global Proteome Machine Organization and
contain spectra that have previously been confidently assigned to a particular peptide sequence. 
The advantage of this spectral library database searches is that the shape of a spectrum is known a priory
and does not need to be in-silico predicted, as it is common for FASTA file based database searches (see previous
section).  Predicting fragmentation patterns  (appearance  and intensity  of  sequence specific  fragment  ions)  is
generally a difficult process  (237). Therefore, matching experimental and library spectra is more accurate and
sensitive compared to FASTA file approaches, due to utilization of known intensities of expected fragment ions.
Furthermore,  the  search  algorithm  seeks  for  unexpected  modifications  or  amino  acid  substitutions  if  the
corresponding spectrum is supplied by the library. One such search algorithm is X!Hunter (238). In analogy to
Peptide-Spectrum-Matching,  the  process  of  identifying  peptides  from  libraries  is  referred  to  as  Annotated
Spectrum Library (ASL) pattern matching. 
The main disadvantage of spectral library searches is that only peptides which were identified before are
integrated into the  spectra library  and can  be searched for.  This  limits  the number  of  peptides  that  can  be
identified. Further, fragmentation pattern vary between instruments due to different technical implementations,
which can decrease the level of homology between experimental and library spectra. Another very important
disadvantage is that no spectra exist in the library for all kind of static modification, e.g., protection of new N-
termini  after  protein  digestion  is  generally  not  included  or  supported.  However,  N-termini  protection  or
modification  is  frequently  required  (60).  Therefore,  spectra  library  searches  are  less  flexible  than  database
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searches using FASTA files and cannot replace them entirely (239). 
Contrary to database searches, de-novo sequencing is usually performed without spectra libraries or FASTA
files  and  used  to  predict  peptide  sequences  of  uncharacterized  proteins  (240).  Abandoning  FASTA files  or
spectral  libraries  increases  the  search  space  and  search  time  as  various  possible  peptide  sequences  (plus
modifications) have to be considered for identification. This can decrease the number of peptides identified, but
can  also  increases  the  accuracy  of  PSMs simultaneously  (241).  For  de-novo analysis,  all  potential  peptide
candidates of a specific precursor ion are calculated, in-silico fragmented, compared to the experimental spectra
and scored. The scoring and validation process is similar to database search approaches. 
The increasing resolution and mass accuracy of mass spectrometers (e.g., mass deviation for precursor ions
< 10 ppm) has allowed to narrow the number of potential peptide sequences to be considered, which improves
the sensitivity of  de-novo peptide sequencing due to a limited search space  (242). Algorithms performing de-
novo sequencing  are  SHERENGA  (243),  Lutefisk97  (244) or  PepNovo+  (245).  Recently,  a  software
(DenovoGUI (240)) was published which supports data-input via a front end to analyze data using PepNovo+. 
However, de-novo peptide identification is not widely used (242). Low resolution and low mass accuracies
of  MS  and,  especially,  tandem  MS  spectra  hinder  an  effective  identification  process.  Further,  incomplete
fragmentation,  the  plethora  of  fragmentation  techniques  which  directly  influence  series  directionality  and
cleavage abnormalities have not paved the way to replace peptide identification by database searches (either by
FASTA files or spectra libraries) by de-novo sequencing (242,246).   
1.2.5 Phosphoproteomics by Mass Spectrometry
The analysis of phosphopeptides is a formidable challenge due to its elaborate nature (short lifetime, sub-
stoichiometric amounts and the existence of phosphorylation isoforms). Approximately 17% of the total amino
acids  content  in  eukaryotes  represents  serine,  threonine and tyrosine residues.  These are the main target  of
phosphorylation events in eukaryotes and it is estimated that 700,000 different potential phosphorylation sites
might exist  (247). These factors (especially the stoichiometric amounts of phosphopeptides) impacts directly
tandem MS strategies which are used to fragment phosphopeptides (e.g., CID-IT and beam-type CID) to identify
the sequence, to localize the exact site of phosphorylation and to quantify the phosphorylation, respectively. 
1.2.5.1 Phosphopeptide Identification by Mass Spectrometry
The phosphate group of phosphopeptides provides a low-energy pathway upon precursor ion excitation.
This leads to a selective and preferred fragmentation at the phosphate group giving raise to non-sequence neutral
loss signals, and depleting sequence specific signals (e.g., b- or y-ions) at the same time. This hampers the ability
to identify and localize the phosphorylated amino acid exactly. 
For pS-peptides, two neutral losses at 98 or 80 Da lower than the precursor are frequently detected in
MS/MS spectra. These originate from the loss of H3PO4 ([M-P]) and HPO3 ([M-P80]), respectively. These signals
are often the major signals in tandem MS spectra of pS-peptides (CID-IT). pT-peptides show a lower extent of
neutral loss events compared to pS-peptide. However, these signals can yet dominate tandem MS spectra (181). 
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The neutral loss events observed for pS- and pT-peptides can be explained by several theories (181). The
charge-remote β-elimination reaction (248,249) predicts a transfer of the hydrogen (located at the α-carbon atom)
towards  the  phosphate  group,  which  allows  the  phosphoryl-moiety  to  leave  the  peptide  while  forming
dehydroalanine  (pS)  and  dehydroaminobutyric  acid  (pT),  respectively.  In  contrast,  the  phosphate  group  is
protonated directly in charge-directed fragmentation mechanisms (E2-elimination  and SN2-neighboring group
participation reactions (250,251)). E2-eliminations are characterized by abstraction of an acidic hydrogen on the
α-carbon by the neighboring carbonyl oxygen after the phosphate group has been protonated. In contrast, for SN2-
neighboring  reactions  the  phosphate  group  is  protonated  by  a  (protonated)  neighboring  amino acid,  which
induces a nucleophilic attack of the β-carbon by the amide carbonyl group onto the side chain of pS or pT.     
However, in experiments to confirm one of the proposed mechanisms, different results have been obtained,
so that neither theory can be excluded. Instead, a competition of both mechanisms (charge-remote and charge-
directed) is speculated, where the latter seems to dominate (181).   
For pY-peptides, the extend of [M-P] neutral loss events is less intense than [M-P80]. This is a consequence
of the aromatic structure and its influence onto the C-O-P bond. For pY-peptides, the C-O bond is stronger,
whereas the O-P bond is weaker compared to pS- and pT-peptides. This favors the loss of [M-P 80]. So far, the
exact mechanism for the neutral loss of HPO3 for pY-peptides is not understood entirely. It has been shown, that
protonated phosphotyrosine peptides do not undergo any neutral loss reaction in the absence of a basic residue
(252–254). In special cases, a signal at 98 Da below the precursor ion can also be monitored for pY-peptides.
However, this is more likely to incorporate a simultaneous loss of H2O alongside [M-P80]. An alternative theory
suggests the transfer of the HPO3 group from pY to an aspartic acid residue, which then cleaves H3PO4 (254).
Peptides containing pT, pS, and pY are subjected to a range of neutral loss reactions, the extent of which is
dependent  on  various  factors  such  as  (i)  amino  acid  sequence,  (ii)  precursor  ion  charge  state,  (iii)  proton
mobility, (iv) collision energy applied, (v) and the fragmentation type  (181). Additionally, the ratio of charge
state versus the number of arginine, lysine and histidine (basic amino acids) influences the neutral loss event. If
the total number of basic residues is smaller than the precursor charge state, the neutral loss occurs to a smaller
extent  (250).  This  may  be  explained  by  the  additional  proton,  which  is  available  favoring  alternative
fragmentation paths according to the mobile proton model. For beam-type CID, the extent of neutral loss events
is lower compared to CID-IT (255). This is due to the fact, that peptide ions are activated within a short period of
time. This does not allow rearrangement reactions and supports multiple cleavage events (256) as the energy is
distributed faster  and  preventing neutral  loss  reactions  at  the  same time;  whereas  slow heating  approaches
through resonant excitation favors low-energy pathways (CID-IT).      
The  intense  neutral  loss  signals  might  compromise  the  ability  to  determine  the  exact  site  of
phosphorylation. This includes the identification of site-determining ions, which are required to validate the
correct localized phosphorylation site (251). This process is complicated due to in gas phase re-arrangement
processes,  in  which  the  phosphate  group  is  transferred  to  another  serine,  threonine  or  tyrosine  upon
fragmentation (257). It has been shown, that the re-arrangement is facilitated if a protonated arginine is presented
and the phosphopeptide is fragmented by CID-IT (258).    
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Alternative techniques to determine the exact site of phosphorylations are MS3 and multistage activation
(MSA), which have also been used in large-scale phosphoproteomics studies (259–261). For MS3 experiments,
the product ions of the neutral loss events (mainly, [M-P] and [M-P80]) are isolated and subjected to excitation,
which  induces  a  higher  degree  of  backbone  cleavage  events  (262).  MS3 experiments  are  usually  triggered
automatically if neutral loss peaks are observed, to prevent an increase in overall cycle time (181). MSA, also
referred  to  as  pseudo-MS3,  combines  the  advantages  of  MS/MS  and  MS3 spectra  (263).  After  MS/MS
fragmentation, a subsequent activation step of the neutral loss fragment ion (e.g., [M-P]) is performed while
trapping the remaining ions in the ion trap. Finally, all ions are scanned out, which results in a spectrum lacking
the intense neutral loss signal. However, the benefit of MS3 and MSA is depending on the sample complexity as
it lowers the total number of MS/MS spectra that can be acquired in a specific time frame. In contrast to these
techniques, high resolution data (for example acquired in Orbitrap mass analyzers) seem to outperform these
techniques, as false-positive localizations are more likely to be excluded due to the improved mass accuracy and
resolution of sequence specific signals in MS/MS spectra (181). 
ETD and ECD are fragmentation techniques preventing the loss of labile groups, such as the phospho-
moiety (194,264–267). However, ETD and ECD require a higher cycle time and highly charged precursors ions
(density per mass) for efficient fragmentation. These represent conditions under which CID does not undergo the
intense neutral loss events, hampering the use of ETD and ECD for phosphopeptide identification (181). 
To complicate the situation of phosphopeptide analysis, the software used for automated interpretation of
MS/MS spectra influences the identification and determination of the exact site of phosphorylation. For example,
some tools can analyze only CID or ETD tandem MS data or favor one of them (268,269). 
Search engines such as Mascot, SEQUEST, OMSSA or X!Tandem do not incorporate the mass accuracy of
Orbitrap mass analyzers for score calculation. Moreover, none of these combines the complementary information
of CID-IT, beam-type CID and ETD, which diminishes the accuracy of identification and phosphorylation site
localization. MS-GF(DB) offers the possibility to combine CID and ETD spectra via p-values (269). However,
no  sequence  tag  prediction  model  is  implemented  which  is  adopted  to  the  different  fragmentation  pattern
observed for phosphopeptides upon precursor ion fragmentation.   
1.2.5.2 Phosphopeptide Quantification by Mass Spectrometry
Quantitative proteomics approaches can assess relative changes in phosphorylation such as deregulated
signaling  in  cancer  (270).  Isobaric  labeling  (iTRAQ  and  TMT)  are  frequently  applied  in  combination  to
phosphopeptide enrichment and their analysis by high-accuracy mass spectrometers such as the LTQ Orbitrap
XL. For this instrument, the collection of CID-IT (fast data acquisition) and HCD (no low mass cut-off) spectra
for identification and quantification, respectively, has been reported recently (211). To combine the advantages
of both, the low m/z region of HCD spectra have been merged with the CID-IT spectra by  in-house written
software. However, this approach does not take advantage of the high mass accuracy of HCD spectra to identify
and localize phosphorylation sites. 
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Further Needs and Obstacles in Quantitative Phosphoproteomics
To further benefit from hybrid MS instruments, such as the LTQ Orbitrap Velos with its newly designed
HCD fragmentation cell,  optimized instrumentation and data interpretation methods are required to identify,
localize the phosphorylation sites and accurately quantify phosphopeptides and their respective proteins. This
includes to elaborate the application of the new HCD fragmentation cells of the LTQ Orbitrap Velos, as its
fragmentation cell is now directly coupled to the C-trap and the Orbitrap mass analyzer to improve peptide
fragmentation and transferring fragment ions to the Orbitrap (compared to the Orbitrap XL; (271)). Compared to
the Orbitrap XL, the new linear ion trap (LIT) of the LTQ Orbitrap Velos uses a high pressure cell to fragment
peptides, and a low pressure cell to read-out the resulting ions (271). Acquiring CID fragment spectra in the ion
trap requires maximal 0.2 seconds, whereas those generated via HCD fragmentation requires up to one second
(Orbitrap mass analyzer; values can be adjusted in Thermo Scientifics software TunePage). In previous studies
using the Orbitrap XL to quantify iTRAQ labeled peptides (63), the prolonged time, which is required to record
HCD spectra,  was  only  invested  in  quantifying  peptides  by  generating  intense  iTRAQ  reporter  ions  upon
precursor fragmentation (at high NCE values of 75%). However, fragmenting phosphopeptides by HCD at well-
balanced NCEs to simultaneously provide accurate identification and quantification is an important aspect in
phosphoproteomics.
Using  optimized  fragmentation  conditions  to  identify  and  quantify  phosphorylated  peptides  is  also
important, as higher precursor charge states and more precursor charge state heterogeneities are observed upon
isobaric labeling (272). Higher charge states can impair phosphopeptide fragmentation events such as the nuetral
loss of the phospho-moiety and the generation of reporter and sequence specific ions (62,272,273). 
Beside optimizing instrumental MS parameters to fragment isobaric labeled phosphopeptides, quantitative
phosphoproteomics studies suffer from iTRAQ modification masses, which are not completely isobaric  (274);
and various tandem MS spectra, which cannot be assigned to peptide sequences (275). Using high quality HCD
MS/MS spectra  obtained  from the  newly  designed  HCD fragmentation  cell  of  the  LTQ Orbitrap  Velos  in
combination  with  sophisticated  computational  proteomics  algorithms  could,  at  least  partially,  solve  these
limitations to obtain more information about differentially regulated phosphoproteins. 
A major drawback of quantitative phosphoproteomics studies using isobaric labeling such as iTRAQ or
TMT is that their quantification relies on only a single peptide sequence; and frequently, only on a single PSM.
In addition, differentially regulated phosphorylation events of a phosphorylated protein do not follow to the
overall  protein ratio (that  is  usually the median of all  unique and quantifiable peptides),  which complicates
quantitative  phosphoproteomics.  Therefore,  establishing  methods  to  increase  the  number  of  quantifiable
phosphopeptides is another important aspect in phosphoproteomics. 
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The analysis of protein phosphorylation is still a challenge in mass spectrometry based proteomics due to
their low stoichiometry and the lability of the phosphate group upon CID fragmentation. The application of
software tools to automatically identify and localize the exact site of phosphorylation events has been studied
recently (276). However, the aspect of isobaric labeling to relatively quantify phosphopeptides, and the influence
of the isobaric tag on phosphopeptide identification has not been considered in this study (276).   
The  aim  of  this  dissertation  (chapter  2)  is  to  establish  a  platform  to  relatively  quantify  non-  and
phosphorylated  peptides  using  iTRAQ  on  the  LTQ  Orbitrap  Velos.  For  this  purpose,  different  aspects  of
proteomics will be joined together to optimize experimental and computational processes for identification and
quantification.
The LTQ Orbitrap  Velos,  which  will  be  used  throughout  this  dissertation,  offers  several  techniques  to
induce precursor ion dissociation, such as CID or HCD. In the first step, the process parameters to efficiently
fragment iTRAQ labeled peptides will be optimized. This includes the analysis of specific sequence ions to
accurately  identify  (phospho)peptides.  Additionally,  the  generation  of  intense  iTRAQ  reporter  ions  for
quantification has to be ensured. These inverse and conflicting demands will be evaluate systematically by the
application of CID and HCD fragmentation at different collision energy regimes (chapter 2.1).
The discrepancy to accurately calculate the in-silico precursor mass upon iTRAQ-4Plex labeling has been
described recently (274). Its influence on database searches will be evaluated systematically in chapter  2.2 by
analyzing the precursor mass accuracy after database searches at different iTRAQ reporter ions ratios. The final
goal is to present an alternative algorithm to improve the precursor ion mass calculation of iTRAQ-4Plex labeled
peptides.   
The decreased number of peptide identifications after database searches is an often criticized aspect of
relative quantification using iTRAQ labeling (63). Beside primary amines, iTRAQ can also react with hydroxyl-
groups of serine, threonine and tyrosine. To study the influence on peptide fragmentation and peptide separation
during  reversed  phase  chromatography,  iTRAQ tyrosine  modified  peptides  will  be  used  to  identify  unique
features to validate peptide identifications (chapter 2.3).  
To complement the establishment of a platform for relative quantification using iTRAQ, the optimized
conditions of the previous sections (chapter  2.1 -  2.3) will be combined into a novel analytical workflow to
relatively quantify phosphoproteins using iTRAQ (chapter 2.4). The new strategy focuses onto the parallel use of
four proteases to receive a high number of unique and quantifiable (phospho)peptides. This high number of
peptides  is  required  due  to  the  reduced  ability  to  identify  posttranslational  modified  peptides  (such  as
phosphopeptides) after iTRAQ labeling (62). Further, quantitative PTM analysis requires stable and reproducible
reporter ions ratios, as PTMs usually do not follow the overall quantitative protein profiling (62). An important
aspect of this workflow is to ensure compatibility between SDS-PAGE, iTRAQ labeling and phosphopeptide
enrichment. The advantages of this quantitative multi-protease strategy will be evaluated to accurately identify
and relatively quantify phosphopeptides using a mix of three multi-phosphorylated proteins.
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In addition to establish a platform to relatively quantify (phospho)proteins (chapter 2), the development of
computational proteomics tools for two side-projects to assist in reproducible and fasts data-analysis is another
aim of this dissertation (chapter 3). 
The aim of the first project of chapter 3 is to develop and establish a computational workflow to combine
protein identification results obtained from multi-database searches. The performance of each database search
engine and the advantages of combining multi-database searches will be evaluated. At the end of the first project,
the need of such a strategy to accurately identify proteins from an 5,300 years old wet-mummy, the Tyrolean
iceman Oetzi, will be highlighted (chapter 3.1).  
The second project of chapter 3 is related to identifying cleavage site motifs of uncharacterized proteases,
which is still a challenging task in analytical proteomics. In traditional bottom-up proteomics approaches, only
the peptide sequence C-terminal to the cleavage site is analyzed and identified by LC MS. The corresponding
peptide sequence N-terminal to the cleavage site can only be extracted from FASTA files containing the entire
proteome sequences of the investigated organism. However, manual cleavage site profiling is a time-consuming
and error-prone  process,  which  is  further  complicated  by peptide  sequence  homologous,  which  have  to  be
evaluate critically. The aim is of the second project of chapter 3 is to compile computational proteomics tools to
filter out non-significant peptides sequences, check for sequence homologies and finally to export the relative
abundance of each amino acid located next to the cleavage site (chapter 3.2).           
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2 Developing  a  Platform for relative  Quantification
using iTRAQ
Quantitative proteomics is a widely applied method of comparing two or more biological states to identify
differentially abundant  proteins.  Beside SILAC  (42),  which has  often been referred to  as  gold-standard for
quantitative proteomics, several studies using iTRAQ for (phospho)peptide and (phospho)protein quantification
have  been  published  (255,272,273,277).  However,  a  complete  shotgun  proteomics  workflow  for  relative
(phospho)protein quantification using isobaric tags depends on several different techniques, such as (i) sample
preparation, (ii) labeling, (iii) LC MS analysis, (iv) data interpretation, (v) data validation and (vi) statistical
analysis. 
Chapter 2 will cover most of these topics, whereas the focus is set considerably onto LC MS analysis and
data interpretation and their validation, starting with the optimization of MS acquisition conditions regarding
phosphorylated and non-phosphorylated peptide identification and quantification (chapter 2.1); the refinement of
precursor  mass  calculation  upon  iTRAQ-4Plex  labeling  (chapter  2.2);  the  discovery  of  unique  features  to
enhance peptide identification of iTRAQ tyrosine labeled peptides (chapter  2.3); and finally, the development
and establishment of a new workflow for relative quantification of phosphoproteins using multiple proteases in
combination to  SDS-PAGE and phosphopeptide  enrichment  (chapter  2.4).  The topic  (vi)  statistical  analysis
represents the end point of each relative quantitative shotgun proteomics experiment and is highly depending on
the sample source (e.g. whole cell lysate or SDS-PAGE purified proteins), its treatment (e.g., protease used for
protein digestion) and experimental plan (e.g., iTRAQ labeling schema including technical and biological replica
measurements). Therefore, this topic needs to be adapted to each sample individually, which is out of the scope
of this dissertation.
2.1 iEM – iTRAQ Evaluation Method1
2.1.1 Introduction 
For  phosphopeptide  identification,  both  ESI  and  MALDI  MS  are  commonly  applied.  For  peptide
fragmentation,  CID-IT and beam-type  CID have been  used  for  a  various  of  experiments,  although CID-IT
excitation forms an intense and characteristic neutral loss of H3PO4 (observed as [M-98/z]z+and referred to as [M-
P] in the following). This process hampers backbone fragmentation and complicates fragment ion matching due
to their depleted intensity. However, CID-IT is still a widely applied fragmentation method for phosphopeptide
identification as it is a sensitive and fast scanning technique (ion trap) improving the total cycle time required for
MS and MS/MS measurement. 
CID-IT is limited by the  1/3rd rule, not allowing to observe low m/z fragments. These signals can be a
certain class of potentially useful and interesting ions, e.g., immonium ion or iTRAQ reporter ions. Recently, a
1 Sections related to phosphopeptide analysis were published in J. Proteome Res. 2013, 12, 2755−2763
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new  beam-type  fragmentation  technique  (HCD)  was  developed  by  Thermo Scientific  and  is  nowadays  an
integral part of Orbitrap hybrid mass spectrometers. HCD does not suffer from the low-mass cutoff limitation, as
fragmentation (dedicated collision cell), ion accumulation (C-Trap) and acquisition (Orbitrap mass analyzer) are
performed in-space rather than in-time  (190). Accordingly, isobaric reporter ions (e.g., iTRAQ-4Plex reporter
ions at m/z 114 - 117) can be acquired with a high mass accuracy which allows to discriminate them from other
ions with similar m/z values. As CID-IT and HCD belong to LE-CID, their spectra are comparable, as they
predominantly generate b- and y-ions (271).
Several  studies  have  been  published  in  which  optimization  procedures  to  identify  and  quantify
phosphopeptide  using  iTRAQ  labeling  are  described  (255,273).  It  has  been  shown  that  both  processes
(identification and quantification) are highly depending on the precursor ion charge states. For doubly charged
precursors, the identification process is demonstrated to be only optimal in a narrow and lower collision energy
(CE) regime, whereas iTRAQ reporter ion intensity increases with elevated CE. However, these optimization of
process parameters has been performed with the Orbitrap XL, whereas the LTQ Orbitrap Velos (equipped with
ETD  support)  is  used  for  LC-ESI  MS  analysis  through  this  thesis.  One  of  the  primary  differences  (and
advantages) between the Orbitrap XL and the LTQ Orbitrap Velos is that a dual pressure linear ion trap is utilized
for  the LTQ Orbitrap Velos.  This separates  the  capturing and  detection process  of  ions,  which doubles  the
number of MS/MS spectra being acquired in the same time frame. Moreover, an integrated C-trap/HCD collision
cell facilitates the ion transfer efficiency by directly coupling the HCD collision cell with the C-trap and the
Orbitrap mass analyzer (271).      
The goal of this study is to optimize fragmentation conditions applied on the LTQ Orbitrap Velos to (i)
obtain an optimal sequence coverage for identification, (ii) detect phospho-specific fragment ions, (iii) allow for
targeted phosphorylation site mapping using a phosphopeptide standard with  a priori known phosphorylation
sites, (iv) enhance identification results (PSMs and XCorr) of non-phosphorylated peptides and (iv) to generate
reporter  ions  derived  from  isobaric  labeling  that  fulfill  the  requirements  for  accurate  quantification.  As
quantitative  phosphoproteomics  studies  require  datasets  of  both,  non-  and  phosphorylated  peptides  for
phosphoprotein quantification, the optimization process is also performed on two non-phosphorylated samples:
the first is a ten protein-mix with approximately 260 unique tryptic peptides. The second sample is a  peptide
digest of human macrophages.  
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2.1.2 Material and Methods
Chemicals used in this study are summarized in chapter 4.1.
2.1.2.1 Sample Preparation
Phosphopeptide Standard
A phosphopeptide standard composed of synthetic peptides, containing single peptides in microtiter plate
wells (Intavis, Cologne, Germany) was used in this study. Each lyophilized phosphopeptide was resuspended at a
concentration of approximately 1.5 pmol/μL in ultrapure water.  For online LC−ESI MS measurements,  two
different sample types were prepared. The first mixture (mix-1),  used for in-depth analysis, consisted of 12
phosphopeptides carrying pS-, pT- and pY-residues (Table 2-1). The second mixture (mix-2), used for validation
of observations obtained in the in-depth analysis, consisted of a complex mixture of 131 phosphopeptides (Table
2-2). Additionally, a selection of peptides from mix-1 were measured separately in offline mode (see Table 2-1).
Table 2-1: Peptides used for the semi-complex mix-1 (online measurement) with a tandem CID-MSA (ion trap)
and HCD (Orbitrap) method. After labeling, the ratio of the four different iTRAQ channels was 1:1:1:1.3 for
114:115:116:117.  Peptides  in  bold  were  used  for  offline  measurements  with  CID,  CID-MSA and  HCD  in
Orbitrap.
Sequence PhosphorylationType
Phosphorylation
Position
iTRAQ 
Labeling Usage
SRNSPLLER pS 1 114 offline/online
VYELMR pY 2 115 offline/online
VIEDNEYTAR pY 7 114 offline/online
STFHAGQLR pT 2 115 offline/online
ATSLPSLDTPGELR pS 6 116 offline/online
ADENYYK pY 6 - online
YMEDSTYYKASK pYpY 7&8 - online
GHLSEGLVTK pS 4 - online
GTVTPPPR pT 3 - online
VQTTPPPAVQGQK pT 3 - online
SRNSPLLER pS 1 - online
VYTHEVVTLWYR pT 3 - online
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Table  2-2: Peptides in complex mixture (mix-2) used for online measurements with a tandem CID-MSA (ion
trap) and HCD (Orbitrap) method. After labeling, the ratio of the two different iTRAQ channels was 1:0.75 for
114:116.
Sequence Phosphorylation Site/Position Sequence
Phosphorylation Site/
Position
AGGKPSQSPSQEAAGE
AVLGAK pS/ 6 ADENYYK pY/ 6
ALQKSPGPQR pS/ 5 DGSLNQSSGYR pY/ 10
AQSFPDNR pS/ 3 DIYSTDYYR pY/ 7
ATSLPSLDTPGELR pS/ 3 EALPMDTEVYESPYADPEEIRPK pY/ 10
ATSPEAGGGGGALK pS/ 3 EDAANNYAR pY/ 7
AVGMPSPVSPK pS/ 9 EPPPVVNYEEDAR pY/ 8
DKSPSSLLEDAK pS/ 3 EVGDYGQLHETEVLLK pY/ 5
DSPGIPPSAGAHQLFR pS/ 8 FSDQAGPAIPTSNSYSK pY/ 15
DSPGIPPSANAHQLFR pS/ 2 GHGQPGADAEKPFYVNVEFHHER pY/ 14
ESKSSPRPTAEK pS/ 4 GLPSDYGR pY/ 6
ETTTSPKKYYLAEK pS/ 5 GQEYLILEK pY/ 4
FGESDTENQNNK pS/ 4 HSWYHGPVSR pY/ 4
FGSLTMDGGLR pS/ 3 HTDDEMTGYVATR pY/ 9
FTNSETAEHIAQGLR pS/ 4 IKSYSFPK pY/ 4
GGFFSSFMK pS/ 6 KYSLTVAVK pY/ 2
GHLSEGLVTK pS/ 4 LIEDNEYTAR pY/ 7
GRGSRDALVSGALEST
K pS/ 4 LSYYEYDFER pY/ 4
GRRSPSPGNSPSGR pS/ 4 NSFNNAYYVLEGV-PHQLLPPEPPSPAR pY/ 8
HSIAGIIRSPK pS/ 9 SISLRYEGR pY/ 6
ILSDVTHSAVFGVPASK pS/ 3 TAGTSFMMTPYVVTR pY/ 11
IPLIKSHNDFVAILDLPE
GEHQYK pS/ 6 TIYVRDPTSNK pY/ 3
IQPAGNTSPR pS/ 8 VIEDNEYTAR pY/ 7
IQPSSPPPNHPNNHLFR pS/ 4 VKEEGYELPYNPATDDYAVPPPR pY/ 17
ISSLGSQAMQMER pS/ 3 VSPSPTTYR pY/ 8
KTSPLNFK pS/ 3 VYELMR pY/ 2
LPLTRSHNNFVAILDLP
EGEHQYK pS/ 6 VYHYR pY/ 2
LQPQEISPPPTANLDR pS/ 7 WTAPESLAYNK pY/ 9
LRSADSENALSVQER pS/ 3 YATPQVIQAPGPR pY/ 1
LTEERDGSLNQSSGYR pS/ 8 YELTGLPEQDR pY/ 1
MMSLSQSR pS/ 5 YIEDEDYYK pY/ 7
MPSHEAR pS/ 3 YMEDSTYYK pY/ 7
NFSAAKSLLNK pS/ 7 YSLTVAVK pY/ 1
NGSLKPGSSHR pS/ 8 YVLDDEYTSSVGSK pY/ 7
NIDQSEFEGFSFVNSEF
LKPEVK pS/ 11 YVLDDQYTSSSGAK pY/ 7
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Table 2-2 (continued): Peptides in complex mixture (mix-2) used for online measurements with a tandem CID-
MSA (ion trap) and HCD (Orbitrap) method. After labeling, the ratio of the two different iTRAQ channels was
1:0.75 for 114:116. (continued)
Sequence Phosphorylation Site/Position Sequence
Phosphorylation Site/
Position
RDSPPPPAR pS/ 3 AYTHQVVTR pT/ 3
RLSIIGPTSR pS/ 3 ETTTSPKKYYLAEK pT/ 2
RLSSFVTK pS/ 3 GTVTPPPR pT/ 4
RLSSTSLASGHSVR pS/ 3 LMTGDTYTAHAGAK pT/ 6
RPGAAASGERDDRGPP
ASVAALR pS/ 7 LQTVHSIPLTINK pT/ 3
RSMSPFRGPK pS/ 4 NSQPNRYTNR pT/ 8
RSPRPDHPGTPPHK pS/ 2 RLEEPEEPKVLTPEEQLADKLR pT/ 12
SDGGVKPQSNNK pS/ 9 STFHAGQLR pT/ 2
SEGSPVLPHEPAK pS/ 4 STGDPQGVIR pT/ 2
SESPPPLSDPK pS/ 3 STLVLHDLLK pT/ 2
SEVAVLSPEKAENDDT
YKDDVNHNQK pS/ 7 TAPTPPKR pT/ 4
SFNGSLKNVAVDELSR pS/ 1 THLGTGMERSPGAMER pT/ 1
SGGQRHSPLSQR pS/ 7 TSPLNFK pT/ 1
SINEKDYHSR pS/ 1 TYTHEVVTLWYR pT/ 3
SLESVLSLGPR pS/ 1 VGSLTPPSSPK pT/ 5
SLPAPQDNDFLSR pS/ 1 VQTTPPPAVQGQK pT/ 4
SNSTSSMSSGLPEQDR pS/ 3 VYTHEVVTLWYR pT/ 3
SPGPSSPKEPLLFSR pS/ 1 ARSRTPPSAPSQSR pSpS/ 3&8
SQERPTFYR pS/ 1 GISRSLESVLSLGPRPTGGGSSPPEIR pSpS/ 3&5
SQSDIFSR pS/ 1 RLSSTSLASGHSVR pSpS/ 3&4
SQSNPILGSPFFSHFDG
QDSYAAAVR pS/ 3 SFGSPNRAYTHQVVTR pSpT/ 4&10
SQSTSEQEK pS/ 1
TSSFAEPGGGGGGGG
GGPGGSASGPGGTGG
GK
pSpS/ 2&3
SRNSPLLER pS/ 4 TVSTSSQPEENVDR pSpS/ 3&5
SRTPPSAPSQSR pS/ 1 IGEGTYGVVYK pTpY/ 5&6
SSSFREMDGQPER pS/ 2 NSFNNPAYYVLEGVPHQLLPPEPPSPAR pYpY/ 8&9
SSSFREMENQPHK pS/ 3 PKPSNPIYNEPDEPIAFYAMGR pYpY/ 8&18
SSSPTQYGLTK pS/ 3 PTTGVILPSGNTLRVK pTpT/ 2&3
STVASMMHR pS/ 1 YIEDEDYYKASVTR pYpY/ 7&8
SVTLPRDLQSTGR pS/ 1 YMEDSTYYKASK pYpY/ 7&8
SVTSMERK pS/ 4 - -
TGMGSGSAGKEGGPF
K pS/ 5 - -
TVSTSSQPEENVDR pS/ 3 - -
VPASPLPGLER pS/ 4 - -
VSGRTSPPLLDR pS/ 6 - -
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For nano-ESI (offline) measurements, individual phosphopeptides were dried by vacuum evaporation and
resolubilized  in  0.1% FA.  To each  sample,  a  specific  iTRAQ reagent  (prepared  according  to  manufactures
protocol) was added, gently stirred, and incubated for 1 h at room temperature. Samples were dried down, then
resolubilized in labeling buffer (172 mM TEAB and 0.172 mM EDTA in 34% ethanol), and desalted via ZipTip
C18.  Cleaned samples  were dried by vacuum evaporation and resolubilized in 3% ACN with 0.2% FA. For
labeling of the semi-complex mixture (mix-1), peptides were combined and dried before being resolubilized in
labeling buffer and split into four equal aliquots. For iTRAQ labeling, each of the four samples was mixed with
one of the iTRAQ-4Plex reagents (114, 115, 116, 117), incubated at room temperature for 2 h, combined and
then dried by vacuum evaporation. For LC−ESI MS measurements, the sample was reconstituted in loading
buffer (3% ACN and 0.1% FA) prior to injection. For preparation of the complex mixture (mix-2), 10 μL of each
of the 131 phosphopeptides were combined. The sample was split into equal aliquots and labeled with iTRAQ
reagents 114 and 116, respectively. The iTRAQ labeling was performed according to manufactures instructions;
subsequently, samples were dried by vacuum evaporation and resolubilized in loading buffer prior to LC−ESI
MS injection and analysis.
Ten protein-mix
The  ten  protein-mix  contained  the  following  proteins:  cytochrome  c,  bovine  serum  albumin,
carboanhydrase, β-casein, lysozyme, myoglobin, ribonuclease a, transferrin, α-Lactoglobulin and β-lactoglobulin
(see Table 4-1 for further details). 
Of each protein, 0.1 mg was used to prepare a protein stock solution (diluted in H 2O), and 200 µg of the
stock  were  dried  by  vacuum evaporation  (speedvac,  30  min,  45°C).  Samples  were  resolubilized  in  40  µL
iTRAQ-4plex dissolution buffer (supplied in the iTRAQ-4plex kit by AB SCIEX), reduced (1 h at 60°C with 2
µL of Reducing Agent supplied by AB SCIEX) and alkylated with IAA (200 mM IAA, room temperature, 30
min, dark). To prevent trypsin inhibition, the sample volume was increased with a further addition of 12 µL
iTRAQ-4plex  dissolution  buffer.  Proteins  were  digested  in-solution  using  trypsin  (4  µg dissolved  in  8  µL
iTRAQ-4plex dissolution buffer) overnight at 37°C under shaking. 
For  iTRAQ  labeling,  a  new  buffer  was  prepared  (denoted  as  iTRAQ-4plex  labeling  buffer).  It  was
composed of 160 µL H2O, 160 µL iTRAQ-4plex dissolution buffer and 80 µL ethanol (supplied in the iTRAQ-
4plex kit).  The digested sample was dried by vacuum evaporation and filled up with 200 µL of the freshly
prepared iTRAQ-4plex labeling buffer resulting in a concentration of 1 µg/µL. To ensure complete rehydration,
the samples were mixed for 15 min at room temperature. Meanwhile, the vials containing the iTRAQ-4plex
labeling reagents were allowed to reach room temperature (5 min) and filled up with 70 µL of ethanol. 
The digested and rehydrated protein sample was split into four aliquots and 25 µL of iTRAQ-4plex reagent
was added to each. Labeling reaction took place for 1 h at room temperature followed by 1 h at 4°C. To obtain an
optimal  iTRAQ-4Plex  labeling,  the  samples  were  stored  at  -20°C for  24 h  prior  use.  Afterwards,  the  four
iTRAQ-4plex labeled samples were dried by vacuum evaporation and each sample was filled up with 100 µL of
3% ACN and 0.1% TFA in deionized water resulting in a concentration of 0.25 µg/µL. For LC-ESI MS analysis,
the samples were combined in a 1:1:1:1 ratio and 1.5 µL of sample was injected. 
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Biological Sample
The biological sample was a composition of three human macrophage samples, which were supplied by the
group  of  Norbert  Reiling,  Departement  Mikrobielle  Grenzflächenbiologie,  Forschungszentrum  Borstel,
Germany. Two of these samples were infected with different Mycobacterium tuberculosis strains (2335 & 7761),
whereas the third sample was not infected with a M. tuberculosis strain. After cell harvesting, all samples were
stored at -80°C prior use. To disrupt cells and extract proteins, the samples were treated five times with freezing -
ultra  sonication intervals  (freezing:  at  -80°C for  5  min;  ultra  sonication:  1  min intervals).  Additionally,  the
samples were once heated up to 95°C for 5 min, followed by a further ultra sonication step (1 minute). To pellet
the  cell  debris,  samples  were  centrifuged  (24,000  rpm,  15  min),  and  the  supernatant  of  each  sample  was
transferred to  new Eppendorf  tubes.  Ice-cold (-20°C) acetone  was added (six times the  sample volume) to
precipitate proteins (overnight, -20°C).  
To remove acetone, samples were centrifuged for 45 min at 14,000 rpm (Thermo Scientific Heraeus Fesco
21). The obtained protein pellet of each biological sample was redissolved in 100 µL iTRAQ-4Plex buffer. After
protein  concentration  determination  using  the  Bradford-assay,  50  µg  of  each  Mycobacterium  tuberculosis
infected sample was used for further processing. The control sample was used twice (control I & control II; each
50 µg). 
Samples were dried by vacuum evaporation, reconstituted in 20 µL iTRAQ buffer and reduced with 2 µL
reducing agent for 1 h at 60°C. After sample cooling to room temperature, 2 µL of alkylation agent were added
(200 mM IAA, room temperature, 30 min, dark). Proteins were digested with trypsin (2 µg dissolved in 10 µL
iTRAQ-4plex  dissolution  buffer)  overnight  at  37°C  under  shaking.  Samples  were  labeled  using  an  entire
iTRAQ-4Plex reagent vial for each of the four samples according to manufacture protocol. The iTRAQ labeling
schema is illustrated in  Table 2-3.  iTRAQ-4Plex reagent  was allowed to react  for  1h at  room temperature,
followed a further incubation at 4°C. Samples were stored at -20°C overnight to allow hydrolysis of remaining
iTRAQ-4Plex reagent prior usage.  
Table 2-3: Summary of the iTRAQ labeling applied for the biological sample.  
Sample iTRAQ Reagent
7761 ITRAQ-114
control I ITRAQ-115
2336 ITRAQ-116
control II ITRAQ-117
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2.1.2.2 Mass Spectrometry
Phosphopeptide Standard
NanoLC−ESI  MS experiments  were  performed  on  a  Dionex  U3000 (Dionex,  Idstein,  Germany)  nano
HPLC system coupled  online  to  a  LTQ Orbitrap  Velos  MS equipped  with  ETD (ThermoFisher  Scientific,
Bremen, Germany). Solvents used for LC separation at 300 nL/min were: solvent A: 0.05% FA, solvent B: 80%
acetonitrile (ACN) and 0.04% FA. For sample loading and desalting on a Acclaim Pepmap C18 300 µm x 10 mm,
5µm, 100 Å trap column, a solution of 3% ACN and 0.1% TFA was used (flowrate 30 µL/min). The semi-
complex  sample  (mix-1)  was  separated  using  a  linear  46  min  gradient  from  5%  B  to  50%  B  on  a
AcclaimPepMap 100 analytical  column (3 μm, 75 μm x 150 mm, Dionex,  Sunnyvale,  CA),  followed by a
column wash step (10 min) with a linear gradient from 50% B to 95% B. Inter-run equilibration of column was
set to 5 min. A tandem CID/HCD method was written using XCalibur (V 2.1): first, a full scan at a resolution of
30,000 with  activated  prescan  was  performed.  In  parallel,  the  3  most  intense  precursors  were  selected  for
fragmentation using CID in the ion trap. CID parameters were set to default (35% NCE), with the exception that
multistage  activation  was  enabled.  For  HCD,  resolution  of  Orbitrap  measurements  was  set  to  7,500.  The
activation time was 0.1 ms, default charge was set to 2+, wideband activation was disabled. Dynamic exclusion
was enabled for all runs. The NCE was varied from 0 to 85% NCE in 5% increments for HCD resulting in a total
of 18 LC runs. Each run was performed twice at each NCE value, however, in order to maximize the number of
selected precursors two dynamic exclusion list settings were used. In the first run, the repeat count was set to 2
with a repeat duration of 45 sec, with precursors selected for MS/MS set for dynamic exclusion for 60 sec. In the
second run, the repeat count was set to 3 with a repeat duration of 30 sec and precursors, selected for MS/MS,
were set for dynamic exclusion for 30 sec. 
For analysis of the complex mixture (mix-2) via HCD and CID, the NCE was varied between 0 and 85%
NCE in 5% steps. The NCE of HCD was 30% higher than for CID until reaching a value of 55%; above this
value,  HCD increased  from zero  in  5% steps  simultaneously with the  increasing CID-NCE.  Samples  were
separated using a linear 80 min gradient from 5% B to 60% B on a AcclaimPepMap 100 analytical column (3
μm, 75 μm x 150 mm, Dionex, Sunnyvale, CA) for the complex sample, followed by a column wash (up to 95%
B) and equilibration. For offline nano-ESI MS measurements, a top 1 method was applied in which the same
precursor was fragmented with CID, CID plus activated MSA (CID-MSA) and HCD with 0−85% NCE in 5%
steps. The repeat count was set to 1 with a dynamic exclusion duration of 5 min. This ensured all precursors with
a charge state higher than 1+ and an intensity >500 counts were selected for fragmentation. The measurement
was stopped manually after the precursor of interest was selected for NCE fragmentation series.
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Ten protein-mix
The same LC-ESI MS setup as for the phosphopeptide samples was used for the ten protein-mix. Samples
were separated using a linear gradient from 5% B to 50% B in 51 min, followed by a column wash step (10 min)
with a linear gradient from 50% B to 95% B. Inter run equilibration of the columns was set to 9 minutes. The
HPLC flow rates were 30 µL/min and 300 nL/min for the loading- and micro pump, respectively.  
A tandem CID/HCD method was written using vendors software: first, a full scan at 60,000 resolution with
activated prescan was performed. In parallel, the 5 most intense precursor ions were selected for fragmentation
using CID in ion trap. CID parameters were set to default. For HCD, resolution of Orbitrap measurements was
set to 7,500. The activation time was 0.1 ms, default charge was set to 2+, wideband activation was disabled.
Dynamic exclusion was enabled for all runs. The repeat count was set to 3 with a repeat duration of 20 sec and
precursors, selected for MS/MS, were set for dynamic exclusion for 30 sec. The NCE value was varied from 0 –
85% NCE in 5% increments for HCD and CID resulting in a total of 2 x 18 LC runs (2 technical injections of 1
µL)
Biological Sample
The same LC-ESI MS settings as for the 10 protein-mix were used, except that the LC gradient time was
prolonged (linear increase of 5% B to 45% B in 146 min, followed by a column wash step for 13 min with a
linear gradient from 45% B to 95% B). Inter run equilibration of the columns was set to 15 minutes.
2.1.2.3 Database Searches and Feature-Detection
Phosphopeptide Standard
For database searches, Proteome Discoverer 1.2 (Thermo-Fisher, San Jose, CA) and the search algorithm
SEQUEST was used. N-terminal and lysine-ε-amino iTRAQ were set as static modifications, and iTRAQ-4Plex
labeling at tyrosine, phosphorylation of tyrosine, threonine and serine, and oxidation of methionine, were set as
variable modifications. The precursor mass tolerance was set to 10 ppm with 0.02 Da fragment mass tolerance
for MS/MS measured via Orbitrap and 0.5 Da fragment mass tolerance measured via ion trap. The database that
was used contained all phosphopeptides from the phosphopeptide standard. 
To evaluate the dependence of normalized collision energy on the XCorr, no FDR filtering was used for the
offline measured samples. However, FDR filtering was applied for the semi- and complex samples (mix-1 and
mix-2, respectively) based on a 1% FDR and search engine rank equal to 1. 
In  the  first  step of  optimizing the  process  parameters,  the  offline measured  samples  were used.  Here,
SEQUESTs XCorr  was  used to  evaluate identification success  across  the NCE range for  the fragmentation
methods applied. Moreover, the m/z values and intensities of each peptide, dependent on NCE and fragmentation
method applied, were exported from XCalibur (Version 2.1) to Excel and processed using in-house VBA scripts
for  Excel  (2010,  64 bit  version).  The script  scans each  spectra  exported for  the precursor  ion (M + nH) n+
(abbreviation: [M]), the neutral loss fragments ([M-P] and [M-P80]), the pY immonium ion, the iTRAQ reporter
-41-
 2 Developing a Platform for relative Quantification using iTRAQ
ions at m/z 114 - 117, and the precursor fragment ions in charged reduced form (n − 1) resulting from loss of
iTRAQ. If a match (mass tolerance set to 0.01 Da) between the theoretical and experimental m/z value was
obtained, the corresponding intensity was set in relation to the most intense fragment ion present in spectra
Equation 2-1. These values were then used to generate the plots shown (Figure 2-5). 
Normalized Intensity (x)=
Intensity (x)[Counts ]
Base Peak [Counts]
Equation 2-1
Moreover, ions of interest (x) were normalized (Equation 2-2) against cumulative counts for all reported
ions within each spectrum (inter alia Figure 2-11).
Relative Intensity (x)=
Intensity (x) [Counts ]
∑
y=100
y=2000
Intensity(y)[Counts]
Equation 2-2
A computer-assisted approach using an  in-house VBA script for the semi-complex sample (mix-1) was
applied. Here, the m/z and ion intensity counts were exported from .mgf files created by Proteome Discoverer
1.2 (signal-to-noise filter was set to 0). To be independent of the identifications reported by SEQUEST for higher
NCE values,  the following criteria (information obtained by scan header in .mgf file) had to be fulfilled to
recognize a precursor selected form MS/MS as a hit:  precursor mass deviation ≤ 10 ppm, correct precursor
charge  state,  and  retention  time  deviation  <  2.5  min  around  individually  predefined  values  (obtained  by
averaging the retention time and precursor mass across all LC runs). If all criteria were met, information for the
fragment ions being searched for was exported to separate text files and then plotted (Figure 2-8,  2-10 & 2-11). 
The approach described above was used to process the data of the complex sample (mix-2), except that the
precursor fragment ions in charged reduced form (n − 1) resulting from loss of iTRAQ was not monitored.
However,  due to  the higher  number of  peptides  present  (about  20 times  higher),  this  data  set  was used  to
correlate the identification success by SEQUEST against peptide identification and correct phosphorylation site
mapping. Therefore, peptide identifications were filtered (FDR < 1% and Rank = 1) and exported. This data set
was further split into correctly and incorrectly mapped phosphorylation sites. Further, these sub- data sets were
split  into  activation  type  (CID  or  HCD)  and  charge  state  (2+,  3+).  Afterwards,  for  each  NCE  value  the
corresponding number of peptide hits (having the same modification form) was summed and used to generate the
plot of correctly and incorrectly identified modifications  (Figure 2-7). Furthermore, the normalized intensities
obtained from .mgf files for the 2+ and 3+ charged precursors for pS-, pT- and pY- peptides were grouped and the
average values for the identified peptides calculated. The dependency of the normalized intensity to NCE was
plotted for the precursor, neutral loss ([M-P] and [M-P80]), pY immonium ion, non-dissociated iTRAQ and the
iTRAQ reporter ions 114 and 116 Figure 2-13).
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Ten protein-mix
For database search using Proteome Discoverer 1.4, a custom build workflow was utilized, which is shown
in Figure 2-1. 
Figure 2-1: Workflow utilized for database search in Proteome Discoverer. The default setting of each node (e.g.,
Spectrum Files) was used if not otherwise specified: (0) Spectrum Files to load in the .raw files; (1) Spectrum
Selector  (pre-slicing  and  filtering  of  MS  and  MS/MS  data);  (2)  MS2-Spectrum  Processor  (deisotope  and
deconvolute), (3) & (7) Scan Event Filter (to split into CID and HCD fragmentation data); (4) & (8) SEQUEST
HT (search algorithm settings, see below); (5) phosphorRS 3.0 (an algorithm to assign phosphorylation sites);
(9) Reporter Ions Quantifier (iTRAQ-4Plex (Thermo Scientific Instruments; Integration Tolerance 20 ppm; Most
Confident  Centroid  as  Integration  Method;  Additional  Settings:  Show the  Raw Quan  Values;  Apply  Value
Corrections,  use  All  Peptides  enabled  and  deactivated  Experimental  Bias);  (10)  Event  Detector  (filter  for
precursor  ion  settings);  (11)  Precursor  Ions  Area  Detector  (reports  XICs  of  identified  peptides);  and  (12)
Percolator (for peptide validation and filtering). 
For database searches using the search engine SEQUEST HT, the reference proteome (see UniProt for
further description) of Escherichia coli (without isoforms, downloaded December 2013) plus cRAP like proteins
(see chapter 4.3), the 180 phosphopeptides of the phosphopeptide-mix and the proteins from the ten protein-mix
were merged into an  in-house build FASTA file (referred to as bF-FASTA; see chapter  2.4.2.3), with a total
number of 4,526 proteins. Enzyme specificity was set to trypsin (full), with a minimum and maximum peptide
length of 4 and 144, respectively. Precursor mass tolerance was set to 10 ppm, 0.3 Da for CID and 0.02 Da for
HCD fragmentation ions. The maximum number of dynamic and equal modifications per peptide was limited to
12 and 8, respectively. Phosphorylation (S, T & Y) and oxidation (M) were set as variable modifications. Static
modifications included iTRAQ-4Plex (peptide N-terminus and K), and carbamidomethylation (C). PSMs were
filtered for high confidence (1% FDR) and exported as .xlsx file. 
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Feature-Detection for Identification
The exported PSMs were processed using in-house build VBA (Excel 2013, 64 bit and GAMBAS Version
3.5.3) scripts. At first, the XCorr, the number unique and total peptides (same m/z value) were extracted. For
peptides with equal m/z values (Δmax= 0.1 Da) and sequence, the corresponding XCorr for each NCE value (0 to
85%, 5% increments), precursor charge state and fragmentation type (CID, HCD) were averaged. Additionally,
the corresponding number of  PSMs was  summed up for  each peptide,  fragmentation type and NCE value,
respectively. The intermediate results were exported to a .txt file and further processed with GAMBAS (Version
3.5.3). In order to count the number of unique and totally identified peptides (PSMs), a master-list was created
including each identified (unique) peptide (m/z, sequence and charge state dependent). According to this list, the
features for each NCE value (if available or as blank if no match was found) was added to the master-list and
exported as .txt  files.  For each charge state  and fragmentation type,  a  separate list  was created,  which was
simultaneously utilized as an input-file being fully compatible with QtiPlot (ProIndep Serv S.r.l., Version 0.9.8.9
svn 2288). Finally, the number of unique (x10 for sophisticated visualization) and total peptides (PSMs) were
plotted (right y-axis) versus the applied NCE. Additionally, a Whiskers-Box-Plot with 25, 50 and 75% (box);
max (upper cross) and min (lower cross);  mean (rectangle); and 5 and 95% (vertical lines) was created for the
XCorr (y-axis) as a function of the NCE value (see Figure 2-14). 
Feature-Detection for Quantification  
For quantification, the same VBA workflow as applied for the phosphopeptide-mix was used to extract the
iTRAQ reporter ion raw, normalized and relative intensities. The quantification features (normalized-, relative
and absolute intensity) of each NCE value and each peptide groups (same m/z charge state and NCE, only HCD)
were merged and plotted in a Whiskers-Box-Plot (Figure 2-16). Additionally, the median of the raw iTRAQ
intensity of each charge state (2 – 4+) was calculated and plotted versus the NCE value applied (Figure 2-21). 
To determine the average length of peptides identified as a function of NCE and charge state (2 – 4 +; Figure
2-15), the number of PSMs for each unique peptide (HCD only and NCE value, respectively) was divided by the
total number of PSMs observed (HCD and each NCE value, respectively). This value was multiplied with the
length (amino acid number) of the monitored peptide (Equation 2-3). To get the averaged peptide length over all
peptides, the sum of all peptides lengths was calculated (Equation 2-4).
Peptide Length (x)=    PSMs(x)
∑ PSMs(x)
×AA Equation 2-3
Peptide Length=∑ Peptide Length(x) Equation 2-4
  x : Peptide from the master-list
AA: Number of amino acids for peptide (x)
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Biological Sample
The same database settings of the ten protein-mix were used for the biological sample (macrophages with
and without infection of  Mycobacterium tuberculosis). Solely, the FASTA file was exchanged by an  in-house
merged FASTA file of human and  M. tuberculosis FASTA files. For both, the reference proteomes including
protein isomers were downloaded from UniProt on 2013.02.11. The taxon identifier  was 9606 and 1773 for
human and M. tuberculosis, respectively.
Variable modification of phosphorylation (S, T, Y) was deactivated, as no phosphopeptide enrichment was
preformed. Deamidation of asparagine and glutamine was activated, as these were common modification for M.
tuberculosis infected human macrophages (278,279). 
Feature-Detection for Identification
Firstly, peptides retention times were averaged based on identical peptide features (sequence, modification,
m/z, charge state) to create a master file containing (averaged) information about all peptides identified. This list
was compared with identified peptides of each raw file (CID and HCD identifications were treated as identical).
For every PSM, the averaged retention time from the master list and the retention time of each raw file were
exported. Both values were plotted to check for retention time shifts. 
For all files, a linear re-calibration was performed to re-calibrate the retention times. In order to re-calculate
the retention times in the raw files, the raw files (binary) were exported into (text-based) .mgf files for CID and
HCD activation, respectively. Each retention time within the .mgf file was read in, re-calibrated using its specific
linear re-calculation term and exported as a new .mgf file. The re-calibration approach will be described in detail
in the results chapter 2.1.3.3. 
The re-calibrated .mgf files were finally used for database searches applying the same workflow as before.
However, as CID and HCD .mgf files were used as input files, in which the information about the fragmentation
type is not included, the database searches were run separately for CID and HCD, respectively. The .msf files of
Proteome Discoverer were opened together. Finally, the PSMs were filtered (1%FDR) and exported to .txt files.
These were processed as described in the ten protein-mix section.  
Feature-Detection for Quantification  
The peptide identifications and .mgf files after re-calculation were used for processing. The same workflow
as for the ten protein-mix was applied. 
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2.1.3 Results
The  three  different  samples  (phosphopeptide  standard,  ten  protein-mix  and  biological  sample)  were
independently analyzed to extract identification and quantification features. 
For the phosphopeptide standard, the detection of phosphorylation specific signals (e.g., neutral loss) in
dependence of the NCE was an important aspect for peptide identification. Additionally, the intensity of iTRAQ
reporter ions was linked to the collision energy to determine the optimal NCE trade off to identify and quantify
phosphopeptides.  
The ten protein-mix was used to establish and validate the newly in-house compiled tools. Moreover, it was
used to characterize the number of unique peptides, PSMs and the XCorr distribution via different collision
energies applied for non-phosphorylated peptides.
   The biological sample (infected human macrophages) was a highly complex sample in terms of MS/MS
spectra recorded per LC-ESI MS run, including a variety of different precursor ion intensities, peptide sequence
lengths and amino acid compositions. This complex sample was used to validate the previously findings of the
phosphopeptide- and ten protein-mix.  
2.1.3.1 Phosphopeptide Standard
For simultaneous identification and quantification of phosphopeptides using isobaric labeling approaches,
different fragmentation events have to be induced: (i) the fragmentation of peptide backbone to form sequence
specific (e.g., b- and y-ions) and phospho-specific ions (e.g., pY immonium ions at m/z 216.04 and low intensity
neutral loss derived signals), and (ii) the formation of isobaric labeling derived reporter ions with sufficient ion
statistics to guarantee accurate quantification results. These events undergo different fragmentation mechanisms,
which, together with the different energies of the cleaved chemical bonds, lead to different energy requirements.
The aim was to determine at which Normalized Collision Energies the different events occur and to find optimal
MS/MS conditions to satisfy the needs of all events. For this purpose, nano-ESI and LC-ESI MS experiments
using  CID,  CID  plus  multistage  activation  (CID-MSA),  and  HCD  were  performed  using  iTRAQ  labeled
synthetic phosphopeptides. The focus was set to precursor charge states 2+ and 3+ as these ions contributed to at
least 80% of all spectra recorded in the phosphopeptide data sets.  
Influence of NCE on Peptide Sequence Assignment
In the first step of optimizing and analyzing the NCEs required for optimal phosphopeptide identification,
three different experimental setups were tested: CID, CID-MSA and HCD. For this purpose, five iTRAQ labeled
phosphopeptides from mix-1 were individually analyzed by offline nano-ESI-Orbitrap MS with NCE values
ranging from 0 to 85%. Application of high resolution and high mass accuracy Orbitrap MS to acquire peptide
MS/MS spectra derived from CID, CID-MSA, and HCD enabled to compare directly the fragmentation patterns
among  three  different  fragmentation  types;  this  overcomes  limitations  accompanied  with  the  use  of  low
resolution ion traps. 
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Figure 2-2: Offline MS/MS measurements in Orbitrap of the iTRAQ labeled phosphopeptide i115-SpTFHAGQLR.
(A) CID, 2+ charged precursor at m/z 620.8; (B) CID, 3+-charged precursor at m/z 414.2. Fragments labeled
with an asterisk (*) have lost a charge. The fragment ion b92+-P shares the same mass as the signal derived from
the precursor including a neutral loss of the phospho-moiety [M-P] and a subsequent loss of water (18/z). 
The 2+ and 3+ charged precursors of peptide i115-SpTFHAGQLR, labeled with iTRAQ reagent 115, were
used as an example for pS- and pT-peptides. The neutral loss of 98/z ([M-P]) represented the most intense peak
in CID fragmentation mode (NCE range 25−85%) for both 2+ and 3+ charged precursors (Figure 2-5 (A, B)). For
both precursor  charge  states  SEQUESTs XCorr  remained  constant  over  the  NCE range of  25−70% due to
SEQUEST matched only a few fragment ion signals (b2+ to b5+; y4+ to y7+; Figure 2-2 (A)) alongside the neutral
loss signals [b9+(-P) equals the precursor mass with subsequent loss of water], while for the 3+ charged precursor,
four y-ions and five b-ions could be matched (Figure 2-2 (B)). The high intensity of the neutral loss signal ([M]-
P]) and poor backbone fragmentation (< 20% compared to neutral loss signal) for CID fragmentation in the ion
trap is illustrated in  Figure 2-2 at an NCE of 35%. Typical for CID, the energy is distributed via the peptide
backbone,  leading  to  breaking  the  weakest  bond  (inducing  the  intense  [M-P]  signal)  rather  than  peptide
backbone fragmentation. To overcome this problem, multistage activation (MSA) was introduced (263).
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In  contrast  to  traditional  MS3,  in  which  the  neutral  loss  fragment  is  isolated  and  used  for  further
fragmentation, the MSA approach stores both, the fragment ions of the MS/MS scan and fragments generated by
a further fragmentation (MS3) of the neutral loss ion. All ions are read out collectively in the ion trap, leading to
spectra referred to as pseudo MS3, as they are a combination of both, MS/MS and MS3 experiments. Using CID-
MSA, the spectra from the 2+ charged precursor were dominated by the neutral loss signal of [M-P] at low NCE
values  (Figure  2-5 (C)).  Increasing  the  NCE  further  resulted  in  the  neutral  loss  signal  decreasing  below
detectable limits. Instead of the neutral loss signal dominating CID spectra, a further loss of 18/z, potentially by
dehydration of the adjacent serine, from the neutral loss fragment [M-P] occurred and dominated spectra when
NCE values of 35 to 50% were applied (Figure 2-5 (C)). For iTRAQ labeled peptides, a precursor fragment ion
had been described previously, which loses iTRAQ and is charge reduced (63). Accordingly, precursors which
had lost the H3PO4  can lose the isobaric tag (144/z + H+) in addition, which was monitored at low collision
energies ([M-P-iTRAQ]* and [M-P-iTRAQ-H
2
O]* in Figure 2-3 (A)).  
Figure 2-3: Offline MS/MS measurements in Orbitrap of the iTRAQ labeled phosphopeptide i115-SpTFHAGQLR.
(A) CID-MSA, 2+ charged precursor at m/z 620.8; (B) CID-MSA, 3+ charged precursor at m/z 414.2. Fragments
labeled with an asterisk (*) have lost a charge. 
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For NCE values below 25% no identification results were obtained. NCE from 25 to 45% predominantly
matched the y4+ − y7+ and b2+-P and b3+-P ions at sufficient ion intensity (Figure 2-3), while at higher NCE values
(>55%), backbone fragmentation increased and more b-series fragment ions appeared. The precursor fragment
ions [M-P-iTRAQ] and [M-P-iTRAQ-H2O] were detectable above an NCE of 25% and increased with increasing
NCE. Similar  to CID,  the XCorr for  CID-MSA remained constant  over the NCE range applied. For the 3+
charged precursor, the neutral loss intensity distributions of [M-P] and [M-P80], are similar to that for the 2+
charged precursor (Figure 2-5).
For HCD, the neutral loss signals of [M-P] and [M-P80] showed a maximum intensity at 35% NCE (Figure
2-5 (E)) while the curve shape is more similar to CID-MSA than to CID. For the 2+ charged precursor after HCD
excitation, fragment ion matching performed by SEQUEST showed a different behavior compared to CID and
CID-MSA. For NCE values < 35% no fragment ions could be mapped. For the NCE values of 40 and 45%, the
majority of the y-ion series was mapped, along with several from the b-ion series (Figure 2-4). Increasing the
NCE to 50 and 55% a decreased number of ions was mapped. For NCE values >55%, mainly the b1+ and y1+ ions
remained observable. For the 3+ charged precursor, the assigned fragment ions for NCE values of 40 to 60%
were identical. Increasing the NCE further led to peptide backbone fragmentation resulting in internal ions and
immonium ions at the low m/z region. Comparison of the resulting XCorrs for fragments matched for the 2+ and
3+ charged precursors, revealed that the bell shape like curve for the 2+ charged precursor is primarily due to the
higher number of ions being mapped at NCE values 35 − 60%. In contrast, more fragment ions can still be
matched at higher NCE values for 3+ charged precursors. 
Two pY-peptides were analyzed by offline-nano-ESI (Figure 2-6). Consistent with previously published
findings (181), the peptide i115-VpYELMR, when subjected to CID fragmentation, generated an intense neutral
loss signal of [M-P80]. This ion represents the most intense signal for NCE values higher than 25%. The intensity
of the neutral loss signal of [M-P] is approximately 20% of the [M-P80] signal. However, contrary to the previous
findings, the intensities of both the [M-P] and [M-P80] ion signals produced by the peptide i114-VIEDNEpYTAR
were comparable which might be the result of an additional neutral loss of water. Using CID-MSA, the number
of fragment ions matched was comparable to CID; however, the neutral loss signals of [M-P] and [M-P80] were
reduced. For HCD fragmentation of the pY-peptides, the neutral loss signal of [M-P80] was detectable, and the
XCorr values followed the same trend as with the pS- and pT-peptides, with the maxima centered at 45% NCE.
The intensity of the important modification-specific and diagnostic pY immonium ion at m/z 216.04 (190) was
also found to increase with increasing NCE. For these two peptides, a NCE of 35−40% was required to detect the
diagnostic pY immonium ion in spectra. 
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Figure 2-4: Offline MS/MS measurements in Orbitrap of the iTRAQ labeled phosphopeptide i115-SpTFHAGQLR. 
(A) HCD, 2+ charged precursor at m/z 620.8; (B) HCD, 3+ charged precursor at m/z 414.2. Fragments labeled 
with an asterisk (*) have lost a charge. The green labeled signal at m/z 110 (left to iTRAQ-115 (B)) belongs to 
the histidine immonium ion.  
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Figure 2-5: Dependence of ion intensities and XCorrs of labeled phosphopeptide i115-SpTFHAGQLR acquired in
offline nano-ESI-Orbitrap MS on the  NCE. (A) CID, 2+ charged precursor at m/z 620.8; (B) CID 3+  charged
precursor at m/z 414.2; (C) CID-MSA, 2+; (D) CID-MSA, 3+; (E) HCD, 2+; (F) HCD, 3+.
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Figure 2-6: Offline MS/MS measurement of tow iTRAQ labeled, 2+ charged pY-peptides i115-VpYELMR (A, C, E),
m/z 517.7; and i114-VIEDNEpYTAR (B, D, F) at m/z 717.3. (A, B): CID; (C, D): CID-MSA; (E, F): HCD.
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Phosphorylation Site Mapping
Database  search  algorithms  such  as  SEQUEST,  Mascot,  X!Tandem,  and  OMSSA  allow  automatic
evaluation for the quality of Peptide-Spectrum-Matches, enabling to process a large number of spectra rapidly.
However,  correct  and confident  identification of the phosphorylation amino acid,  particularly assignment of
closely spaced or adjacent phosphorylation sites, remains challenging. Furthermore, interference from noise and
impurities during the precursor selection process can result in inaccurate assignments (280). The use of Mascot
Delta Score (MD-score) has been proposed to evaluate the false-positive phosphorylation site localization results
searched by MASCOT (276,281), while in conjunction with SEQUEST search results, a probability based score,
termed ambiguity score (Ascore), has been introduced as a cutoff value to determine if a phosphorylation site has
been correctly assigned (282). These scoring algorithms were not applied in this study, to be consistent with the
results described above using SEQUEST XCorr. 
For this purpose, data acquired from mix-2 (131 iTRAQ labeled phosphopeptides) were searched with
Proteome Discoverer/SEQUEST. The rank 1 peptide hits with FDR < 1%, acquired either by HCD or CID-MSA-
IT (acquired in the ion trap mass analyzer), were exported to Excel for examining the phosphorylation site(s)
mapped by SEQUEST and summarized according to the peptide charge states and the fragmentation types in
relation to the NCE applied (Figure 2-7). As expected by the XCorr distribution (Figure 2-5 (C)) for 2+ charged
precursors fragmented by CID-MSA, the number of identifications remained almost constant over a wide NCE
range (25−70%), with a maximum at 45% NCE. This value also represented the optimal ratio for correctly vs
incorrectly assigned phosphorylation sites (see Figure 2-7). In the NCE range of 25 − 70%, a larger number of 2+
charged  compared to  3+ charged precursors  were identified.  This  is  possibly due to  the charge distribution
observed in these measurements (50% and 31% for 2+ and 3+ charged precursors, respectively). Furthermore, the
number of phosphopeptides with incorrectly mapped phosphorylation sites is at least equal than the 2+ charged
precursors.  For  HCD,  a  higher  dependency  on  the  NCE  applied  can  be  observed  for  2+ and  3+ charged
precursors. For 2+ charged precursors, the optimal NCE value lies between 35 and 45% NCE. For 3+  charged
precursors, the optimal values were shifted to  40 - 50% NCE. However, as observable by the XCorr behavior
(Figure 2-5 (E, F)), the 2+ charged precursors are more sensitive to the applied NCE values than the 3+ charged
precursors.   
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Figure  2-7: Comparison of the number of peptide identifications (ID) of mix-2 between correct (blue; lower
number) and incorrect  mapped phosphorylations sites (orange; upper number) at different NCE values.  (A)
CID-MSA, 2+ charged precursors; (B) CID-MSA, 3+; (C) HCD, 2+; (D) HCD, 3+. The first number represents
correct and the second number the incorrect identifications.  
Influence of NCE on Phosphopeptide Quantification 
Protein  quantification  with  iTRAQ labeling  is  based  on  the  generation  of  specific  reporter  ions  after
MS/MS fragmentation. Furthermore, for proper quantification, sufficient ion statistics (i.e., peak intensities) of
the reporter ions is a critical parameter. To obtain high signal intensities for reporter ions in the low m/z region,
high NCE values can be applied. However, this is accompanied by a loss of signal intensities and sequence
information in the middle to high m/z region (63). Furthermore, the acquisition time for HCD (up to 1 sec) is
much higher than for CID-IT (ion trap, 0.1−0.2 sec) for the LTQ Orbitrap Velos (see  Figure 1-12). Also, as
shown above, the application of HCD at high NCE values negatively affects both peptide identification and
phosphorylation site mapping. 
A further aspect was to determine which NCE value should be applied for proper quantification of iTRAQ
labeled phosphopeptides. For this purpose, four equal amounts of mix-1 were labeled individually with iTRAQ-
4Plex reagents before combining and performing LC−ESI MS analysis using HCD fragmentation, and Orbitrap
MS/MS detection. The iTRAQ reporter ion (114−117) raw intensities were exported from the .mgf file and
further processed with the in-house scripts (VBA) to calculate the averaged normalized iTRAQ signal intensity,
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the averaged relative iTRAQ signal intensity, the iTRAQ ratio (114 set as the denominator), and the standard
deviation calculated for each data point. The peptide i114-117-SpTFHAGQLR (Figure 2-8) is used as an example for
discussion. 
For the 2+ charged precursor,  no iTRAQ reporter  ion signals  were observed at  NCE below 30%. The
averaged relative intensity of iTRAQ reporter ions rose sharply between NCE of 30 − 40%, and reached a
maximum at  NCE of  45  ±  5%,  decreasing  gradually  with  higher  NCE (Figure  2-8 (A)).  The  decrease  of
normalized iTRAQ reporter ion intensities at NCE above 55% was mainly due to the strong immonium ion of
histidine (m/z at 110.072 Da) which dominated the spectrum at higher NCE. The relative intensity of iTRAQ
reporter ions remained constant at NCE of 55 − 85% (Figure 2-9 (A)). Along with the iTRAQ reporter ions, the
release of the intact protonated isobaric tag (m/z 145.10) was monitored. As expected by the maxima at 40%
shown for [M-P-iTRAQ] the non-dissociated iTRAQ also showed maximal intensities at the same NCE (Figure
2-8 (A)). 
As the presence of the histidine immonium ion reduces the impact of iTRAQ reporter ions as most intense
signals in spectra at  higher NCE values,  confirmation of the observable trends was assessed using two pY-
peptides  without  histidine  (i114-117-VpYELMR  and  i114-117-VIEDNEpYTAR).  Again,  the  normalized  iTRAQ
reporter ion intensity reached its maximum at 45% NCE (Figure 2-10). 
For the  3+ charged  precursor  (Figure  2-8 (B)),  a  markedly different  curve  shape  was observable.  The
intensity did not increase in the same manner, instead the intensity (compared to base peak) increased linearly
with NCE. The isobaric tag signal at m/z 145.10 had a lower intensity in comparison to the 2+ charged precursor.
This might be due to the overall low intensity of the iTRAQ signal.
Figure  2-8: Quantitative analysis of the peptide i114−117-SpTFHAGQLR in dependence of NCE applied in HCD
measurements; (A) 2+ and (B) 3+ precursor ion charge state.
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Figure  2-9:  Online  LC-ESI  MS  measurements  of  the  iTRAQ  labeled  phosphopeptide  i114-117-SpTFHAGQLR
fragmented by HCD in dependence on the NCE. (A, B) relative intensities; (C, D) normalized intensities; for the
2+ charged precursor m/z 620.8 (A, C) and 3+ charged precursor (B, D) at m/z 414.2.
Figure 2-10: Comparison of normalized iTRAQ reporter ion intensities, the protonated non-dissociated isobaric
tag  (iTRAQ  +  balancer  group)  at  m/z  145.10  and  the  corresponding  iTRAQ  ratios  (reporter  ion  114  as
denominator) depending on NCEs for HCD fragmentation for the 2+ charged precursors of peptides (A) i114-117-
VpYELMR and (B) i114-117 -VIEDNEpYTAR.
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Additionally, the generation of iTRAQ reporter ions from the pS-peptide i114-117-GHLpSEGLVTK for both
the 2+ and 3+ charged precursors are illustrated (Figure 2-11). Again, the normalized iTRAQ reporter ion intensity
reached its maxima at an NCE of 45 − 50% for the 2+ charged precursor and remained stable. However, for the
3+ charged precursor, the histidine effect to replace iTRAQ reporter ion signals as most intense signals observed
for  the  i114-117-SpTFHAGQLR  peptide  was  notably  reduced.  In  agreement  with  the  majority  of  other
phosphopeptides, the iTRAQ reporter ions represented the most intense signal at NCE values greater than 60%.
Further,  the sensitivity and precision of iTRAQ ratios obtained at different NCE values was evaluated. The
iTRAQ ratio for the 2+ charged precursor remained constant and showed only a small standard deviation for
NCE values >30%. In contrast, the iTRAQ ratio for the 3+ charged precursor was more variable with a larger
standard deviation (Figure 2-8 (A, B) or Figure 2-11 (E, F)). When the ratios of the other peptides analyzed were
taken  into  account,  an  NCE  value  of  55%  represents  the  minimum  value  required  for  accurate  iTRAQ
quantification of 3+ charged phosphopeptides.
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Figure 2-11: Online LC-ESI-MS/MS measurements of the iTRAQ labeled phosphopeptide i114-117-GHLpSEGLVTK
fragmented by HCD. (A, B) relative intensities; (C, D) normalized intensities; (E, F) the corresponding iTRAQ
ratios (reporter ion 114 as denominator), for the 2+ charged precursor at m/z 704.9 (A, C, E) and the 3+ charged
precursor (B, D, F) at m/z 470.3.
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The Compromise Between Identification and Quantification of Phosphopeptides
As described above, the requirements for both identification and quantification follow inverse trends, being
optimal at considerably different NCE values. To determine the optimal NCE for simultaneous identification and
quantification via HCD while performing CID-MSA-IT for identification in parallel a complex peptide mixture
(mix-2) containing 131 phosphopeptides was analyzed. The normalized signal intensities of the precursor and
fragment ions described before were plotted for pS-, pT- and pY-peptides for both 2+ and 3+ charged states
(Figure 2-13). The trends described for the single peptides were fully reflected in the average values obtained for
this  complex  mixture.  For  the  optimization  of  fragmentation  for  phosphopeptide  identification  and  correct
phosphorylation  site  mapping  (Figure  2-7),  CID-MSA-IT  had  only  a  low  level  of  dependency  on  NCE.
Additionally, pT-, pS-, and pY-residues were readily identifiable across a large range of NCE values (25 − 70%).
However, for HCD, there is a much greater dependency on NCE for identification of phosphopeptides, and a
comparatively narrow optimal range compared to CID. Therefore, the use of a higher NCE value of 45% to
ensure  optimal  identification  and  phosphorylation  site-mapping  mapping  in  HCD can  be  recommended.  In
addition, the generation of the highly specific pY immonium ion signal at m/z 216.04 was monitored. Detection
of this ion was only possible above a minimum NCE value of 45% after which it increased steadily with NCE
(Figure 2-13 (E, F)). 
Figure 2-12: Comparison and overlap of the number of peptide identifications of mix-2 at different NCE. Green
bars: peptide identified by both, CID-MSA-IT and HCD; blue bars: peptide only identified by CID; orange bars:
peptide only identified by HCD. (A) 2+ charged precursors; (B) 3+ charged precursors.
Combined analysis of CID-MSA-IT and HCD spectra for identification and phosphorylation site mapping
can considerably boost identification efficiency (Figure 2-12). Generally, CID in ion trap is a resonance based
process, whereas HCD represents a beam-type CID event (283), which leads to different fragmentation patterns
(Figure 2-2 to 2-4). For HCD, increasing NCE correlates to excessive fragmentation and a subsequent decrease
in  identification  success  (Figure  2-7).  The  acquisition  of  complementary  fragmentation  data  can  improve
phosphopeptide identification. This becomes important if the applied NCE for HCD is high. This leads to the
formation of intense iTRAQ reporter ions signals and to the formation of b1+ and y1+ ions, as an excess amount of
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energy  is  introduced  while  peptide  fragmentation.  In  such  cases,  CID-MSA-IT spectra  ensure  high  quality
identification, including phosphorylation site mapping. Quantification of isobaric labeled phosphopeptides by
HCD also showed a dependency on the applied NCE. Furthermore, it was determined that the fragmentation
efficiency was dependent on the charge state distribution of the precursor ions being analyzed. In line with this,
recommendations for identification and accurate quantification of 2+ charged precursors is a minimal NCE value
of 45%, while for 3+ charged phosphopeptides a higher NCE value of 60% is recommended. 
Figure 2-13: Comparison of online LC-ESI MS measurements of the iTRAQ labeled i114/i116-phosphopeptide mix-2
fragmented by HCD at various NCE. Normalized intensities are shown, averaged over all identified peptides.
(A): 51 pS-peptides, 2+ charged; (B): 52 pS-peptides, 3+ charged; (C): 14 pT-peptides, 2+ charged; (D) 15 pT-
peptides, 3+ charged. (E): 30 pY-peptides, 2+ charged; (F) 25 pY-peptides, 3+ charged.
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2.1.3.2 Ten Protein-mix
For simultaneous identification and quantification of complex samples, such as whole cell lysate, different
requirements have to be fulfilled: for identification purposes, SEQUESTs XCorr and the number of identified
peptides (unique and PSMs) are important criteria, whereas the formation of isobaric labeling derived reporter
ions to guarantee accurate quantification is of highest demand for peptide and protein quantification. 
The applied workflow to optimize tandem MS measurement parameters for non-phosphorylated peptides
was similar to the one applied for phosphopeptides (chapter 2.1.3.1). The limited number of 260 tryptic peptides
(in-silico digestion with:  minimum peptide mass of  500 Da;  no missed cleavages;  no protein  isoforms;  no
modifications) allowed to reproducibly select and fragment precursor ions of the ten protein-mix. This limited
variations  in  precursor  selection,  which  can  be  observed  for  more  complex  samples  (81).  Moreover,  the
precursor ion intensities were evenly distributed, and the effect of co-isolated precursors ions was minimized.
This allowed to combine results of different LC-ESI MS experiments, each measured with a different NCE value
for CID-IT and HCD fragmentation.
Identification in Dependence of NCE
In the first step of optimizing and analyzing the NCE values required for optimal peptide identification, the
focus was set on SEQUESTs XCorr and the number of unique and totally identified (PSMs) peptides (Figure 2-
14).  For  this  purpose,  the  multistage  feature  of  CID-IT  was  deactivated  due  to  the  low  number  of
phosphopeptides, only originated from α- and β-casein in the ten protein-mix. The NCE values were ranged from
0 to 85% for CID-IT and HCD, respectively. CID-IT spectra were recorded exclusively in the ion trap to benefit
from its sensitivity and scan speed, whereas HCD spectra were recorded in the high resolution Orbitrap mass
analyzer. 
Upon CID-IT fragmentation, the 2+ and 3+ charged precursor ions were not affected by an increasing NCE
from 30 – 60%. Both, the XCorr and the number of peptides (unique and PSMs) remained constant (Figure 2-14
(A, C)). A further increase of the NCE (> 60%) resulted in a fewer number of peptide identifications and a
decreasing XCorr. 4+ charged precursor,  which were not analyzed in the phosphopeptide standard, were less
affected by NCE variation compared to 2+ charged precursor ions, although the trends observed for the 2+ and 3+
charge states were very similar (Figure 2-14 (E)).  
For the peptide identification performed by SEQUEST of 2+ charged precursors, HCD showed a different
behavior compared to CID-IT (Figure 2-14 (B)). For NCE values < 25% only a limited number of peptides (<
100 PSMs) could be identified. For the NCE values of 30 – 50%, a constantly high number of peptides were
identified.  At 40% NCE, the highest number of peptides (unique and PSMs) were identified.  Moreover,  the
XCorr was maximal at this NCE value. 
Increasing the NCE to 55 and 60% decreased the ability to identify peptides, as 25% and 50% less peptides
(PSMs)  were  identified,  compared  to  the  maximal  number  of  identification  at  40%  NCE.  This  was  a
consequence of the XCorr, which decreased from a mean value of 2.7 at 40% NCE to 1.8 and 1.5 for 55% and
60% NCE, respectively. For NCE values ≥ 60%, the number of peptide identifications decreased further. 
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For the 3+ charged precursors (Figure 2-14 (D)), the number of identified peptides for NCE values of 30 to
60% remained constant. However, the XCorr was affected by an elevated NCE value. The maximal XCorr of 3.0
was observed at 40% NCE, whereas the XCorr decreased almost linearly to 1.9 at an NCE value of 65%.  
The number of identified peptides was barely affected by the NCE for 4+ charged precursor ions. The
maximal number of identifications (PSMs and unique) was observed at 50% NCE, whereas the maximal mean
XCorr was calculated to be 3.5 at 45% NCE (Figure 2-14 (F)).
Figure 2-14: Comparison of SEQUESTs XCorr (Whiskers-Box-Plots) and the number of unique (x10) and total
number of peptides identified via different NCEs applied for CID (A, C, E) and HCD (B, D, F) for 2+ (A, B), 3+
(C, D) and 4+ (E, F) charged precursor ions. 
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Influence of NCE on the Formation of iTRAQ Reporter Ions
Recently  published  methods  for  relative  quantification  using  iTRAQ  applied  CID-IT  spectra  for
identification and HCD spectra for quantification. This was a common approach for instruments such as the
Orbitrap XL. To obtain a maximal number of peptide identifications, the low m/z region of HCD spectra was
merged with the corresponding CID-IT spectra. These hybrid files were then applied to database searches (177).
In other studies (211), an NCE value of 75% was used to guarantee intense reporter ions. However, these HCD
spectra  could  only  be  utilized  for  quantification  rather  than  both,  identification  and  quantification
simultaneously. This diminished the number of identified peptides after HCD fragmentation, as these spectra
showed exclusively iTRAQ reporter ions signals and contained only a very few peptide backbone fragments
(except such as y1 and b1) with low intensities. 
Results from the phosphopeptide standard showed, that a minimal NCE of 45% and 55% is required for
iTRAQ reporter ion formation for 2+ and 3+  charged precursor ions, respectively. However, as the number of
precursor ions of the phosphopeptide standard was limited, the ten protein-mix sample was subjected to in-depth
analysis. The focus was set on the intensity of the iTRAQ reporter ions, as stable iTRAQ ratios were observed
upon applying 45% NCE. Therefore, the analysis of the iTRAQ ratios, such as iTRAQ114/iTRAQ115 was omitted.
Along the normalized intensity (NI,  Equation 2-1), also the relative intensity (RI,  Equation 2-2) and the
mean intensity was calculated for 2+, 3+ and 4+ charged precursor ions upon HCD fragmentation (Figure 2-16). 
For 2+  charged precursor ions, barely no iTRAQ reporter ion signals were observed at NCE values below
35%. The averaged normalized intensity of iTRAQ reporter ions rose sharply between NCE of 35 and 45%, and
remained almost constantly (Figure 2-16 (A)). The lower 5% value along with the averaged normalized intensity
was mainly due to immonium ions such as histidine which dominate the spectra at higher NCE values, as it was
shown for the phosphopeptides. For 3+ charged precursor ions, a markedly different curve shape was observed
(Figure 2-16 (B)). The normalized intensity did not increase sharply, instead the NI increased almost linearly
with the NCE and remained constant at NCE values > 70%. A minimum NCE value of 40% was required to
detect iTRAQ reporter ions. 
The curve shape of the 4+ and 3+ charged precursors were comparable, although NCE values ≥ 75% were
required for maximal normalized intensities (Figure 2-16 (C)). An NCE of 45% was the minimum value to detect
iTRAQ reporter ions, which was 10% and 5% higher than for 2+ and 3+ charged precursor ions. This might at
least be partially an effect of the peptide lengths (Figure 2-15 (A)), which was significantly higher for 3+ (Ø 12.5
amino acids,  AA)  than for  2+ charged precursors  (Ø  9.3 AA).  Compared to  doubly charged precursors,  the
number of amino acids per peptide almost doubled for 4+ charged peptides (Ø 17.5 AA).  
For 2+ charged precursor ions, the relative intensity vs. NCE plot can be described as a sigmoid curve (S-
Function) and be grouped into two parts: a (roughly) linear one from 25 – 45% (with t < 2; Equation 2-5) and a
point of inflection at 50 – 55% (Figure 2-16 (D)). This curve shape was not observed for the 3+ and 4+ charged
precursors (Figure 2-16 (E & F)). Instead, the curve shape was linear throughout the complete NCE range tested.
This might be a consequence of the higher NCE value required for precursor charge states > 2+.   
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sig (t)= 1
(1+e−t)
Equation 2-5
As a higher variability of iTRAQ ratios was reported for lower (iTRAQ reporter ion) signals  (284), the
iTRAQ reporter ion data were further analyzed by their mean signal intensity (Figure 2-16 (G-I)): in Thermo
Scientifics instrument software tune page, the target number of ions to be accumulated for a HCD scan is set to
1x105 with a maximal injection time of 1 sec per default. Assuming, that one ion releases only one iTRAQ
reporter ion, this also represents the maximal intensity (in counts) to be expected. 
For  2+  charged  precursor  ions,  the  averaged  intensity increased  from 30 – 55% NCE and reached its
maximal value at 6.9x104 (counts). The iTRAQ intensity decreased if NCE values >55% were applied (Figure 2-
15 (B) and Figure 2-16). This might be caused by consecutive fragmentation events of the iTRAQ reporter ions.
For 3+ charged precursors,  the averaged reporter ion intensity increased linearly and its  maximal value was
reached at 80% NCE. Only one further NCE value was tested (85%), therefore, it cannot be excluded that the
intensity might increase further with NCE. The curve shape of the 4+ charged precursor was similar to the one for
3+ charged precursor ions.  
Figure 2-15: Averaged lengths of identified peptides for CID-IT and HCD in dependence of NCE applied for 2 +,
3+ and 4+ charged precursor ions (A) and the median raw intensity of iTRAQ reporter ion (B).
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Figure 2-16: Whiskers-Box-Plots of iTRAQ reporter ion intensities after HCD fragmentation for the the protein-
mix in dependence of NCE applied for 2+ (A, D, G), 3+ (B, E, H) and 4+ (C, F, I) charged precursor ions. (A - C)
Normalized Intensities; (D - F) Relative Intensities; (G - I) Intensities (raw values).
The Compromise Between Identification and Quantification
The  requirements  for  both  identification  and  quantification  follow  inverse  trends,  as  it  was  shown
previously  for  the  phosphopeptide  standard.  Although  CID-MSA-IT  was  applied  for  the  phosphopeptide
samples, the results for non-phosphorylated peptides fragmented by CID-IT were similar. It was determined that
CID-IT had only a low level of dependency on NCE and that peptides were readily identifiable across a large
range of NCE values (25 – 60%).
However, for HCD, there was a much greater dependency on NCE for identification. Using an NCE of 40%
ensured optimal identification results (Figure 2-14). At higher NCE values, the excessive fragmentation and the
formation of iTRAQ reporter ions correlated with a subsequent decrease in identification success. In agreement
with previous results of the phosphopeptide standard, an NCE value of 45% represented the optimal compromise
to identify and quantify 2+ charged precursor ions. Barely higher NCE values were required for 3+ and 4+ charged
precursors with 60% and 65 – 70% NCE, respectively. This ensured to obtain a sufficient number of iTRAQ
reporter ions signals, but yet a high number of tandem MS spectra were identifiable.
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2.1.3.3  Biological Sample
The tryptic human macrophage digest had a higher complexity compared to the ten protein-mix. From
previous  experiments  using  a  2D-LC-ESI  MS  approach,  the  number  of  identifiable  proteins  from  human
macrophages was enumerated to be within the range of 1,000 to 1,500 (with FDR ≤ 1%; 2 unique peptides per
protein). 
 Peptides derived from tryptic digest were iTRAQ-4Plex labeled and subjected to 1D-LC-ESI MS analysis
on the LTQ Orbitrap Velos; this is similar to the ten protein-mix sample preparation. The CID-IT and HCD NCE
values were sequentially increased from 0 to 85%. Peptides were separated using a linear three hour gradient;
each NCE value was analyzed in duplicates to diminish technical variations. 
Pre-Processing of Tandem MS Data
To increase the number of precursor ions selected, the number of repeating scans of the same precursor ion
(m/z) was set to three and one for the first and second replicate measurements, respectively. The mean number of
MS1 scans was barely affected by the different strategies. On average, approximately 4,500 for the first and
5,000 for the seconds technical replicate were acquired (Figure 2-17). However, the number of MS2 spectra of
the  first  technical  replicate  (25,000)  was doubled  compared  to  the  second technical  replicate  (10,000 MS2
spectra). The lower number of acquired MS/MS spectra for the second technical replicate may be both beneficial
(i.e., a higher change to select low-abundant precursor ions) and detrimental (i.e., less MS2 spectra for a specific
precursor ion for data merging processes). By combining both technical replicates, the input (in terms of tandem
MS spectra) to extract peptide features as a function of NCE value for CID-IT and HCD was at its best.
Figure 2-17: Whiskers-Box-Plot for both technical replicates TR1 (gray, green) and TR2 (blue, orange) showing
the number of MS (gray and blue) and MS/MS scans (green and orange). The diversity of different MS/MS scans
was related to the dynamic exclusion settings, as the number of repeating scans was lowered from 3 (TR1) to 1
(TR2) to increase the possibility for selecting low abundant precursor ions and precursors of different charge
states, respectively.  
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Analyzing the Retention Time Difference between Technical Replicates
In total, 36 LC-ESI MS runs were analyzed (2 TR x 18 LC MS runs). Although the LC gradient was not
changed for the first and second technical replicate measurement, the retention time of peptides changed, as it is
illustrated in Figure 2-18. 
Figure 2-18: Total Ion Chromatogram of two technical replicate (TR1 (orange) and TR2 (blue)) demonstrating
the effect of shifted retention times. The samples Normalized Collision Energy settings were: CID-IT 20%, HCD
50%.   
The first peptides of the first technical replicate were detected at minute 20 (approximately) and at minute
30  for  the  second  replicate.  In  Thermo  Scientific´s  acquisition  Software  DCMS  Link  in  combination  to
Chromeleon Xpress, the pressures for the loading- and micro pump were recorded in .raw files. Using these
pressure profiles it was monitored, that after switching the 10-port valve from the loading- into the micro-pump
flow, the LC column pressure for the micro-pump dropped sharply from approximately 170 to 120 bar. It was
assumed, that this was the reason of the prolonged retention time. However, the column pressure drop only
affected the retention time of peptides, but not their order of separation. Moreover, it was observed, that the
effect of retention times difference between the first and second replicate (ΔRT) was more significant for lower
retention times (m/z 560, ΔRT ~ 6 min) than with prolonged retention times (m/z 729, ΔRT ~ 2.3 min) as illustrated
in Figure 2-19. 
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Figure 2-19: Extracted Ion Chromatograms (XICs) of five different precursor masses (m/z values) being roughly
equally distributed via the LC separation from minute 40 to 100 to highlight the extend of retention time shifting.
Retention Time Re-Calibration
The retention time can be used as a feature (in combination to precursors m/z and charge state) to re-map
identify peptides at elevated NCE values if a series of replicates of the same sample is measured by LC-ESI MS.
Frequently, this process is applied in label-free quantification experiments to align different samples; a process
referred to as re-match between runs (e.g., in MaxQuant; (285)).  
To finally use the retention time as a peptide re-mapping feature in combination to the precursor m/z value
and charge state, all 36 LC-ESI MS were subjected to retention time re-calibration. 
In the first step, a peptide master list was created in which all extracted LC-ESI MS run features were
merged.  This  included  information  about  the  sequence,  modification  and  charge  state  (static  features).
Additionally, the retention time and m/z value of peptides (dynamic features) were averaged via all 36 LC runs
recorded to balance out the observed retention time shift (shown in Figure 2-18 and 2-19). 
In the next step, each Peptide-Spectrum-Match (PSM) was compared to the master list.  Both retention
times (of a particular peptide species) from the master list and the LC-ESI MS run, were exported into a .txt file.
This was done for each LC MS experiment separately. Additionally, the sequence, modification, charge states
and m/z value of the peptide was exported.   
The stepped NCE values applied for CID-IT and HCD (e.g., CID-IT 0% and HCE 30% within an LC-ESI
MS run) allowed to receive a sufficient number of identifications for each .raw file. It is noteworthy, that the
identifications obtained for CID-IT and HCD tandem MS spectra were merged for retention time re-calibration.
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Finally, the lists containing the information about the retention times for the experimental and the master
file  were  imported  into  QtiPlot.  To  obtain  parameters  to  re-calculate  retention  times,  a  linear  curve  fitting
approach was used. This is illustrated in Figure 2-20 for two technical duplicates. 
Figure 2-20: XY-scatter plot for sample CID 40 – HCD 70 for both the 1 st  and 2nd technical LC run measured.
For sample normalization, a linear fit model was applied, as samples (=peptides) elution profile was shifted in
total rather than changing the LC profile. The linear fit function was exported for each of the 36 runs and used
for recalculation of retention times.
Using all 36 data sets separately in QtiPlot, the linear fit  function for each LC- ESI MS run could be
exported. Their corresponding curve fitting parameters are summarized in Table 2-4.  
The retention time alignment plots (Figure 2-20) and the curve fitting parameters revealed that both, the
retention time of the master file and each LC-ESI MS run were narrower for peptides eluting before minute 120
(approximately). At higher retention times (approx. 150 min), the number peptides that did not fit  the linear
curve  fitting  ascended.  Potentially,  these  were  peptides  not  sufficiently  eluted  from the  trap-column in  the
previous LC-ESI MS run.  
However, the linear curve fitting parameters (A & B in Table 2-4) were subsequently used to re-calculate
each retention time point in the .mgf files. As the information about the fragmentation type is not encoded in
.mgf files, this process was performed for CID-IT and HCD separately. 
For the final database search, the retention time re-calibrated .mgf files were imported into the Spectrum
Files node instead of the original .raw files (Figure 2-1). To obtain peptide list which were compatible to the
previously  compiled  tools  (e.g.,  chapter  2.1.3.2),  peptide  and  protein  features  for  CID-IT  and  HCD  were
exported into a single .txt file. 
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Table  2-4: The linear curve fitting (y = A*x +B) parameters A, B and R² related to each LC run used for
retention time recalculation in .mgf files.
Sample Information
[AT & NCE]
TR1 TR2
A B R² A B R²
CID 00% HCD 30% 0.93 7.02 0.96 0.99 -0.61 0.98
CID 05% HCD 35% 0.89 9.54 0.94 1 -0.77 0.98
CID 10% HCD 40% 1.04 -12.05 0.94 1.01 -2.13 0.96
CID 15% HCD 45% 1.01 -5.3 0.96 1.01 -1.51 0.95
CID 20% HCD 50% 0.88 8.54 0.92 1 -0.74 0.98
CID 25% HCD 55% 0.89 8.34 0.92 1.01 -0.89 0.97
CID 30% HCD 60% 0.93 6.83 0.95 1 -0.69 0.97
CID 35% HCD 65% 0.93 7.19 0.95 0.99 0.42 0.97
CID 40% HCD 70% 0.97 3.02 0.96 1 -0.49 0.97
CID 45% HCD 75% 0.95 5.9 0.96 1 -0.71 0.97
CID 50% HCD 80% 0.94 6.31 0.96 1 -0.38 0.96
CID 55% HCD 85% 0.96 5.69 0.96 1.01 -0.65 0.96
CID 60% HCD 00% 0.96 5.7 0.96 1.01 -1.51 0.96
CID 65% HCD 05% 0.97 5.16 0.96 1 -0.89 0.97
CID 70% HCD 10% 1.01 -4.29 0.97 1 -1.47 0.95
CID 75% HCD 15% 1.01 -3.46 0.96 1 -1.23 0.96
CID 80% HCD 20% 0.99 -1.14 0.97 1 -0.71 0.97
CID 85% HCD 25% 0.98 -0.12 0.96 0.99 -0.05 0.97
Peptide Identification and Quantification in Dependence of NCE
To evaluate the performance of CID-IT and HCD for iTRAQ labeled peptides, a human macrophage digest
was analyzed to evaluate the optimal conditions for identification and quantification, as it  was done for the
phosphopeptide standard and the ten protein-mix. 
The number of peptides identified upon CID-IT and HCD fragmentation were plotted as a function of the
NCE (Figure 2-21). As expected from previous results, the number of peptides identified (unique and totally)
upon CID-IT excitation was steady at various NCE values (25 to 55%) for all charge states monitored (2+ to 4+;
Figure 2-21 (A, C, E)). However, the number of identification was always significantly lower (approximately
50%) than those identified by HCD (Figure 2-21 (B, D, F)).  
For HCD, the number of peptides identified was highly dependent on the NCE value. The highest number
of peptides (unique and PSMs) were identified in the NCE range of 40  ± 10%. However,  the identification
appeared to be more sensitive to NCE increases for 2+ than for 3+ and 4+ charged precursors, as the extent of the
bell-curve shape was most significant for 2+ charged precursors. This curve shape was also observed for the
remaining charge states. 
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Figure  2-21:  Comparison of  SEQUESTs  XCorr  (Whiskers-Box-Plots)  and  the  number  of  unique  and  total
number of peptides identified via different Normalized Collision Energies applied for CID (A, C, E) and HCD
(B, D, F) for 2+ (A, B), 3+ (C, D) and 4+ (E, F) charged precursor ions. 
For  quantification,  the  normalized  intensity,  the  relative  intensity  and  the  mean  signal  intensity  were
calculated for HCD as a function of the NCE value and the charge state of the precursor (Figure 2-22). 
For 2+ charged precursors, no iTRAQ reporter ion signals were observed at NCE values below 30%. The
normalized intensity rose sharply between 35 and 45% and stayed constant (Figure 2-22 (A)).  Contrary,  the
relative  intensity  reached its  maximal  value  at  elevated  NCE values  (>  65%;  Figure  2-22 (D)).  The mean
intensity (Figure 2-22 (G)) decreased linearly after applying NCE values greater than 45 – 60%.   
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The curve shape of the normalized and relative intensity of the 3+ and 4+ charged precursor ions was
remarkably different. Instead of the sharp rise, the intensity (relative and normalized) increased almost linearly
with NCE (e.g., Figure 2-22 (E)). However, the maximal mean intensity was at 60% NCE (Figure 2-22 (H & I)),
whereas the mean intensity at 45% is speculated to represent an outlier. In summary, similar optimal NCE values
were explored for the peptide digest obtained from human macrophages to identify and quantify iTRAQ labeled
peptides, compare to the previously analyzed iTRAQ labeled phosphopeptide standard and ten protein-mix. 
Figure 2-22: Whiskers-Box-Plots of iTRAQ reporter ion intensities after HCD fragmentation for the the protein-
mix in dependence of NCE applied for 2+(A, D, G), 3+ (B, E, H) and 4+ (C, F, I) charged precursor ions. (A - C)
Normalized Intensities; (D - F) Relative Intensities; (G - I) Intensities (raw values).
-72-
2.1 iEM – iTRAQ Evaluation Method
2.1.4 Conclusion
The applied Normalized Collision Energy (NCE) is a parameter affecting spectra quality for identification
and quantification, respectively. For identification, varying the NCE did not affect CID-IT and CID-MSA(-IT)
spectra significantly if values between 25 – 55% were applied. However, for HCD optimal NCE values for 2+, 3+
and 4+ charged precursors were monitored: 2+ charged precursors were highly affected by elevated NCE values,
whereas the dependency was lower for precursors with charge states >2+. This was observed for both, non- and
phosphorylated peptides. Generally, 4+ charged peptides were tolerant to a wide range of applied NCE values.
Although the NCE values mentioned here were obtained from a single LTQ Orbitrap Velos instrument,  the
values  reported  should  be  comparable  to  different  instruments  as  the  NCE value  is  re-adjusted  during  the
instrument calibration and tuning procedure. 
Low m/z fragment  ions (such as  iTRAQ reporter  ions)  cannot be stabilized in ion traps  after  CID-IT
activation. To overcome this problem, HCD must therefore be applied. Generally, for reporter ion generation,
MS/MS spectra with intense iTRAQ reporter ions are required. For 2+ charged precursors, an NCE of 45% was
evaluated to be sufficient to receive intense iTRAQ reporter ions and stable iTRAQ reporter ratios. This also
represented the NCE value, at which iTRAQ reporter ions represent the base peak in MS/MS spectra. For 3+
charged precursors, an elevated NCE was required (> 55%); which increased further (> 65%) for 4 + charged
precursor ions. 
The acquisition of both, CID(-MSA)-IT and HCD in parallel represented an (almost) optimal trade-off for
identification  and  quantification  of  iTRAQ  labeled  phosphorylated-  and  non-phosphorylated  peptides,
respectively.  Although HCD MS/MS spectra contain both information (fragment  and iTRAQ reporter  ions),
(phospho)peptide identification and correct phosphorylation site mapping (for phosphopeptides only) was still
challenging  if  solely  HCD was  applied,  as  the  number  of  ions  with  sequence  information  decreased  with
increasing NCE value. Generally, the process of phosphopeptide identification is enhanced by the application of
both, CID-(MSA-)IT and HCD. While the MS full scan acquisition in the Orbitrap mass analyzer, precursor ions
begin to be fragmented by CID-IT and are being analyzed in the ion trap in parallel to the completion of the MS
full scan in the Orbitrap mass analyzer. This reduces the overall scan cycle compared to sequential MS full scan -
CID/HCD measurement approaches (see Figure 1-12). 
From  the  technical  point  of  view,  CID-IT  takes  advantage  of  sensitivity  and  speed,  whereas  HCD
(recorded in Orbitrap mass analyzer) benefits from high mass accuracy. Consequently, complement data sets
regarding measurement  and fragmentation conditions are obtained by simultaneous application of both.  For
phosphopeptide analysis, CID-MSA-IT is superior to CID-IT as it creates sufficient b- and y-ion fragmentation.
This minimizes neutral loss signals (e.g., [M-P]) but requires additional scan time. An additional benefit of CID-
(MSA-)IT is that these spectra are more reproducible. Changing the NCE value did not effect the identification
success as they do not show iTRAQ reporter ions. Consequently, CID data are more robust in terms of stable
identifications, as the XCorr is directly correlated to the number of detected fragment ions observed. In contrast,
HCD  spectra  benefit  from  the  Orbitrap  mass  analyzer  and  the  shorter  but  energetically  more  intense
fragmentation processes, which leads to (at least) comparable identification results between CID-IT and HCD.
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Moreover, spectra shape differs in terms of intensity distribution for b- and y-ions. In addition,  a- and significant
diagnostic  (e.g.,  for  pY-peptides  at  m/z  216.04)  or  other  immonium ions  can  only  be  detected  after  HCD
excitation and acquisition in the Orbitrap mass analyzer. 
Interestingly, the number of identifications obtained by CID-IT dropped for the biological sample, where
HCD  clearly  outperformed  CID-IT.  This  might  be  an  effect  of  the  increased  search  space  (human  +  M.
tuberculosis vs. E. coli FASTA file) and the lower resolution of ion traps. However, the phosphopeptide and the
ten  protein-mix  were  measured  2012 and  2013,  whereas  the  peptide  digest  from human macrophages  was
measured 2014. An instrument maintenance was performed prior sample measurement, which also included a
clean of the ion trap. Possibly,  particles (such as dust) might be present in the ion trap, which leads to de-
charging of fragment ions. Consequently, less ions can be recorded in the ion trap which decreases the sensitivity
of the ion trap, and could (at least partially) explain the drop in identification rate of CID-IT compared to HCD. 
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2.2 n-iTRAQ – Handling of Nominal Isobaric Labelings
2.2.1 Introduction
By variation of the Normalized Collision Energies applied for CID-IT, CID-MSA-IT and HCD, optimal
fragmentation conditions for identification and quantification of iTRAQ-4Plex labeled peptides were established
(see chapter 2.1). However, the isobaric labeling reagent iTRAQ-4Plex used in the previous section, is available
in four different  forms which generate the particular  reporter  ions observed at  m/z 114 to 117.  Due to the
composition of the reagents, encompassing different combinations of 13C and 15N isotopes, different modification
masses are observed (see Figure 1-3): iTRAQ114 has the highest (144.105918 Da) and iTRAQ115 the lowest mass
(114.099599 Da) of  the four iTRAQ reagents;  whereas  iTRAQ116&117 share the same number of  carbon and
nitrogen isotopes and, consequently have the same mass (144.102063 Da).  
As a default setting for iTRAQ-4Plex experiments, database searches are performed with the modification
mass of iTRAQ116&117, according to the Unimod recommendation (Accession # 214). During  in-silico peptide
index creation, this value is added to each static (N-terminal and K) and dynamic (Y) modification (see Figure 1-
1). However, for peptides with intense iTRAQ114 or iTRAQ115 reporter ions, the in-silico calculated values have
been demonstrated to differ from the experimental mass even (up to 3.8 ppm) for newly tuned and calibrated
instruments (274). Peptides of severe differentially abundant proteins tend to contain intense iTRAQ reporter ion
signals of one channel. Consequently, these peptides might be lost during database searches if the precursor mass
tolerance window is set to narrow due to the only nominal isobaric iTRAQ-4Plex reagents.  
High resolution mass spectrometers such as the LTQ Orbitrap Velos, can resolve ions from a resolution of
7,500 to 100,000 (Orbitrap mass analyzer). The highest resolution mode permits to differentiate ions at m/z 400
with Δ = 0.004. This is not sufficient to baseline separate two iTRAQ labeled precursor ion peaks (i.e., the same
peptide with (i)  iTRAQ114 and (ii) iTRAQ115  labeling), but it is sufficient to monitor how the precursor mass
behaves at varying iTRAQ114 to iTRAQ115 ratios. 
In order to demonstrate the potential errors introduced due to non isobaric iTRAQ reagent masses, ten
samples with different iTRAQ reporter ion ratios are analyzed by LC-ESI MS and their  in-silico calculated
features systematically monitored: This is the (in-silico introduced) precursor mass shift at different iTRAQ114 to
iTRAQ115 ratios, and the number of peptide identifications at different precursor mass tolerance windows set for
database  searches.  The final  goal  is  to  present  an  alternative  algorithm to  improve the  precursor  ion  mass
calculation of iTRAQ-4Plex labeled peptides.
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2.2.2 Material and Methods
2.2.2.1 Chemicals
Chemicals used in this study are summarized in chapter 4.1.
2.2.2.2 Sample Preparation
Protein Digestion and iTRAQ-4Plex Labeling
The iTRAQ labeled ten protein-mix (chapter  2.1.2.1) was used for sample preparation and LC-ESI MS
analysis. The four iTRAQ labeled samples were combined in different ratios, resulting in a total of ten samples
to simulate differentially abundant peptides, which are summarized in Table 2-5.
Table  2-5: Mixing schema of the ten protein-mix to obtain samples with (simulated) different peptide ratios.
iTRAQ-114 to iTRAQ-117 represent the starting material after labeling, which were also measured.
Sample
[Name]
iTRAQ ratio
[/]
# MS/MS Spectra
[Counts]
iTRAQ-114 1:0:0:0 2232.00 ± 119.65
iTRAQ-115 0:1:0:0 2789.00 ± 479.39
iTRAQ-116 0:0:1:0 2583.67 ± 379.76
iTRAQ-117 0:0:0:1 2620.67 ± 94.24
A(1:1:1:1) 1:1:1:1 2417.00 ± 56.04
B(4:4:1:1) 4:4:1:1 2760.67 ± 49.40
C(4:3:1:1) 4:3:1:1 2461.67 ± 127.58
D(3:4:1:1) 3:4:1:1 2346.67 ± 621.07 
E(4:1:1:1) 4:1:1:1 2539.00 ± 68.51
F(1:4:1:1) 1:4:1:1 2586.33 ± 29.50
2.2.2.3 Mass Spectrometry and Database Searches
Instrument Setup
For LC-ESI MS measurements, the LTQ Orbitrap Velos coupled to a Dionex U3000 HPLC system was
employed (see chapter 2.1.2.2 and chapter 4.1 for additional details). After peptide loading and desalting (4 min;
30 µL/min), peptide separation (300 nL/min) was performed with a linear gradient from 5% to 40% B in 40 min,
followed  by  a  column wash  step  (total:  12  min)  with  a  linear  gradient  from 40% B to  95% B.  Inter  run
equilibration of the columns was set to 9 minutes. A Top 5 HCD method was written manually using vendors
software:  First,  a  full  scan  at  a  resolution of  100,000 with  activated  prescan  was  performed.  For  MS/MS,
resolution of Orbitrap measurements was decreased to 7,500. The activation time was 0.1 ms, default charge was
set to 2+, isolation width m/z 3. To obtain outbalanced HCD fragment ion spectra for simultaneous identification
and quantification, the NCE was set to 47.5%. This value represents a compromise between 2+ and 3+ charged
precursor ion fragmentation. Dynamic exclusion was enabled for all runs. The repeat count was set to 3 with a
repeat duration of 20 sec and precursors, selected for MS/MS, were set for dynamic exclusion for 30 sec. Lock
mass correction was enabled using the polydimethylcyclosiloxane signal m/z 445.120024.
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Database Searches
Fixed Precursor Mass 
Recorded .raw files were processed using Proteome Discoverer (Version 1.4). Each of the ten samples (see
Table 2-5) was searched in a MudPIT approach combining all three technical injections. The FASTA file was the
same as applied before for the ten protein-mix (see chapter 2.1.2.3). 
The workflow applied was build up by 9 different nodes (similar to Figure 2-1) with default settings if not
otherwise specified: (0) Spectrum Files; (1) Spectrum Selector; (2) Scan Event Filter; (3) SEQUEST HT (see
below);  (4)  Target  Decoy PSM Validator  (Target  FDR (Strict):  0.01  and  Target  FDR (Relaxed):  0.05);  (5)
Reporter Ions Quantifier (iTRAQ-4Plex, respectively (Thermo Scientific Instruments; Integration Tolerance 20
ppm; Most Confident Centroid as Integration Method; Additional Settings: Show the Raw Quan Values; Apply
Value Corrections, use All Peptides enabled and deactivated Experimental Bias). 
The following settings were used  for  SEQUEST HT (3),  enzyme name:  trypsin (semi specific);  max.
missed cleavage sites: 2; min. peptide length: 6; max. peptide length: 144;  precursor mass tolerance: 10 ppm;
fragment mass tolerance: 0.02 Da; weight of all ions but b and y ions was 0, weight of b & y Ions: 1; dynamic
modifications:  phosphorylation  (S,  T,  Y);  oxidation  (M),  iTRAQ4plex  (Y);  static  modifications:  peptide  N-
Terminus: iTRAQ4plex (any N-Terminus); carbamidomethyl (C), iTRAQ4plex (K). 
For evaluation of mass deviations introduced in-silico, Peptide-Spectrum-Matches obtained from Proteome
Discoverer database search were filtered for high confidence (FDR 1%) and exported to .xlsx files. 
Variable Precursors Mass Tolerance
The precursor mass tolerance window was varied from 0 (exactly: 0.01) to 20 ppm in 1 ppm steps for the
workflow applied (see above). For analysis, only the four sample iTRAQ-114 to iTRAQ-117 combined in a
MudPIT approach  were  used.  All  12 runs  (4  samples,  3  technical  replicates)  were  combined  into a  single
database search per each of the 21 ppm values set. Lists containing the Peptide-Spectrum-Matches were exported
with high confidence only (1% FDR) and used for further data analysis.  
Data Processing
Data Conversion
For .raw-file conversion into a text base format (.mgf), Proteome Discoverer was utilized. The workflow
used before was applied, but nodes (3) – (5) were replaced by a Spectrum Exporter Node. 
Data-Analysis (Fixed Precursor Mass Tolerance Window) 
Lists containing the Peptide-Spectrum-Matches were filtered for the  in-silico calculated ppm value. Each
entry was rounded to integer numbers (bin size 1 ppm) and the number of features within each bin was counted
(Figure 2-23 and 2-24 (A)). Additionally, the PSM list of iTRAQ-114 was split into three different parts: the first
contained peptides with 1x iTRAQ114 modification, the second with 2x iTRAQ114 modification and the third with
-77-
 2 Developing a Platform for relative Quantification using iTRAQ
> 2x iTRAQ114 modifications. Each of the lists was also used for feature calculation (Figure 2-24 (B)). 
Data-Analysis (Variable Precursor Mass Tolerance Window)
To demonstrate the dependency of PSMs to the precursor mass tolerance window set, each of the 21 PSM
lists was searched separately (batch mode) with an in-house developed GAMBAS script. The number of PSMs
for each sample (including the three technical replicates) and each precursor ppm value set was counted and
exported into a tab-separated file. This list was imported into QtiPlot for data visualization (Figure 2-26). 
Algorithm to Re-Calculate the Precursor Mass (Fixed Precursor Mass Tolerance Window)
Three in-house developed VBA scripts were used to re-calculate the precursor mass (m/z value). Script (i)
exported the information about iTRAQ reporter ions and header informations (retention time, precursor charge
state, scan number, precursor m/z and raw file name) into a tab-separated .txt file (referred to as iTRAQ-list). For
iTRAQ reporter ion signals, their intensity and the corresponding m/z values (withing 5 ppm) were exported.
Additionally, the relative intensities of iTRAQ reporter ions were calculated (Equation 2-6). The iTRAQrelative
intensity in combination to the known modification mass of iTRAQ 114-117 (see  Figure 1-3;  Equation 2-7) was
used to calculate a specific iTRAQ modification mass for every single tandem MS spectrum (Equation 2-8). The
amino acid masses (monoisotopic) used for precursor mass (m/z value) calculation are summarized in chapter
4.2.  
iTRAQrelative Intensity (x)=
     iTRAQ-Intensity (x)
∑
x=114
x=117
iTRAQ-Intensity (x)
Equation 2-6
iTRAQ part(x)=iTRAQrelative Intensity (x)×iTRAQmz (x) Equation 2-7
iTRAQ corrected =∑
x=114
x=117
iTRAQ relative Intensity (x) Equation 2-8
Script (ii) imported the information after database search (PSM list) and the previously created iTRAQ-list
[see (i)]. Firstly, features of the identified peptides were loaded (sequence, modification, raw file, retention time,
precursor  charge state,  tandem MS scan number,  mass  accuracy,  precursor  mass  (m/z))  and the  number  of
modifications (iTRAQ, oxidation and carbamidomethyl)). Afterwards, the iTRAQ-list (i) was searched for the
corresponding spectrum hit. A hit was true if both (PSM and entry within the iTRAQ-list) share the same RT,
charge, precursor mass, scan number and raw file name.
The previously calculated iTRAQcorrected value from the iTRAQ-list (i) was then used to re-calculated the
peptides  precursor  mass  and  the  corresponding mass deviation (in  ppm).  To test  the  applied  workflow, the
calculation was repeated replacing iTRAQcorrected with its classical value (iTRAQ116&117 :144.120026 Da).
Script (iii) was used for data visualization. The mass deviation values (for each, the original ppm value
obtained by Proteome Discoverer and the re-calculated) were rounded to integer values and the number of hits
within one bin (one bin = 1 ppm) was counted. 
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2.2.3 Results and Discussion
2.2.3.1 Monitoring ppm Deviations Introduced by Different iTRAQ Ratios
To analyze differences (introduced by varying iTRAQ ratios) for in-silico calculated precursor masses, ten
samples were analyzed by MS. Six of these samples showed different iTRAQ ratios. The latter four (iTRAQ-114
to iTRAQ-117) represented the maximal permissible value, as they only contained one iTRAQ labeling (see
Table 2-5 for details). 
Sample A showed iTRAQ ratios of 1:1:1:1 (iTRAQ114 : iTRAQ115 : iTRAQ116 : iTRAQ117). After performing
a database search in MudPIT approach 2,016 PSMs were exported at 1% FDR (see Figure 2-23) and the average
mass accuracy was calculated to be 0.5 ppm via all PSMs. Grouping the PSMs by creating bins of 1 ppm size by
rounding to integer values, most of the peptides were identified in the ±0 ppm (37%) and +1 ppm (38%) bin,
respectively.  This  represented  approximately  75%  of  all  identified  peptides.  One  tenth  of  the  peptide
identification was found in the -1 ppm bin. This mass deviation distribution and accuracy was expected due to
the application of lock mass correction for MS and MS/MS analysis, as shown recently (85). For this test sample
A(1:1:1:1), no negative effect was observed using the iTRAQ116&117 mass (144.102063 Da) for database searches. 
Increasing the amount of both, iTRAQ114 and iTRAQ115 (sample B(4:4:1:1);  Figure 2-23 (B)) in relation to
iTRAQ116 and iTRAQ117, a similar distribution to sample A(1:1:1:1) was observed. However, the percentage of PSMs
within the bins ±0 ppm and +1 ppm was lowered to 50%. A further of 10% was identified within the bins -1 and
+2 ppm, respectively. The averaged mass deviation was still very accurate at + 0.7 ppm. 
For the sample C(4:3:1:1) a shift to slightly higher mass deviations (+ 1.7 ppm) was observable (Figure 2-23
(A)). Beside this, also the distribution in the bin 0 to +2 ppm changed. Only 14% of PSMs were identified in the
±0 ppm, whereas approximately 30% were identified within the +1 ppm bin. A further of 20% was found with a
mass  accuracy  of  2  ppm.  The  shift  to  higher  masses  deviations  for  this  sample  C(4:3:1:1)  was  introduced  as
iTRAQ114 has  a  higher  mass  and intensity  than iTRAQ115.  Moreover,  the outbalancing effect,  as  shown for
sample A(1:1:1:1) and B(4:4:1:1) of iTRAQ114 and iTRAQ115 , was not sufficient, resulting in the observed mass shift. For
sample D(4:3:1:1)   this was less prominent and can be explained by the smaller mass deviation of  iTRAQ115  (-
0.002464 Da) compared to iTRAQ116&117, whereas iTRAQ114 differs by +0.003855 Da (Figure 2-23 (B)). 
Simulating four times higher abundant proteins (sample E(4:1:1:1); Figure 2-23 (A)), the mass discriminating
effect increased significantly. The average deviation was calculated to be 2.8 ppm, although lock mass correction
was enabled. 50% of PSMs were grouped to the +2 and +3 ppm bin, and a further of 12% and 15% to the bins +1
and +4 ppm, respectively. Again, the mass shift effect was less prominent for samples with dominating iTRAQ115
(sample F(1:4:1:1); Figure 2-23 (B)). Approx. 66% of all PSMs were identified within the bins -1 and -2 ppm.
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Figure  2-23:  The frequency of  peptides  identified  within the  bins  of  -10 to  +10 ppm for  the samples  with
increasing content of iTRAQ114 labeling (A, C & E) (left side (A)) and with increasing content of iTRAQ115 (B,
D, & F) (right sight (B)).
Assuming, a protein is highly abundant in only one of the four biological entities, the mass deviation effect
should increase if these samples were labeled with iTRAQ114 or iTRAQ115. This was simulated by analyzing the
four iTRAQ labelings separately (samples: iTRAQ-114, iTRAQ-115, iTRAQ-116 and iTRAQ-117 (Figure 2-24
(A)). Again, for all measurements, the lock mass correction was enabled to ensure comparable results. For the
samples iTRAQ-116 and iTRAQ-117, the averaged mass deviation was 0.1 and 0.0 ppm, demonstrating perfectly
the advantageous application of lock mass for internal re-calibration. For both samples, more than 55% of PSMs
were grouped into the ±0 ppm bin. Enlarging the monitored mass deviation window to -1 to +1, more than 92%
of the PSMs were matched. 
For the sample iTRAQ-115 and iTRAQ-114, the average mass shift was -2.8 and +4.3 ppm, respectively.
Again, the effect was smaller for iTRAQ115 labeled samples, as it was shown before. Moreover, the PSM per bin
distribution was significantly different compared to the samples labeled with iTRAQ116 and iTRAQ117. For the
iTRAQ-114 sample, at least 10% of the PSMs were found in each of five bins (+2 to +6 ppm). Again, this was
less intense for the sample iTRAQ-115 (-1 to -5 ppm). 
Figure 2-24: The frequency of peptides identified within the bins of -10 to +10 ppm for the samples iTRAQ-114
to iTRAQ-117 (A) and in-depths analyzing the number of iTRAQ labelings attached for sample iTRAQ-114 (B).
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By clustering the identified peptides into groups with one (N-terminal only), two (N-terminal +  C-terminal
K) or more (>2, N-terminal +  C-terminal K + tyrosine or a missed cleavage) iTRAQ labelings attached, a
correlation between the number of iTRAQ labelings and the mass deviation was discovered (Figure 2-24 (B)).
For singly iTRAQ114 labeled peptides, the average mass deviation shifted to +2.5 ppm, whereas it increased to
+4.4 ppm for doubly labeled peptides. If a peptide species contained more than two iTRAQ114 labelings, the mass
deviation was calculated to be +6.5 ppm (in average). 
In summary, the application of iTRAQ116&117 as input-values to calculate the theoretical precursor masses
and mass deviation values, respectively, did not alter the theoretically calculated precursor masses (m/z) if the
iTRAQ reporter  ions were equivalent distributed (sample A to D).  However,  for peptides with significantly
differing iTRAQ ratios (sample E, F and iTRAQ-114, iTRAQ-115, respectively) the application of iTRAQ 116&117
as input-values for mass calculation effected the PSMs results. In consequence, these relevant peptides might not
be considered as peptide candidates for database searches if the precursor mass tolerance window is set to ± 5
ppm.  
To demonstrate the relation of iTRAQ ratios to the mass accuracy distribution (ppm), Whiskers-Box-Plots
were created for all ten samples analyzed (Figure 2-25). The maximal (x), the 1%; 99% cut-off (triangle) and
5%; 95% (end of vertical lines) values were included to extend the significance. The maximal values were
frequently close to ± 10 ppm, as expected for a database search with a precursor mass tolerance window set to ±
10 ppm. However, the 5%; 95% values shifted step less to higher (or lower) mass deviations with increasing
iTRAQ114 (iTRAQ115) intensities. Additionally, the distribution accumulated with increasing number of iTRAQ
labelings being attached to a peptide. For iTRAQ-116 and iTRAQ-117, the distribution (25, 50 & 75%) were
close to 0 ppm, whereas iTRAQ-114 mass accuracy was broader distributed (as explained before). Peptides with
severe differences in iTRAQ ratios represent those being (potentially) biologically relevant,  which might be
prone by an in-silico introduced imprecision during precursor mass calculation.  
Figure  2-25: Whiskers-Box-Plots for the ten samples analyzed regarding the in-silico introduced mass shift.
Rectangular: median value; triangle: 1%, 99%; x: maximal values. Box-Plots represent values of 25, 50 and
75%.  
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2.2.3.2 Variations of Precursor Mass Accuracy Window
As outlined in the previous section, the theoretically calculated peptide mass and its mass deviation were a
function  of  the  iTRAQ  reporter  ion  intensities  observed  in  MS/MS  spectra.  To  evaluate  if  this  (in-silico
introduced) mass shift had an influence on the number of peptide identified, a series of 21 database searches
were performed. For each, the precursor mass tolerance window was increased by 1 ppm from 0 ppm (actually
0.01 ppm as the minimum value available in Proteome Discoverer 1.4) to 20 ppm. Finally, the number of PSMs
within one sample (e.g., iTRAQ-114) and one precursor mass tolerance value set (e.g., 5 ppm), respectively,
were exported. For visualization, the PSMs of the four samples (iTRAQ-114 to iTRAQ-117) were plotted in
relation to the precursor mass tolerance window (Figure 2-26). 
Figure 2-26: Number of identified peptides for the samples iTRAQ-114 to iTRAQ-117 with a low (0.01 ppm) to a
high (20 ppm) predefined precursor mass tolerance. 
iTRAQ116&117  are the default iTRAQ modification masses used for database search. This relation was also
obvious for the number of Peptide-Spectrum-Matches. For both, iTRAQ-116 and iTRAQ-117, a low precursor
mass tolerance window of 2 ppm was required to receive stable Peptide-Spectrum-Matches (change < 10%).
This was in good agreement with previous results, as the averaged mass deviation value (with a fixed precursor
mass tolerance of 10 ppm) was close to ±0 ppm. 
The mass difference between iTRAQ115 and iTRAQ116 (Δ=0.002464 Da) is smaller compared to the one for
iTRAQ114 and iTRAQ116 (Δ=0.003855 Da) This was also reflected by the number of PSMs: for iTRAQ-115, the
number of PSMs was stable (change < 10%) if a precursor mass tolerance window of 5 – 6 ppm was defined in
Proteome Discoverer. In contrast, a value of approx. 7 ppm was required for the sample iTRAQ-114. 
Summarizing, the minimum precursor mass tolerance values set for database searches reported here for
iTRAQ-114 to iTRAQ-117 reflected the maximal values, which should be considered to be expected for high
precision MS data (e.g., by the application of lock mass correction or offline re-calibration). For outbalanced  or
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ratios of  1.3:1 (iTRAQ114 and iTRAQ115),  the mass shift  effect  was not significant.  For highly differentially
abundant proteins (such as recombinant ones), a higher precursor mass tolerance window might be required.
First, the introduced in-silico mass shifts due to different iTRAQ modification masses and, second, by a general
(experimental) calibration shift due to climatic and electronic changes of the instrument.
2.2.3.3 Post Database Search Re-Calculation of Precursor Masses 
In general, proteins included in FASTA files are in-silico digested to receive a list of peptide candidate for
Peptide-Spectrum-Matching processes. To each peptide within the list, the corresponding masses of static and
dynamic modifications are added and the final peptide masses calculated. For isobaric iTRAQ-4Plex labeling
experiments, the masses of iTRAQ116&117 are used for peptides mass calculation. This agrees with the UniMod
recommendation (Accession # 214) and is acceptable for similar iTRAQ reporter ion intensities. However, this
procedure  is  not  optimal  for  highly  up-  or  down-regulated  proteins.  In  the  following section,  an  upstream
workflow to database searches is described which eliminates the observed effect. Principally, this procedure is
not limited to an upstream approach but requires a more flexible FASTA file index creation (see discussion).
Extracting the Required Information for Precursor Mass Re-Calculation 
During precursor selection for MS/MS fragmentation, information about the precursor (e.g., charge state
and m/z value) were directly available in the scan header.  Similar,  the iTRAQ reporter ion intensities were
present in MS/MS spectra (e.g., .mgf files) after precursor fragmentation using suitable collision energies and
fragmentation techniques (see chapter  2.1). After having performed a database search and peptide validation,
information about the precursor amino acids composition and its modifications were immediately available. All
these features were required to re-calculate the precursor mass more accurately. 
Re-Calculating the Precursors Masses
The complete workflow to re-calculate the iTRAQ modification and precursor mass is illustrated in Figure
2-27. As an example, the tryptic peptide TLNFNAEGEPELLMLANWRPAQPLK, labeled on the N-terminus
and the C-terminal lysine, was chosen. In addition to FDR based peptide validation, the peptide was annotated
in-silico (filter: 20 ppm mass accuracy, intensity cut-off filter: 5%; see Figure  2-27 (A)) to verify the correct
peptide spectrum match. 
The first step in re-calculating the precursor mass (m/z value) was to sum up the four iTRAQ intensities
(iTRAQtotal  intensity). For the example peptide, this equaled an intensity of iTRAQ total  intensity= 26,525.68 (compare
Figure  2-27 (B)).  Each of the four iTRAQ reporter  ion intensities  were then set  into relation to this value,
resulting  in  values  referred  to  as  iTRAQrelative  intensity(x)  with  x  =  114  to  117.  The  corresponding  percentile
distribution is illustrated by a pie-chart (Figure 2-27 (C)). As shown by zoom-in for the lower m/z area (Figure 2-
27 (B)), iTRAQ114 dominated the remaining iTRAQ reporter ions channels with a very high relative intensity of
iTRAQrelative intensity 114 =  64.52%. 
To correct the iTRAQ modification mass, classically utilized (144.102063 Da) for the observed distribution
(here: with over dominating iTRAQ114), each of the relative intensities were multiplied by its known and correct
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modification mass. For iTRAQ114, the relative intensity (0.6452) was multiplied by 144.105918 Da resulting in a
value of  iTRAQpart_114  = 92.970245 Da (see box in Figure  2-27 (D)).  Finally,  all  four product  values  were
summed  up  (see  histogram  in  Figure  2-27 (D)). This  resulted  in  the  new  iTRAQ  modification  mass
(iTRAQcorrected  = 144.104275 Da), which was highly specific for this MS/MS spectra. This value was utilized
instead  of  the standard iTRAQ mass (144.102063 Da)  to  re-calculated  the  precursors  mass  and m/z  value,
respectively.  For  the  Peptide-Spectrum-Match  shown here,  the  newly  calculated  iTRAQ modification  mass
(iTRAQcorrected) differed by 0.002212 Da to the classically applied iTRAQ mass (iTRAQ116&117). This difference,
which  was  solely introduced  during  precursor  mass  calculation  and  did  not represent  an  experimental
measurement  error,  caused  a  mass  shift  to  2.1  ppm. For  the  iTRAQ intensity  corrected  modification  mass
(iTRAQcorrected), the mass deviation was calculated to be 0.7 ppm, which was significantly more accurate.   
Figure  2-27: Workflow applied in this study to re-calculate the peptides precursor mass for every spectrum
separately. (A) represents the acquired and annotated HCD MS/MS spectra;  (B) a zoom-in of the lower m/z
region with the four iTRAQ reporter ions and their raw intensities; (C) pie-chart demonstrating the impact of
each  iTRAQ reporter  ion  to  the  sum of  all  four;  (D)  the  specific  iTRAQpart values  and  their  final,  newly
calculated iTRAQ mass. 
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The Application of Highly Specific iTRAQ Modification Masses
The workflow to re-calculate the precursor mass (m/z value) described above was additionally applied to
the four iTRAQ channels measured separately (iTRAQ-114 to iTRAQ-117) and the six different iTRAQ ratio
samples (samples A1:1:1:1 to F1:4:1:1). The developed algorithm was not only calculating the precursor mass (m/z)
based  on the  iTRAQ reporter  ions observed,  but  also used the classical  approach  (iTRAQ116&117 masses)  to
validate the correctness of the calculations compared to Proteome Discoverer. Here, the differences introduced
were smaller than 0.05 ppm and were related to the combinational effect of different decimal places used during
calculation and the formation of 1 ppm bins for data visualization.  
Figure 2-28: The frequency of peptides identified within the bins of -10 to +10 ppm for the samples A (1:1:1:1) to
F(4:1:1:1) were plotted with (iTRAQcorrected, red color) and without (iTRAQ116&117, blue color) utilization of the re-
calculation algorithm.
For sample A1:1:1:1, a high mass accuracy was observed (0.5 ppm) even without iTRAQ modification mass
correction, as it was expected due to the outbalancing effect of iTRAQ114 and iTRAQ115. However, the little shift
to positive values can be explained by the higher mass difference of iTRAQ114 compared to iTRAQ115. This effect
was not observed after  the iTRAQ reporter ion intensities were taken into account.  Here,  the median mass
accuracy was calculated to be 0.0 ppm (exactly -0.01 ppm). Additionally, the frequency of PSMs within the ±0
ppm bin increased and the number of PSMs was distributed equally in the ±1 ppm bins (Figure 2-28 (A)). For
the sample B(1:1:1:1), a similar effect was observed (Figure 2-28 (B)). In Sample C(4:3:1:1), the effect of dominating
iTRAQ114 was  more  significant  with  +1.7  ppm.  By  using  the  re-calculation  algorithm,  the  mass  accuracy
improved by 1.1 ppm to a final (averaged) value of 0.6 ppm. Again, a higher number of PSMs were found within
the ±0 ppm bin (Figure 2-28 (C)).  Only for sample D(3:4:1:1) was a slightly negative effect observed after re-
calculation (before: -0.3 ppm and after re-calibration: -0.4 ppm). Currently, the cause of this effect is unknown.
For  the  highly  differentially  regulated samples  E(4:1:1:1) and  F(1:4:1:1),  the  effect  of  improved  precursor  mass
calculation was significant. For sample E, the mass deviation decreased from 2.8 to 0.6 ppm and from -1.3 to
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-0.2 ppm for sample F, respectively. 
The improved mass accuracy described so far represented values, which might be observed in biological
samples. To demonstrate the maximal improvement by applying the re-calculation algorithm, samples iTRAQ-
114 to iTRAQ-117 were analyzed accordingly (Figure 2-29 (A - D)). 
Figure 2-29: The frequency of peptides identified within the bins of -10 to +10 ppm for the samples iTRAQ-114
to iTRAQ-117 (A - D) were plotted with (iTRAQcorrected, red) and without (iTRAQ116&117, blue) utilization of the re-
calculation algorithm.
As expected, the differences for iTRAQ-116 and iTRAQ-117 were negligible (mass accuracy greater than
0.1 ppm; (Figure 2-29 (C & D)). For iTRAQ-115, the mass accuracy increased from -2.8 ppm to 0.0 ppm. This
represented a shift of nearly 3 ppm, which was also demonstrated by its frequency histogram (Figure 2-29 (B)).
Before re-calculation, the largest mass deviation (+4.3 ppm) was observed for the sample iTRAQ-114. Taking
the iTRAQ intensity into account, the mass accuracy significantly improved (0.0 ppm, in average). Additionally,
the effect of higher mass deviations with a higher number of iTRAQ labelings attached was compensated. This
was demonstrated by the high number of PSMs within the ±0 ppm (53%), -1 ppm (20%) and +1 ppm (17%) bin,
respectively.
The distribution and statistical relevance of the identified peptides was plotted via a Whiskers-Box-Plot
(Figure  2-30),  as  it  was done for  the  original  data (Figure 2-25).  Before re-calibration,  the data with high
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iTRAQ114  and iTRAQ115  intensities  shifted to higher and lower mass deviations,  respectively.  Additionally,  a
broader distribution was observed. However, after re-calibration, the positive effect was not only recognize able
by the average mass deviation (in ppm), but also by smaller 5%; 95% and 25%; 75% values ( triangle and
vertical line endings).   
Figure  2-30: Whiskers-Box-Plots for the ten samples analyzed regarding the in-silico introduced mass shift.
Rectangular: median value; triangle: 1%, 99%; x: maximal values. Box-Plots represent values of 25, 50 and
75%.
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2.2.4 Conclusion
Relative quantification of proteins is a key feature to identify differentially regulated proteins of two or
more biological entities. Using isobaric tags for relative and absolute quantitation (iTRAQ) differences in protein
abundance  are  monitored  via  different  iTRAQ  reporter  ion  intensities  upon  precursor  fragmentation.
Consequently, the iTRAQ reporter ion distribution can be interpreted as a collection of differentially labeled
precursor ions, each with a specific mass which depends on the iTRAQ-4Plex reagent being used. 
This mass shift is induced by different iTRAQ reagents masses and is outbalanced if equally distributed
iTRAQ reporter ion intensities are present in MS/MS spectra. Generally, the intensity of iTRAQ reporter ions in
tandem MS spectra  is  linearly  correlated  to  the  corresponding  precursor  ion composition (see  Figure  1-4).
However,  by  increasing  the  amount  of  iTRAQ114 and  iTRAQ115 labeled  precursor  ions  for  fragmentation,
respectively, a mass shift (ppm) is introduced compared to the in-silico calculated peptide masses, which utilize
iTRAQ116&117 as the default input value for precursor mass calculation. This effect was most prominent in the
analyzed data set if precursor ions accumulated for MS/MS fragmentation were dominated by iTRAQ114 and
iTRAQ115, respectively. As iTRAQ reagents are coupled predominantly to primary amines (N-terminal & K) and
to a smaller extend to tyrosines, the mass shifting effect is also a function of the number of labelings attached. 
This difference in iTRAQ reagent masses also affected database search results, as a minimum precursor
mass tolerance window of 5 – 7 ppm was required for exclusively iTRAQ114 and iTRAQ115 labeled peptides. This
is  close  to  the  gold-standard applied  nowadays in  proteomics  experiments  (10 ppm),  reducing the allowed
experimental  mass  shift  to  3  ppm instead  of  10 ppm.  To compensate for  this  error  introduced  by  in-silico
calculation of the precursor mass, an algorithm was developed which used the iTRAQ reporter ion intensities to
re-calculated the precursor mass accordingly. With its application, the mass accuracy of samples dominated by
iTRAQ114 could significantly be improved from +4.3 to 0 ppm. 
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2.3 Y-iTRAQ – Accurate Identification of iTRAQ Tyrosine 
Labeled Peptides 
2.3.1 Introduction
The increasing mass accuracy and resolution of mass spectrometers has shown, that the non-equivalent
masses  of  the  four  iTRAQ-4Plex  reagents  affect  database  search  results.  Suitable,  high  resolution  MS
instruments have also allowed to detect and discover a variety of diagnostic immonium ions, such as for pY-
peptides or specific fragmentation pathways (190,286). However, a high number of MS/MS spectra still remains
unidentified (275). Only 5 - 20% of low resolution ion trap and 15 - 70% quadrupole TOF tandem MS spectra
are typically identified and validated peptide hits (287–290). In addition, it has been reported that the number of
identified peptides decreases after isobaric labeling. Here, the number of identified peptides decreases while the
mass of isobaric tags increases, i.e., iTRAQ-4Plex yields higher identification rates than TMT-6Plex or iTRAQ-
8Plex do (63,272). 
In order to establish a platform for relative quantification of (phosphorylated) peptides using isobaric tags,
in-depth  analysis  was  performed  to  further  validate  and  enhance  peptide  identifications  of  iTRAQ labeled
peptides. Modification of tyrosine, a side-reaction during iTRAQ labeling, is commonly neglected in database
search  approaches.  However,  the  Paragon  algorithm  of  the  software  suite  ProteinPilot  allows  for  this
modification. In contrast to conventional search engines in which discrete settings are required, peptide features
such as cleavage events, amino acid polymorphism or modifications are modeled with probability values by the
Paragon algorithm (275). Although the probability of the iTRAQ labeling is set considerably to lysine and N-
termini  (fixed groups;  Paragon probability:  0.993 and  0.932,  respectively),  the (relative)  high abundance of
iTRAQ labeled tyrosine, serine and threonine has been demonstrated recently (291) and is also regarded by the
Paragon algorithm  (variable groups;  Paragon probability: 0.036, 0.011, 0.0027, respectively). This is a rather
high frequency compared to biological relevant (dynamic) modifications, such as phosphorylation events (pS,
pT, pY with  Paragon probabilities of 0.002, 0.007 and 0.00001, respectively), which are often set as variable
modification  in  database  searches  although  no  phosphopeptide  enrichment  and  emphasis  analysis  was
performed. 
MS/MS spectra of peptides containing tyrosine exhibit an immonium ion at m/z 136.07 (292). Further, pY-
peptides frequently deliver a diagnostic ion at m/z 216.04 (190). Both immonium ions differ only by the mass of
a phosphate group (79.97 Da; Unimod Accession # 21). As both, the iTRAQ reagent and the phospho-moiety
bind to the phenolic hydroxyl group of tyrosine, an iY-iTRAQ-4Plex immonium ion at m/z 280.17 (136.07 Da
+144.10 Da) is expected. The aim of this section is to demonstrate the occurrence of this ion under different
fragmentation conditions and  to  analyze  their  fragmentation  pattern  and  influence  on  the  retention time of
reversed phase chromatography. 
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2.3.2 Material and Methods
2.3.2.1 Chemicals
Chemicals used in this study are summarized in chapter 4.1.
2.3.2.2 Sample Preparation and iTRAQ Labeling
Protein Digestion and iTRAQ-4Plex Labeling
The same ten protein-mix used to optimize iTRAQ labeled peptide fragmentation conditions (chapter 2.1)
was used in this section. In addition, a single protein (α-lactalbumin; 100 µg starting material) digestion and
iTRAQ-4Plex labeling was applied using the same workflow as for the ten protein-mix.
Phosphoprotein Digestion and iTRAQ-8Plex Labeling
The protocol applied for SDS-PAGE, in-gel digestion and subsequent iTRAQ-8Plex labeling is described in
chapter 2.4.2.2.  
Dephosphorylation and iTRAQ-4Plex Labeling of a Phosphopeptide Standard
Phosphopeptides were iTRAQ-4Plex labeled as described previously (chapter  2.1.2.1). Divergent to the
previous  protocol:  for  dephosphorylation,  the  sample  (131 phosphopeptides;  10  µL each)  was  split  in  two
aliquots  and  both  (D  for  dephosphorylation,  P1&2 for  phosphorylation)  were  dried  by  vacuum evaporation.
Afterwards, sample D was resolubilized in 40 µL alkaline phosphatase buffer (1:10 diluted; supplied by Roche
Diagnostics GmbH) and 20 U of alkaline phosphatase were added. The reaction mixture was incubated at 37°C
for 3 h with gentle shaking. Heat inactivation of the alkaline phosphatase was performed by incubation of the
samples at 95°C for 10 minutes. Afterwards, sample D was evaporated to dryness. Both samples (D & P) were
resolubilized in 35 µL buffer A (25% ethanol, 50% iTRAQ dissolution buffer (both provided by AB SCIEX),
23.75% H2O and 1.25% EDTA solution (10mM)). 40 µL of iTRAQ reporter ion solution were added to each
sample accordingly: iTRAQ-4plex-114 P1; iTRAQ-4plex-116 P2; iTRAQ-4plex-115 sample D. After labeling,
each sample was evaporated to dryness and resolubilized for 10 minutes in 20 µL of 3% ACN with 0.1% FA.
Finally, samples were diluted to a total of 30 µL. For LC-ESI MS measurements, 2 µL of sample were injected
per run (only LTQ Orbitrap Velos).    
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2.3.2.3 Mass Spectrometry, Database Searches and Data Analysis 
LC-ESI MS on a LTQ Orbitrap Velos Equipped with ETD Support
Instrumental Setup
The same measurement parameters as described previously (phosphopeptide mix-2 and ten protein-mix,
chapter 2.1) were applied. In addition to CID-IT and HCD, also PQD was used for fragmentation and analysis in
the ion trap mass analyzer (iTRAQ-4Plex labeled ten protein-mix). Again, 18 raw files with different collision
energies were recorded (0 – 85% NCE; only PQD). For peptide separation, the LC-ESI MS setup was unchanged
except specific PQD settings: activation Q 0.9; activation time 0.1.      
For  ETD analysis, a TOP 5  Nth order double play method was applied to analyze the singly digested
protein  α-lactalbumin.  Samples  were  loaded  with 30 µL/min and  separated  using  300 nL/min.  For  peptide
separation, a shorter gradient was applied: 5 – 10% B within 1 min, 10 – 15% B within 1 min, 15 – 40% B
within 9 min, following column washing (40 – 95% B within 1 min kept constant for 1 min, followed column re-
calibration at 5% B for 15 min). MS full scans were recorded in the Orbitrap mass analyzer with a resolution of
30,000.  Subsequently,  the  five  most  intense  precursor  ions  were  selected  (isolation  window of  3  Da)  and
fragmented with ETD using a minimal signal required of 500 (counts), a default charge of 2+, an activation Q
and time of 0.25 and 160 ms, respectively. First mass was set to m/z 100. Lock mass correction was enabled with
m/z 445.120024. Precursor charge states < 2+ were rejected. Dynamic exclusion list options were: repeat count 1,
repeat duration 30, exclusion list size 500, exclusion duration 30 sec, exclusion mass width relative to low/high ±
10 ppm.      
Database Searches
Recorded .raw files (iTRAQ-4Plex only) were searched using Proteome Discoverer (1.4) against the bF-
FASTA (see chapter  2.1.2.3). For analyzing the phosphopeptide standard, the same FASTA file was used but
without the E. coli proteins. For the iTRAQ-8Plex samples, the same bF-FASTA file was used.   
The workflow applied was build up by 11 different nodes with default settings if not otherwise specified:
(0) Spectrum Files; (1) Spectrum Selector, (2) MS2-Spectrum Processor, (3) & (7) Scan Event Filter to split into
CID and HCD fragmentation; (4) & (8) SEQUEST HT (see ten protein-mix in chapter 2.1.2.3); (5) phosphoRS
3.0;  (9)  Reporter  Ions  Quantifier  (iTRAQ-4Plex,  respectively  (Thermo  Scientific  Instruments;  Integration
Tolerance 20 ppm; Most Confident Centroid as Integration Method; Additional Settings: Show the Raw Quan
Values;  Apply Value  Corrections,  use  All  Peptides  enabled  and  deactivated  Experimental  Bias);  (10)  Event
Detector; (11) Precursor Ions Area Detector and (12) Percolator. 
For PQD and ETD data, only the Scan Event Filter was changed to PQD (ion trap) and ETD (Orbitrap),
respectively. Settings for the mass analyzers remained unchanged.  
-91-
 2 Developing a Platform for relative Quantification using iTRAQ
Data Analysis
The following analysis was performed for the iTRAQ-4Plex labeled ten protein-mix and iTRAQ-8Plex
labeled phosphoprotein sample acquired on the LTQ Orbitrap Velos. Peptide-Spectrum-Matches (PSMs) were
filtered for high confidence (FDR = 1%) and exported to .txt files. 
Firstly, exported PSMs were filtered for iTRAQ-4/8Plex modifications on tyrosine, respectively. An  in-
house written  Command  Line  Interface (CLI)  script  (using  GAMBAS)  was  used  to  count  the  number  of
identified peptides  of  the  Y-iTRAQ modified peptide and its  unmodified  counterpart  in  all  recorded  2x 18
(iTRAQ-4Plex; ten protein-mix) and 9 (iTRAQ-8Plex; phosphoprotein sample) LC-ESI MS runs, respectively.
Simultaneously, the median of the retention time of each peptide (Y-iTRAQ and its unmodified counterpart,
respectively) was calculated and used to analyze potential retention time shifts after iTRAQ labeling (Table 2-6
& 2-7). To compare precursors intensities of Y-iTRAQ labeled peptides with their unmodified form, extracted
ion chromatograms (XICs) for each precursor were calculated and exported using XCalibur. Data were imported
into QtiPlot for visualization (Figure 2-40).     
For automated fragment ion matching of MS/MS spectra, an in-house written CLI script (GAMBAS) was
used. Here, the precursor mass and the corresponding b- and y-fragment ions (minimum fragment ion charge
state = 1+; max.: precursor charge state) were imported and automatically annotated using a ±20 ppm fragment
ion window (Orbitrap mass analyzer). Only m/z signals having a relative intensity of 5 (HCD data) or 1% (ETD
data) compared to the base peak were used for annotation. For CID and PQD data (ion trap), a cut off filter at 1%
of the most intense peak was applied. The mass accuracy was 0.2 Da at m/z 400, equaling a mass accuracy
windows of 500 ppm. The generated tab-separated lists were finally imported into QtiPlot for visualization. 
For analyzing the relative intensities (intensity of ion of interest versus the most intense signal in spectra) of
specific peptide signals,  the same framework utilized previously (chapter  2.1) was used in this section with
minor modifications. Peptide features of HCD data (retention time (RT), charge state (z) and m/z value) for both,
the  modified  (Y-iTRAQ)  and  unmodified  form,  were  used  to  identify  the  corresponding  spectra  with  the
following settings: retention time (RT) window of 5 min; mass deviation of maximal 20 ppm. Here, the intensity
of  the  precursor  [M],  iTRAQ  reporter  ions,  undissociated  iTRAQ  (iTRAQ  +  Balancer  Group),  tyrosine
immonium ion (iY),  tyrosine immonium ion with intact  iTRAQ (iY-iTRAQ) and the most intense signal in
spectra (base peak) were exported for each spectra,  m/z value,  charge state and NCE, respectively.  Finally,
features were grouped (with: same m/v value (20 ppm), charge state, RT (5 min) and NCE) for median and
standard deviation calculation. The four iTRAQ reporter ion signals were grouped and averaged. All monitored
ions were set into relation to the base peak. Finally, data were plotted versus the applied NCE value ( Figure 2-
38).
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LC-ESI MS on a Synapt G2s
Instrumental Setup
Nano-HPLC tandem mass spectrometric experiments were performed on a Dionex U3000 (Dionex, Idstein,
Germany)  coupled  to  a  Synapt  G2s (Waters,  Milford,  MA).  Solvents  and  flow rates  for  HPLC remained
unchanged  compared  to  the  previously  described  setup  of  the  LTQ  Orbitrap  Velos.  iTRAQ-4Plex  labeled
peptides originated from α-lactalbumin digestion were separated using the following gradient: 5% B to 10% B
within 1 minute, linear increase from 10% B to 50% B within 40 min, followed by a column wash step (5 min)
with a linear gradient from 50% B to 95% B. Inter run equilibration of the analytical and pre-column was set to
11 minutes.
Synapt G2Ss source temperature was set to 80°C, and the sampling cone and source offset voltage to 40
and 80 V, respectively. Full MS scans were recorded for 1 sec in resolution mode using continuum data format.
Lowest and highest masses were set to m/z 300 and 2,000. For MS/MS, a maximal scan time of 0.5 sec was
allowed. The lower mass range was enlarged to m/z 50, keeping the highest mass constant. No lockmass was
used for the analysis. Trap collision energy was increased in 5 eV increments, starting with 0 eV ending with 100
eV, resulting in a total of 21 LC-ESI MS runs. 
Data Conversion and Database Search
Recorded .raw folders were converted to .mgf file using ProteoWizard (Version 3.0.5759; (293)). Files were
re-written using an  in-house build script (GAMBAS) to be compatible for database search using SearchGUI
(Version 1.16.2;  (294)) and PeptideShaker (Version 0.25.2;  (295)). The database search was only performed to
ensure  comparable  retention  times  of  the  peptide  species  via  the  21  LC-ESI  MS  runs.  The  final  peptide
identification was performed manually. Search settings were: 10 protein-mix FASTA file containing the used
proteins; enzyme specificity was set to trypsin;  fixed modification: carbamidomethyl (C),  iTRAQ-4Plex (N-
Terminal & K); variable modifications: oxidation (M), iTRAQ(Y); max. missed cleavage: 2; precursor mass
tolerance: 200 ppm; fragment mass tolerance: 0.5 Da; fragment ion type: b and y ions; min and max precursor
charge  state:  2+ and  5+,  respectively.  As  done  for  LTQ  Orbitrap  Velos  data,  the  peptide  of  interest
(VGINYWLAHK) was manually validated by fragment ion annotation (see LTQ Orbitrap Velos data analysis
section)  and  LC retention  time within the  21 raw files  recorded.  For  visualization  purpose,  spectra  with  a
collision energy of 45 eV were chosen (100 ppm, cut-off filter: 2.5% of most intense ion). The analysis of the CE
versus relative intensity plots (Figure 2-38) were done as described before for LTQ Orbitrap Velos HCD data.
Solely, the mass accuracy window was enlarged to 100 ppm. 
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LC-MALDI MS on an AB SCIEX MALDI TOF/TOF 5800 
Instrumental Setup
Prior to MS analysis with a MALDI TOF/TOF 5800 mass spectrometer (AB Sciex, Darmstadt, Germany),
two technical replicates were separated on a Dionex U3000 nano-LC system (Dionex, Idstein, Germany) and
subsequently spotted on a MALDI target (AB Sciex) using a Probot microfraction collector (Dionex). One µL of
iTRAQ-4Plex  labeled  peptides  originated  from  α-lactalbumin  digestion  were  injected  for  each  technical
replicate. Columns, solvents and flow rates applied for peptide separation were the same as described above for
LTQ Orbitrap Velos setup with the exception that eluates A and B (mirco-pump) contained TFA instead of FA.
After desalting the samples 4 min on the trap column, the following gradient was applied: 5 to 10% B in 1 min,
10 to 50% B in 55 min, 50 to 95% B in 10 min, 95% B for 5 min, 95 to 5% B in 0.1 min, 5% B for 19.9 min. The
eluate from HPLC separation was automatically mixed in a ratio of 1:3 (3 mg/mL in 70% ACN, 0.1% TFA with
CHCA matrix, 14 nM Glu-fibrinopeptide B as internal calibrant) and spotted onto the target from 10 to 84 min
(15 s intervals per spot).
Default calibration with the 4700 Proteomics Analyzer Standards Kit was performed in MS and MS/MS
mode prior to MS measurements. In addition, MS spectra were internally calibrated to Glu-fibrinopeptide B. MS
spectra of the fractions 25 to 65 minutes were acquired in a mass range of 700 to 4000 m/z with 1000 total shots
per spectrum. Precursors were selected by the 4000 Series Explorer Software (AB SCIEX) using the following
criteria: minimum S/N ratio: 25; minimal fraction width: 1; maximal precursors per spot: 10. MS/MS spectra of
the strongest precursors were acquired first at either medium or high gas pressure with 3000 total shots per
precursor.
Data Conversion
Spectra were exported to .mgf files using the TS2Mascot software (version 1.0.0, Matrix Science, London,
UK). Settings were: export of peaks from 60 Da to 35 Da below the precursor mass; minimum of S/N ratio: 0;
monoisotopic  peaks  only.  Subsequently,  database  searches  were  performed  using  Proteome  Discoverer  to
validate peptide identifications in addition to manual spectra validation by fragment annotation (see  above).
Database Searches
Proteome Discoverer workflow was build up by 5 different nodes with default settings if not otherwise
specified: (0) Spectrum Files; (1) Spectrum Selector (min precursor mass: 700 Da, max precursor mass: 4000
Da), (2) Scan Event Filter (Mass Analyzer: TOFMS); (3) Mascot (Version: 2.2.07, further details see below) and
Target Decoy PSM Validator. A Mascot database search versus a 10 protein-mix FASTA file containing cRAP
like proteins (see chapter 4.3) with a maximum of 2 missed cleavage sites allowed was performed. Instrument
was set to MALDI-TOF-TOF with a precursor mass tolerance of 100 ppm and a fragment mass tolerance of 0.3
Da.  Other  settings:  fixed  modifications:  carbamidomethyl  (C),  iTRAQ-4Plex  (N-terminal  &  K);  dynamic
modifications: iTRAQ (Y), phosphorylation (S,T,Y), oxidation (M). For spectra annotation, a ppm window of
100 and an intensity cut-off of 2.5% of most intense signal was set.
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2.3.3 Results
2.3.3.1 Detection of iY-iTRAQ-4Plex Specific Immonium Ions
iTRAQ-4/8Plex reagents are coupled via NHS chemistry onto primary amines of peptides (N-termini and
lysine  side  chains).  However,  to  a  smaller  extent  (<  3%;  (60))  the  reagents  can  also  react  with  tyrosine's
hydroxyl-group (Figure 2-31). 
Using higher collision induced dissociation (HCD) on the Orbitrap Velos  and  beam-type CID on TOF
instruments, the generation of the prominent tyrosine immonium ion (iY) at m/z 136.07 is a known fact. After
phosphorylation (and its increase in mass (+ 79.96 Da)) a characteristic immonium ion (pY, m/z 216.04) is
observable for phosphotyrosine (see  Figure 2-31 and chapter  2.1.3.1).  Consequently,  for Y-iTRAQ modified
peptides, which are also bound via the hydroxyl-group to tyrosine, a specific immonium ion should be detectable
after HCD fragmentation at m/z 280.17.  
Figure 2-31: Structure and m/z value of the immonium ions generated after MS/MS fragmentation for the native
(-H), phosphorylated (H3PO4) and iTRAQ labeled tyrosine.
In the following, iTRAQ-4Plex labeled tandem MS data upon HCD fragmentation on the LTQ Orbitrap
Velos will be described. Within the ten protein-mix analyzed, the peptide VGINYWLAHK (Figure 2-32) was
confidently identified in two forms: (i) one was iTRAQ labeled at the N-terminus and at the ε-amino group of
lysine (m/z: 744.93, z=2+; referred to as unmodified, iVGINYWLAHiK), whereas the second form (ii) showed an
additional iTRAQ modification on position Y5 (m/z 816.98; z = 2+; iVGINiYWLAHiK)). The annotated spectra
of the unmodified iTRAQ tyrosine peptide (Figure 2-32 (A)) showed an outbalanced b- and y-ion series with
intense iTRAQ reporter ions. The b-ion series could be identified from b1+ – b8+; except b6+ and b9+, which did not
pass  the filter  set  to  20 ppm and the relative intensity cut-off  set  to 5%, respectively.  Similar  results were
observed for the y-ion series. All fragment ions were matched from y1+ to y7+. y8+ and y9+  did not pass the mass
accuracy filter set. The y10+  fragment ion was only monitored as non dissociated precursor ion [M+2H]2+. The
peak  labeled  with  an  asterisk  (*)  represented  the  charge  reduced  intact  precursor  with  a  loss  of  iTRAQ.
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Undissociated but singly charged iTRAQ (m/z 145.10) was also detected with a relative intensity of 50% (not
marked in (Figure 2-32)). The iY immonium ion at m/z 136.07 was observed with a relative intensity of 1.3%.
For the Y-iTRAQ modified form (Figure 2-32 (B)), a similar fragment ion pattern was observed. All but
four fragment ions (b9+,  b10+,  y8+ and y10+) could be matched. After labeling tyrosine with iTRAQ, a shift of
+144.10 Da for the b5+ (m/z 691.38 → 835.48) and y6+ (m/z 961.53 → 1105.63) masses (and following ones) was
observed. The manual annotation confirmed, in addition to the precursor mass and identification by SEQUEST,
the correct  peptide identification in both forms. The proposed Y-iTRAQ immonium ion (iY-iTRAQ) at  m/z
280.17 was detected for the Y-iTRAQ modified form (Figure 2-32 (B)) but not for the unmodified one; its
relative intensity was 3.3% (compared to the most intense signal in the spectrum).    
Figure 2-32: Annotated MS/MS spectra after HCD fragmentation (LTQ Orbitrap Velos) shows the b- and y-ions
matched for the peptide VGINYWLAHK in its typical iTRAQ labeled form  iVGINYWLAHiK (A) and with an
additional iTRAQ labeling at tyrosine iVGINiYWLAHiK (B). The additional iTRAQ modification is observable by
a mass increase of +144.10 Da for the b5+ and y6+ (and following) ions. At m/z 280.17, the Y-iTRAQ(-4Plex)
immonium ion is labeled and only present in the modified form (B).  The peaks labeled with an asterisk (*)
belong to the intact precursor ion, which has lost one (charged) iTRAQ labeling (+ balancer group).
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Using Q-TOF and TOF/TOF instruments, which also generate beam-type CID spectra, the same peptide
(VGINYWLAHK) was analyzed in its unmodified and Y-iTRAQ labeled form on the Synapt G2s (LC-ESI MS)
and the AB Sciex 5800 MALDI TOF/TOF (LC-MALDI MS).
For the 2+ charged precursor (Synapt G2S, Figure 2-33), the a- (a3+ – a6+), b- (b1+ – b6+) and y-ion (y1+ – y5+)
series were observed for the unmodified form. Most of the immonium ions were present but not fulfilling the
mass accuracy criteria or intensity cut-off filter set.  The coverage of a-, b- and y-ion series of the Y-iTRAQ
modified form were similar (a3+ – a6+; b1+ – b8+; y1+ – y8+), also including the Y-iTRAQ modified b5+- and y6+-ions.
Using a collision energy of 45eV, the iY-iTRAQ immonium ion (m/z 280.17) intensity was (approximately) half
the intensity of the iTRAQ reporter ions. Consequently, this diagnostic ion was one of the most intense signals in
the spectra. 
Figure 2-33: Annotated MS/MS spectra after CID fragmentation (Synapt G2s, ESI mode) shows the b- and y-
ions matched for the peptide VGINYWLAHK in its common iTRAQ labeled form iVGINYWLAHiK (A) and with
an additional  iTRAQ labeling  on  the  tyrosine  iVGINiYWLAHiK (B).  The  additional  iTRAQ modification  is
observable by a mass increase of +144.10 Da for the b5+ and y6+ (and following) ions. For the latter, the Y-
iTRAQ immonium is present at m/z 280.17, whereas the tyrosine immonium ion (m/z 136.07) shows a similar
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intensity for the doubly iTRAQ derivatized form (A). 
Switching to LC-MALDI MS (AB SCIEX 5800 MALDI TOF/TOF), in which predominantly 1 + charged
precursors are formed during ionization, an almost complete sequence coverage was observed (Figure 2-34). For
both peptide species, the b1+ – b9+and y1+ – y9+ ion series were identified. Additionally, the complete a-ion series
was matched but a4+ for the unmodified and a8+ and a9+ for the Y-iTRAQ modified form (not annotated in spectra).
Taking advantage of TOF instruments to detect low mass ions, all but two (iG & iI) immonium ions were present
(not annotated in spectra). Importantly, the iY-iTRAQ immonium ion at m/z 280.17 was present in the modified,
but missing in the unmodified form. The intensity of this ion was approximately 15% and 10% compared to the
iTRAQ reporter ions for high and medium gas pressure (Figure 2-34 (B, D)).
Figure  2-34: Annotated MS/MS spectra after  CID fragmentation (AB SCIEX 5800 MALDI TOF/TOF) with
higher (A, B) and medium gas pressure (C, D) for the peptide VGINYWLAHK in its native iTRAQ labeled form
iVGINYWLAHiK (A,C) and with the additional iTRAQ labeling on tyrosine  iVGINiYWLAHiK (B,  D).  The Y-
iTRAQ immonium at  m/z  280.17  is  only  present  in  the  Y-iTRAQ modified  form and more  prominent  after
fragmentation with higher gas pressure (B). Matrix used for MALDI measurements was CHCA. 
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Figure  2-34 (continued):  Annotated  MS/MS  spectra  after  CID  fragmentation  (AB  SCIEX  5800  MALDI
TOF/TOF) with higher (A, B) and medium gas pressure (C, D) for the peptide VGINYWLAHK in its native
iTRAQ labeled form iVGINYWLAHiK (A,C) and with the additional iTRAQ labeling on tyrosine iVGINiYWLAHiK
(B, D). The Y-iTRAQ immonium at m/z 280.17 is only present in the Y-iTRAQ modified form and more prominent
after fragmentation with higher gas pressure (B). Matrix used for MALDI measurements was CHCA. 
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Low m/z ions (such as iTRAQ reporter ions) are difficult to detected in ion trap mass analyzers due to their
instabilities while trapping (208); which is referred to as 1/3rd cut-off. Therefore, the lowest m/z value monitored
for the peptide VGINYWLAHK was m/z 210 using CID-IT fragmentation on the LTQ Orbitrap Velos. The ion
series coverage was comparable for both (Figure 2-35), the unmodified and Y-iTRAQ modified form (b1+ – b9+,
y1+ – y9+ but b1+ for the modified form), validating the correct peptide identification. In contrast to quadrupole like
fragmentation techniques, the iY-iTRAQ immonium ion was not detected (CID-IT). 
Figure 2-35: Annotated MS/MS spectra after CID fragmentation (Orbitrap Velos, recorded in ion trap) shows
the b- and y-ions matched for the Peptide VGINYWLAHK in its typical iTRAQ labeled form iVGINYWLAHiK (A)
and with an additional iTRAQ labeling on the tyrosine iVGINiYWLAHiK (B). The additional iTRAQ modification
is observable by a mass increase of +144.10 Da for the b5+ and y6+ (and following) ions.
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PQD is a fragmentation technique introduced to overcome the problem to detect low m/z ions in ion traps.
It  was  also  used  to  analyze  the  presence  of  the  iY-iTRAQ  immonium  ion.  Similar  to  CID  in  ion  trap
fragmentation, an almost complete ion series was detectable (b2+ – b9+, y1+ – y9+  but b1+ & b2+ for the modified
form;  Figure  2-36).  However,  the  iY-iTRAQ immonium was  not  detected.  Because  neither  the  iY-iTRAQ
immonium ion nor iTRAQ reporter ions were detected, the fragmentation settings for PQD may need to be
further optimized. 
Figure 2-36: Annotated MS/MS spectra after PQD fragmentation (LTQ Orbitrap Velos) shows the b and y-ions
matched for the Peptide VGINYWLAHK in its common iTRAQ labeled form iVGINYWLAHiK (A) and with an
additional iTRAQ labeling on the tyrosine iVGINiYWLAHiK (B).
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ETD is a fragmentation technique generating c- and z-ions and therefore compliments collision induced
fragmentation techniques. ETD was also used to fragment the peptide  VGINYWLAHK in both modifications
forms (Figure 2-37). Using a relative long activation time (160 ms) to fragment the 3+ charged precursor ion, an
almost complete ion series was observed for the unmodified peptide (c1+ – c8+, z1+ – z9+, (Figure 2-37 (A)). For
the Y-iTRAQ modified form (Figure 2-37 (B)), the ions c2+ – c4+ , c6+ and z1+ – z9+ were matched. Both immonium
ions (iY at m/z 136.07 and iY-iTRAQ at m/z 280.17) were not detectable, similar to CID and PQD.  
Figure  2-37:  The annotated  MS/MS spectra after  ETD fragmentation (Orbitrap  Velos,  spectra  recorded  in
Orbitrap mass analyzer) for the peptide VGINYWLAHK in its native iTRAQ labeled form iVGINYWLAHiK (A)
and with the additional iTRAQ labeling on tyrosine iVGINiYWLAHiK (B).
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2.3.3.2 Y-iTRAQ Immonium Ion Formation in Dependance of Collision Energy
As shown previously, the intensity of pY immonium ion from pY-peptides increased with applied collision
energy (see chapter 2.1.3.1). In contrast, the Y-iTRAQ-4Plex immonium ions carry a group (iTRAQ + balancer
group) which is designed to dissociate readily. Therefore, the Y-iTRAQ-4Plex modified peptides were further
analyzed to evaluate how the precursor [M], iTRAQ reporter ions [iTRAQ], non-dissociated iTRAQ (= iTRAQ
+ balancer group, [non-dissociated iTRAQ]) and the tyrosine related immonium ions [iY and iY-iTRAQ-4Plex]
were present in spectra at different collision energies. For analysis, the 2+ charged precursors of the peptide
VGINYWLAHK was chosen and subjected to fragmentation by LC-ESI MS on the LTQ Orbitrap Velos (HCD
fragmentation) and Synapt G2S (CID, trap fragmentation).
In  agreement  with  previous  results  for  HCD  fragmentation  (Orbitrap  Velos;  see  chapter  2.1.3.1),  the
precursor ion represented the most intense ion for 2+ charged precursors in spectra up to an NCE of 35% (Figure
2-38 (A & B)). With a further increase of 10%, the precursor was no longer detectable. The iTRAQ reporter ion
signal  reached  highest  signal  intensity  when  NCE  energies  ≥ 40%  were  applied.  Undissociated  iTRAQ
represented a singly charged ion liberated from precursors without further dissociation and showed its maximal
relative intensity at 40% NCE. A further increase in NCE lead to a drop in intensity, possibly caused by a further
fragmentation into reporter ions.
For the unmodified peptide, the tyrosine immonium ion (iY) at m/z 136.07 was detectable after applying an
NCE of 40% and its intensity increased linearly with NCE (Figure 2-38 (A), blue line). In contrast, the iY-
iTRAQ-4Plex immonium ion (iY-iTRAQ) behaved very differently (Figure 2-38 (A),  green line):  for NCEs
between 35  –  40%, this ion was detectable and its intensity increased up to 60% NCE. At higher NCEs, its
intensity dropped, but still had an intensity of approximately 20% compared to iTRAQ reporter ions at 85%
NCE. 
For the Synapt G2s, which was operated in trap CID mode (from 0 to 100 eV in 5eV steps per LC run),
similar trends were observable. For the unmodified form (Figure 2-38 (C)), the tyrosine immonium ion (iY)
increased  in  intensity  with  increasing  CE  as  observed  for  HCD  fragmentation.  The  undissociated  iTRAQ
reporter  ion  (iTRAQ +  balancer  group)  was  decreasing  with  increasing  CE values  after  exceeding  40  eV.
However, the most prominent difference was observed for the iY-iTRAQ immonium ion compared to HCD data
(Figure 2-38 (D)): for CE values of 60 – 65 eV, the ion intensity was comparable with iTRAQ reporter ions. A
further increase in CE resulted in a lower relative intensity of iY-iTRAQ as seen for HCD fragmentation.    
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Figure 2-38: The relative intensity (see Material and Methods for description) was calculated for the precursor
[M],  the  non-dissociated  iTRAQ reporter  ions  (iTRAQ + balancer  group),  iTRAQ reporter  ions  iTRAQ 114-
iTRAQ117,  tyrosine  iTRAQ-4Plex  immonium  ion  (iY-iTRAQ-4Plex)  and  the  tyrosine  immonium  ion  (iY)  at
different collision energies (NCEs & CEs) for the peptide VGINYWLAHK. Ion properties were calculated for the
common iTRAQ modified  (iVGINYWLAHiK, (A, C)) and the Y-iTRAQ modified form (iVGINiYWLAHiK, (B, D))
for 2+ charged precursors.  HCD data (LTQ Orbitrap Velos;  A,B) and CID data (Synapt  G2S; C, D) were
compared to demonstrate similar fragmentation pattern.
2.3.3.3 Detection of iY-iTRAQ-8Plex specific Immonium Ions
After demonstrating the presence of an iY-iTRAQ immonium ion for iTRAQ-4Plex labeled peptides, a
dataset of iTRAQ-8Plex labeled phosphoproteins was investigated to evaluate the presence of an iY-iTRAQ-
8Plex  immonium ion  after  beam-type  CID  fragmentation,  although  the  structure  of  iTRAQ-8Plex  has  not
published. 
The peptide LFRQFYQLD was used as an example, which was identified in both forms (with and without
iTRAQ modification, Figure 2-39). After HCD fragmentation of the 2+ charge precursor, the matched number of
b-  and  y-fragment  ions  by  SEQUEST  was  significantly  higher  for  the  unmodified  peptide  (10/18;
iLFRQFYQLD) rather than the modified (iLFRQFiYQLD) form (7/18). Not all of the fragment ions matched by
SEQUEST exceeded the intensity cut-off value of 1% (compared the most intense signal in spectra) used to mark
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fragments ions in tandem MS spectra in Figure 2-39. Within the peptide, tyrosine is located at the sixth position.
Both b62+ ions were detected at m/z 580.33 and 732.43 for the unmodified and modified form, respectively. This
clearly showed the correct identification of this peptide in addition to validate the peptide by database search. 
For the modified form (iLFRQFiYQLD, Figure 2-39 (B)), a signal at m/z 440.28 was detected with a high
intensity similar to the remaining b- and y-ions. This signal matched to the theoretically calculated iY-iTRAQ-
8Plex immonium ion. Supportingly, this ion was not detectable in the unmodified form. 
Additionally, an iTRAQ-8Plex modified tryptic peptide (EPMIGVNQELAYFYPELFR,  Figure 2-39 (C))
was also analyzed. For the unmodified form ( iEPMIGVNQELAYFYPELFR), 17 of 38 b- and y-fragment ions
could be matched by SEQUEST. For the Y-iTRAQ-8Plex labeled form (iEPMIGVNQELAiYFYPELFR), slightly
more fragment ions could be matched (21/38). The iY-iTRAQ-8Plex specific immonium ion at m/z 440.28 was
again only present in the Y-iTRAQ modified peptide (Figure 2-39 (D)). This indicates its uniqueness in terms of
detection. 
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Figure 2-39: Annotated MS/MS spectra after HCD fragmentation (LTQ Orbitrap Velos) shows the b- and y-ions
matched for the Staphylococcus aureus V-8 Protease (GluC) derived peptide LFRQFYQLD (A, B) and the tryptic
peptide  EPMIGVNQELAYFYPELFR  in  its  common  iTRAQ  labeled  form  iLFRQFYQLD  (A),
iEPMIGVNQELAiYFYPELFR (C) and with an additional iTRAQ labeling on the tyrosine,  iLFRQFiYQLD (B),
iEPMIGVNQELAiYFYPELFR (D). The additional iTRAQ modification mass shift  is obvious for the b6+ (and
following) ions. For the latter,  the iY-iTRAQ immonium is present at  m/z 440.28, which equals the mass of
tyrosine immonium ion (m/z 136.07) plus an iTRAQ-8Plex labeling (+304.20 Da for iTRAQ 115,  118,  119  & 121 and
+304.21 Da for iTRAQ113, 114, 116 & 117; according to UniMod Accession numbers 730 and 731).
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2.3.3.4 Influence of iTRAQ tyrosine Labeling on the LC Retention Time
After  demonstrating the  uniqueness  of  iY-iTRAQ-4/8Plex immonium ions for  iTRAQ tyrosine  labeled
peptides, the influence of this additional iTRAQ modification was further investigated. Not only did the peptide
mass increase by 144.0995 Da (iTRAQ-4Plex)  and 304.2053 Da (iTRAQ-8Plex),  respectively,  but  also the
physiochemical properties of a peptide changed. Therefore, the retention time difference for unmodified and
iTRAQ tyrosine labeled peptides were compared to elucidate if one of the species eluted earlier by reversed
phase LC separation. Such information can be used to validate potential Y-iTRAQ modified peptides in large
scale iTRAQ proteomics studies. 
For the peptide VGINYWLAHK, the XICs of  the unmodified (red)  and Y-iTRAQ-4Plex labeled form
(blue) were extracted and plotted (Figure 2-39). Two pieces of information can be seen in this figure: First, the
XIC of the modified form (8.51x105)  was significantly lower compared to the unmodified form (1.16x107).
However, the modified form exhibits 7% of the unmodified maximal XIC intensity. Second, the Y-iTRAQ-4Plex
modified form eluted approximately 4 minutes earlier.  To verify if  this was reproducible for other peptides
showing both  modification  forms,  the  analysis  was  repeated  for  the  peptide  HIIVACEGNPYVPVHFDASV
(unmodified:  green and Y-iTRAQ-4Plex: pink) and NDTGSTDYGILQINSR (unmodified:  orange Y-iTRAQ-
4Plex: dark yellow). Again, the retention time shift was varying between three to four minutes. Here, the relative
intensity  of  the  Y-iTRAQ-4Plex  modified  forms  were  10  and  14%,  respectively.  This  high  XIC  ratio  was
unexpected due to the described number of side-reactions being smaller than 3%, but might be caused by the
excess of iTRAQ reagent used for labeling. A further set of 36 peptides was analyzed based on their retention
time difference between the unmodified and Y-iTRAQ-4Plex modified form (Table 2-6). Only for the peptide
VAGTWYSLAMAASDISLLDAQSAPLR,  a  higher  retention  time  was  observed  for  the  Y-iTRAQ-4Plex
modified peptide. The overall retention time difference was about 3.3 minutes.
A further analysis of the iTRAQ-8Plex labeled peptides showed similar results (Table 2-7). In total, 79
peptides  could  be  identified  in  both  forms  (unmodified  and  Y-iTRAQ-8Plex).  75  iTRAQ-8Plex  modified
peptides, equaling 95% of the peptides, elute earlier than their unmodified counterpart. Only four iTRAQ-8Plex
modified peptides did not follow this trend (marked bold in  Table 2-7). Three of the four peptides shared the
same peptide  structure  (T)VYQHQ(KA),  which  might  be an  indicator  that  this  is  a  peptide  specific  effect.
Moreover, these peptides eluted earliest (at approx. 22 min) compared to the remaining peptides listed in Table
2-7.  For  the forth peptide (QYLYQGPIVLNPWDQV),  the  higher  retention time of  the Y-iTRAQ modified
peptide cannot be explained.  In average, the difference in retention time between unmodified and Y-iTRAQ-
8Plex increased to 4.15 minutes. This might be caused by slight variations during LC separation or, more likely,
the overall bigger structure of iTRAQ-8Plex compared to iTRAQ-4Plex. 
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Figure 2-40: Overlay of Extracted Ion Chromatograms (XICs) for three tryptic peptides (iTRAQ-4Plex labeled)
being modified on the ε-amino and N-terminal amino group (upper row, unmodified) or carrying an additional
modification on tyrosine (lower row, Y-modified). 
__________________________________________________________________________________________
Table  2-6: Median retention times [min] and the number of features (counts) were calculated for the iTRAQ-
4Plex labeled ten protein-mix. Based on the total number of Peptide-Spectrum-Matches of 2x 18 LC runs, the
retention time differences  for  tyrosine  iTRAQ-4Plex  (Y-iTRAQ) labeled  and in its  native  form (unmodified,
without  iTRAQ  modification  on  tyrosine).  Except  one  peptide  (VAGTWYSLAMAASDISLLDAQSAPLR),  the
retention time for the Y-iTRAQ labeled peptide species was usually lower compared to the native form. 
Peptide Sequence Modification Median RT [min] 
Number of
Features
- (including the Y-iTRAQ) Y-iTRAQ native Y-iTRAQ native
TVYQHQK N-Term(iTRAQ4plex); Y3(iTRAQ4plex); K7(iTRAQ4plex) 23.74 24.92 2 128
RHGLDNYR N-Term(iTRAQ4plex); Y7(iTRAQ4plex) 25.59 25.84 53 166
HGLDNYR N-Term(iTRAQ4plex); Y6(iTRAQ4plex) 26.38 27.16 107 316
KYIPGTK N-Term(iTRAQ4plex); K1(iTRAQ4plex); Y2(iTRAQ4plex);K7(iTRAQ4plex) 28.73 30.64 50 229
AVPYPQR N-Term(iTRAQ4plex); Y4(iTRAQ4plex) 29.35 31.83 90 144
YPNCAYK N-Term(iTRAQ4plex); Y1(iTRAQ4plex);C4(Carbamidomethyl); K7(iTRAQ4plex) 30.00 32.68 105 219
KPVEEYANCHLAR N-Term(iTRAQ4plex); K1(iTRAQ4plex); Y6(iTRAQ4plex);C9(Carbamidomethyl) 31.46 33.39 131 193
KTGQAPGFTYTDANK N-Term(iTRAQ4plex); K1(iTRAQ4plex); Y10(iTRAQ4plex);K15(iTRAQ4plex) 32.05 34.07 40 664
QHMDSSTSAASSSNYCNQMMK N-Term(iTRAQ4plex); Y15(iTRAQ4plex);C16(Carbamidomethyl); K21(iTRAQ4plex) 32.19 34.32 159 100
DGPLTGTYR N-Term(iTRAQ4plex); Y8(iTRAQ4plex) 31.26 34.50 76 139
YIPGTK N-Term(iTRAQ4plex); Y1(iTRAQ4plex); K6(iTRAQ4plex) 32.08 35.50 44 372
KPVDEYKDCHLAQVPSHTVVAR K1(iTRAQ4plex); N-Term(iTRAQ4plex); Y6(iTRAQ4plex);K7(iTRAQ4plex); C9(Carbamidomethyl) 34.40 35.71 2 63
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Table 2-6 (continued): Median retention times [min] and the number of features (counts) were calculated for the
iTRAQ-4Plex labeled ten protein-mix. Based on the total number of Peptide-Spectrum-Matches of 2x 18 LC
runs,  the  retention  time  differences  for  tyrosine  iTRAQ-4Plex  (Y-iTRAQ)  labeled  and  in  its  native  form
(unmodified,  without  iTRAQ  modification  on  tyrosine).  Except  one  peptide
(VAGTWYSLAMAASDISLLDAQSAPLR), the retention time for the Y-iTRAQ labeled peptide species was usually
lower compared to the native form. 
Peptide Sequence Modification Median RT [min] 
Number of
Features
- (including the Y-iTRAQ) Y-iTRAQ native Y-iTRAQ native
TGQAPGFTYTDANK N-Term(iTRAQ4plex); Y9(iTRAQ4plex); K14(iTRAQ4plex) 33.61 36.68 95 423
YLGEEYVK N-Term(iTRAQ4plex); Y1(iTRAQ4plex); K8(iTRAQ4plex) 36.38 40.19 83 190
KTEREDLIAYLK N-Term(iTRAQ4plex); K1(iTRAQ4plex); Y10(iTRAQ4plex);K12(iTRAQ4plex) 38.20 41.31 3 413
YAAELHLVHWNTK N-Term(iTRAQ4plex); Y1(iTRAQ4plex); K13(iTRAQ4plex) 40.15 43.15 47 255
ADRDQYELLCLDNTR N-Term(iTRAQ4plex); Y6(iTRAQ4plex);C10(Carbamidomethyl) 39.70 43.25 15 282
NTDGSTDYGILQINSR N-Term(iTRAQ4plex); Y8(iTRAQ4plex) 40.04 44.56 182 609
VLVLDTDYK N-Term(iTRAQ4plex); Y8(iTRAQ4plex); K9(iTRAQ4plex) 39.75 44.72 89 249
TEREDLIAYLK N-Term(iTRAQ4plex); Y9(iTRAQ4plex); K11(iTRAQ4plex) 41.62 44.81 11 286
EETLMEYLENPKK N-Term(iTRAQ4plex); Y7(iTRAQ4plex); K12(iTRAQ4plex);K13(iTRAQ4plex) 43.38 47.40 7 416
GYSLGNWVCAAK N-Term(iTRAQ4plex); Y2(iTRAQ4plex);C9(Carbamidomethyl); K12(iTRAQ4plex) 42.26 47.60 103 728
HIIVACEGNPYVPVHFDASV N-Term(iTRAQ4plex); C6(Carbamidomethyl);Y11(iTRAQ4plex) 45.51 48.77 189 424
EDPQTFYYAVAVVK N-Term(iTRAQ4plex); Y7(iTRAQ4plex); K14(iTRAQ4plex) 45.58 50.82 41 335
MYLGYEYVTAIR N-Term(iTRAQ4plex); Y2(iTRAQ4plex) 45.87 51.14 167 272
EDLIAYLK N-Term(iTRAQ4plex); Y6(iTRAQ4plex); K8(iTRAQ4plex) 44.29 51.23 66 1441
EETLMEYLENPK N-Term(iTRAQ4plex); Y7(iTRAQ4plex); K12(iTRAQ4plex) 46.56 51.85 98 490
VGINYWLAHK N-Term(iTRAQ4plex); Y5(iTRAQ4plex); K10(iTRAQ4plex) 41.37 51.95 303 3047
AVVQDPALKPLALVYGEATSR N-Term(iTRAQ4plex); K9(iTRAQ4plex); Y15(iTRAQ4plex) 48.28 52.68 38 610
GITWKEETLMEYLENPK N-Term(iTRAQ4plex); K5(iTRAQ4plex); Y12(iTRAQ4plex);K17(iTRAQ4plex) 50.03 53.34 13 305
VYVEELKPTPEGDLEILLQK N-Term(iTRAQ4plex); Y2(iTRAQ4plex); K7(iTRAQ4plex);K20(iTRAQ4plex) 50.27 53.74 15 279
TAGWNIPMGLLYNK N-Term(iTRAQ4plex); Y12(iTRAQ4plex); K14(iTRAQ4plex) 49.40 54.32 65 257
YLLFCMENSAEPEQSLACQCLV
R
Y1(iTRAQ4plex); N-Term(iTRAQ4plex);
C5(Carbamidomethyl); C18(Carbamidomethyl);
C20(Carbamidomethyl)
51.13 55.52 10 280
YGDFGTAAQQPDGLAVVGVFLK N-Term(iTRAQ4plex); Y1(iTRAQ4plex); K22(iTRAQ4plex) 53.56 58.05 33 421
VAGTWYSLAMAASDISLLDAQS
APLR N-Term(iTRAQ4plex); Y6(iTRAQ4plex) 59.43 58.29 135 24
AIAANEADAVTLDAGLVYDAYL
APNNLKPVVAEFYGSK
N-Term(iTRAQ4plex); Y21(iTRAQ4plex); K28(iTRAQ4plex);
K38(iTRAQ4plex) 58.10 59.66 6 75
YLEFISDAIIHVLHSK N-Term(iTRAQ4plex); Y1(iTRAQ4plex); K16(iTRAQ4plex) 58.52 59.80 18 70
SAGWNIPIGLLYCDLPEPR N-Term(iTRAQ4plex); Y12(iTRAQ4plex);C13(Carbamidomethyl) 54.59 59.81 98 574
DMPIQAFLLYQEPVLGPVR N-Term(iTRAQ4plex); Y10(iTRAQ4plex) 55.34 60.22 52 521
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Table  2-7: Median retention times [min] and the number of features (counts) were calculated for the iTRAQ-
8Plex  labeled  10  protein-mix.  Based  on  the  total  number  of  Peptide-Spectrum-Matches  of  9  LC runs,  the
retention time differences for tyrosine iTRAQ-8Plex (Y-iTRAQ) labeled and in its native form (without iTRAQ
modification on tyrosine). Except four peptides (bold), the retention time for the Y-iTRAQ labeled peptide species
was usually smaller compared to the native form.
Peptide Sequence Modification Median RT [min] 
Number of
Features
- (Including Y-iTRAQ) Y-iTRAQ native Y-iTRAQ native
TVYQHQK N-Term(iTRAQ8plex); Y3(iTRAQ8plex); K7(iTRAQ8plex) 22.27 22.21 1 75
VYQHQ N-Term(iTRAQ8plex); Y2(iTRAQ8plex) 22.67 20.29 21 4
VYQHQKA N-Term(iTRAQ8plex); Y2(iTRAQ8plex); K6(iTRAQ8plex) 23.16 21.97 15 37
AVPYPQR N-Term(iTRAQ8plex); Y4(iTRAQ8plex) 25.96 26.20 7 65
ITVDDKHYQK N-Term(iTRAQ8plex); K6(iTRAQ8plex); Y8(iTRAQ8plex);K10(iTRAQ8plex) 26.25 27.07 1 20
QLDAYPS N-Term(iTRAQ8plex); Y5(iTRAQ8plex) 29.59 30.70 12 2
VPYPQRDMPIQA N-Term(iTRAQ8plex); Y3(iTRAQ8plex); M8(Oxidation) 29.61 31.09 11 14
QYTDAPSFS N-Term(iTRAQ8plex); Y2(iTRAQ8plex) 30.56 32.78 7 34
KAVPYPQRDMPIQAF N-Term(iTRAQ8plex); K1(iTRAQ8plex); Y5(iTRAQ8plex);M10(Oxidation) 31.33 32.96 15 116
RYLGYLE N-Term(iTRAQ8plex); Y5(iTRAQ8plex) 32.95 35.11 1 2
VPYPQRDMPI N-Term(iTRAQ8plex); Y3(iTRAQ8plex) 33.10 35.25 2 34
RQFYQLDAYPS N-Term(iTRAQ8plex); Y9(iTRAQ8plex) 33.15 35.39 2 21
SRYPSYGLNYY N-Term(iTRAQ8plex); Y3(iTRAQ8plex) 33.48 40.99 2 6
YKVPQLEIVPNSAEER N-Term(iTRAQ8plex); Y1(iTRAQ8plex); K2(iTRAQ8plex) 33.57 35.36 3 90
KAVPYPQRDMPIQAF N-Term(iTRAQ8plex); K1(iTRAQ8plex); Y5(iTRAQ8plex) 33.59 35.46 19 93
DVPSERYLGYLE N-Term(iTRAQ8plex); Y7(iTRAQ8plex); Y10(iTRAQ8plex) 33.67 35.26 2 94
QKFPQYLQY N-Term(iTRAQ8plex); K2(iTRAQ8plex); Y9(iTRAQ8plex) 33.96 35.69 1 26
YYVPLGTQY N-Term(iTRAQ8plex); Y2(iTRAQ8plex); Y9(iTRAQ8plex) 34.32 36.56 3 50
YVPLGTQY N-Term(iTRAQ8plex); Y8(iTRAQ8plex) 34.37 37.60 43 41
YKVPQLEIVPNSAEER N-Term(iTRAQ8plex); Y1(iTRAQ8plex); K2(iTRAQ8plex);S12(Phospho) 34.49 43.48 46 255
FYQLDAYPS N-Term(iTRAQ8plex); Y2(iTRAQ8plex); Y7(iTRAQ8plex) 34.87 36.99 1 22
KAVPYPQRDMPIQAFL N-Term(iTRAQ8plex); K1(iTRAQ8plex); Y5(iTRAQ8plex);M10(Oxidation) 34.93 36.79 2 58
ALPQYL N-Term(iTRAQ8plex); Y5(iTRAQ8plex) 35.14 39.69 10 9
DVPSERYLGYLE N-Term(iTRAQ8plex); Y10(iTRAQ8plex) 35.26 38.56 96 151
QLDAYPSGAW N-Term(iTRAQ8plex); Y5(iTRAQ8plex) 35.33 39.70 26 76
QFYQLDAYPS N-Term(iTRAQ8plex); Y8(iTRAQ8plex) 35.98 39.84 3 14
FALPQYLK N-Term(iTRAQ8plex); Y6(iTRAQ8plex); K8(iTRAQ8plex) 36.02 38.99 2 72
ALNEINQFYQK N-Term(iTRAQ8plex); Y9(iTRAQ8plex); K11(iTRAQ8plex) 36.09 38.41 3 185
YPFPGPIPN N-Term(iTRAQ8plex); Y1(iTRAQ8plex) 36.34 40.73 3 16
YQKFPQYLQY N-Term(iTRAQ8plex); K3(iTRAQ8plex); Y10(iTRAQ8plex) 36.37 38.51 3 64
YYVPLGTQY N-Term(iTRAQ8plex); Y9(iTRAQ8plex) 36.58 40.57 50 31
LLYQEPVLGPVR N-Term(iTRAQ8plex); Y3(iTRAQ8plex) 36.62 40.06 2 93
NQFYQKFPQYL N-Term(iTRAQ8plex); K6(iTRAQ8plex); Y10(iTRAQ8plex) 36.73 39.80 3 16
YPELF N-Term(iTRAQ8plex); Y1(iTRAQ8plex) 37.08 41.87 2 1
FYQLDAYPS N-Term(iTRAQ8plex); Y7(iTRAQ8plex) 37.36 42.29 39 66
LAYFYPE N-Term(iTRAQ8plex); Y3(iTRAQ8plex); Y5(iTRAQ8plex) 37.52 40.38 2 29
YPFPGPI N-Term(iTRAQ8plex); Y1(iTRAQ8plex) 37.53 42.76 1 11
QLDAYPSGAWY N-Term(iTRAQ8plex); Y11(iTRAQ8plex) 37.63 41.86 80 42
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Table 2-7 (continue): Median retention times [min] and the number of features (counts) were calculated for the
iTRAQ-8Plex labeled 10 protein-mix. Based on the total number of Peptide-Spectrum-Matches of 9 LC runs, the
retention time differences for tyrosine iTRAQ-8Plex (Y-iTRAQ) labeled and in its native form (without iTRAQ
modification on tyrosine). Except four peptides (bold), the retention time for the Y-iTRAQ labeled peptide species
was usually smaller compared to the native form.
Peptide Sequence Modification Median RT [min] 
Number of
Features
- (Including Y-iTRAQ) Y-iTRAQ native Y-iTRAQ native
LYQEPVLGPV N-Term(iTRAQ8plex); Y2(iTRAQ8plex) 37.78 42.66 1 25
VLSRYPSYGLNYY N-Term(iTRAQ8plex); Y13(iTRAQ8plex) 37.84 47.27 2 31
VYPFPGPIPN N-Term(iTRAQ8plex); Y2(iTRAQ8plex) 37.99 42.94 4 47
YFYPELFRQ N-Term(iTRAQ8plex); Y3(iTRAQ8plex) 38.38 42.64 30 125
MPFPKYPVEPFTE N-Term(iTRAQ8plex); K5(iTRAQ8plex); Y6(iTRAQ8plex) 38.50 41.87 3 58
VYPFPGPI N-Term(iTRAQ8plex); Y2(iTRAQ8plex) 38.76 44.78 21 44
YFYPELF N-Term(iTRAQ8plex); Y1(iTRAQ8plex); Y3(iTRAQ8plex) 39.08 42.81 1 20
LFRQFYQLD N-Term(iTRAQ8plex); Y6(iTRAQ8plex) 39.28 43.44 75 166
QYTDAPSFSDIPNPI N-Term(iTRAQ8plex); Y2(iTRAQ8plex) 39.56 43.77 29 209
QSLVYPFPGPIPN N-Term(iTRAQ8plex); Y5(iTRAQ8plex) 39.65 44.75 43 143
WYYVPLGT N-Term(iTRAQ8plex); Y2(iTRAQ8plex) 39.69 45.83 1 1
VYPFPGPIPNSLPQ N-Term(iTRAQ8plex); Y2(iTRAQ8plex) 39.79 45.27 2 62
FLLYQEPV N-Term(iTRAQ8plex); Y4(iTRAQ8plex) 39.79 45.68 35 63
SLVYPFPGPIPN N-Term(iTRAQ8plex); Y4(iTRAQ8plex) 39.86 45.17 9 40
GYLEQLL N-Term(iTRAQ8plex); Y2(iTRAQ8plex) 39.91 45.22 6 54
YIPIQYVLSR N-Term(iTRAQ8plex); Y6(iTRAQ8plex) 39.96 43.34 1 40
LVYPFPGPIPN N-Term(iTRAQ8plex); Y3(iTRAQ8plex) 40.24 46.44 2 23
LAYFYPE N-Term(iTRAQ8plex); Y5(iTRAQ8plex) 40.34 45.60 49 66
INNQFLPYPY N-Term(iTRAQ8plex); Y8(iTRAQ8plex) 40.67 44.85 6 42
QSLVYPFPGPI N-Term(iTRAQ8plex); Y5(iTRAQ8plex) 40.84 46.75 48 75
IHPFAQTQSLVYPFPGPIPN N-Term(iTRAQ8plex); Y12(iTRAQ8plex) 40.98 44.63 44 63
GAWYYVPL N-Term(iTRAQ8plex); Y5(iTRAQ8plex) 41.13 47.12 2 13
AQTQSLVYPFPGPIPNSLPQ N-Term(iTRAQ8plex); Y8(iTRAQ8plex) 41.39 46.37 10 39
SLVYPFPGPI N-Term(iTRAQ8plex); Y4(iTRAQ8plex) 41.47 47.14 2 44
FYPELF N-Term(iTRAQ8plex); Y2(iTRAQ8plex) 41.52 47.62 13 9
SLVYPFPGPIPNSLPQ N-Term(iTRAQ8plex); Y4(iTRAQ8plex) 42.29 47.48 2 45
YFYPELF N-Term(iTRAQ8plex); Y3(iTRAQ8plex) 42.85 49.81 10 30
AYFYPELF N-Term(iTRAQ8plex); Y4(iTRAQ8plex) 42.92 49.13 16 32
DMPIQAFLLYQEPVLGPVR N-Term(iTRAQ8plex); M2(Oxidation); Y10(iTRAQ8plex) 43.36 47.30 22 117
LYQGPIVLNPW N-Term(iTRAQ8plex); Y2(iTRAQ8plex) 43.83 49.21 15 77
FLLYQEPVLGPV N-Term(iTRAQ8plex); Y4(iTRAQ8plex) 43.92 50.56 43 257
LYQEPVLGPVRGPFPIIV N-Term(iTRAQ8plex); Y2(iTRAQ8plex) 44.29 48.37 3 77
DMPIQAFLLYQEPVLGPVR N-Term(iTRAQ8plex); Y10(iTRAQ8plex) 45.02 49.34 10 87
EPMIGVNQELAYFYPELFR N-Term(iTRAQ8plex); M3(Oxidation); Y14(iTRAQ8plex) 45.24 49.22 41 57
LLYQEPVLGPVRGPFPIIV N-Term(iTRAQ8plex); Y3(iTRAQ8plex) 45.99 50.63 8 79
AYPSGAWYYVPLGTQYTDAP
SFSDIPNPIGSENSE N-Term(iTRAQ8plex); Y16(iTRAQ8plex) 47.27 51.85 2 22
LGYLEQLL N-Term(iTRAQ8plex); Y3(iTRAQ8plex) 47.57 54.27 35 81
AYPSGAWYYVPLGTQYTDAP
SFSDIPNPIGSE N-Term(iTRAQ8plex); Y16(iTRAQ8plex) 47.88 52.72 2 3
YLGYLEQLLR N-Term(iTRAQ8plex); Y1(iTRAQ8plex) 49.49 51.06 4 74
CYQSYSTMSITDCRETG
N-Term(iTRAQ8plex); C1(Carbamidomethyl);
Y5(iTRAQ8plex); S6(Phospho); T7(Phospho); M8(Oxidation);
S9(Phospho); C13(Carbamidomethyl)
50.91 52.10 11 8
QYLYQGPIVLNPWDQV N-Term(iTRAQ8plex); Y2(iTRAQ8plex) 52.78 50.31 2 102
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2.3.3.5 N-terminal Tyrosine as a Special Variant of Y-iTRAQ Modifications
In an  in-silico trypsin digested human proteome (reference proteome; no isoforms; no miss cleavages;
minimal mass: 400 Da; maximal mass: 10,000 Da; downloaded May 2014), approximately 3.5% of all peptides
contained an N-terminal tyrosine. Although this is a rather small number, the fragmentation behavior and the
generation  of  specific  immonium  ions  of  N-terminal  iTRAQ  labeled  tyrosine  peptides  were  analyzed.
Furthermore, its N-Terminal phosphorylated form was analyzed accordingly. 
The peptide YSLTVAVK was chosen as a model peptide, which was identified in three forms: (i) with
iTRAQ labeling at the N-Terminus and the C-terminal lysine ( iYSLTVAViK; unmodified), (ii) with an additional
phosphorylation at  the N-Terminus (i,pYSLTVAViK; phosphorylated)  or  (iii)  with with an additional  iTRAQ
labeling at the N-terminus (i,iYSLTVAViK; Y-iTRAQ modified). 
For the unmodified peptide (i), an almost complete b-ion series (b1 – b6) was observed, although b5  and b6
did not pass the mass accuracy filter limited to 20 ppm (Figure 2-41 (A)). Additionally, the y-ions y1 – y4 were
detected, which proved the correct peptide identification. The Y-iTRAQ specific immonium ion at m/z 280.17
described  previously is  identical  in  mass  and  structure to  the a1+-ion for  N-terminal  tyrosine iTRAQ-4Plex
labeled peptides (unmodified). As commonly observed for HCD fragmentation (189), the a1+ ion was observed
(relative intensity of 2.5%). Its corresponding b1+-ion was detected with a relative intensity of 12.8%, which was
significantly higher compared to the a1+-ion. This was expected, as the frequency and abundances of a-ions are
often lower than those of corresponding b1+-ions (296). This higher intensity of the b1+-ion helps to differentiate
between an iY-iTRAQ immonium ion generated from peptides like  iVGINiYWLAHiK (iY-iTRAQ immonium
ion), and N-terminal peptides carrying one iTRAQ modification (iYSLTVAViK with a1+- and b1+-ion).
Further, the phosphorylated form (ii) of this peptide was analyzed (i,pYSLTVAViK, Figure 2-41 (B)). Again,
the same b- and y-ions were detected and passing the filter settings of 20 ppm (b 1 – b4 & y1 – y4). Interestingly,
the corresponding a-ion series (a1 – a6) was more intense (and passing the filter settings), indicating that the
phosphorylation of tyrosine changes the fragmentation behavior of this peptide. Again, the a1+- and b1+-ions were
detected  with  a  relative  intensity  of  2.3%  and  12.9%,  respectively.  The  intensity  was  similar  to  the  non
phosphorylated peptide (iYSLTVAViK; unmodified). 
A special modification represented the doubly iTRAQ-4Plex labeling of the N-terminal tyrosine within the
peptide i,iYSLTVAViK (Figure 2-41 (C)). Here, iTRAQ is once coupled via the primary amino group and once
via the hydroxyl group to tyrosine. The b-ions (b1 – b6) were detected, whereas the y-ion series was similar to the
two other peptide forms (y1 – y5). Remarkably, the corresponding a-ion series was also present (a1 – a5). Here, the
doubly iTRAQ-4Plex labeled a1-ion was not detected in its singly charged form, but with a relative intensity of
12.8% in its doubly charged form (a12+). This higher intensity might be caused by the iTRAQ-4Plex labelings,
which have a higher proton affinity (approximately 50 kJ/mol higher for tertiary amines than for primary amines
(297)). A similar effect was observed for the remaining b-ions. However, the y-ion series was present in its singly
charged form, which can be explained by the attachment of only one (C-terminal lysine) instead of two (N-
terminal and hydroxyl-group of tyrosine) iTRAQ-4Plex labelings. 
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For the Y-iTRAQ modified peptide (iii), the relative intensity of the a 12+-ion was higher (12.8%) compared
to the corresponding b1+ and b12+ ion (2.5% and 7.2%). Surprisingly, the iY-iTRAQ immonium ion at m/z 280.17
was also detected with a relative intensity of 7%. At this point, it cannot be confirmed whether this ion was
caused by N-terminal or side chain dissociation of the iTRAQ-4Plex group or a combination of both.
However,  the  three  peptide  modification  forms  (i  –  iii)  and  their  fragmentation  behavior  was  further
analyzed under elevated NCE conditions (NCE = 75%) to verify the presence of the iY-, pY- and iY-iTRAQ
immonium ions (Figure 2-42). Unexpected, the pY- and iY-iTRAQ-4Plex immonium ions represented the most
intense sequence specific signals in spectra; only the non-sequence informative iTRAQ reporter ions were of
higher relative intensity. This supported the assumption that the N-terminal iTRAQ dissociated further rather
than the side chain iTRAQ group of tyrosine.
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Figure  2-41:  The  iTRAQ-4Plex  labeled  peptide  YSLTVAK  was  identified  to  be  present  in  three  forms:
iYSLTVAViK (A), with an additional phosphorylation at the N-terminus  i,pYSLTVAViK (B) and in a N-terminal
doubly iTRAQ labeled form i,iYSLTVAViK (C). For iYSLTVAViK (A), the Y-iTRAQ specific immonium ion at m/z
280.17 is equaling the a1+ ion. After phosphorylation (B), the pY-iTRAQ immonium ion (= a1+ ion) was detected
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at  m/z  360.14.  Replacing  the  phospho-moiety  with  an  iTRAQ  group,  the  Y-2x(iTRAQ)  immonium  ion  was
detected  at  m/z  424.27.  All  MS/MS spectra  were  acquired  after  HCD fragmentation  in  the  Orbitrap  mass
analyzer. For the latter peptide (i,iYSLTVAViK), the additional iTRAQ modification had an influence on the b-
and a- ion series, which were predominantly present in the doubly charged form.
Figure 2-42: Peptide fragmentation of the iTRAQ-4Plex labeled peptide YSLTVAVK was shown before (Figure 2-
41) for the three observed modification forms:  iYSLTVAViK (A), with an additional phosphorylation at the N-
terminus i,pYSLTVAViK (B) and in a N-terminal doubly iTRAQ labeled form i,iYSLTVAViK (C). To demonstrate the
impact/presence of the observed specific immonium ions, the MS/MS spectra after HCD fragmentation at NCE =
75% are shown. For iYSLTVAVK, the Y-iTRAQ immonium ion was not detectable. For the phosphorylated form,
the tyrosine- (iY, m/z 136.07), the phosphotyrosine- (pY, m/z 216.04) and the phosphotyrosine-iTRAQ immonium
ion (pY-iTRAQ, m/z 360.14) were detectable. For the doubly iTRAQ labeled N-terminal tyrosine ( i,iYSLTVAViK),
the tyrosine- (iY, m/z 136.07) and Y-iTRAQ immonium (Y-iTRAQ, m/z 280.17) were present. The doubly iTRAQ
labeled immonium ion (Y-2x(iTRAQ), m/z 424.27) was not detectable.
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2.3.4 Conclusion
Only 5 - 20% of low resolution ion trap and 15 - 70% quadrupole TOF tandem MS spectra are typically
identified and validated peptide hits (287–290). The causes are various: (i) only 6-10 modifications are usually
considered to limit the search space during database search, which in combination to (ii) unexpected cleavage
sites, (iii) modifications or (iv) amino acid substitutions causes most of the spectra to be unassigned (275).
For iTRAQ labeling experiments, an unwanted and often neglected modification represents the binding of
iTRAQ to the hydroxyl-group of  tyrosine.  However,  as  this  modification is  known to occur  (60,291),  it  is
mandatory to include this dynamic modification in computational proteomics workflows to identify and validate
Peptide-Spectrum-Matches by database search algorithms.  
To further validate this modification manually or by computational proteomics pipelines, a diagnostic iY-
iTRAQ ions can assist this process. For both iTRAQ-4Plex and iTRAQ-8Plex, specific signals at m/z 280.17 and
440.28, respectively, could be unambiguously presented. These immonium ions were (potentially) generated by
double side cleavage (C- and N-terminal) which is common for immonium ions. Although a variety of different
fragmentation techniques were applied, these ions were only detected after beam-type CID fragmentation (e.g.,
HCD on the Orbitrap Velos). Its relative intensity in MS/MS spectra was demonstrated to be a function of the
applied  collision  energy,  and  exhibits  a  maximal  intensity  at  (slightly)  elevated  collision  energies.  It  is
noteworthy that this ion was also detected at higher NCE values, increasing its diagnostic ion significance, as
other sequence specific fragment ions were depleted at these energy regimes. Further, the Y-iTRAQ modification
of tyrosine changed the retention time compared to their unmodified counterparts upon peptide separation by
reversed phase chromatography. 
Summarizing, Y-iTRAQ features (iY-iTRAQ immonium ion in combination with the shorter retention time
by reversed  phase  chromatography)  will  help  to  increase  the  number  of  identifiable  spectra  in  quantitative
proteomics approaches. It is important to include all sequence specific signals (so-called tags) of tandem MS
spectra, as this information is useful in validating peptide identifications. This is especially true for the amino
acid tyrosine (and other amino acids such as phenylalanine, valine, isoleucine, leucine, tryptophan, proline and
histidine) which was demonstrated previously to be a good predictor of peptide composition (298). These ions
cannot be detected in ion trap devices, however, the incorporation of immonium ions into search engines could
improve the application of beam-type CID fragmentation, as a higher number of signals of MS/MS spectra are
used which will increase the homology between the experimental and theoretically calculated spectrum.  
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2.4 MECi – Targeted Phosphoprotein Quantification
2.4.1 Introduction
For quantitative phosphoproteomics studies using iTRAQ labeling, optimal MS instrumentation conditions
for adequate fragment ion (identification) and reporter ion generation (quantification) have been established
(chapter 2.1). In addition, the effect of non accurate in-silico precursor mass (m/z value) calculation for highly
differentially abundant peptides could be compensated by an in-house developed algorithm. To further increase
the number of Peptide-Spectrum-Matches after iTRAQ labeling, a diagnostic ion for iTRAQ-4Plex and iTRAQ-
8Plex labeled tyrosine peptides has been identified, which can be used as additional features to validate peptide
identifications.    
The complement the platform to relatively quantify phosphopeptides by isobaric labeling, the establishment
of a new procedure to improve the identification and relative quantification of phosphoproteins by increasing
the number of quantifiable (phospho)peptides is the aim of this section. 
An important aspect of phosphoprotein analysis is to localize the phosphorylation site exactly, which is
despite improvements  (e.g.,  Phospho RS  (299), Mascot MD-Score  (276), MaxQuant PTM score  (300), NCE
optimization (chapter  2.1))  still  challenging  (301).  To enlarge the number of  phosphorylated peptides to  be
selected for fragmentation and subsequent peptide identification (or to localize the phosphorylation site), the
application of a multi-protease approach has been shown to be superior to the single protease digestion  (302)
either in parallel or subsequently use (303–307). 
Several workflows have been published to quantify changes of phosphorylated protein abundances using
isobaric labeling strategies (277,308,309). However, to increase the number of phosphorylated peptides that can
be used for identification and determination of the exact phosphorylation site, a novel multi-protease digestion
procedure (two specific and two unspecific proteases) in combination to iTRAQ labeling will be established.
This workflow aims to increase the number of quantifiable (phospho)peptides to accurately relatively quantify
the difference in phosphoproteins. An important aspect of this workflow is to ensure the compatibility of isobaric
labeling with SDS-PAGE and phosphopeptide enrichment strategies using TiO2. 
To demonstrate the influence and the advantage of a multi-protease digest method with subsequent iTRAQ
labeling, various identification features (such as the sequence coverage) will be compared to the results of single
protease digestion. Further, the compatibility of the multi-protease approach with relative phosphorylation site
quantification will be shown.  
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2.4.2 Material and Methods
The complete workflow of the newly developed approach covering all the steps except MS analysis is
summarized schematically in Figure 2-43. 
Figure 2-43: Schematic diagram of the multi-protease workflow for relative quantification using iTRAQ-8Plex.
The control  sample  ("P"hosphorylated)  was  directly  used  for  iTRAQ labeling,  whereas  the  treated  sample
("D"ephosphorylated) was a 1:1 mixture of the phosphorylated and dephosphorylated sample. This simulated
two biologically differently phosphorylated samples. Afterwards, both samples are digested separately using four
enzymes  (chymotrypsin,  elastase,  Staphylococcus  aureus  V-8  Protease  (GluC)  and  trypsin).  Each  digest  is
labeled with a unique iTRAQ-8Plex channel. The pooled sample is then enriched for phosphopeptides in a batch
process using TiO2  (ratio 1:20). Samples labeled with gray dashes (“Single Protease Analysis”) are only used
for method development and not part of the workflow for analysis. All samples were subsequently analyzed by
LC-ESI MS.
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2.4.2.1 Chemicals
Chemicals used in this study are summarized in chapter 4.1.
2.4.2.2 Sample Preparation and Analytical Workflow 
Preparation of SDS-Gel
The  SDS-gels  were  prepared  using  standard  techniques  (310).  Briefly,  the  resolving  gel  (12%)  was
prepared by adding 3.4 mL ddH20, 4ml 30% acrylamind/bisacrylamid, 2.5 mL gel buffer (1.5 M Tris-HCl, pH
8.8) and 0.1 mL 10% SDS. Immediately prior to casting, 50 µL 10% APS (ammonium persulfate) and 5 µL
TEMED were added and swirled gently to initiate polymerization. After 2h of polymerization, the stacking gel
(8%) was prepared accordingly: 4.7% ddH20, 2.7 ml 30% acrylamind/bisacrylamid, 2.5 mL gel buffer (0.5 M
Tris-HCl, pH 6.8) and 0.1 mL 10% SDS. Prior to pouring, 50 µL 10% APS and 10 µL TEMED were added. To
ensure complete polymerization, the gels were left overnight at 4°C, prior to sample loading.
Preparation of Casein-Sample
To simulate a control and treated sample, the proteins α-S1-, α-S2- and β-casein were treated with alkaline
phosphatase (AP). Ten µL of β-casein and 10 µL of α-casein solution (c = 10 µg/µL in H2O) were combined. The
sample was buffered with 40 µL of  AP-buffer  (diluted 1:10 with ddH20; AP-buffer was supplied by Roche
Diagnostics GmbH, Mannheim, Germany) and split into two aliquots: 6 µL of the AP solution (containing the
alkaline phosphatase) was added to one sample, referred to as 1D(ephosphorylated), while 6 µL of ddH2O was
added to the control sample or 1P(hosphorylated). Both samples were incubated at 30°C overnight. Samples were
dried using vacuum centrifugation and reconstituted in 50µL TEAB solution (50 mM) and 50 µL sample buffer
(0.5 M Tris-HCL, 1mM EDTA, pH 8.5). Samples were denatured at 85°C for 5 min and 5 µL loaded onto each
SDS gel band. 
SDS-Gel Separation
SDS-Gels were run using 80 Volts for 30 min, for sample concentration, followed by an increase to 110
Volts for protein separation. SDS-gels were fixed for 2 h (50% methanol, 2% phosphoric acid (PA)) and stained
for 10 min (34% methanol, 2% PA, 17% ammonium sulphate (AS), 0.066% Coomassie Brilliant Blue G-250).
SDS-gel were destained overnight with 5% ethanol and 10% acetic acid. 
Gel-Slice Exaction and Protein Digestion
Gel bands were excised and then simultaneously destained and washed (3 times) with a 30% ACN solution
(100 µL) followed by an additional wash with 50% ACN (100µL). Prior disulfide-bond reducing, samples were
dried  under  vacuum  centrifugation  for  30  min  at  30°C.  Reduction  was  performed  using  80  µL  TCEP
(6mg/10mL) at  50°C for 30 min. Samples were stored at  4°C for 1-2 h prior to alkylation. Alkylation was
performed for 25 min in dark at room temperature using IAA (50 µL IAA solution with 2.5 mg IAA/1mL) and
50 µL of TEAB buffer (50 mM). Residual IAA was quenched using a solution of 50 µL TCEP and 200 µL TEAB
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buffer for 15 min (room temperature), followed by an additional washing step with 200 µL TEAB buffer (15
min, room temperature). Gel pieces were shrunk for 15 min at room temperature (100 µL; 50% ACN, 50%
TEAB) and dried under vacuum centrifugation for 30 min. 
For protein digestion, chymotrypsin, elastase, Staphylococcus aureus V-8 Protease (GluC) and trypsin were
used. With the exception of trypsin, a protease:protein ratio of 1:10 (w/w) was applied. For trypsin a ratio of 1:20
was used. Each protease stock solution was diluted with TEAB buffer and 20 µL of protease solution was added
to the dehydrated gel pieces. Gels were allowed to swell for 15 min at room temperature. Afterwards, 100 µL of
TEAB buffer was added and the samples were left to digest overnight at 37°C. 
For extraction of peptides, 50 µL of TEAB added. After 30 min at room temperature, the supernatant was
transferred to a new Eppendorf tube and 200 µL extraction buffer (60% v/v ACN, 0.5% v/v TFA) was added to
the gel pieces. Sample extraction was performed for 30 min, followed by a second extraction with 100% ACN
(30 min). The pooled samples were dried under vacuum centrifugation and resuspended in 16 µL of loading
buffer  A (3% ACN, 0.1% TFA).  One µL of this sample was removed and used for  MS analysis to  ensure
complete digestion (not included in Figure 2-43). To simulate differentially regulated phosphorylation degrees,
the  samples  originated  from  control  were  used  without  any  further  processing  for  iTRAQ  labeling.  The
dephosphorylated sample instead, was a 1:1 combination of both, the control and treated sample, as outlined in
Figure 2-43 by gray dotted line.  
iTRAQ Labeling
Samples were dried under vacuum centrifugation and re-hydrated using 20 µL of iTRAQ-8Plex labeling
buffer  (60%  isopropanol,  40%  iTRAQ-Dissolution-Buffer).  iTRAQ  reporter  ion  solutions  were  prepared
according to the manufacture's instructions. For labeling, samples were incubated with a 2 fold molar excess of
iTRAQ reagent (10 µL) for 2 h in the dark at room temperature. The labeling schema is outlined in Table 2-8 and
Figure 2-43. To ensure complete labeling and to hydrolyze unreacted iTRAQ reagents, samples were stored at
-20°C prior to vacuum centrifugation. Samples were rehydrated with 15 µL of loading buffer A and 1 µL was
used for iTRAQ labeling screening.
Table  2-8: Each of the two samples (control (P) and treated sample (D)) were digested with one of the four
proteases applied and labeled with one of  the eight iTRAQ-8Plex reagents, respectively.  By shuffling of  the
iTRAQ reporter ion channels, samples can also be analyzed by HCD (as performed in this study) and ETD,
which gives complementary fragment ions (c- and z-ions).
iTRAQ Reporter Ion Enzym Sample HCD Reporter Ion ETD Reporter Ion
113 elastase (El) D 113 101
114 chemotrypsin (Ch) D 114 101
115 GluC (Gl) D 115 102
116 chemotrypsin (Ch) P 116 104
117 GluC (Gl) P 117 104
118 trypsin (Tr) D 118 106
119 elastase (El) P 119 106
121 trypsin (Tr) P 121 108
-120-
2.4 MECi – Targeted Phosphoprotein Quantification
Phosphopeptide Enrichment with TiO2 resin
Phosphopeptide enrichment was performed as described previously (311). Briefly, TiO2 was resuspended in
loading buffer I (80% ACN, 5% TFA, 1M glycolic acid (GA)) to a TiO2  concentration of 1 – 10 g/L. After
vortexing,  TiO2,  equivalent  to  20  times  the  weight  of  starting  protein  material,  was  transferred  to  a  new
Eppendorf tube and  the volume adjusted to 100 µL using loading buffer I. After 15 min of shaking, TiO 2  was
pelleted by centrifugation and the supernatant discarded. 
Samples were re-suspended in loading buffer I (20 µL) and transferred to the TiO 2  beads, vortexed and
shaken  at  high  rpm  (1300)  for  15  min.  TiO2 was  pelleted  and  the  supernatant  removed  (fraction:  non-
phosphopeptide). Three washing steps (100 µL each) with washing buffer I (80% ACN, 1%  TFA), washing
buffer II (20% ACN, 0.2% TFA) and water were performed for  15 min and the supernatant from all  wash
fractions combined (fraction: wash). Prior to phosphopeptide elution, the TiO2   beads were dried under vacuum
centrifugation (30 min, room temperature) and eluted using 100 µL of elution buffer (1% NH4OH, approx. pH
10). After 15 min of incubation, the sample was centrifuged and the supernatant transferred to a new Eppendorf
tube (fraction: phosphopeptide). 
2.4.2.3 Mass Spectrometry
LC-ESI MS
The same LTQ Orbitrap Velos / HPLC setup as described before (chapter 2.1) was utilized for HPLC-ESI
MS experiments.  Generally,  9  µL of  sample  (12  µL for  LC-ESI  MS experiments  with  imported  precursor
exclusion lists) was injected and desalted for 4 min (30 µL/min), prior to peptide separation (300 nL/min) using
a linear increasing gradient of solvent B from 5% to 55% within 51 min. A column washing step was added by
increasing the solvent B to 95% within 5 min and kept constant for an additional 5 min. Afterwards, the column
was re-equilibrated for  9 min using 5% solvent B. Between each sample injection, a wash run with the same
method was applied. 
XCalibur was used to write a tandem MS/MS method utilizing both, CID-IT and HCD fragmentation (see
Figure 1-12). The MS method was split into MS full scan (Resolution 60,000; m/z 300 – 2000) with prescan
activated. In parallel, the 5 most intense precursor ions were selected for CID-IT fragmentation (35% NCE) and
recorded in ion trap. For HCD, the same precursor ions were selected and fragmented with an NCE of 45%.
Fragment ions were recorded with a resolution of 7,500 in Orbitrap mass analyzer (m/z selection window 3; first
m/z value:  100).  Only precursors with a charge state > 1+ and an intensity > 500 counts were selected for
fragmentation.  Repeat count was set to 3 within a repeat duration of 20 sec. After fragmentation, each precursor
was dynamically excluded for 30 sec.
The  exclusion  lists  were  generated  after  performing  the  database  searches  (see  below)  of  the  3
phosphopeptide enrichment runs (non- phosphopeptide-,  wash-,  and phosphopeptide-fraction) with all  PSMs
passing  the  set  filters  (high  confidence,  1st Rank only).  Export  options  used:  (i)  export  to  m/z  values;  (ii)
retention time windows width (min): 5; (iii) lower retention time window (min): 5; upper retention time windows
(min): 75; (iv) mass precision (decimals) 5; (v) max concurrent entries: maximum. 
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Database Searches
For data analysis, Proteome Discoverer 1.4 with the search algorithm SEQUEST HT (supplied with PD
1.4.0.288) was used. The workflow was built up as outlined in Figure 2-1 with default settings unless otherwise
specified: (0) Spectrum Files; (1) Spectrum Selector; (2) MS2-Spectrum Processor; (3) & (7) Scan Event Filter
to  split  into CID and HCD fragmentation;  (4)  & (8)  SEQUEST HT (see  below);  (5)  phosphorRS 3.0;  (9)
Reporter Ions Quantifier: iTRAQ-8Plex (Thermo Scientific Instruments; Integration Tolerance 20 ppm; Most
Confident  Centroid  as  Integration  Method;  Additional  Settings:  Show the  Raw Quan  Values;  Apply  Value
Corrections, use All Peptides enabled and deactivated Experimental Bias); (10) Event Detector; (11) Precursor
Ions Area Detector and (12) Percolator or Target Decoy PSM Validator.
For SEQUEST HT database searches,  two different FASTA files  were used: (sF) with 403 entries  (10
protein-mix, 180 phosphopeptide sequences (Intavis standard) and keratin related proteins (see chapter 2.1.2.3))
and  (bF) containing the proteins within the sF-FASTA file and in addition, the reference proteome of  E. coli,
resulting in a total number of 4526  proteins.  No-enzyme specificity was used with a minimum and maximum
peptide length of 4 and 144, respectively. Precursor mass tolerance was set to 10 ppm, 0.3 Da for CID and 0.02
Da for HCD fragmentation. The maximum number of dynamic and equal modifications allowed per peptide
were 12 and 8, respectively. Phosphorylation (S, T & Y) and oxidation (M) were set as variable modifications.
Static modifications included iTRAQ-8Plex (peptide N-terminus and K), and carbamidomethylation (C). Results
were  filtered  with  medium  confidence  (5%  FDR)  and  high  confidence  (1%  FDR)  for  identification  and
quantification, respectively. 
For  evaluation  of  the  computational  workflow,  four  different  settings were  tested:  Target  Decoy PSM
Validation  (supplied with  Proteome Discoverer  1.4)  with  sF-  and  bF-FASTA and Percolator  (supplied  with
Proteome Discoverer  1.4 )  with sF- and bF-FASTA file,  respectively.  For final  data analysis,  the workflow
containing Percolator and bF-FASTA file was chosen (referred to as reference workflow). 
Data-Analysis
Optimization of the Computational Proteomics Workflow for No-Enzyme Database Searches
Grouped  and  ungrouped  peptides  (5% FDR)  for  the  four  different  enzymes  (see  section  above)  were
exported  into  different  .xls  files.  Information  regarding  protein  sequence  coverage  [%],  number  of  unique
peptides and Peptide-Spectrum-Matches (PSMs) were extracted from protein tables without any additional post-
processing (Figure 2-44).  For the comparison of PSMs identified by CID and HCD (Figure 2-45),  for both
phosphorylated and non-phosphorylated peptides, in-house developed VB(A) scripts were used to split the data.
Three biological replicates were used to outbalance variations within samples.  
RatioHCD ,PSM=
HCD
(CID+HCD)
Equation 2-9
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Identification: Determining the Benefit of the Multi-Protease Approach 
For each of the iTRAQ labeled protease digests (chymotrypsin (Ch), elastase (El), GluC (Gl), trypsin (Tr))
the  sequence  coverage  [%],  number  of  unique  peptides  and  the  Peptide-Spectrum-Matches  (PSMs)  were
exported to .xls files (see section above) and compared (Figure 2-46). 
The in-silico combined samples from the Single Protease Analysis (Figure 2-43) were referred to as CETG.
Technical replicates from the same sample were analyzed in a MudPIT approach. 
Following  TiO2  enrichment,  two  technical  replicates  and  an  exclusion  list  LC-ESI  MS  run  of  the
phosphopeptide-, wash- and non-phosphopeptide fraction were searched in a MudPIT approach (referred to as
CF). All database searches used the reference workflow.  
A heat map algorithm using RGB style for visualization of amino acid occurrence was programmed (blue
for low (0%), green (50%) and red for high values (100%)) and used to visualize the different frequency of
amino acids in the experiments. For calculation of the corresponding RGB color, the lowest and highest number
of amino acid occurrence was searched within all input files (Figure 2-47 to 2-49). The function to calculate the
RGB color is shown in chapter 4.1.  
Phosphopeptide Identification: Application of Multiple Proteases to Increase the Number of
Unique Phosphopeptides
The exported peptide group lists for identification of the sample CF (.xlsx files, see above) were used to
compare the four different proteases in terms of their number of unique phosphopeptide sequences identified. To
further classify the peptides according to one of the proteases used for digestion, the C-terminal amino acid was
used. Chymotrypsin and GluC share two cleavage sites (D, E). Elastase and chymotrypsin share leucine cleavage
specificity. These were classified as Ch-Gl and Ch-El, respectively (Figure 2-51). The total number of C-terminal
amino acids not being derived by one of the protease were grouped under the term unspecific (un). Histidine (un-
H) and tyrosine (un-T) were highly present within the group  unspecific C-terminal amino acids and shown
additionally (Figure 2-51. 
To  compare  the  number  of  identified  unique  phosphopeptides  (A,  C,  E)  and  the  number  of  Peptide-
Spectrum-Matches  of  phosphorylated  peptides  (B,  D,  F)  for  the  four  singly  used  proteases,  their  in-silico
combined sample (CETG) and the enriched fraction CF were plotted (Figure 2-50).  
iTRAQ Quantification
For  the  quantitative  phosphopeptide  analysis,  only  PSMs with  high  confidence  were  used  to  exclude
potentially wrong annotations.  Due to the  no-enzyme database search, every possible peptide sequence of the
supplied FASTA file  (falling within the specified precursor  mass  tolerance window) can be matched to  the
fragmented precursor and be used for subsequent fragment ion matching and scoring. Although peptides used for
analysis needed to pass FDR < 1%, only  peptides having the correct C-terminus (e.g. R or K for trypsin) and
high intensive reporter ion channels (118 (sample D) and 121 (sample P) for trypsin) in comparison to the
residual iTRAQ reporter ion channels were used (minimum value iS > 0.4; iS calculation see Equation 2-10).  
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iS=
iTRAQ Reporter Ion x1+iTRAQ Reporter Ion x2
∑ iTRAQ Reporter Ion
Equation 2-10
Afterwards, based on the sequence and its singly charged precursor mass (mass deviation < 30 ppm), the
median and standard deviation of the iTRAQ w-Ratio (see Equation 2-11) of the reporter ions were calculated. 
w -Ratio=
                   iTRAQ Reporter Ion x 1
iTRAQ Reporter Ionx 1+iTRAQ Reporter Ion x2
Equation 2-11
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2.4.3 Results
The aim of this  study was to  create a  workflow using a multi-protease approach in combination with
iTRAQ-8Plex labeling to comprehensively identify, assign and quantify protein phosphorylation between two
biological entities. The workflow was designed to be fully compatible with SDS-PAGE, iTRAQ labeling and
phosphopeptide  enrichment.  For  digestion,  two unspecific  (chymotrypsin,  elastase)  and  two highly  specific
(trypsin, GluC) proteases were chosen to generate a variety of unique and overlapping peptide sequences. An in-
silico digestion (mmass, Version 5.5.0) of α-S1-, α-S2-, β- and κ-casein was performed using elastase (V, I, A, L,
S,  G),  chymotrypsin (Y,  W,  F,  L),  GluC (only  E,  TEAB buffer  (312))  and  trypsin (R,  K)  with no  missed
cleavages allowed. The minimal peptide length was four amino acids, other peptides were filtered out. Average
peptide lengths of 6, 12, 14 and 16 amino acids were obtained for elastase, chymotrypsin, GluC and trypsin,
respectively. This indicated a good distribution of unique peptide sequence lengths for the four proteases used.
2.4.3.1 Percolator and FDR Analysis to Identify iTRAQ-8Plex Labeled Peptides
The quantitative multi-protease approach with iTRAQ-8Plex labeling for targeted phosphopeptide analysis
requires either (i) a database search without enzyme specificity or (ii) a custom digested protein FASTA file
combined at the peptide level with preselected missed cleavage specifications. For the latter, identified peptides
have to be mapped back to their protein origin either manually or with additional scripting tools. In contrast, the
unspecific (no-enzyme) database search can be implemented in Proteome Discoverer directly. For  no-enzyme
searches, the entire protein is indexed which increases the number of potential peptide candidates used for the
database search compared to a targeted approach.  In  targeted approaches,  only peptides with predefined C-
terminal residues are used (e.g., R and K for trypsin). Therefore, a higher number of peptide decoy sequences is
available  for  no-enzyme database  searches  and  can  be  used  as  for  Peptide-Spectrum-Match  analysis  and
validation. Thus, (phospho)peptides passing the FDR approach were of higher quality compared to those from a
smaller decoy database.  For the aforementioned reasons an unspecific database search was used for peptide
identification applying the multi-protease approach. 
An important aspect of this workflow was to analyze the differences between two FASTA files: (i) a FASTA
file containing 403 protein entries (10 protein-mix plus impurities listed in chapter 4.1) and (ii) the same FASTA
with the addition of an E. coli reference proteome (see chapter 2.1.2.3 for details) resulting in a total of 4,526
protein sequences. In addition, two peptide validation strategies commonly used for peptide identification were
evaluated: the FDR approach (Peptide Validator) was compared to the machine learning code Percolator. 
Independent of the validation method and FASTA file utilized during database search, an almost complete
sequence coverage  was observed  for  the three  target  proteins:  α-S1-,  α-S2 and β-casein (Figure  2-44 (A)).
Additionally,  κ-casein was also identified. However, this protein is a known contamination for α- and β-casein
protein standards. For both FASTA files an average increase of ~10% in unique peptides was observed for all
three biological replicates if the Peptide Validator (FDR approach) is replaced by the semi-supervised machine
learning code Percolator (Figure 2-44 (B)). This effect was slightly more pronounced for the bF-FASTA file.
This was expected due to the higher number of potential peptide sequences falling within the ± 10 ppm precursor
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mass tolerance window set in Proteome Discoverer. About 66% of the unique peptides identified (same sequence
& monoisotopic precursor charge state [M+H]+) were identified by both, the FDR approach and Percolator (bF-
FASTA file). Approximately 10% and 23% peptides were uniquely identified with the FDR or the Percolator
approach, respectively. This is a huge difference considering, that the only change in the workflow was the
peptide validation method. The benefit of using Percolator was even more visible at the PSMs level (Figure 2-44
(C)). An increase of 41% and 55% for the number of PSMs was observed for the small FASTA (sF) and big
FASTA file (bF), respectively. For all protein features monitored (coverage, unique peptides and PSMs), the
standard deviation for  κ-casein was highest, followed by α-S2-casein. The differences were introduced while
sample generation (e.g., excision of the SDS-gel), as the protein area differed significantly for α-S1- and κ-casein
but were matchable for α-S1- and β-casein (Figure 2-44 (D)).
Figure  2-44:  For  the  two  workflows  using  a  small  FASTA  file  (sF)  and  a  10x  bigger  FASTA  file  (bF),
respectively,  the  protein  sequence  coverage  with  a  classical  FDR  approach  and  the  improvement  after
percolating the results are demonstrated for the protein coverage (A), the number of unique peptides (B), the
PSMs (C) and the protein area (D). For data generation the casein sample after iTRAQ-8Plex labeling and
enrichment  for  phosphorylated  peptides  was  used  (sample  CF,  see  workflow).  These  cover  the  non-
phosphorylated- (NP), wash- (WF) and phosphorylated fraction (PF) and were searched in MudPIT approach.
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For data acquisition, a dual CID/HCD fragmentation method was applied to generate a dataset of CID-IT
(resonance) and beam-type CID spectra. As different energy regimes are applied and the time of energy transfer
to peptide species differs between the two fragmentation types, the spectra shape can be significantly different
(283,313), as it was shown before for pS-peptides (Figure 2-2 to Figure 2-4). 
The Peptide-Spectrum-Matches were further split into CID-IT and HCD fragmentation and plotted (Figure
2-45 (A)) for the FDR and Percolator approach. For HCD spectra, the increase in identifications was ~20% and
~26% for the sF- and bF-FASTA file, respectively, after percolating (compared to FDR). In contrast, the number
of  identification  increased  significantly  by  96%  and  169%  (sF-  and  bF-FASTA file,  respectively)  after
percolating the CID-IT data. 
The significant  increase in identifications for  CID-IT after  percolating was further  compared to  HCD.
Generally, HCD identified more peptides, independently on the applied peptide validation method. However,
with the classical FDR approach, the RatioHCD,PSM was 73% and 80% (sF- and bF-FASTA file), demonstrating the
clear benefit of beam-type fragmentation followed by analysis in the high resolution Orbitrap mass analyzer.
After percolation, the ratio dropped for both, the sF- and bF-FASTA file (RatioHCD,PSM  = 62% and 65%). 
The  dataset  was  further  split  into  phosphorylated  and  non-phosphorylated  peptides  to  determine  the
influence  of  Percolator  and  FDR  analysis.  After  percolating,  the  increase  in  phosphorylated  and  non-
phosphorylated peptides identified was ~7% and ~31% for HCD and ~75% and ~200% for CID-IT, respectively
(data not shown). For both fragmentation techniques combined (CID + HCD), the increase in Peptide-Spectrum-
Matches was higher for  non-phosphorylated peptides (Figure 2-45 (B)).  This might be due to (i)  the lower
overall number of (experimental and theoretical possible) phosphorylated peptides, (ii) the lower fragmentation
efficiency of phosphopeptides using CID-IT (intense neutral loss signal) or (iii) the Percolator algorithm is more
efficient for peptides with only fixed modifications forms. Generally, accurate peptide identification based on
fragment ion matching approaches were more sensitive for CID-IT in terms of search space increase due its
lower mass accuracy (analyzed in ion trap mass analyzer) compared to HCD, which can only be analyzed in the
Orbitrap mass analyzer.
To  summarize,  Percolator  performed  significantly  better  than  a  classical  FDR  analysis.  This  was
independent  of  the  fragmentation  or  peptide  type.  Interestingly,  percolating  on  an  E.  coli sized  database
performed similar to a FASTA file with approximately one tenth of the proteins, using the FDR approach. As a
consequence of these findings, all subsequent database searches were performed using the bF-FASTA file with
Percolator.
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Figure  2-45:  For  the  two  workflows  using  a  small  FASTA  file  (sF)  and  a  10x  bigger  FASTA  file  (bF),
respectively, (A) PSMs were split into CID-IT and HCD fragmentation and (B) for non- and phosphorylated
peptides. For data generation the casein sample after iTRAQ-8Plex labeling and enrichment for phosphorylated
peptides  was used (sample CF, see workflow).  These cover  the non-phosphorylated- (NP), wash- (WF) and
phosphorylated Fraction (PF) and were searched in MudPIT approach.
2.4.3.2 The Advantage of a Multi-Protease Approach 
To determine the benefit of the multi-protease versus a single protease approach, the sequence coverage
[%],  the number of  unique peptides  and PSMs for  all  data-sets were compared (Figure 2-46).  Trypsin (Tr)
achieved  a  protein  coverage  ranging  from  ~  63  to  78%  (except  κ-casein;  Figure  2-46 (A)).  The  relative
unspecific  protease  elastase  (El)  performed  best  with  protein  coverages  of  ~  73  to  89%.  The  in-silico
combination of the four proteases (CETG)  and the sample CF (covering the non-phosphorylated, wash and
phosphopeptide enriched fractions) both resulted in protein coverages of ~ 92% for the three major proteins (α-
S1-, α-S2- & β-casein). 
Protein sequences were imported from UniProt without any further slicing. Therefore, the first ~15 amino
acids  (~7%  of  the  protein  sequence)  represented  signal  peptides  not  translated  to  the  full  length  protein.
Consequently,  the  92% (in-silico CETG and CF sample)  represented  the  maximal  to  be  expected sequence
coverage. These data showed, that by using multiple proteases the protein sequence coverage increased. It is
noteworthy, that all fractions after phosphopeptide enrichment were analyzed by mass spectrometry.
To further analyze the identification results, the number of unique peptides for each protease, their in-silico
combination (CETG) and for the sample CF were plotted (Figure 2-46 (B)). On average (three biological replica
analyzed),  only  91 unique  casein-related  peptides  were  identified  with trypsin.  This  represented  the  lowest
number of unique peptides identified from the individual proteases (GluC: 104, chymotrypsin: 162, elastase:
246). 
The  in-silico  combination (CETG) and the multi-protease approach (CF) clearly outperform the single
protease approach with a total of 550 and 463 unique peptides, respectively. Alongside to the number of unique
peptides, similar results were obtained for the PSMs. Due to the higher number of .raw files used for database
search, the number of PSMs were biased towards the multi-protease approach (CETG and CF).
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Figure  2-46: To visualize the differences in protein coverage (A), the number of unique peptides (B) and the
number of PSMs, these values were plotted for the four singly used proteases (chymotrypsin (Ch), elastase (El),
GluC (Gl) and trypsin (Tr); each sample D + P in MudPIT approach), for the in-silico combination of the four
proteases and the phosphopeptide enrichment fractions (CF).
To determine which protein sequences were more likely to be identified (and not only the number and
sequence of unique peptides)  the occurrence of each amino acid by  unique peptides was compared for each
individual  protease,  the  in-silico  combination  (CETG)  and for  the  multi-protease  approach  (CF)  after  TiO2
enrichment, respectively. Here, the Heat-Map minimal and maximal values were extracted from all data-sets
(referred to as  global,  Figure 2-47 (A) to  2-49 (A)). Whereas for the second data analysis, the minimal and
maximal values were extracted within each data-set (e.g., trypsin for α-S1-casein), referred to as local (Figure 2-
47 (B) to 2-49 (B)). 
For α-S1- and α-S2-casein, the number of amino acids extracted from identified unique peptides was rather
low for the four singly applied protease digests (Ch, El, Gl & Tr), being indicated by a mainly blue to slightly
green color (up to 30%,  Figure 2-47 (A)) for the global analysis approach. For β-casein, a higher number of
amino acids using the proteases elastase and chymotrypsin were present. 
Comparing the in-silico combination (CETG) and the enriched sample, the benefits were obvious by the
increased  frequency  of  the  amino  acids.  This  trend  was  similar  for  all  three  casein-proteins.  With  this
visualization method, the increase in phosphopeptide identifications after TiO2 enrichment is clear, for example,
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the phosphorylated amino acids pS56, pS61,pS63 and pS130 showed a higher frequency after enrichment compared
to the in-silico combined sample (CETG).
Each data-set was also subjected to Heat-Map generation using the local maximal values (Figure 2-47 (B)
to 2-49 (B)). This permits to observe specific advantages for each of the proteases used for protein digestion and
subsequent analysis of the number of unique peptides. 
For α-S1-casein, the amino acids within the sequence IGVNQEL (position #150) were frequently identified
using chymotrypsin.  For the remaining proteases,  different  sequences from α-S1-casein were predominantly
identified after database search such as, SMKEGIHAQQKEPM (position #139) for elastase, DQAME for GluC
(position #66) and DIGSESTEDQAMEDIK (position # 58) for trypsin. 
The sequence  (..R)L(KKY..)  (#116)  of  α-S1-casein was  difficult  to  be  identified  independently  of  the
protease used. This was also reflected for the in-silico combined sample (CETG) and phosphopeptide enriched
fraction  (CF)  and  might  give  a  hint  towards  inadequate  ionization  and  fragmentation  or  amino  acid
polymorphisms, which has to be analyzed subsequent by X!Tandem, de-novo and manual spectra interpretation. 
For β-casein, similar effect were regarding the protein coverages were observed (Figure 2-48). Trypsin
identified hardly sequences between the amino acids #128 to #190. Here, the obtained tryptic peptides contained
more  than  25  amino acids.  Peptide  fragmentation  and  identification  is  usually  optimal  for  peptides  with  a
sequence length of  5 to 25 AA  (314).  Consequently,  the protein section #128 – #190 was hampered to be
identified. However, these protein sections were frequently identified after protein digestion using elastase and
chymotrypsin. Another interesting protein section is located at position #101 (PFLQPEVVM). This section was
identified frequently (red colored) by chymotrypsin, elastase and GluC (red colored) but less by trypsin (only
green colored). By applying the multi-protease approach (CETG & CF), almost all protein regions could be
identified. Solely the region of INKKI (position #41) was not identified in any sample.  
The results obtained by α-S2-casein digestion were different among the four proteases. For every protease,
different protein sequences were identified. For example, the triply-phosphorylated peptide (with pS71-73) was
predominantly identified using GluC and elastase,  whereas the rate of identifying this triply-phosphorylated
peptide was much lower for trypsin.
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Figure  2-47:  Heat-Map in RGB style to visualize the frequency of each amino acid found within all unique
peptide groups identified by Proteome Discoverer for α-S1-casein using the reference workflow. The information
about the four singly used proteases chymotrypsin, elastase, GluC and trypsin, the in-silico combined sample
(CETG)  are  compared  to  the  enriched  sample  (CF).  The  enriched  fraction  covers  the  samples  non-
phosphorylated- (NP), wash- (WF) and phosphopeptide-fraction (PF). The same data sets (unique peptides)
were used. However, for (A) the highest number of amino acid occurrence was identified within each experiment,
whereas for (B), this was performed over all experiments. Especially for the phosphorylated amino acids pS 56,
pS61, pS63 and pS130 the positive effect of phosphopeptide enrichment using TiO2 is clearly demonstrate able. 
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Figure  2-48:  Heat-Map in RGB style to visualize the frequency of each amino acid found within all unique
peptide groups identified by Proteome Discoverer for β-casein using the reference workflow. Here, the number of
PSMs within a peptide groups was not taken into account. The information about the four singly used proteases
chymotrypsin (Ch), elastase (El), GluC (Gl) and trypsin (Tr), the combination of all four (ME) as well as the in-
silico combined sample (CETG) are compared to the enriched sample (CF). The enriched fraction covers the
samples non-phosphorylated- (NP), wash- (WF) and phosphopeptide-fraction (PF). The same data sets (unique
peptides) were used.
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Figure  2-49: Heat-Map in RGB style to visualize the frequency of each amino acid found within all unique
peptide  groups  identified  by  Proteome  Discoverer  for  α-S2-casein  using  the  reference  workflow.  Here,  the
number of PSMs within a peptide groups was not taken into account. The information about the four singly used
proteases chymotrypsin (Ch), elastase (El), GluC (Gl) and trypsin (Tr), the combination of all four (ME) as well
as the in-silico combined sample (CETG) are compared to the enriched sample (CF). The enriched fraction
covers the samples non-phosphorylated- (NP), wash- (WF) and phosphopeptide-fraction (PF). The same data
sets (unique peptides) were used.
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2.4.3.3 Enrichment of iTRAQ-8Plex labeled Phosphopeptides
Enrichment  techniques  are  a  prerequisite  for  the  analysis  of  phosphorylated  peptides  in  large-scale
phosphoproteomics studies, as they are frequently of low stoichiometry (122). In this study, TiO2 was chosen for
enrichment as it is robust regarding buffer and salts  (125). Three fractions were collected and analyzed: non-
phosphorylated-,  wash-  and  the  phosphopeptide  enriched  fraction.  In  pre-experiments  using  β-casein,  the
enrichment efficiency and selectivity was tested using different ratios of TiO 2 : starting from the widely applied
1:5 or 1:6 (protein:TiO2) ratio for in-solution full proteome studies (272), increasing amounts of TiO2 (1:10, 1:15
and 1:20) were used for workflow optimization. Finally, a protein to TiO2 ratio of 1:20 was found to be optimal
for  enrichment.  At  lower ratios,  the phosphopeptide pS50  was also identified in the non-phosphorylated and
washing  fractions.  This  phenomenon  can  be  caused  by  the  high  amount  of  phosphorylated  peptides  or  by
impurities introduced by SDS-PAGE separation performed at protein level.
In order to demonstrate the benefits of using a multi-protease approach (Figure 2-50), the number of unique
(A,  C,  E)  phosphopeptides  and  the  total  number  of  Peptide-Spectrum-Matches  (PSMs)  of  phosphorylated
peptides  (B,  D, F)  were analyzed for  the four proteases  alone,  their  in-silico combination (CETG) and the
phosphopeptide enriched fraction (CF). Although the sample complexity is rather low compared to a whole cell
lysate,  not all phosphorylated amino acids could be identified with the four proteases in the single protease
approach. By combining the four proteases  in-silico, not surprisingly, both, the number of unique and PSMs
increased.  However,  the  best  result  was  obtained  after  TiO2  enrichment,  which  demonstrated  the  excellent
compatibility of the chemicals used with the optimized TiO2 enrichment procedure. In particular for α-S2-casein,
the number of identified peptides (both unique and PSMs) was significantly higher after enrichment compared to
the in-silico combined sample (Figure 2-50; (E & F)).
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Figure 2-50: Number of unique identified phosphopeptide sequences (A, C, E) and their total Peptide-Spectra-
Matches  (PSMs;  (B,  D,  F))  for  α-S1-casein  (A,  B),  β-casein  (C,  D)  and  α-S2-casein  (E,  F)  identified  by
Proteome Discoverer  1.4 using the reference workflow (see Material  and Methods for further  details).  The
column diagrams contain the information about the four singly used proteases chymotrypsin (Ch), elastase (El),
GluC (Gl) and trypsin (Tr). Additionally, the in-silico combined sample (CETG) is compared to the enriched
sample  (CF).  The  enriched  fraction  covers  the  samples  non-phosphorylated-  (NP),  wash-  (WF)  and
phosphopeptide-fraction (PF). 
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2.4.3.4 Phosphoprotein Quantification using iTRAQ-4x2Plex
The multi-protease approach has been shown to yield an increased number of phosphorylated peptides in
terms of PSMs and unique peptide sequences (302). However, the previously published methods (302,315) lack
either (i) a quantitative dimension or (ii) the multi-protease approach. The experimental design (Figure 2-43)
described in the present work filled this gap by using a quantitative (iTRAQ-8Plex labeling) multi-protease
approach which allowed to perform relative quantification. Due to the unique iTRAQ reporter ion labeling,
principally this can be achieved using both HCD and ETD fragmentation (Table 2-8). 
Grouping of Quantifiable Peptides
To  quantify  phosphorylated  peptides,  it  was  not  possible  to  simply  group  unique  peptide  sequences
according to the C-terminal amino acids (Figure 2-51). This is due to the overlapping cleavage site specificities
of proteases: for chymotrypsin two overlapping amino acids (D, E) with GluC and one overlapping amino acid
(L) with elastase are known.  These were classified as  Ch-Gl and Ch-El,  respectively.  For singly & doubly
phosphorylated peptide sequences (pS56,  pS61,  pS63 and pS130 of α-S1-casein) the number of unique peptides
identified  was  similar  between  the  four  proteases  (protease  groups,  respectively).  However,  for  peptide
sequences in which multiple phosphorylation sites (e.g., pS81-83 of α-S1-casein) were present, the detection and
identification was more difficult. This can be seen for α-S1-caseins phosphorylated amino acids pS79 and pS81-83
for which considerably fewer unique peptides were identified. 
Beside the specific C-terminal amino acids, a high number of unspecific cleavage events were identified,
such as C-terminal threonine and histidine (Figure 2-51). From pre-experiments performed with a similar mix of
β-,  α-S1-  and  α-S2-casein,  these  were  shown to  mainly  originate  from elastase  (T)  and  chymotrypsin  (H)
cleavage. However, using the iTRAQ ratios (IS ratio; Equation 2-10) peptides could be easily be re-mapped to
the specific protease from which they were generated (for direct comparison). 
The peptide iLEIVPNpSAEERL was chosen as an example which, from the C-terminal amino acid, can not
be unambiguously assigned to either chymotrypsin or elastase due to overlapping cleavage specificities.  I/L
cannot be differentiated by LE-CID and are often set  equally for database searches.  However,  based on the
intense iTRAQ113 and iTRAQ119 signals, it was unambiguously that this peptide was generated by elastase rather
than chymotrypsin (Figure 2-52). 
Information regarding the iTRAQ reporter  ions was used in combination with the peptides  C-terminal
amino acid to remove potential false positive identifications.  In-house developed VB(A) scripts were used to
group peptides according to the protease,  which they were formed by based on the C-terminal amino acid.
Moreover, the iTRAQ reporter ions intensities were used to calculate the median and standard deviations for the
w-Ratio (Equation 2-11). The corresponding peptide w-ratios are summarized in chapter 4.4.
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Figure 2-51: The identified phosphorylated peptides within the protein β-casein (A) and α-S2-casein (B) were
split into protease groups according to the C-terminal amino acid. Chymotrypsin and GluC (Ch-Gl) share two
P1' and chymotrypsin and elastase (Ch-El) one P1' cleavage sites, respectively, making them indistinguishable
without further bioinformatics tools  (147). For the remaining cleavage sites (chymotrypsin, Ch; elastase, El;
GluC, Gl; trypsin, Tr) only unique C-terminal cleavage sites are known. Other C-terminal amino acids were also
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summed up and shown (unspecific, un).  The amino acids threonine (un-T) and histidine (un-H) were highly
present and shown additionally. For the peptide group 130, all unspecific amino acids were also a part of the
Histidine group (un-H). 
Figure  2-52:  The  annotated  HCD MS/MS spectrum (filter:  max  fragment  ion  deviation:  ±  20ppm,  signal-
intensity  >  5% of  most  intense  signal  in  spectra)  for  the  iTRAQ-8Plex  labeled  peptide  iLEIVPNpSAEERL
showing an almost complete sequence coverage (b- and y-ion series combined). Additionally, fragment ions
formed  by  neutral  loss  events  similar  to  [M-P],  were  observed  (e.g.,  y6+-P).  Although this  peptide  can  be
generated by elastase or chymotrypsin cleavage (I & L can be set to equal in database searches, e.g., MaxQuant
(300))  the iTRAQ reporter  ion intensities  (without  impurity  correction) clearly shows its  origin by elastase
digestion (intense iTRAQ113 and iTRAQ119 signal).
Implementation of (Phospho)Peptide Group Quantification
Classically for iTRAQ related proteomics studies, the iTRAQ ratio is generated by dividing one iTRAQ
reporter  ion  signal  intensity  (or  area)  by  another  (e.g.,  iTRAQ115/iTRAQ114).  In  this  study,  an  alternative
calculation was used (w-Ratio) to overcome the problem of division by 0, which was expected to occur for
dephosphorylated peptides. The w-Ratio scale of 0 to 1 improved the data visualization process to compare
differentially abundant peptides. In the following, the numerator was chosen to be the iTRAQ reporter ion of the
dephosphorylated  sample  D  for  all  calculations  of  the  w-Ratio.  With  the  experimental  sample  set  up,
dephosphorylated peptides should show w-Ratios towards 1, as these non-phosphorylated peptides should be
only  present  in  low  abundance  (or  not  at  all)  in  the  natively  phosphorylated  sample.  In  contrast,  the
phosphorylated counterparts should have a w-Ratio of 0.3 (equals iTRAQ ratio of 0.5), because the sample D is a
1:1 composition of dephosphorylated sample and the natively phosphorylated casein sample. 
The chosen  standard  proteins  α-S1-,  α-S2-  and  β-casein  were  used  to  validate  the  quantitative  multi-
protease workflow. The number of phosphorylation sites and its degree is high (α-S1-casein = 8-9, α-S2-casein =
10-13 and β-casein = 4-5 number of phosphorylation sites). Rather than being distributed evenly across the entire
protein, many of the phosphoserine residues exist in clusters, e.g., pS81-83 in α-S1-casein and pS32-34 in β-casein.
Therefore, caseins are the ideal model substances to evaluate whether the developed workflow was capable of
identifying both singly- and multiply-phosphorylated peptides.
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For quantification, only high confident peptides (FDR < 1%) were used which is a common approach for
quantitative proteomics studies (113). For demonstration purposes, all quantified tryptic peptides for α-S1-casein
(Figure 2-53) were extracted from the data-set to present differences for de- & phosphorylated peptides (w-Ratio
of 1 and 0.3, respectively) and peptide without differential expression (w-Ratio = 0.5). Peptide groups were
clustered according to their iTRAQ-8Plex reporter ions so that the results achieved by each protease could be
compared for the three casein proteins (Figure 2-54 to 2-58).
Figure 2-53: All tryptic peptides identified and quantified for α-S1-casein. After re-grouping of unique peptides
the median and the standard deviation for each peptide group was calculated. For dephosphorylated peptides, a
w-Ratio towards 1 is expected, whereas for the phosphorylated counterpart a w-Ratio of 0.3 should be observed.
Quantifying (Phospho)Peptide Groups obtained by a Multi-Protease Digest
Quantification Results for α-S1-Casein
α-S1-casein contains phosphorylated serines at positions 56, 61, 63, 79, 81-83, 90 and 130 many of which
were quantified by tryptic peptides (Figure 2-54 (D)). The triply phosphorylated peptide (Peptide52-73), containing
one tryptic missed cleavage, and the doubly phosphorylated form (without a missed cleavage; Peptide58-73) were
quantified with w-Ratios of 0.27 and 0.31, respectively. Interestingly, both peptides were also identified with a
missing phosphorylation site exhibiting slightly higher  w-Ratios than their triply and doubly phosphorylated
counterparts (e.g., peptide #4 and #5 in Figure 2-54 (D)). Similar results were obtained with GluC and elastase,
i.e., various degrees of phosphorylation were observed for phosphopeptides containing residues pS56, pS61 and
pS63 (see below). Both α-S1- and α-S2-casein contain various number of phosphorylated serines (α-S1 = 8-9, α-
S2 = 10-13) and thus, the various degrees of peptide phosphorylation for these proteins may be a result of
phosphoheterogenity, which is characteristic for casein proteins (316), or be a result of the alkaline phosphatase
treatment. 
For the tryptic peptide58-73,  both forms (de- and phosphorylated)  were present.  The non-phosphorylated
peptide (#7 and #8 in Figure 2-54 (D)) showed a w-Ratio of 1, whereas their phosphorylated counterparts (#9 –
#12) showed the expected  w-Ratio of 0.3. The results found for this peptide demonstrated the advantages of
analyzing  all  fractions  of  the  phosphopeptide  enrichment.  Both  the  phosphorylated  and  non-phosphorylated
forms can be identified giving complementary quantitative information. For the phosphorylation site at pS130,
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both the dephosphorylated and phosphorylated forms were identified for each peptide with w-Ratios of 0.9 and
0.3 for dephosphorylated and the phosphorylated peptides, respectively. In total for trypsin, 11 phosphopeptides
and  6  dephosphorylated  counterparts  were  identified  for  α-S1-casein.  However,  while  many  of  the
phosphorylation sites on α-S1-casein were identified with trypsin, phosphoserine residues at positions pS79, pS81-
83 and pS90 were not. The remaining peptides, not being part of a potential phosphorylation site, were also plotted
together with the de- and phosphorylated to demonstrate that these scatter around a w-Ratio of 0.5 (Figure 2-53).
Interestingly, for GluC (Figure 2-54 (C)), only singly and doubly phosphorylated peptides were identified.
This might be caused by the acidic C-Terminal amino acid (E) in addition to the negatively charged phospho-
moiety lowering the ionization efficiency. The peptide55-65 and peptide55-76 were identified in both the doubly
phosphorylated and completely dephosphorylated forms, with expected w-Ratios.  The peptide77-92 covered in
total five known phosphorylations sites, but only the completely dephosphorylated form was identified (w-Ratio
= 0.9). Although the phosphorylated form was not identified from GluC digests, a potential posttranslational
modification can be assumed due to the high iTRAQ w-Ratio, which is in contrast to the remaining peptides (see
Table 4-4 for  further details).  This demonstrated again the benefit  of analyzing all  fractions following TiO 2
enrichment.  The  phosphorylation  site  at  position  pS90,  was  covered  by  both  forms  with  expected  w-Ratios
(Peptide86-92). The phosphorylation site pS130 (Peptide126-132/133/140) was identified with various sequence lengths
(with or without missed cleavages) and with and without oxidation of methionine, all of which were quantified
correctly. 
For the elastase digest (Figure 2-54 (B)), all phosphorylation sites (source: UniProt, last modified June 11,
2014, version 118) within the protein α-S1-casein were quantified. This was not observed for peptides obtained
from the GluC and trypsin digest. This again clearly demonstrated the benefit of a quantitative multi-protease
approach. Similarly to GluC and trypsin, the peptide53-72/75 covering three phosphorylation sites (pS56, pS61, pS63)
was  identified  as  a  triply  and  doubly  phosphorylated  peptide  with  elastase.  Surprisingly,  no  completely
dephosphorylated  counterpart  was  identified.  The  peptide76-107 covered  five  phosphorylation  sites,  and  this
peptide was also identified with the correct w-Ratio. The Peptide81-89, covering four potential phosphopeptides
positions (pS81, pS82, pS83 & pS90) was identified in its dephosphroylated form with the correct w-Ratio of 0.9. As
demonstrated before for  GluC, the phosphorylation site  pS130 was identified in a  various  peptide sequence
lengths (missed cleavages) and dynamic modifications (peptides #8 – #16 in Figure 2-54 (C)).         
In terms of quantifying α-S1-casein phosphorylation sites, identification and quantification performed the
worst for the chymotrypsin digest (Figure 2-54 (A)). The Peptide77-85 showed w-Ratios of ~ 0.4 which did not
match to those observed with the other proteases. For the phosphorylation site pS130, the expected w-Ratios were
observed although, one of the peptides (Peptide126-140) had a to low w-Ratio. 
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Figure 2-54: α-S1-casein peptides covering a potential phosphorylation site were extracted from the identified
PSM list and further split into the related proteases according to their C-terminus and the iTRAQ reporter ion
signals for easier visualization (chymotrypsin in yellow, elastase in cyan, GluC in olive and trypsin in gray).
Finally, after re-grouping of unique peptides the median and the standard deviation for each peptide group was
calculated. For dephosphorylated peptides, a w-Ratio towards one is expected, whereas for the phosphorylated
counterpart a w-Ratio of 0.3 should be observed.
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Figure 2-54 (continued): α-S1-casein peptides covering a potential phosphorylation site were extracted from the
identified PSM list and further split into the related proteases according to their C-terminus and the iTRAQ
reporter ion signals for easier visualization (chymotrypsin in yellow, elastase in cyan, GluC in olive and trypsin
in gray). Finally, after re-grouping of unique peptides the median and the standard deviation for each peptide
group was calculated.  For dephosphorylated peptides,  a  w-Ratio towards one  is  expected,  whereas for  the
phosphorylated counterpart a w-Ratio of 0.3 should be observed.
Quantification Results for β-Casein
β-casein contains two isolated (pS30 and pS50) and three clustered (pS32,33,34) phosphorylation sites. Due to
the lower number of phosphorylation sites, all peptides identified with the four proteases were plotted on one
graph (Figure 2-55). Using the quantitative multi-protease approach, all phosphorylation sites could be identified
and correctly quantified (except the chymotryptic Peptide44-67). For tryptic β-casein digestion, only two peptide
sequences (without missed cleavages or  dynamic modifications) were expected due to the clustering of  the
phosphorylation  sites  (pS30-34).  Experimentally,  these  two  peptide  sequences  were  identified  using  trypsin
(Peptide16-40 and Peptide48-63).  Additionally,  one tryptic  phosphorylated peptide (Peptide45-63)  with one missed
cleavage site was identified and quantified correctly (w-Ratio = 0.3). Elastase was cleaving after residue L 21 and
L31 and producing a shorter phosphopeptide (Peptide22-31,  w-Ratio of 0.4 and 0.9 for the phosphorylated and
-142-
2.4 MECi – Targeted Phosphoprotein Quantification
dephosphorylated form, respectively). The phosphorylation site pS50 was quantified correctly using GluC derived
peptides (w-Ratio of 0.3 and 0.9 for the phosphorylated and dephosphorylated form, respectively),  although
three  phosphorylated  peptides  with  one  to  three  missed  cleavages  were  identified.  However,  the  triply
phosphorylated peptide was not identified after elastase or GluC digestion. 
For chymotrypsin, only the phosphorylation pS50 was identified. Two of the corresponding phosphorylated
peptides  (Peptide42-67 and  Peptide46-67)  were  quantified  with  the  expected  w-Ratios  of  0.3.  Surprisingly,  the
chymotryptic peptide KIEKFQSEEQQQTEDELQDKIHPF (Peptide44-67) showed a w-ratio of approx. 1 for both,
the  phosphorylated  and  dephosphorylated  peptide  (Peptide49-67).  This  was  unexpected  due  to  the  excellent
performance of the remaining three proteases.  By closer inspection of the raw-data,  this phenomenon could
(partially) be explained. The phosphopeptide was identified twice as 5+ and three times as 4+ charged precursor.
All of these share the same retention time window (within 30 sec due to dynamic exclusion) and precursor mass
deviation (3 ppm). However, the iTRAQ ratios for the 5+ charged precursor followed the expected trends (w-
ratio = 0.3), whereas those of the 4+ charged precursor ion did not meet the expectations (w-ratio = 1). Here, only
the iTRAQ reporter ion at m/z 114 was detected in tandem MS spectra. Currently, this observation cannot be
explained. 
With the multi-protease approach, in total 16 peptides were quantified for β-casein; with averaged w-Ratios
of 0.32 and 0.89 for the phosphorylated and dephosphorylated peptides, respectively. 
Figure 2-55: β-casein peptides covering a potential phosphorylation site were extracted from the identified PSM
list and further split into the related proteases according to their C-terminus and the iTRAQ reporter ion signals
for easier visualization (chymotrypsin in yellow, elastase in cyan, GluC in olive and trypsin in gray). Finally,
after  re-grouping  of  unique  peptides  the  median  and  the  standard  deviation  for  each  peptide  group  was
calculated. For dephosphorylated peptides, a w-Ratio towards 1 is expected, whereas for the phosphorylated
counterpart a w-Ratio of 0.3 should be observed.
Quantification Results for α-S2-Casein
All  phosphoserine  residues  of  α-S2-casein  were  identified  and  quantified  (Figure  2-56 to  2-58).
Interestingly,  the  phosphoserine  at  pS46 showed  no  quantitative  difference  (w-Ratio  =  0.5)  for  both  the
phosphorylated or dephosphorylated forms. For this two phosphoserine residue, peptides from each protease
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exhibited a w-Ratio of ~ 0.5. The different degree of phosphorylation was stimulated by alkaline phosphatase
treatment.  This  phosphoserine  residues  may  not  be  accessible  to  the  alkaline  phosphatase.  Samples  were
incubated  under  relatively  mild  conditions:  30°C overnight  at  pH 8.0 (Tris-HCl).  Elevated  temperatures  or
denaturing conditions, e.g., low amounts of detergents, may have resulted in a more complete dephosphorylation
of α-S2-casein. The remaining phosphorylated peptides, however, behaved as expected with an average w-Ratio
of 0.3 for the remaining phosphopeptides. 
In  summary,  the  phosphorylation  sites  from  all  the  caseins  were  accurately  quantified  with  the  new
developed workflow.  With quantitative  information from four  proteases,  the  multi-protease  iTRAQ-4x2Plex
labeling strategy could be used not only to identify global changes in protein phosphorylation but also accurately
identify up- and down-regulation of individual phosphorylation sites, as shown for α-S2-casein at pS31 and pS46. 
Figure 2-56: α-S2-casein chymotryptic peptides covering a potential phosphorylation site were extracted from
the identified PSM list and further split into the related proteases according to their C-terminus and the iTRAQ
reporter ion signals. Finally, after re-grouping of unique peptides the median and the standard deviation for
each peptide group was calculated. For dephosphorylated peptides, a w-Ratio towards 1 is expected, whereas
for the phosphorylated counterpart a w-Ratio of 0.3 should be observed.
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Figure  2-57: α-S2-casein elastase derived peptides covering a potential phosphorylation site were extracted
from the identified PSM list and further split into the related proteases according to their C-terminus and the
iTRAQ reporter ion signals. Finally, after re-grouping of unique peptides the median and the standard deviation
for  each  peptide  group  was  calculated.  For  dephosphorylated  peptides,  a  w-Ratio  towards  1  is  expected,
whereas for the phosphorylated counterpart a w-Ratio of 0.3 should be observed.
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Figure 2-58: α-S2-casein GluC derived peptides covering a potential phosphorylation site were extracted from
the identified PSM list and further split into the related proteases according to their C-terminus and the iTRAQ
reporter ions signal. Finally, after re-grouping of unique peptides the median and the standard deviation for
each peptide group was calculated. For dephosphorylated peptides, a w-Ratio towards 1 is expected, whereas
for the phosphorylated counterpart a w-Ratio of 0.3 should be observed.
-146-
2.4 MECi – Targeted Phosphoprotein Quantification
Figure 2-59: α-S2-casein trypsin derived peptides covering a potential phosphorylation site were extracted from
the identified PSM list and further split into the related proteases according to their C-terminus and the iTRAQ
reporter ion signals. Finally, after re-grouping of unique peptides the median and the standard deviation for
each peptide group was calculated. For dephosphorylated peptides, a w-Ratio towards 1 is expected, whereas
for the phosphorylated counterpart a w-Ratio of 0.3 should be observed.
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2.4.4 Conclusion
To accurately identify and quantify phosphorylation sites between two different biological conditions, a
multi-protease  approach  for  phosphoprotein  analysis  published  earlier  (302) was  extended  here  by  the
implementation of the possibility for relative quantification. 
In  this  study,  iTRAQ-8Plex was not  applied in  its  routinely form to compare eight  different  states  in
parallel. In contrast, the experimental setup can be described as an iTRAQ-4x2Plex labeling. This overcomes the
requirements to generate eight intense reporter ions for quantification, as commonly only two different peptide
species (from one protease) were selected simultaneously for fragmentation. The phosphopeptide enrichment
protocol was adjusted to be fully compatible to iTRAQ labeling and phosphopeptide enrichment using TiO2. As
both biological states and each of the four different digestions were combined, potential sample-handling effects
introduced by parallel  enrichment were at  least  reduced.  This included the utilization of (an experimentally
optimized) Protein:TiO2 ratio of 1:20 for casein-proteins separated by SDS-PAGE. Using higher amounts of
titanium dioxide material  increased the robustness  of  the enrichment  procedure.  Consequently,  not  only the
number of unique peptide species originated from different protease digestions increased, but also the number of
phosphorylated PSMs. 
The identification of a numerous complementary non- and phosphorylated peptide species was achieved
using a CID-IT/HCD approach, which benefited from optimal measurement settings (see chapter 2.1). For multi-
protease  studies,  identified  peptides  should  be  validated  using  the  semi-supervised  machine  learning  code
Percolator (chapter 1.2.4), as this improved the number of PSMs for both CID-IT and HCD fragmentation. It is
speculated that Percolator benefits from the similar but different peptide sequences, their corresponding retention
times in combination to peptide features which are used to dynamically learn to distinguish between false and
true positive peptide hits. 
By combination of relative quantification with the multi-protease approach, more accurate identification
and quantification was achieved. The number of  unique phosphopeptides increased significantly,  which was
particularly true for proteases with low-specificity. These generated a very high number of unique peptides with
overlapping sequences.  An increased  number of  unique  peptides  also assisted in  filtering out  false  positive
identifications. In addition, by analyzing all fractions after enrichment, complementary information on the non-
phosphorylated peptides was retained. This can be used to normalize quantitative data to compensate any bias
introduced during sample processing. Finally, the quantitative multi-protease approach shown here is not limited
to the analysis of phosphorylation sites. Principally,  any kind of dynamic modification can be analyzed and
relatively quantified using this method in a very accurate and precise manner.
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2.5 Discussion and Outlook
The identification and quantification of iTRAQ labeled (phospho)peptides is crucial to characterize and
understand proteome dynamics.  To obtain optimal results, process parameters, such as Normalized Collision
Energies for peptide fragmentation, have to be evaluated critically. It was the major goal of this thesis, to develop
an  analytical  platform  for  relative  quantification  using  iTRAQ  on  an  LTQ  Orbitrap  Velos  to  analyze
comprehensively phosphorylated and non-phosphorylated proteins. In summary, this was successfully realized
by  combining  four  different  research  areas  within  proteome  science;  beginning  with  the  evaluation  of
fragmentation conditions to identify and quantify (phospho)peptides.     
(1st) Optimized Fragmentation Conditions for iTRAQ Labeled (Phospho)Peptides
The parallel  acquisition  of  CID-(MSA)-IT and HCD spectra  provided  an  almost  optimal  trade-off  for
identification and quantification of iTRAQ labeled (phospho)peptides on an LTQ Orbitrap Velos.
CID-(MSA)-IT  fragmentation  was  both  beneficial  (fast  spectra  acquisition  due  to  the  ion  trap)  and
detrimental  (low  mass  accuracy  and  resolution  of  tandem  MS  spectra).  It  has  to  be  highlighted,  that
phosphopeptide spectra upon CID-IT decomposition were still dominated by signals obtained by neutral losses
of  phospho-moiety  rather  than  by  signals  derived  by  iTRAQ  fragmentation.  To  analyze  iTRAQ  labeled
phosphopeptides,  the  multistage  activation  feature  of  CID  should  be  activated,  as  the  identification  and
localization of the phosphorylation site was strongly enhanced by this technique, and even outperformed HCD.
This was rather unexpected, as high resolution mass spectra upon HCD excitation were claimed to be superior
for phosphopeptide identification (181). 
CID-IT MS/MS spectra were diminished by the 1/3rd rule of ion traps by which they were not optimal for
iTRAQ  quantification.  Therefore,  CID-(MSA-)IT  spectra  should  exclusively  be  used  for  identification  of
peptides by applying optimized NCE values. In previous studies, HCD spectra were predominantly used for
quantification at elevated NCE values to generate intense iTRAQ reporter ions. However,  by fine-tuning of
fragmentation parameters, an optimal trade-off was evaluated in this study to benefit of HCDs high resolution
and mass accuracy spectra for identification and quantification, respectively.  
A suggestive dual fragmentation (CID-IT/HCD) measurement cycle on LTQ Orbitrap Velos instruments,
starts with the MS prescan at low resolution (7,500), followed by a full scan at high resolution in the Orbitrap
(FT-MS). In parallel, with the beginning of the high resolution full scan, CID-(MSA-)IT spectra can already be
acquired in the ion trap, taking advantage of its sensitivity and speed of acquisition. After the MS full scan has
completed,  HCD  spectra  are  recorded  in  the  Orbitrap  mass  analyzer  (see  Figure  1-12).  Importantly,  the
application of a dual fragmentation mechanisms does not lead to significantly prolonged cycle times. 
However, optimal NCE values were charge-state dependent for HCD fragmentation. The current instrument
setup of the LTQ Orbitrap Velos did not allow the application of  on-the-fly decision-tree approaches,  which
would greatly increase the performance of HCD. Features for the decision-tree could be: (i) different NCE values
in dependence of the precursor mass, (ii) adjustment of NCE values and the number of µ-scans in combination
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with dynamic in- & exclusion lists to improve the signal-to-noise ratios, (iii) variation of the precursor mass
isolation  windows  to  minimize  co-isolation  effects,  (iv)  perform  on-the-fly identification  of  peptides  by
parallelized processing using graphic processing units (GPUs) to exclude repeating fragmentation of the same
precursor or (v) selection of the same peptide ion with different charge states for more accurate identification and
quantification.
In this study, peptides were re-identified across all LC-ESI MS runs for data evaluation by a combination of
three features (retention time, precursor m/z and charge state), a process similar to the  re-match between runs
option in MaxQuant. It is noteworthy that this method of data-extraction and data-analysis are unique and have
not been performed in any other iTRAQ evaluation study published (177,255,273,274,277,317,318). 
By applying this re-mapping approach, data points from elevated Normalized Collision Energies (> 65%),
such as the iTRAQ reporter  ions intensity,  were also included in data-analysis and re-mapped to a  specific
peptide. As search engine scores were suppressed at higher NCE values due to the limited number of significant
b- and y-ions alongside intense (and non-sequence informative) iTRAQ reporter ion signals  (211), these data
were not reallocated to a specific peptide species in previous reports published. In this study, by combining the
precursors m/z value, its retention time and charge state, these data could unambiguously be reassigned to a
specific  peptide.  Although the focus was set  to optimize collision energies  for  any kind of  iTRAQ labeled
peptides, the data of each (phospho)peptide can also be used to identify sequence specific motifs which might
help to predict peptide fragmentation patterns more precisely. 
  The  computational  proteomics  tools  used  for  process  optimization  in  this  study,  are  planned  to  be
published under the GNU General Public License. This allows for studying, sharing and modifying the software
or  directly  re-using  the  implemented  tools  to  perform  optimization  processes  for  MS  instruments  before
beginning with large scale (phospho)proteomics studies. Beside that, the .raw files of this study should be made
public  to  the proteomics  community.  Open-source initiatives,  such as  X!Hunter  from The Global  Proteome
Machine Organization, publish spectra libraries for reliable peptide identification. For this purpose, information
about the shape of tandem MS spectra from a particular peptide are normalized via several and independent
instruments. These reference spectra could be improved further by the incorporation of spectra-series, which
were recorded at various NCE values. 
(2nd) Refinement of Precursor m/z Calculation of iTRAQ Labeled Peptides
Przybylski et al. (274) described the discrepancy to accurately calculate the precursor mass (m/z value) of
iTRAQ-4Plex labeled peptides; which resulted in a mass shift of up to 3.8 ppm for peptides labeled exclusively
with iTRAQ114. Przybylski et al.  (274) advised to increase the precursor mass tolerance window from 5 to 10
ppm in database search settings.  
The  effect  of  inaccurate  precursor  mass  calculation was  analyzed  systematically  in  this  thesis.  It  was
demonstrated that the mass accuracy was depending on the number of iTRAQ modifications per peptide. This
directly affected database search results as different minimal precursor mass tolerance windows were required to
obtain comparable protein identification results. 
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To circumvent this, a newly post-database search algorithm was compiled which used the iTRAQ reporter
ion intensities of tandem MS spectra to calculate the precursor mass (m/z value) more precisely. This was an
important  advantage,  as the precursor mass of  exclusively iTRAQ114 or iTRAQ115 labeled peptides could be
corrected from 4.3 to 0.0 ppm. 
The next step is to integrate this algorithm into database search suites. This can for example be performed
by creating four peptide precursor lists during peptide indexing. Three of them are used for iTRAQ 114, iTRAQ115
and iTRAQ116&117 peptide mass calculation; while the last one is a linear combination of the observed iTRAQ
intensities in each tandem MS spectrum, multiplied by the different peptide masses from the remaining lists.
Although this process has to be performed for every single MS/MS spectrum, hence it will increase the search
time, the results and accuracy of precursor mass calculations after database search will improve. 
(3rd) Improving the Identification of iTRAQ Tyrosine Labeled Peptides
To further improve database search results obtained for iTRAQ labeled peptides, a new immonium ion for
iTRAQ labeled tyrosine peptides was discovered for both iTRAQ-4Plex and iTRAQ-8Plex upon beam-type CID
fragmentation. This modification influenced the tandem MS fragmentation pattern and, additionally the retention
time in reversed phase chromatography. 
Both features can be used, amongst others, in semi-supervised machine learning codes to further improve
the validation process of peptides by applying more than one peptide feature, as it is done for FDR calculation.  
(4th) Quantitative Phosphoproteomics Using a Multi-Protease-Approach
Finally, an analytical workflow for relative quantification of phosphoproteins was established. It combined
the benefit of increasing sequence coverage and the likelihood to localize the exact site of phosphorylation by
applying a multi-protease approach  (302) with subsequent iTRAQ labeling for relative quantification, with a
selective  choice  of  buffers  and  chemicals  to  ensure  the  compatibility  with SDS-PAGE and phosphopeptide
enrichment using TiO2.   
The number of unique and quantifiable (phospho)peptides increased due to the combination of two low and
two high specific proteases and the higher sample amount of iTRAQ labeled peptides which can be used for LC
MS analysis. Increasing the sample amount does not overload the analytical column, as peptides exhibit a wide
range of physiochemical properties (size,  charge, hydrophobicity) which lead to large differences (ionization
efficiency and retention time) in LC-ESI MS experiments. 
To apply the newly implemented strategy to whole cell lysate, peptide fractionation is a prerequisite to
simplify the complexity of the sample. This can, for example, be a combination of a 3D-LC approaches with an
additional phosphopeptide enrichment (e.g., TiO2) step (i) to increase the number of identified and quantifiable
peptides, (ii) validate the localized site of phosphorylation by more than one spectra and one phosphopeptide-
sequence and (iii) to receive a higher number of (unique) peptides per protein to improve the accuracy of protein
quantification. 
Further,  it  is suggested to use the data of the quantitative multi-protease approach to measure the site-
-151-
 2 Developing a Platform for relative Quantification using iTRAQ
specific degree of phosphorylations. A recently published work by Steen et al.  (319) addressed this issue by
incorporation of a  flyability factor  to compare the intensities of phosphorylated and the non-phosphorylated
counterparts. As their strategy was build on a label-free approach, the XICs of the non- and phosphorylated
peptides were directly available. For the relative quantification strategy using iTRAQ, these XICs are only in-
directly available, as the precursor ions are isobaric and appear as a single signal in MS scan (see Figure 1-4).
However, the content of each XIC from each biological entity is directly proportional to the iTRAQ reporter ion
distribution in the tandem MS spectra, and the partial XIC for every biological entity can be calculated. To
finally establish and examine this technique, further LC MS experiments are required. 
Final Statement
The development of an analytical platform for relative quantification using iTRAQ on an LTQ Orbitrap
Velos to analyze comprehensively phosphorylated and non-phosphorylated proteins was the major goal of this
dissertation. This task was successfully accomplished and the newly established and developed methods can be
used directly to analyze proteins from biological material. This can be biological samples derived from whole
cell lysate to identify dis-regulated signaling pathways by relative quantification using iTRAQ under disease
states (e.g., cancer or tuberculosis) to elevate the feasibility to discover new therapeutic treatment options.
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3 Development  of  Computational  Proteomics
Pipelines for Automated Data Processing
3.1 Paleoproteomics – Studying the Iceman's Brain Tissue2
The ice mummy Oetzi was discovered in 1991 by two German mountaineers in an Italian alpine glacier. By
freeze drying, the iceman's corpus was well  preserved, making it  a scientifically and historically interesting
research project (320,321). Genome sequencing of this mummy has allowed researches to get an idea about his
phenotype and origin  (322). The analysis of lipids and proteins on the other hand, which are preserved better
than DNA (323), might uncover new scientific breakthroughs, such as the reason of his death. 
It  is  known from gel-based  paleoproteomics  studies  on  mummy tissues  that  degradation  processes  of
fibrous (collagen) and globular proteins into smaller peptides occurs (324,325). These degradation processes can
be caused by a variety of sources during and/ or after the mummification process. Rapid pH drops, post mortem
formation  of  reactive  oxygen  species  (ROS)  in  addition  to  intracellular  and  microbial  enzymes  are  some
examples of processes that induce protein denaturation and degradation (326–328). Additionally, environmental
factors play an important role: e.g., temperature changes between seasons, which can increase the degradation
processes; facts limiting the degradation process and support protein preservation are rapid desiccation, as it was
the case for the iceman (329).
Studies published so far have focused on collagen in ancient material. This protein complex seems to be
well preserved and could even be identified in dinosaur fossils. Additionally, other peptidic remains have been
identified in grape seeds, archaeological potsherd, and in a Neanderthal bone (330–332). The most successful of
these studies in terms of protein identifications has been published after  analyzing a 43,000 years old mammoth
bone samples (333).  
The focus of this paleoproteomics project is to identify proteins from two soft tissue samples of the iceman
Oetzi. The cooperative work between the first authors (F. Maixner, T. Overath and D. Linke) is shared equally
into  biological,  experimental  (sample  preparation  and  mass  spectrometry)  and  computational  proteomics
sections. The development and establishment of a workflow to combine results from multi-database searches is
the major aim this chapters (3.1.1 & 3.1.2). Further, the performance of each database search engine is evaluated.
Additionally, the use of such a strategy to accurately identify proteins for a 5,300 years old wet-mummy, the
Tyrolean iceman Oetzi, will be highlighted.  
2 Parts of the chapter 3.1 were published in Cell. Mol. Life Sci. (2013) 70:3709–3722
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3.1.1 Material and Methods
Chemical and instrumental description can be found in the chapter 4.1.
3.1.1.1 Sample Preparation
Two tissue biopsies (denoted as 1024 and 1025 in the following) from the dark area of the occipital lobe of
the iceman Oetzi were extracted (Figure 3-1). Briefly summarized, a two step extraction process was applied for
both tissue samples, which is illustrated in Figure 3-2 (A). After protein extraction, samples of strategy A (1024-
A,  1025-A) were separated by SDS-PAGE (Figure 3-2 (B)),  whereas the supernatant and cell  derbies were
subjected to a second extraction process with subsequent in-solution digestion. A more detailed description can
be found in (310). 
Figure  3-1:  “Transverse  CT section  through  the  skull  shows  an  irregular  area  (actual  sampling  site)  of
increased radiographic transparency in the posterior cerebral regions (asterisk). The meninges have become
detached from the skull vault and surround the shrunken, inhomogenously disintegrated brain” (310).
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Figure  3-2:  (A)  Sample preparation workflow applied to  process  both,  sample 1024 and 1025,  for  protein
extraction, digestion and sample separation. All samples were analyzed by online LC-ESI MS, with a subsequent
multi-dimensional database search. Finally protein identifications were combined for biological evaluation of
proteomics  data.  (B)  1D-SDS-PAGE of  two protein  extracts  from the  Iceman   ́ s  brain  tissue  samples.  Both
samples (approx. 22 μg for sample 1024-A lane 1 and approx. 11 μg for sample 1025-A lane 2) were separated
on a 12% SDS-PAGE and colloidal coomassie stained. (B left side) shows the gel without excision labels; (B
right side) shows the gel slices excised for tryptic digestion.
3.1.1.2 Mass Spectrometry
Samples obtained from in-gel and in-solution digest (Figure 3-2) were reconstituted in 12 µL loading buffer
(0.1%  (v/v)  TFA,  3%  (v/v)  ACN  in  ddH2O)  and  analyzed  by  LC-ESI  MS  using  reversed  phase  liquid
chromatography  coupled  online  to  a  LTQ  Orbitrap  Velos  (see  chapter  2 and  chapter  4.1 for  additional
information). For each sample injection, 10 µL of redissolved peptides were loaded and desalted for 6 min (flow
rate: 30 µL/min). Peptides were separated at a flow rate of 300 nL/min using eluent A (0.05% (v/v) formic acid
(FA)) and eluent B (0.1 FA, 80% ACN). The gradient, which was used to separate peptides, varied: for the in-gel
digested samples (band 1-20) and in-solution digested samples, a 110 min linear gradient from 0 to 50% B was
used. For the gel band 21 & 22, the gradient was prolonged to 150 min (linear increase from 0 to 50% B). 
XCalibur (Version 2.1) was used to create a TOP 15 method for the LTQ Orbitrap Velos. Full scans were
required in the Orbitrap mass analyzer (m/z 300 – 1600) at a resolution of 60,000. The 15 most intense ions
(signal intensity ≥ 500; charge state > 1+) were selected for CID-IT fragmentation acquired in the ion trap (IT).
CID-IT settings were set to default (NCE: 35%, activation Q: 25; activation time: 10 ms). Dynamic exclusion
was enabled (isolation width ± 10 ppm; exclusion duration: 60 sec, maximum list size: 500).
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3.1.1.3 Database Searches
Recorded .raw files  were sliced  and  re-calibrated  prior  to  the main-database  search  using the Re-Call
Offline feature of XCalibur. Preliminary database searches were performed using SEQUEST (settings see below)
to  evaluate  the  highest  and  lowest  retention  times  observed  (FDR <  10%)  used  for  raw  file  slicing.  The
polysiloxane signal at m/z 445.120026 was used for re-calibration of MS data.
The main database evaluation was performed using four different search engines: SEQUEST (implemented
in Proteome Discoverer v.1.2), Mascot (Matrix Science, v.2.2.04), OMSSA (Open Mass Spectrometry Search
Algorithm, v.2.1.9) and X!Tandem (v. CYCLONE 2010.12.01). SEQEUST and Mascot database searches were
performed using the software Proteome Discoverer (v.1.2), whereas OMSSA and X!Tandem were part of the
cross-platform Java based programs SearchGUI (v.1.7.3) and PeptideShaker (v.0.16.2). The latter two used .mgf
as input files. These were generated by the spectrum exporter node (default settings) within Proteome Discoverer
1.2. 
All settings (e.g., ppm window, modifications added) were in-house standardized for this project and used
for all four database searches. Due to spectra re-calibration, precursors ppm tolerance window was set to 5 ppm.
For the size exclusion flow-through samples, the precursor ppm window was lowered to 3 ppm. Fragment ions in
CID-IT MS/MS spectra were matched with a tolerance of 0.5 Da. Two missed cleavages for trypsin digestion
were allowed. Carbamidomethylation of cysteine was set as a fixed modification, while oxidation of methionine
was set as a variable modification. Additional database searches were performed including deamidation of N and
Q  as  variable  modification  (only  used  in  chapter  3.1.2.2,  Deamidation  of  Proteins  due  to  Protein  Aging
Processes).
Peptides were classified as high confident with an FDR < 1% and as medium confident with 1% < FDR <
5%. Proteins were reported as identified if within one search engine approach at  least  2 high or 3 medium
peptides  were  reported.  Additionally,  database  searches  without  protease  specification  (no-enzyme)  were
performed to allow for the identifications of peptides derived from non-tryptic protein degradation. 
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3.1.2 Results and Discussion
The  identification  of  proteins  obtained  from an  ice-mummy is  a  challenging  task.  Not  only  does  the
degradation  of  proteins  over  years  (5,300  years  for  the  iceman  Oetzi)  hinder  the  application  of  classical
experimental  proteomics  approaches  (e.g.,  sample  extraction  and  SDS-PAGE separation),  but  it  also  forces
computational proteomics analysis workflows to be adopted against this (e.g., selection of the correct protease
specificity). To incorporate these obstacles, a highly specified data analysis has to be performed. 
Therefore,  a computational workflow was developed and established which (i)  combined four different
search engines, (ii) analyzed the degree of non-tryptic peptides, (iii) identified (potential degraded) proteins and
(iv) estimated the degree of protein deamidation; an either artificial or biological induced dynamic modification.
In the following chapter  3.1.2.1, the benefit of using a two-stage extraction process will be described.
Further, the overlap of protein identification by combining four search engines is presented, and the performance
of each search algorithm to identify proteins is evaluated. 
In chapter 3.1.2.2, protein aging processes (e.g., truncated proteins) will analyzed and presented. Although
the main aim of the project was to develop a computational proteomics pipeline,  the implementation of the
developed  tools  is  not  described,  instead  biological  meaningful  results  are  presented  to  demonstrate  the
requirement of developing such a highly specialized data evaluation pipeline.  
3.1.2.1 Protein Identification Using a Multi-Database Search Engine Approach
Overlap in Protein Identification for Samples 1024 & 1025
Combining the identified proteins from both samples, 1024 and 1025, as well for the in-gel and in-solution
digestion methods, a total of 502 proteins were identified. From these, 98% were identified within sample 1024
while only 44% were identified within sample 1025. In calculating the overlap of identified proteins (Figure 3-3)
it  was appeared that  sample 1025 represented a subset  of  sample 1024 with only 14 additional  and unique
identified proteins. The lower number of identified proteins for sample 1025 was not unexpected due to lower
amount of starting material available (6.5 mg for 1024-A, 3.5 mg for 1025-A). This also resulted in a decreased
number of PSMs (approx. 23% less) for sample 1025-A compared to 1024-A. 
Analyzing the number of proteins identified by the different experimental setups applied (in-gel versus in-
solution digest), the highest number (and percentage in relation to the total number of identified proteins) was
observed for the in-gel digestion method. Here, 38% (187/488) and 51% (113/222) of the total identified proteins
were identified for sample 1024-A and 1025-A, respectively (Figure 3-3 (B)). The overlap of identified proteins
between in-gel and in-solution digestion approach was 42% (207/488) for sample 1024 and 43% (95/222) for
sample  1025,  respectively.  For  the  in-solution  digest  of  1025,  the  number  of  identified  proteins  decreased
significantly (6% of total proteins identified (14/222)). For sample 1024, 19% (94/488) of the proteins were only
identified after in-solution digestion. Although the effect of a combined two-step extraction process (first in-gel,
second in-solution) was limited for sample 1025, the information about the doubly identified proteins is of high
importance. Being independently searched and validated, these proteins represented a set of repeatedly identified
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proteins, even though only every second protein was identified in both experimental setups. 
Figure 3-3: Overlap of identified proteins from sample 1024 and 1025 (A), and the number of proteins identified
for the in-gel & in-solution digested sample. (B) Overlap between in-gel and in-solution for both samples.
Analyzing the Effect of a Multi-Database Search
The protein identifications presented so far were based on the application and combination of four different
search algorithms. Proteins were categorized as confidential  identified if  at  least  two high or three medium
confident peptides could be mapped back to the protein within one search. To further analysis this data, the
proteins were grouped according to number of search engines by which the protein was identified (Table 3-1). 
It revealed, that by combining and averaging the percentage distributions of all samples from Table 3-1,
about 27.4% of the proteins were identified with four search engines, 12.6% with three, 25.6% with two and only
34.4% of the proteins were identified with only one search engine. 
These distributions were reflected by the majority of the individual samples in Table 3-1. However, the no-
enzyme searches of samples 1024-B, 1025-A and 1025-B showed a high number of proteins identified (45 –
58%) by only one search engine, whereas the five remaining database searches followed the overall trend.  
Table  3-1: Number of proteins identified for the in-gel and in-solution digested samples 1024 and 1025 with
trypsin (Tr) and without enzyme specification (no-enzyme, NoE). Additionally, the percentage distribution of the
search engine hits for each sample is shown (% of total Proteins).     
Sample
1 Search Engine 2 Search Engines 3 Search Engines 4 Search Engines
# Proteins % of total Proteins # Proteins
% of total 
Proteins # Proteins
% of total 
Proteins # Proteins
% of total 
Proteins
In-Gel
1024 Tr 84 24.3 73 21.2 51 14.8 137 39.7
1024 NoE 82 23.3 120 34 69 19.5 82 23.2
1025 Tr 51 26.3 47 24.2 26 13.4 70 36.1
1025 NoE 75 50 30 20 16 10.7 29 19.3
In-
Solution
1024 Tr 60 20.3 79 26.8 37 12.5 119 40.3
1024 NoE 114 45.8 54 21.7 34 13.7 47 18.9
1025 Tr 28 26.9 39 37.5 13 12.5 24 23.1
1025 NoE 44 57.9 15 19.7 3 3.9 14 18.4
Median - 34.4 - 26.6 - 12.6 - 27.4
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By eliminating duplicates entries and merging the identified proteins from the different approaches (in-gel,
in-solution; tryptic and no-enzyme), 502 proteins were identified as illustrated in Figure 3-3. Of these proteins,
more than 82% were identified with at least two search engines (62% with four, 12% with three and 13% with
two). Only 13% were identified by one of the four search engines, which clearly showed the advantage of using
multiple search algorithms. Not only the number of protein identifications raised, but also the confidence of
identifications increases, as each search engine applies its own algorithm to identify Peptide-Spectrum-Matches.
Analyzing the Performance of Each Search Engine
The performance of each search engine to identify proteins was critically evaluated using data sets of the
four in-gel digested samples (1024-A & 1025-A, with trypsin and without enzyme specificity). It revealed, that
X!Tandem  identified  the  highest  number  of  proteins  (264  proteins),  followed  by  Mascot  (258  proteins),
SEQUEST (206 proteins) and OMSSA (203 proteins). The corresponding distribution is illustrated in Figure 3-4
(A).
Further, it was analyzed which combination of three search engines was optimal to obtain a high number of
protein identifications. It revealed, that the overlap was highest for Mascot, OMSSA and X!Tandem (referred to
as MAOMXT) followed by SEQUEST, Mascot and X!Tandem (SEMAXT; as indicated in Figure 3-4 (B)). This
result was expected, as X!Tandem and Mascot identified most of the proteins. For the combination of two search
engines, solely the overlap between SEQUEST and Mascot was significant (SEMA). The remaining did not
show  clear  trends.  The  results  of  the  three  remaining  samples  showed  similar  distributions,  which  are
summarized in Table 3-2.
Figure 3-4: The number of proteins identified for sample 1024-A with trypsin specificity: (A) the total number of
proteins by each search engine; (B) the overlap of three search engines; (C) the overlap of two search engines;
(D) proteins identified with only one search engines. SE: SEQUEST, MA: Mascot, OM: OMSSA, XT: X!Tandem.
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Table  3-2: Number of proteins identified for the samples 1024-A and 1025-A with overlapping search engine
identifications (4 – 1 Search Engines) and the number of identified proteins by each search engines (last row).
SE: SEQUEST, MA: Mascot, OM: OMSSA, XT: X!Tandem.
Overlap Search Engines
1024 1025
Trypsin No-Enzyme Trypsin
No-
Enzyme
4 Search Engines SEMAOMXT 137 82 70 29
3 Search Engines
SEMAOM 4 14 2 2
SEMAXT 17 46 8 7
SEOMXT 2 5 0 0
MAOMXT 28 4 16 7
2 Search Engines
SEMA 40 69 25 7
SEOM 0 1 0 0
SEXT 3 12 4 1
MAOM 7 7 5 1
MAXT 7 18 13 7
OMXT 16 13 0 14
1 Search Engines
SE 3 1 0 0
MA 18 7 38 14
OM 9 4 0 0
XT 54 70 13 61
Total Identifications by each
Search Engine
SE 206 230 109 46
MA 258 247 177 74
OM 203 130 93 53
XT 264 250 124 126
3.1.2.2 Protein Aging Processes
Mummies frozen in ice for several thousands of years were exposed to environmental and microbial factors
which might lead to protein degradation or the introduction of modifications, such as deamidation. Degradation
and modification of proteins  harpers  the identification by database searches and to take these into account,
database  searches with  and  without  the  specification  of  an enzyme or  the incorporation  of  deamidation of
asparagine and glutamine as variable modifications were performed.  
At this point, it  is noteworthy that the .raw files of the in-gel digested samples were not searched in a
MudPIT approach  but  in  batch  mode,  that  means  every  .raw file  was  searched  separately.  This  helped  to
eliminate protein identifications caused by random false positive hits. These hits were more likely to be observed
for protein identifications by combining PSMs from multiple gel slices. Moreover, the no-enzyme search offered
the chance to identify truncated proteins.
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Truncated Proteins
Testing  for  no-enzyme specificities  was  an  important  aspect,  as  protein  degradation  and  denaturation
processes were previously reported for mummy tissues (327). Therefore, the overlap of identified proteins with
and without enzyme specificity will be compared to evaluate how many proteins might partially be truncated.
For sample 1024-A (in-gel), the overlap of identified proteins with tryptic and no-enzyme specificity was
high (78%); the number of unique proteins for the tryptic (10%) and  no-enzyme (12%) database search were
similar (Figure 3-5 (A)). The overlap of identified proteins (66%) was significantly lower for the in-gel digested
sample 1025-A (Figure 3-5 (C)). Here, the number of proteins identified with tryptic specificity was high (28%),
whereas only a few additional protein were identified with no enzyme specificity (6% no-enzyme). 
For the in-solution digested samples (Figure 3-5 (B) & (D)), only 2% and 3% unique proteins (1024-B and
1025-B, respectively) were identified using a  no-enzyme specificity. The relatively high number of identified
proteins with a  no-enzyme approach for the in-gel samples might be an indicator for protein degradation over
5,300 years.  The higher number of  no-enzyme identified proteins for the in-gel  sample compared to the in-
solution digested sample can be explained; it is more likely to extract truncated proteins in the first (in-gel) rather
than in the second extraction process (in-solution). 
Figure  3-5: Overlap of identified proteins with (trypsin) and without enzyme specificity for the two samples
(1024 & 1025) digested in-gel and in-solution. (A) 1024-A in-gel, (B) 1024-B in-solution, (C) 1025-A in-gel, (D)
1025-B in-solution.
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Detection of Truncated Proteins
Protein degradation can lead to the presence of a variety of different protein forms, which might only be
identified by an unspecific (no-enzyme) database search. The computational proteomics pipeline developed for
this project also considered truncated protein forms; by returning a boolean value if the protein was or was not
identified within a specific gel band. 
Various proteins were identified in more than one band. One of these, synaptosomal-associated protein 25
(SNAP-25), was identified in  7 gel  bands.  SNAP-25, which has  a  mass of  23,315 Da,  was expected to be
identified in gel bands #14 – #16 (as determined by molecular weight marker;  Figure 3-2 (B)). Based on the
number of PSMs for each gel band, the protein was most abundant in bands #18 – #21, which might be an
indicator for protein degradation. A similar observation was made for the protein dermicin (11,284 Da),  for
which peptides were randomly identified across 10 of the 22 bands.
Although these proteins might contribute to the observed smearing effect after protein staining (Figure 3-2
(B)), other proteins, e.g., dermokine, were confidently (all four search engines) identified in only a single gel
band.
An other interesting candidate represented copine-5 (65,734 Da). This protein was only identified in the
bands #20 – #22, which might be an indicator for protein degradation. 
Proteolipid Protein – a Truncated Protein
Another protein, which might have undergone degradation is the myelin proteolipid protein (PLP, 30,077
kDa). Peptides of this protein were identified in a multiple of gel bands. These are summarized in Table 3-3 for
the gel bands #1 – #19, and Table 3-4 for the gel bands #20 – #22. 
As it was present in all but three gel bands, this protein might have been undergone degradation. To verify
this, each peptide sequences identified in relation to the .raw file was used to map back the position of the first
peptide amino acid within the protein. Therefore, the amino acid N-terminal to the cleavage site was extracted
from the FASTA file, and grouped into non-tryptic (no R or K), semi-tryptic (one R or K) or fully tryptic (two R
or K) peptides based on the amino acids N-terminal to the cleavage site (extracted from the FASTA file) and the
C-Terminal amino acid of the identified peptide sequence, respectively.   
In all gel bands, none of the peptides was identified as non-tryptic. However, for the gel bands #1 – #19, 32
semi and 39 fully tryptic peptides were found. This was rather unexpected as trypsin is known to be a very
specific protease (67). 
In the gel bands #20 – #22, the number of semi-tryptic peptides was significantly higher with 48 semi- and
22  fully  tryptic  peptides.  In  addition,  sequence  latter  such  as  RMYGVXPWNAFPGK,  MYGVXPWN,
MYGVXPWNAF, MYGVXPWNAFPG, MYGVXPWNAFPGK and MYGVXPWNAFPGKV were observed in
band #22. 
Unfortunately,  these  identified  peptides  did  not  automatically  prove  a  degradation  effect,  e.g.,  by
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exopeptidases. But, the intense smearing, a similar effect for other proteins (e.g., cytochrom c subunit 2; bands
#15 – #21: 90% tryptic cleavage sites; band #22: 5 of 10 identified peptides with non-tryptic cleavage sites) were
a good hint for environmental, bacterial or enzymatic protein degradation, as it was expected for 5,300 years old
tissue samples. 
Deamidation of Proteins Due to Protein Aging Processes
The deamidation of asparagine and glutamine is a modification process, which can be induced during either
sample preparation or through biological processes, and is known to occur in protein aging (334). To identify
this effect,  additional  database searches were performed in a MudPIT approach for  both,  the in-gel  and in-
solution  digested  samples.  Here,  peptides  identified  from  all  gel  bands  were  merged  together  for  peptide
validation. At the peptide level, 20% of the peptides identified for sample 1024-A (in-gel) and 16% in 1025-A
(in-gel) showed deamidation reactions. For the in-solution digested samples, about 28% deamidated peptides
were identified. However, the overall number of identified proteins did not change after taking this modification
into account.
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Table 3-3: Peptides identified from myelin proteolipid protein (PLP). The amino acid in P1 and the C-terminal
amino acid were extracted to allow for fully-, semi-, no tryptic cleavage sites, respectively, via the different gel
bands (#1 – #19).   
P1 Peptide Sequence C-Term
Gel
Band P1 Peptide Sequence C-Term
Gel
Band
M GXXECCA R 1 K GXSATVTGGQ K 14
K GXSATVTGGQ K 1 K TSASXGSXCADA R 14
K TSASXGSXCADA R 1 T SASXGSXCADA R 14
T SASXGSXCADA R 1 K GXSATVTGGQ K 15
A SXGSXCADA R 1 T SASXGSXCADA R 15
R MYGVXPWNAFPG K 1 R MYGVXPWNAFPG K 15
G SNXXSXC K 1 K GXSATVTGGQ K 16
K XXETYFS K 2 K TSASXGSXCADA R 16
K GXSATVTGGQ K 2 T SASXGSXCADA R 16
K TSASXGSXCADA R 2 R MYGVXPWNAFPG K 16
T SASXGSXCADA R 2 K GXSATVTGGQ K 17
A SXGSXCADA R 2 T SASXGSXCADA R 17
K GXSATVTGGQ K 3 A SXGSXCADA R 17
K TSASXGSXCADA R 3 M GXXECCA R 18
T SASXGSXCADA R 3 K XXETYFS K 18
R MYGVXPWNAFPG K 3 K XXETYFSK N 18
K TSASXGSXCADA R 4 R QXFGDY K 18
T SASXGSXCADA R 4 R QXFGDYK T 18
A SXGSXCADA R 4 K GXSATVTGGQ K 18
K TSASXGSXCADA R 5 K TSASXGSXCADA R 18
T SASXGSXCADA R 5 T SASXGSXCADA R 18
A SXGSXCADA R 5 A SXGSXCADA R 18
K GXSATVTGGQ K 8 R MYGVXPWNAFPG K 18
K TSASXGSXCADA R 8 K VCGSNXXSXC K 18
T SASXGSXCADA R 8 M GXXECCA R 19
R MYGVXPWNAFPG K 8 R QXFGDY K 19
K TSASXGSXCADA R 9 R QXFGDYK T 19
A SXGSXCADA R 9 K GXSATVTGGQ K 19
K TSASXGSXCADA R 11 K TSASXGSXCADA R 19
K TSASXGSXCADA R 12 T SASXGSXCADA R 19
T SASXGSXCADA R 12 S ASXGSXCADA R 19
K GXSATVTGGQ K 13 A SXGSXCADA R 19
K TSASXGSXCADA R 13 R MYGVXPWNAFPG K 19
T SASXGSXCADA R 13 K VCGSNXXSXC K 19
A SXGSXCADA R 13 G SNXXSXC K 19
R MYGVXPWNAFPG K 13
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Table 3-4: Peptides identified from myelin proteolipid protein (PLP). The amino acid in P1 and the C-terminal
amino acid were extracted to allow for fully-, semi-, no tryptic cleavage sites, respectively, via the different gel
bands (#20 – #22). 
P1 Peptide Sequence C-Term
Gel
Band P1 Peptide Sequence C-Term
Gel
Band
M GXXECCA R 20 R CXVGAPFASXVAT G 22
K XXETYFS K 20 R CXVGAPFASXVATG X 22
K XXETYFSKN Y 20 G CGHEAXTGTE K 22
R QXFGDY K 20 C GHEAXTGTE K 22
R QXFGDYK T 20 G HEAXTGTE K 22
R QXFGDYKTTXCG K 20 G TEKXXETYFS K 22
K GXSATVTGGQ K 20 T EKXXETYFS K 22
K GXSATVTGGQKG R 20 K XXETYFS K 22
K GXSATVTGGQKGR G 20 K XXETYFSK N 22
W TTCQSXAFPS K 20 G AXXXAEGFYTTGAV R 22
P SKTSASXGSXCADA R 20 X AEGFYTTGAV R 22
K TSASXGSXCADA R 20 R QXFGDY K 22
T SASXGSXCADA R 20 R QXFGDYK T 22
S ASXGSXCADA R 20 R QXFGDYKT T 22
A SXGSXCADA R 20 K GXSATVTGGQ K 22
R MYGVXPWNAFPG K 20 K GXSATVTGGQK G 22
K VCGSNXXSXC K 20 K GXSATVTGGQKG R 22
G HEAXTGTE K 21 K GXSATVTGGQKGR G 22
G TEKXXETYFS K 21 W TTCQSXAFPS K 22
T EKXXETYFS K 21 P SKTSASXGSXCADA R 22
K XXETYFS K 21 K TSASXGSXCA D 22
K XXETYFSK N 21 K TSASXGSXCADA R 22
K XXETYFSKN Y 21 T SASXGSXCADA R 22
R QXFGDY K 21 S ASXGSXCADA R 22
K GXSATVTGGQ K 21 A SXGSXCADA R 22
K GXSATVTGGQK G 21 S XGSXCADA R 22
K GXSATVTGGQKG R 21 A RMYGVXPWNAFPG K 22
K GXSATVTGGQKGR G 21 R MYGVXPW N 22
W TTCQSXAFPS K 21 R MYGVXPWNA F 22
P SKTSASXGSXCADA R 21 R MYGVXPWNAFP G 22
K TSASXGSXCADA R 21 R MYGVXPWNAFPG K 22
T SASXGSXCADA R 21 R MYGVXPWNAFPGK V 22
S ASXGSXCADA R 21 Y GVXPWNAFPG K 22
A SXGSXCADA R 21 K VCGSNXXSXC K 22
R MYGVXPWNAFPG K 21 G SNXXSXC K 22
K VCGSNXXSXC K 21
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3.1.3 Conclusion
Two dark spots of the Tyrolean iceman´s brain were subjected to protein analysis by mass spectrometry. As
protein identification of a 5,300 years old sample was expected to be complicated task, a two-step extraction
process was performed to increase the number of identifiable proteins. The aim of this project was to established
a computational proteomics pipeline to identify a maximal number of proteins by using multi-database search
results as input-files to finally combine them (e.g., the number of clearly identified proteins) into spreadsheet like
file for data evaluation and visualization. 
The  combination  of  several  database  search  approaches  not  only  increased  the  number  of  proteins
identified, but also their confidence was higher if a protein was identified by more than one search engine. So-
called one-hit  wonders  were  excluded and only proteins  with at  least  two high or  three medium confident
peptides  were  considered  as  identified.  This  represented  a  conservative  data-analysis  approach,  which  was
necessary to exclude, or at least reduce the number of, false positive protein identifications. This was important,
as datasets of more than one search engine were combined.        
Data were solely acquired by CID-IT, which is a sensitivity and fast fragmentation technique, but lacking
the high mass accuracy of Orbitrap mass analyzers. Under these conditions, X!Tandem and Mascot performed
best.  From previous measurements,  the enhanced performance of  Mascot  compared to SEQUEST to match
peptides from CID-IT data was known. The overall excellent performance of X!Tandem might be a result of its
algorithm  (335).  Principally,  it  performs two different database searches.  The first  uses the complete list  of
digested proteins (including fixed and dynamic modifications), whereas the second search utilizes only proteins
being identified in the previous search. As the search space decreases significantly, variable modifications (e.g.,
posttranslational modifications), sequence polymorphisms and semi-tryptic peptides can be included without an
increase in the search space.  Finally,  probability scores are calculated (Hyperscore and  E-Value)  to validate
Peptide-Spectrum-Matches. It can only be speculated, that including unexpected protein variations in the second
analysis step resulted in similar results for both, the tryptic and no-enzyme database search.  
In the end, by using the newly implemented computational proteomics workflow combining four search
engines, 502 confident and validated protein were identified. This represents a relatively high number of protein
identifications for a 5,300 years old wet-mummy, highlighting the profit to use more than one search engine for
protein identification.  
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3.2 PCSP – Computational Proteomics Tools for Protease 
Cleavage Site Determination3
Proteolysis  is  an  irreversible  posttranslational  protein  modification  and  involved  in  various  biological
processes.  The  determination  of  protease  cleavage  site  preferences  is  an  important  aspect  to  understand
biochemical pathways triggered by proteolysis activity. 
A number of methods for the identification of protease cleavage sites have been developed in the past. Two
such methods are the PICS (Proteome-derived, database-searchable peptide libraries for  identifying protease
cleavage  sites;  (336))  and  Q-PICS  (Quantitative  Protease  Cleavage  Site  Profiling  using  Tandem-Mass-Tag
Labeling; (312)) approach. Both use a proteomics library of peptides which is obtained by digestion of a model
proteome (e.g., from cell culture) with a first (so-called) work-protease. After N-termini protection, the peptide
library is subjected to a second digest with a  target-protease, which is the protease under investigation. In the
PICS approach, newly generated N-termini are biotinylated, enriched and identified by LC-ESI MS. This allows
the characterization of the specificity of the target-protease by comparing the P1 and P1' sites via the complete
peptide library (see Figure 3-8). The P1' site is directly available upon peptide identification, whereas the P1 site
information is encoded in the protein sequence. 
The Q-PICS approach represents a further development of the PICS approach by incorporation of isobaric
labeling for simultaneous identification and quantification of cleavage sites.  The Q-PICS approach has been
further refined by (i) integration of technical replicates, (ii) measuring the intact peptide library in addition to the
digested (target) peptide library, and (iii) the application of both, LC-ESI MS and LC-MALD MS (147). 
In order to process the identified peptides after database search in a fast, reproducible and automated way,
two software tools are required for cleavage site identification. The focus of the first program is (i) to filter-out
low confident peptides and (ii) remove peptides which are present in both the intact and digested peptide library,
and (iii) perform data-picking. The second tool is used (i) to select only unique peptides, (ii) to remove sequence
homologies and (iii) to calculate the relative distribution of each amino acid in relation to each position (P1-P5
and P1'-P5', respectively (see Figure 3-8)).    
 In the following sub chapters, the implementation of these two tools is described separately. It should be
noted  that  the  two  tools  are  linked,  PeptideMerger generates  the  input  files  for  the  second  tool,
AminoAcidFinder. The implementation will be described with ADAM10 as target- and GluC as work-protease. 
3 The tools described were part of the publication J. Proteome Res., 2014, 13 (4), pp 2205–2214
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3.2.1 Implementation of PeptideMerger
PeptideMerger is  a  GUI based  application,  that  accepts  Proteome Discoverer  Peptide-Spectrum-Match
(PSM) list files in .csv file format and exports processed lists into a tab-separated .txt file, which is directly
compatible to the AminoAcidFinder.
In the first steps, the user imports the PSM file(s) for the target-protease digested peptide library (ADAM
10), followed by the PSM file(s) for the work-protease (GluC) via the Tap Import Blank PSM List (Figure 3-6).
To include only confident peptide identifications, a selection rule can be applied; e.g., the peptide has to be found
at least twice within three technical injected LC MS runs. These settings are adjusted in the Replica Selection
tab.
To increase the flexibility of the tool, the first line of the comma separated PSM files containing the header
information is imported and displayed in a user controlled pull down menu. Here, the entry containing the .raw
file  information has to be selected.  This selection menu allows also other  database search file results (e.g.,
derived from PeptideShaker) to be imported. The Peptide Identification Criteria tab is used to assign the peptide
sequence  and  protein  accession  number,  respectively.  Both  values  have  to  be  assigned  as  these  are  the
information which will be exported. To include additional information, these can be activated under Appendix
tab. Theoretically, all information can be selected which then will be joined together by a semicolon in the final
tab-separated .txt file. 
By starting the script (Save & Start tab), the PSM lists of both the target and work-protease are imported.
During the import, the number of different .raw file name(s) are culled and stored temporary. Within each PSM
list, the peptides passing the minimum replica selection number, defined in the Replica Selection tab, are marked
as  true.  Finally,  the PSM lists from the target-protease (ADAM 10) are compared versus the work-protease
(GluC) PSM list. Peptides found in both blank and target-protease lists are not exported. PSMs identified in only
the target-protease PSM list are exported with the sequence, protein accession number and the appendix entries.
Figure 3-6: Graphical User Interface (GUI) for data import. The first tab, which is shown here, imports the list
of peptide identifications. The remaining tabs are grouped into different criteria (e.g., blank) to separate these
and improve the lucidity. 
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3.2.2 Implementation of AminoAcidFinder
AminoAcidFinder is a fork of the Excel and Perl published tools (336). This was demanded in order to be more
flexible  in  terms  of  usability  (interactive  GUI;  Figure  3-7)  data  filtering,  source  code  manipulation  and
reproducibility. Running the same data set repeatably with those tools, discriminative result files were obtained
by each repetition.
Three different input-files are required for the  AminoAcidFinder: (i) a FASTA file in  UniProt formatting
containing the protein sequences of the organism the peptide library originates from. (ii) an additional FASTA
file  containing  the  sequence  information  about  the  target-protease  (and/  or  other  to  be  excluded  protein
sequences) is imported. This is in addition and in contrast to the previously published tools. During processing,
these sequences will not be included in the final result file to compensate potential biases introduced. (iii) a tab
separated .txt file, which can be created by the  PeptideMerger  is imported. To be flexible, all other .txt files
fulfilling the input characteristic are accepted, too. 
Figure  3-7: Graphical User Interface (GUI) to load in data calculated previously using PeptideMerger. The
options for file loading are color-coded (green) and required. Via a pull down menu, the number of amino acids
in P and P' positions are selected.
The option to chose either “accession number” or “description” within the FASTA file is not supported at
the point of release; as the FASTA file format is limited to those of UniProt (Figure 3-7). In addition the input
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option for “handling of protein amount” is still under development. This function will allow the user to chose
between a variety of decision trees methods how redundant peptides will be handled by calculating protein FDR
values alongside a protein score. These are used to decide from which protein a shared peptide is more likely to
belong to, based on the assumption that higher scoring proteins are higher abundant in the sample.
The last user input deals with the number of amino acids positions to be reported (referred to as P maxPosition;
default: 5) and to which position sequences should be compared (default: 5). Best results are received if both
values are set to the same integer value.  
By starting the tool (Start Compare button), first, the identified peptide list is read in. Due to a software
issue in Proteome Discoverer 1.4 when used in combination with Mascot (Version 2.2.07), peptide hits with
randomly  missing  accession  numbers  are  frequently  exported.  For  peptide  sequences  with  missing  protein
accession numbers a function is called which scans the FASTA file for this specific peptide sequence(s) and
attaches the corresponding protein accession number to the peptide sequence in the list. 
For demonstration purposes the peptide SQSLTLTDVE from β-casein has been used in this section and is
highlighted in orange (Table 3-5). This peptide  is compared to the protein sequence in the FASTA file. If the
sequence was found within the protein sequence and  not within the working protease list simultaneously, the
amino acids in the prime (P;  EPFTE,  highlighted in gray) and non-prime (P';  SQSLTLTDVE) positions, up to
PmaxPosition, are extracted, temporary joined and stored. For the cases in which the number of amino acids to be
extracted (PmaxPosition)  is  lager than the number of positions available in the protein sequence, the number of
assigned amino acids is adjusted accordingly. Additionally, amino acids N-terminal to a work-protease cleavage
site (e.g., D, E for GluC) in P position are removed (PKYPV, highlighted in cyan). The next step is to remove
duplicate sequences with identical identified P (EPFTE) and P' (SQSLTLTDVE) sequences, which can (e.g.) be
obtained from protein isoforms. As an intermediate result, the frequency of each amino acid in relation to a
specific position (e.g, lysine in P1') is calculated and exported into a tab-separated .txt file. 
Table 3-5:  Protein sequence of β-casein. The peptide sequence identified by LC MS is highlighted in orange, its
corresponding prime sequence in gray, and the sequence N-terminal to a work-protease cleavage site in cyan.
Only the gray (P) and orange (P') labeled sequences are used, whereas the cyan labeled sequence is removed. 
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The next step is to remove identical peptide sequences (P', e.g.  SQSLTLTDVE) with non-identical prime
sequences (P), which occurs due to natural variations such as the exchange of glutamic acid with glutamine at
position 132 for β-casein, resulting in EPFTE and PKYPVQPFTE. 
If multiple non-identical prime sequences for the same peptide sequence (non-prime) are found, the prime
sequences (EPFTE and PKYPVQPFTE) are checked for similarity, and only identical amino acids at a specific
position are kept, with the first amino acid that differs replaced with an X (e.g., XPFTE). The intermediate results
are again exported, the peptide list is sorted by the sequence name, and the frequency of each amino acid, in
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relation to a specific position, is exported into a tab-separated .txt file (see Table 3-6). 
Table 3-6:  Tab-separate .txt file containing the frequency of each of the twenty amino acids (AA) from the prime
site 5 (P5) to the non-prime site 5 (P5'). 
AA P5 P4 P3 P2 P1 'P1 'P2 'P3 'P4 'P5
A 29 17 38 39 49 21 17 45 22 24
C 5 1 2 0 3 1 1 2 1 2
D 11 6 2 18 2 0 0 7 14 11
E 16 20 3 27 10 0 2 4 7 20
F 8 10 3 7 14 6 15 4 5 7
G 15 5 7 16 10 0 10 32 31 14
H 0 6 1 4 5 0 5 3 5 2
I 9 10 13 0 0 25 27 7 9 15
K 0 0 0 0 0 0 0 4 0 1
L 12 20 16 35 11 58 12 10 25 21
M 0 2 5 7 4 1 3 0 3 2
N 5 10 4 3 6 2 6 12 9 11
P 21 15 24 0 24 0 2 1 18 20
Q 1 6 7 6 9 1 16 10 5 8
R 0 9 0 16 22 0 19 10 7 11
S 12 12 14 14 12 6 13 23 10 4
T 12 19 12 0 5 9 14 11 10 8
V 23 15 34 4 0 71 32 14 18 20
W 0 2 0 1 0 2 1 1 0 0
Y 9 9 9 0 14 0 8 3 4 2
The result file (see Table 3-6) can be imported directly in any spreadsheet related programs to create Heat-
Maps using RGB scale (similar to those presented in chapter  4.1) to demonstrate the specificity of a target-
protease, as outline in Figure 3-8. 
Figure 3-8: Heat-Map created by in-house developed VBA script using minimum (blue) and maximum (red) as
delimiter to calculate the appropriate RGB code. Values used as input were created by AminoAcidFinder. 
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3.2.3 Conclusion
In contrast to previously published tools  (336), the newly developed PeptideMerger allows (i) a specific
filtering of the input data in terms of minimum number of identification within technical  injections and (ii)
creation of “;”-joined strings which contain user demanded informations. The exported files, which are directly
compatible to AminoAcidFinder, can also be used for alternative purposes, e.g., filtering of data for exclusively
for identification purposes. 
The tool  AminoAcidFinder is developed in an open and easily customized way. At any point within the
source code,  new algorithms (ideally added as  a  new function) can be added.  Moreover,  in contrast  to  the
previously published tools (336), all intermediate results are exported. This allows (i) to analyze the functions
used, (ii) find potential software issues or (iii) to use these intermediate results file in alternative strategies to
test, develop or modify the currently available tool(s). 
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Computational proteomics is a key factor in semi- or large-scale experiments to process MS .raw files.
Classically, it covered the steps of protein identification, modification determination, quantification and sample
comparison (337). By the rapid improvement of mass spectrometers (e.g., mass accuracy and MS/MS scan cycle
speed), the application, possibility and importance to automate tasks grew exponentially. Generally, handling
thousands of peptide identifications (e.g., obtained by the biological sample used for NCE optimization, chapter
2.1.3.3) is an error-prone and time-consuming process if it is performed manually. This is especially crucial as
non-systematical (random) errors are introduced.   
Nowadays, the research subject of computational proteomics needs to be enlarged, as upstream processing
(that is after database searches) are more important, as the number of peptides (or proteins) identified increased
significantly. Upstream processing of identification results was also the subject of chapter 3, as two independent
project tasks were answered by the assistance of computational tools. 
These tools were written in-house, which allowed modification and enhancement of previously described
workflows. For the paleoproteomics study, results from four different search engines were combined, which
significantly increased the number of identified proteins. Moreover, the application of a multi-database search
algorithm approach demonstrated the importance of selecting the right search algorithm for each task. X!Tandem
was found to perform the best, which is speculated to be a consequence of its two step database search approach,
including the variations amino acids polymorphisms, semi-tryptic peptides and unexpected modifications in the
second database search procedure. 
To calculate the number of non-, semi- or fully tryptic peptides in the low mass region of SDS-gels is a
time consuming and error-prone process. For each protein and peptide sequence the amino acids in -1 position to
the N-terminus have to be extracted from the FASTA file. Principally, the same problem was solved within the
project PCSP (chapter 3.2), as the information about the amino acid sequences N-terminal to the new cleavage-
site were demanded. This task was fully fulfilled by compiling two tools to filer, analyze and export the relative
frequency of amino acids in the P1-P5 and P1'-P5' position of the new-N-terminus.
Both  projects  cannot  be  grouped  into  bioinformatics,  as  they  were  lacking  statistical  data  evaluation.
However, these upstream tools aided in processing data, as random errors were minimized and new data can be
processed using exactly the same workflow as before. One additional feature was to modify existing algorithms
at specific positions and to re-run the script to generate a second output file, which subsequently allows for more
efficient and reproducible evaluation of proteomics data. 
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Chemicals
iTRAQ  Reagents  4/8plex  Kit  including  tetraethylammonium  bromide  (TEAB),  tris(2-
carboxyethyl)phosphine (TCEP) and ethanol (Et-OH) were purchased from AB SCIEX (Darmstadt, Germany).
Acetonitrile  (ACN),  formic  acid  (FA),  trifluoroacetic  acid  (TFA),  triethylammonium  bicarbonate  (TEAB),
methanol  (Me-OH),  phosphoric  acid  (PA)  glycolic  Acid  (GA),  ethylenediaminetetraacetic  acid  (EDTA),
iodoacetamide  (IAA)  and  coomassie  blue were  purchased  from  Sigma-Aldrich  (Munich,  Germany).  The
proteases chymotrypsin (V106A), elastase (V189A), Staphylococcus aureus V-8 Protease (GluC; V165A) and
trypsin (V5111) were purchased from Promega Corporation (Madison, WI, USA). Alkaline phosphatase (AP, EC
3.1.3.1) was purchased from Roch (Roche Diagnostics GmbH, Roche Applied Science, Mannheim, Germany).
Ammonium  sulfate  was  purchased  from  Merck  (Darmstadt,  Germany),  titanium  dioxide  (TiO
2
)  from  GL
Sciences (via MZ-Analysentechnik, Mainz, Germany).  ZipTip C18 was purchased from Millipore (Darmstadt,
Germany). 
Sample Material
Phosphopeptide standard (chapter 2.1) was purchased from Intavis (Cologne, Germany). Proteins used for
the ten protein-mix are summarized in Table 4-1 and were purchased from Sigma-Aldrich (Munich, Germany). 
Table 4-1: Proteins used for the ten protein-mix.
Protein Species SwissProt Accession Number
albumin (BSA) bovine P02769
carbonic anhydrase bovine P00921
catalase bovine P00432
cytochrome C equine P00004
α-Casein bovine P02662
β-Casein bovine P02666
α-lactalbumin bovine P00711
β-Lactoglobulin bovine P02754
lysozym chicken B8YK79
myoglobin equine P68082
ribonuclease A bovine P61823
transferrin human P02787
Buffers and Eluents not supplied by Vendors
 iTRAQ-4plex labeling buffer: 160 μL H2O, 160 μL iTRAQ-4plex dissolution buffer and 80 μL ethanol
 AP-buffer (dephosphorylation) was diluted 1:10 with dd H2O 
 Loading buffer (LC-ESI & LC-MALDI MS): 3% ACN, 0.05% TFA 
 Eluent A (LC-ESI MS): 0.05% FA in H2O
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 Eluent B (LC-ESI MS): 80% ACN, 0.04% FA in H2O
 Eluent A (LC-MALDI MS): 0.05% FA in H2O
 Eluent B (LC-MALDI MS): 80% ACN, 0.04% FA in H2O
Instrumentation
 Sample drying was performed via SpeedVac (Eppendorf, Hamburg, Germany). 
 Water used in all experiments was purified by an arium 611VF system (Satorious, Göttingen, Germany). 
 SDS-PAGE: Biorad Mini Protean Tetrasystem & Power Pack Universal
 Ultrasonic bath: Elmasonic SH40
 Centrifuge: Thermo Scientific Heraeus Fesco 21 & Biofuge Statos
Mass Spectrometry Instrumentation
LTQ Orbitrap Velos
NanoLC−ESI MS experiments  were performed on a Dionex U3000 (Dionex,  Idstein,  Germany) nano-
HPLC system coupled online to a LTQ Orbitrap Velos MS equipped with ETD support (ThermoFisher, Bremen,
Germany). Samples were trapped on an Acclaim Pepmap C18, 300µmm x 10mm, 5µm, 100 Å trap column and
separated on a an AcclaimPepMap 100 analytical column (3 μm, 75 μm × 150 mm, Dionex, Idstein, Germany).
Synapt G2s
NanoLC−ESI  MS experiments  were  performed on  a  Dionex U3000 (Dionex,  Idstein,  Germany)  nano
HPLC system coupled online to a Synapt G2s  (Waters, Milford, MA). Samples were trapped on an Acclaim
Pepmap C18, 300µmm x 10mm, 5µm, 100 Å trap column and separated on a an AcclaimPepMap 100 analytical
column (3 μm, 75 μm × 150 mm, Dionex, Idstein, Germany).
AB SCIEX MALDI TOF/TOF 5800 
Prior to MS analysis with a MALDI TOF/TOF 5800 mass spectrometer (AB Sciex, Darmstadt, Germany),
samples were separated on a Dionex U3000 nano-LC system (Dionex, Idstein,  Germany, including samples
trapping on an Acclaim Pepmap C18,  300µmm x 10mm, 5µm, 100 Å trap column and separated  on a an
AcclaimPepMap 100 analytical column (3 μm, 75 μm × 150 mm, Dionex, Idstein, Germany) and subsequently
spotted on a MALDI target (AB Sciex) using a Probot microfraction collector (Dionex). 
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Software
Protein Identification Suites & Nodes
 Proteome Discoverer (Thermo- Fisher, San Jose, CA): Version 1.2, 1.3 and 1.4
 MS2-Spectrum Processor (http://ms.imp.ac.at): Version v. 0.9 
 phosphoRS (299): Version 3.1 
 Percolator (236): Version 2.04 (supplied by Proteome Discoverer) 
 SearchGUI: Version 1.16.2 (chapter 2.3) & 1.7.3 (chapter 3.1) (294)
 PeptideShaker: Version 0.25.2 (chapter 2.3) & 0.16.2 (chapter 3.1) (295)
Search Algorithms
 SEQUEST & SEQUEST HT: supplied with each Proteome Discoverer Version
 Mascot: Version 2.2.0.7 (chapter 2.3) & 2.2.0.4 (chapter 3.1) 
 OMSSA (supplied by SearchGUI): Version 2.1.9 (chapter 2.3) & (chapter 3.1) 
 X!Tandem (supplied by SearchGUI): Version 2.2.0.7 (chapter 2.3) & 2.2.0.4 (chapter 3.1)  
 TS2Mascot software (version 1.0.0, Matrix Science, London, UK)
Raw-Data 
 XCalibur (Thermo Fischer): Version 2.1 (32 bit Windows), Version 2.2 SP1.48 (64 bit Windows)
 MassLynx (Waters): Version SCN 883
 TOF/TOF Explorer (AB SCIEX): Version 4.0.0 (build 8)
 Proteowizard: Version 3.0.5759 (293) 
 mmass: Version 5.5.0 (338)
Programming Languages & Plotting Tools
 GAMBAS: Version 3.5.3
 Visual Basic for Applications: included in Microsoft Office Excel 2007, 2010 & 2013
 QtiPlot: Version 0.9.8.9 svn 2288
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Paragon Mod Feature Set 
<MOD_FEATURE_SET xml:id="MOD_FEATURE_SET:71" name="Std iTRAQ 4plex set">
<MOD_FEATURE mod="iTRAQ4plex">
<OCCURRENCE target="Lysine" prob="0.993"/>
<OCCURRENCE target="Tyrosine" prob="0.036"/>
<OCCURRENCE target="Histidine" prob="0.0053"/>
<OCCURRENCE target="Serine" prob="0.011"/>
<OCCURRENCE target="Threonine" prob="0.0027"/>
</MOD_FEATURE>
<MOD_FEATURE mod="Terminal iTRAQ4plex">
<OCCURRENCE target="" term_spec="PepNTerm" prob="0.932"/>
</MOD_FEATURE>
</MOD_FEATURE_SET>
<MOD_FEATURE_SET xml:id="MOD_FEATURE_SET:11" name="Standard biological mod set">
<MOD_FEATURE mod="Phospho(Ser,Thr)">
<OCCURRENCE target="Serine" prob="0.002"/>
<OCCURRENCE target="Threonine" prob="0.0007"/>
</MOD_FEATURE>
<MOD_FEATURE mod="Phospho">
<OCCURRENCE target="Tyrosine" prob="0.00001"/>
<OCCURRENCE target="Lysine" prob="0.0001"/>
<OCCURRENCE target="Histidine" prob="0.0001"/>
<OCCURRENCE target="Aspartic Acid" prob="0.0001"/>
<OCCURRENCE target="Arginine" prob="0.0001"/>
<OCCURRENCE target="Cysteine" prob="0.00001"/>
</MOD_FEATURE>
</MOD_FEATURE_SET>
Function heatMapColor 
minValue: minimal  number  of  amino acid identifications;  maxValue as  the maximal  number  of  amino acid
identifications;  currentValue: represents the number of the amino acid being investigated. The corresponding
color  code  (in  RGB  style)  is  returned  as  heatMapColor.  Code  is  adopted  from  Bruce  McPherson,
http://ramblings.mcpher.com.
Private Function heatMapColor(minValue As Variant, maxValue As Variant, currentValue As Variant) As Long
    Dim spread As Double, ratio As Double, red As Double, green As Double, blue As Double
    spread = maxValue - minValue
    ratio = (currentValue - minValue) / spread
    If ratio < 0.25 Then
        blue = 1
        green = 4 * ratio
    ElseIf ratio < 0.5 Then
        green = 1
        blue = 1 + 4 * (minValue - currentValue + 0.25 * spread) / spread
    ElseIf ratio < 0.75 Then
        green = 1
        red = 4 * (currentValue - minValue - 0.5 * spread) / spread
    Else
        red = 1
        green = 1 + 4 * (minValue - currentValue + 0.75 * spread) / spread
    End If
    heatMapColor = RGB(red * 255, green * 255, blue * 255)
End Function
V
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Table 4-2: The chemical composition, the 3 and 1 letter code and the monoisotopic and average mass for each
amino acid.
Residue
3-
letter
code
1-
letter
code
Mono-
isotopic
mass
Average
mass
Alanine
C
3
H
5
NO Ala A 71.037114 71.0779
Arginine
C
6
H
12
N
4
O Arg R 156.101111 156.1857
Asparagine
C
4
H
6
N
2
O
2
Asn N 114.042927 114.1026
Aspartic acid
C
4
H
5
NO
3
Asp D 115.026943 115.0874
Cysteine
C
3
H
5
NOS Cys C 103.009185 103.1429
Glutamic acid
C
5
H
7
NO
3
Glu E 129.042593 129.114
Glutamine
C
5
H
8
N
2
O
2
Gln Q 128.058578 128.1292
Glycine
C
2
H
3
NO Gly G 57.021464 57.0513
Histidine
C
6
H
7
N
3
O His H 137.058912 137.1393
Isoleucine
C
6
H
11
NO Ile I 113.084064 113.1576
Leucine
C
6
H
11
NO Leu L 113.084064 113.1576
Lysine
C
6
H
12
N
2
O Lys K 128.094963 128.1723
Methionine
C
5
H
9
NOS Met M 131.040485 131.1961
Phenylalanine
C
9
H
9
NO Phe F 147.068414 147.1739
Proline
C
5
H
7
NO Pro P 97.052764 97.1152
Serine
C
3
H
5
NO
2
Ser S 87.032028 87.0773
Threonine
C
4
H
7
NO
2
Thr T 101.047679 101.1039
Tryptophan
C
11
H
10
N
2
O Trp W 186.079313 186.2099
Tyrosine
C
9
H
9
NO
2
Tyr Y 163.06332 163.1733
Valine
C
5
H
9
NO Val V 99.068414 99.1311
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4.3 cRAP FASTA File
Table 4-3: Proteins contained in the cRAP like FASTA file. All proteins used originated from UniProtKB/Swiss-
Prot.
Unique 
Identifier EntryName
Unique 
Identifier EntryName
Unique 
Identifier EntryName
Q13515 BFSP2_HUMAN Q14532 K1H2_HUMAN P60411 KR109_HUMAN
P31944 CASPE_HUMAN P35908 K22E_HUMAN P60014 KR10A_HUMAN
Q9UMD9 COHA1_HUMAN Q3TTY5 K22E_MOUSE P60412 KR10B_HUMAN
P15924 DESP_HUMAN Q01546 K22O_HUMAN P60413 KR10C_HUMAN
P11532 DMD_HUMAN Q7Z794 K2C1B_HUMAN Q8IUC1 KR111_HUMAN
O75190 DNJB6_HUMAN P04264 K2C1_HUMAN P59990 KR121_HUMAN
Q9UW98 DPP5_TRIRU P04104 K2C1_MOUSE Q9Z287 KR121_MOUSE
Q03001 DYST_HUMAN A5A6M6 K2C1_PANTR P59991 KR122_HUMAN
Q92817 EVPL_HUMAN P12035 K2C3_HUMAN P60328 KR123_HUMAN
Q8TES7 FBF1_HUMAN P19013 K2C4_HUMAN P60329 KR124_HUMAN
P20930 FILA_HUMAN P13647 K2C5_HUMAN Q8IUC0 KR131_HUMAN
Q8NI17 IL31R_HUMAN A5A6M8 K2C5_PANTR Q52LG2 KR132_HUMAN
P07476 INVO_HUMAN P02538 K2C6A_HUMAN Q3SY46 KR133_HUMAN
P16144 ITB4_HUMAN P50446 K2C6A_MOUSE Q3LI77 KR134_HUMAN
A6NCN2 K121P_HUMAN Q4FZU2 K2C6A_RAT Q3LI76 KR151_HUMAN
P13645 K1C10_HUMAN P04259 K2C6B_HUMAN A8MUX0 KR161_HUMAN
Q99456 K1C12_HUMAN Q9Z331 K2C6B_MOUSE Q9BYP8 KR171_HUMAN
P13646 K1C13_HUMAN P48668 K2C6C_HUMAN Q8IUB9 KR191_HUMAN
P02533 K1C14_HUMAN Q3SY84 K2C71_HUMAN Q3LHN2 KR192_HUMAN
P19012 K1C15_HUMAN Q14CN4 K2C72_HUMAN Q7Z4W3 KR193_HUMAN
P08779 K1C16_HUMAN Q86Y46 K2C73_HUMAN Q3LI73 KR194_HUMAN
Q04695 K1C17_HUMAN Q7RTS7 K2C74_HUMAN Q3LI72 KR195_HUMAN
A5A6M0 K1C17_PANTR O95678 K2C75_HUMAN Q3LI70 KR196_HUMAN
P05783 K1C18_HUMAN Q8N1N4 K2C78_HUMAN Q3SYF9 KR197_HUMAN
P05784 K1C18_MOUSE Q5XKE5 K2C79_HUMAN Q3LI54 KR198_HUMAN
P08727 K1C19_HUMAN P08729 K2C7_HUMAN Q3LI63 KR201_HUMAN
P35900 K1C20_HUMAN Q9DCV7 K2C7_MOUSE Q3LI61 KR202_HUMAN
Q9C075 K1C23_HUMAN A5A6N0 K2C7_PANTR Q3LI60 KR203_HUMAN
Q2M2I5 K1C24_HUMAN Q8HZR5 K2C7_POTTR Q3LI62 KR204_HUMAN
Q7Z3Z0 K1C25_HUMAN Q6KB66 K2C80_HUMAN Q3LI58 KR211_HUMAN
A5A6N2 K1C25_PANTR P05787 K2C8_HUMAN Q3LI59 KR212_HUMAN
Q9BGM5 K1C25_SHEEP Q02156 KPCE_HUMAN Q3LHN1 KR213_HUMAN
Q7Z3Y9 K1C26_HUMAN P60331 KR101_HUMAN Q3MIV0 KR221_HUMAN
Q7Z3Y8 K1C27_HUMAN P60368 KR102_HUMAN Q3LI68 KR222_HUMAN
Q7Z3Y7 K1C28_HUMAN P60369 KR103_HUMAN A1A580 KR231_HUMAN
Q6A163 K1C39_HUMAN P60372 KR104_HUMAN Q3LI83 KR241_HUMAN
Q6A162 K1C40_HUMAN P60370 KR105_HUMAN Q3LHN0 KR251_HUMAN
P35527 K1C9_HUMAN P60371 KR106_HUMAN Q6PEX3 KR261_HUMAN
Q15323 K1H1_HUMAN P60409 KR107_HUMAN Q3LI81 KR271_HUMAN
A5A6M5 K1H1_PANTR P60410 KR108_HUMAN A8MX34 KR291_HUMAN
VII
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Table  4-3 (continued):  Proteins  contained  in  the  cRAP like  FASTA file.  All  proteins  used  originated  from
UniProtKB/Swiss-Prot.
Unique 
Identifier EntryName
Unique 
Identifier EntryName
Q9BYQ6 KR411_HUMAN Q9BYQ0 KRA98_HUMAN
Q9BQ66 KR412_HUMAN Q9BYP9 KRA99_HUMAN
Q6L8G5 KR510_HUMAN O76011 KRT34_HUMAN
Q6L8G4 KR511_HUMAN Q92764 KRT35_HUMAN
Q07627 KRA11_HUMAN O76013 KRT36_HUMAN
Q8IUG1 KRA13_HUMAN O76014 KRT37_HUMAN
P0C5Y4 KRA14_HUMAN O76015 KRT38_HUMAN
Q9BYS1 KRA15_HUMAN Q14533 KRT81_HUMAN
Q9BYU5 KRA21_HUMAN Q9NSB4 KRT82_HUMAN
Q9BYT5 KRA22_HUMAN P78385 KRT83_HUMAN
P0C7H8 KRA23_HUMAN Q9NSB2 KRT84_HUMAN
Q9BYR9 KRA24_HUMAN P78386 KRT85_HUMAN
Q9BYR8 KRA31_HUMAN O43790 KRT86_HUMAN
Q9BYR7 KRA32_HUMAN P97861 KRT86_MOUSE
Q9BYR6 KRA33_HUMAN Q8N1A0 KT222_HUMAN
Q9BYQ7 KRA41_HUMAN O76009 KT33A_HUMAN
Q9BYR5 KRA42_HUMAN A5A6P3 KT33A_PANTR
Q9BYR4 KRA43_HUMAN Q14525 KT33B_HUMAN
Q9BYR3 KRA44_HUMAN Q8N6L1 KTAP2_HUMAN
Q9BYR2 KRA45_HUMAN Q5QHG5 LAP1_TRIRU
Q9BYQ5 KRA46_HUMAN Q5QHG6 LAP2_TRIRU
Q9BYR0 KRA47_HUMAN A6XGK3 MCPA_TRIRU
Q9BYQ9 KRA48_HUMAN Q8NIB6 MEP1_TRIRU
Q9BYQ8 KRA49_HUMAN Q6WIH8 MEP3_TRIRU
Q6L8H4 KRA51_HUMAN Q8NIJ4 MEP4_TRIRU
Q701N4 KRA52_HUMAN Q29983 MICA_HUMAN
Q6L8H2 KRA53_HUMAN P07197 NFM_HUMAN
Q6L8H1 KRA54_HUMAN Q99650 OSMR_HUMAN
Q701N2 KRA55_HUMAN Q8TEW0 PARD3_HUMAN
Q6L8G9 KRA56_HUMAN P41219 PERI_HUMAN
Q6L8G8 KRA57_HUMAN Q13835 PKP1_HUMAN
O75690 KRA58_HUMAN Q2G2B2 SASG_STAA8
P26371 KRA59_HUMAN Q69F58 SUB1_TRIRU
Q3LI64 KRA61_HUMAN Q69F56 SUB3_TRIRU
Q3LI66 KRA62_HUMAN Q69F35 SUB4_TRIRU
Q3LI67 KRA63_HUMAN Q69F34 SUB5_TRIRU
Q8IUC3 KRA71_HUMAN Q9NZ50 SYUG_BOVIN
Q8IUC2 KRA81_HUMAN O76070 SYUG_HUMAN
A8MXZ3 KRA91_HUMAN Q9BT92 TCHP_HUMAN
Q9BYQ4 KRA92_HUMAN Q15628 TRADD_HUMAN
A5A6P5 KRA92_PANTR Q07283 TRHY_HUMAN
Q9BYQ3 KRA93_HUMAN P06922 VE4_HPV16
Q9BYQ2 KRA94_HUMAN P06459 VE4_HPV6B
A8MVA2 KRA96_HUMAN P08670 VIME_HUMAN
A8MTY7 KRA97_HUMAN
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4.4 Supplemental Tables for Chapter 2.4
Table 4-4: Overview of identified and quantified peptides obtained by proteolytic digestion of α-S1-casein
Protein
Accession 
Number
Protease Sequence Modification* Position # of q-PSMs W-Ratio S.D.
Phosho-
Index
P02662 Ch RPKHPIKHQGLPQEVLNE - 16-34 2 0.63 0.07 -
P02662 Ch RPKHPIKHQGLPQEVLNENLL - 16-37 3 0.53 0.27 -
P02662 Ch QGLPQEVL - 24-32 1 0.33 0.00 -
P02662 Ch QGLPQEVLNENLL - 24-37 11 0.45 0.02 -
P02662 Ch GLPQEVLNENLL - 25-37 3 0.49 0.01 -
P02662 Ch EVLNENLL - 29-37 4 0.68 0.17 -
P02662 Ch NENLLRFF - 32-40 4 0.51 0.01 -
P02662 Ch FFVAPFPEVF - 38-48 6 0.78 0.15 -
P02662 Ch FVAPFPEVF - 39-48 20 0.43 0.02 -
P02662 Ch VAPFPEVF - 40-48 74 0.44 0.03 -
P02662 Ch GKEKVNEL - 48-56 4 0.42 0.00 S1_56
P02662 Ch AESISSSEE - 77-86 2 0.41 0.00 S1_79
P02662 Ch HIQKEDVPSERY - 95-107 1 0.81 0.00 -
P02662 Ch IQKEDVPSERY - 96-107 8 0.36 0.02 -
P02662 Ch KEDVPSERY - 98-107 9 0.36 0.01 -
P02662 Ch LGYLEQL - 107-114 12 0.43 0.02 -
P02662 Ch LGYLEQLL - 107-115 18 0.46 0.03 -
P02662 Ch LRLKKY - 114-120 3 0.38 0.02 -
P02662 Ch KVPQLEIVPNSA  S11(Phospho) 120-132 1 0.37 0.00 S1_130
P02662 Ch KVPQLEIVPNSAEERL  S11(Phospho) 120-136 2 0.37 0.04 S1_130
P02662 Ch IVPNSAEERLHSMKE  M13(Oxidation) 126-141 1 0.54 0.00 S1_130
P02662 Ch HSMKEGIHA - 136-145 2 0.58 0.06 -
P02662 Ch SMKEGIHAQQKEPM - 137-151 1 0.41 0.00 -
P02662 Ch SMKEGIHAQQKEPMIGVNQEL
 M2(Oxidation);
M14(Oxidation) 137-158 1 0.53 0.00 -
P02662 Ch SMKEGIHAQQKEPMIGVNQELAY  M2(Oxidation) 137-160 2 0.43 0.07 -
P02662 Ch SMKEGIHAQQKEPMIGVNQELAYF
 M2(Oxidation);
M14(Oxidation) 137-161 1 0.52 0.00 -
P02662 Ch AQQKEPM - 144-151 1 0.41 0.00 -
P02662 Ch AQQKEPMIGVNQELAY  M7(Oxidation) 144-160 8 0.42 0.03 -
P02662 Ch AQQKEPMIGVNQELAY - 144-160 3 0.42 0.02 -
P02662 Ch AQQKEPMIGVNQELAYF  M7(Oxidation) 144-161 5 0.42 0.02 -
P02662 Ch AQQKEPMIGVNQELAYF - 144-161 1 0.42 0.00 -
P02662 Ch IGVNQEL - 151-158 3 0.49 0.03 -
P02662 Ch IGVNQELAY - 151-160 8 0.41 0.02 -
P02662 Ch IGVNQELAYF - 151-161 6 0.42 0.01 -
P02662 Ch AYFYPELF - 158-166 10 0.45 0.01 -
P02662 Ch FYPELF - 160-166 20 0.43 0.02 -
P02662 Ch YQLDAYPSGAW - 169-180 6 0.44 0.02 -
P02662 Ch YQLDAYPSGAWY - 169-181 4 0.45 0.02 -
P02662 Ch QLDAYPSGAW - 170-180 13 0.45 0.02 -
P02662 Ch QLDAYPSGAWY - 170-181 12 0.42 0.04 -
P02662 Ch WYYVPL - 179-185 1 0.48 0.00 -
P02662 Ch YYVPLGTQY - 180-189 10 0.42 0.01 -
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P02662 Ch YVPLGTQY - 181-189 6 0.42 0.00 -
P02662 Ch VPLGTQY - 182-189 3 0.45 0.01 -
P02662 Ch QYTDAPSFSDIPNPI - 187-202 2 0.48 0.01 -
P02662 Ch TDAPSFSDIPNPIGSENSEKTTMPLW  M23(Oxidation) 189-215 3 0.69 0.02 -
P02662 Ch TDAPSFSDIPNPIGSENSEKTTMPLW - 189-215 1 0.75 0.00 -
P02662 Ch DAPSFSDIPNPI - 190-202 1 0.44 0.00 -
P02662 Ch SFSDIPNPIGSENSEKTTMPLW  S1(Phospho);M19(Oxidation) 193-215 7 0.00 0.03 -
P02662 Ch GSENSEKTTMPLW  M10(Oxidation) 202-215 1 0.48 0.00 -
P02662 El RPKHPI - 16-22 7 0.35 0.01 -
P02662 El RPKHPIKHQGLPQEVLNENLL - 16-37 3 0.52 0.06 -
P02662 El KHQGLPQEV - 22-31 13 0.76 0.07 -
P02662 El GLPQEV - 25-31 2 0.40 0.01 -
P02662 El RFFVAPFPEVFGKEKV - 37-53 4 0.39 0.03 -
P02662 El VAPFPEVFGKEKV - 40-53 1 0.39 0.00 -
P02662 El NELSKDIGSESTEDQAMEDI
 S4(Phospho);
S9(Phospho);
S11(Phospho)
53-73 1 0.33 0.00 S1_56
P02662 El NELSKDIGSESTEDQAMEDI  S11(Phospho);T12(Phospho) 53-73 1 0.30 0.00 S1_56
P02662 El NELSKDIGSESTEDQAMEDI
 S9(Phospho);
S11(Phospho);
M17(Oxidation)
53-73 1 0.32 0.00 S1_56
P02662 El NELSKDIGSESTEDQAMEDIKQM
 S9(Phospho);
S11(Phospho);
M23(Oxidation)
53-76 5 0.31 0.01 S1_56
P02662 El NELSKDIGSESTEDQAMEDIKQM
 S9(Phospho);
S11(Phospho) 53-76 2 0.30 0.01 S1_56
P02662 El NELSKDIGSESTEDQAMEDIKQM
 S9(Phospho);
S11(Phospho);
M17(Oxidation);
M23(Oxidation)
53-76 1 0.36 0.00 S1_56
P02662 El EAESISSSEEIVPNSVEQKHIQKEDVPSERYL
 S4(Phospho);
S6(Phospho);
S7(Phospho);
S8(Phospho);
S15(Phospho)
76-108 1 0.38 0.00 S1_79
P02662 El KEDVPSERYL - 98-108 1 0.42 0.00 -
P02662 El DVPSERYLGYLE - 100-112 1 0.64 0.00 -
P02662 El GYLEQLL - 108-115 13 0.35 0.01 -
P02662 El YLEQLL - 109-115 5 0.38 0.08 -
P02662 El KKYKVPQLEIVPNSAEERL  S14(Phospho) 117-136 2 0.28 0.02 S1_130
P02662 El LEIVPNSAEERL  S7(Phospho) 124-136 8 0.32 0.03 S1_130
P02662 El LEIVPNSAEERLHSMKEGI  S7(Phospho);M15(Oxidation) 124-143 8 0.32 0.03 S1_130
P02662 El LEIVPNSAEERLHSMKEGIHA  S7(Phospho);M15(Oxidation) 124-145 5 0.33 0.02 S1_130
P02662 El SAEERL - 130-136 1 0.80 0.00 S1_130
P02662 El SAEERLHSMKEGIHA  M9(Oxidation) 130-145 1 0.83 0.00 S1_130
P02662 El HSMKEGI  M3(Oxidation) 136-143 7 0.48 0.01 -
P02662 El HSMKEGIHA  M3(Oxidation) 136-145 13 0.63 0.01 -
P02662 El HSMKEGIHA - 136-145 1 0.59 0.00 -
P02662 El SMKEGI  M2(Oxidation) 137-143 1 0.42 0.00 -
P02662 El SMKEGIHA - 137-145 3 0.43 0.01 -
P02662 El SMKEGIHA  M2(Oxidation) 137-145 2 0.43 0.00 -
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P02662 El HAQQKEPMIG  M8(Oxidation) 143-153 1 0.44 0.00 -
P02662 El HAQQKEPMIGV - 143-154 2 0.42 0.03 -
P02662 El HAQQKEPMIGVNQELA  M8(Oxidation) 143-159 4 0.44 0.04 -
P02662 El QQKEPMIG  M6(Oxidation) 145-153 5 0.39 0.01 -
P02662 El QQKEPMIG - 145-153 2 0.44 0.01 -
P02662 El QQKEPMIGV - 145-154 5 0.37 0.01 -
P02662 El QQKEPMIGVNQELA - 145-159 9 0.37 0.01 -
P02662 El QQKEPMIGVNQELA  M6(Oxidation) 145-159 21 0.38 0.02 -
P02662 El YFYPELF - 159-166 14 0.42 0.02 -
P02662 El RQFYQLDAYPS - 166-177 2 0.39 0.04 -
P02662 El QFYQLDAYPS - 167-177 4 0.41 0.01 -
P02662 El FYQLDAYPS - 168-177 13 0.40 0.01 -
P02662 El YQLDAYPS - 169-177 2 0.40 0.00 -
P02662 El QLDAYPS - 170-177 12 0.42 0.01 -
P02662 El GAWYYVPL - 177-185 15 0.40 0.03 -
P02662 El WYYVPL - 179-185 10 0.39 0.01 -
P02662 El YVPLGTQY - 181-189 2 0.55 0.13 -
P02662 El GTQYTDAPSFSDIPNPI - 185-202 3 0.35 0.00 -
P02662 El QYTDAPSFS - 187-196 8 0.41 0.01 -
P02662 El QYTDAPSFSDIPNPI - 187-202 24 0.37 0.02 -
P02662 El QYTDAPSFSDIPNPI  S7(Phospho) 187-202 4 0.29 0.05 -
P02662 El DAPSFSDIPNPI - 190-202 7 0.39 0.02 -
P02662 El SFSDIPNPI - 193-202 1 0.45 0.00 -
P02662 El FSDIPNPI - 194-202 13 0.43 0.02 -
P02662 El DIPNPI - 196-202 13 0.43 0.04 -
P02662 El GSENSEKTTMPL  M10(Oxidation) 202-214 2 0.43 0.01 -
P02662 El GSENSEKTTMPLW  M10(Oxidation) 202-215 3 0.36 0.00 -
P02662 El TMPLW - 210-215 2 0.37 0.02 -
P02662 Gl RPKHPIKHQGLPQEVLNE - 16-34 13 0.41 0.08 -
P02662 Gl GLPQEVLNE - 25-34 6 0.44 0.02 -
P02662 Gl NLLRFFVAPFPE - 34-46 39 0.52 0.02 -
P02662 Gl FFVAPFPE - 38-46 6 0.49 0.01 -
P02662 Gl FVAPFPE - 39-46 3 0.42 0.01 -
P02662 Gl VAPFPE - 40-46 3 0.45 0.00 -
P02662 Gl VFGKEKVNE - 46-55 2 0.45 0.01 -
P02662 Gl LSKDIGSESTE - 55-66 5 0.81 0.07 S1_56
P02662 Gl LSKDIGSESTE  S7(Phospho);S9(Phospho) 55-66 1 0.30 0.00 S1_56
P02662 Gl LSKDIGSESTEDQAME
 S7(Phospho);
S9(Phospho);
M15(Oxidation)
55-71 1 0.33 0.00 S1_56
P02662 Gl LSKDIGSESTEDQAMEDIKQME
 M15(Oxidation);
M21(Oxidation) 55-77 3 1.00 0.00 S1_56
P02662 Gl LSKDIGSESTEDQAMEDIKQME  M15(Oxidation) 55-77 2 1.00 0.00 S1_56
P02662 Gl LSKDIGSESTEDQAMEDIKQME
 S7(Phospho);
S9(Phospho);
M15(Oxidation);
M21(Oxidation)
55-77 2 0.31 0.05 S1_56
P02662 Gl DQAMEDIKQME  M4(Oxidation);M10(Oxidation) 66-77 2 0.75 0.10 -
P02662 Gl AESISSSEEIVPNSVE - 77-93 6 0.87 0.05 S1_79
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P02662 Gl IVPNSVE - 86-93 8 0.91 0.04 S1_90
P02662 Gl IVPNSVE  S5(Phospho) 86-93 4 0.34 0.02 S1_90
P02662 Gl QKHIQKE - 93-100 1 0.51 0.00 -
P02662 Gl KEDVPSERYLGYLE - 98-112 1 0.42 0.00 -
P02662 Gl DVPSERYLGYLE - 100-112 26 0.43 0.01 -
P02662 Gl RYLGYLE - 105-112 5 0.45 0.02 -
P02662 Gl LEIVPNSAEE  S7(Phospho) 124-134 2 0.32 0.02 S1_130
P02662 Gl LEIVPNSAEERLHSMKE  S7(Phospho);M15(Oxidation) 124-141 6 0.32 0.03 S1_130
P02662 Gl IVPNSAE  S5(Phospho) 126-133 2 0.37 0.01 S1_130
P02662 Gl IVPNSAEE - 126-134 7 0.83 0.06 S1_130
P02662 Gl IVPNSAEE  S5(Phospho) 126-134 7 0.32 0.01 S1_130
P02662 Gl IVPNSAEERLHSMKE  M13(Oxidation) 126-141 2 0.86 0.04 S1_130
P02662 Gl IVPNSAEERLHSMKE  S5(Phospho) 126-141 31 0.32 0.02 S1_130
P02662 Gl IVPNSAEERLHSMKE  S5(Phospho);M13(Oxidation) 126-141 36 0.32 0.03 S1_130
P02662 Gl RLHSMKE  M5(Oxidation) 134-141 1 0.72 0.00 -
P02662 Gl GIHAQQKEPMIGVNQE  M10(Oxidation) 141-157 27 0.43 0.02 -
P02662 Gl GIHAQQKEPMIGVNQE - 141-157 16 0.41 0.02 -
P02662 Gl KEPMIGVNQE  M4(Oxidation) 147-157 2 0.46 0.02 -
P02662 Gl LAYFYPE - 157-164 29 0.44 0.03 -
P02662 Gl LFRQFYQLD - 164-173 33 0.44 0.02 -
P02662 Gl AYPSGAWYYVPLGTQYTDAPSFSDIPNPIGSE - 173-205 4 0.61 0.27 -
P02662 Gl AYPSGAWYYVPLGTQYTDAPSFSDIPNPIGSENSE - 173-208 5 0.48 0.36 -
P02662 Tr HPIKHQGLPQEVLNENLLR - 19-38 1 0.56 0.00 -
P02662 Tr HQGLPQEVLNENLLR - 23-38 41 0.47 0.04 -
P02662 Tr FFVAPFPEVFGK - 38-50 78 0.50 0.04 -
P02662 Tr EKVNELSK - 50-58 1 0.51 0.00 S1_56
P02662 Tr EKVNELSKDIGSESTEDQAMEDIK
 S7(Phospho);
S12(Phospho);
S14(Phospho);
M20(Oxidation)
50-74 4 0.27 0.05 S1_56
P02662 Tr VNELSKDIGSESTEDQAMEDIK
 S5(Phospho);
S10(Phospho);
S12(Phospho)
52-74 3 0.28 0.02 S1_56
P02662 Tr VNELSKDIGSESTEDQAMEDIK
 S5(Phospho);
S10(Phospho);
S12(Phospho);
M18(Oxidation)
52-74 5 0.27 0.02 S1_56
P02662 Tr VNELSKDIGSESTEDQAMEDIK
 S5(Phospho);
S10(Phospho);
M18(Oxidation)
52-74 4 0.31 0.03 S1_56
P02662 Tr VNELSKDIGSESTEDQAMEDIK
 S12(Phospho);
T13(Phospho) 52-74 3 0.31 0.02 S1_56
P02662 Tr DIGSESTEDQAMEDIK  M12(Oxidation) 58-74 6 1.00 0.00 S1_61
P02662 Tr DIGSESTEDQAMEDIK - 58-74 1 1.00 0.00 S1_61
P02662 Tr DIGSESTEDQAMEDIK
 S4(Phospho);
S6(Phospho);
M12(Oxidation)
58-74 10 0.33 0.02 S1_61
P02662 Tr DIGSESTEDQAMEDIK  S4(Phospho);S6(Phospho) 58-74 12 0.31 0.02 S1_61
P02662 Tr DIGSESTEDQAMEDIK  S4(Phospho) 58-74 2 0.33 0.01 S1_61
P02662 Tr DIGSESTEDQAMEDIK  S6(Phospho);M12(Oxidation) 58-74 2 0.37 0.01 S1_61
P02662 Tr QMEAESISSSEEIVPNSVEQK - 74-95 1 0.84 0.00 S1_79
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P02662 Tr HIQKEDVPSER - 95-106 27 0.48 0.02 -
P02662 Tr EDVPSER - 99-106 9 0.45 0.00 -
P02662 Tr YLGYLEQLLR - 106-116 21 0.63 0.05 -
P02662 Tr YKVPQLEIVPNSAEER - 119-135 15 0.92 0.05 S1_130
P02662 Tr YKVPQLEIVPNSAEER  S12(Phospho) 119-135 38 0.33 0.06 S1_130
P02662 Tr VPQLEIVPNSAEER - 121-135 13 0.87 0.12 S1_130
P02662 Tr VPQLEIVPNSAEER  S10(Phospho) 121-135 33 0.34 0.05 S1_130
P02662 Tr EGIHAQQK - 140-148 23 0.47 0.02 -
P02662 Tr EGIHAQQKEPMIGVNQELAYFYPELFR  M11(Oxidation) 140-167 4 0.64 0.05 -
P02662 Tr EPMIGVNQELAYFYPELFR  M3(Oxidation) 148-167 11 0.64 0.05 -
P02662 Tr EPMIGVNQELAYFYPELFR - 148-167 4 0.64 0.02 -
P02662 Tr FYPELFR - 160-167 4 0.46 0.01 -
Table 4-5: Overview of identified and quantified peptides obtained by proteolytic digestion of α-S2-casein
Protein
Accession # Protease Sequence Modification* Position
# of q-
PSMs W-Ratio S.D.
Phosho-
Index
P02663 Ch KQEKNMAINPSKENL  S11(Phospho);M6(Oxidation) 36-51 1 0.37 0.00 S2_46
P02663 Ch MAINPSKENL  M1(Oxidation) 41-51 8 0.43 0.03 S2_46
P02663 Ch MAINPSKENL - 41-51 1 0.48 0.00 S2_46
P02663 Ch NEINQFY - 98-105 13 0.46 0.02 -
P02663 Ch YQKFPQYL - 104-112 10 0.46 0.01 -
P02663 Ch YQKFPQYLQY - 104-114 23 0.45 0.06 -
P02663 Ch YQKFPQYLQYLY - 104-116 3 0.56 0.01 -
P02663 Ch QKFPQYL - 105-112 8 0.48 0.02 -
P02663 Ch QKFPQYLQY - 105-114 22 0.47 0.02 -
P02663 Ch QKFPQYLQYLY - 105-116 3 0.53 0.01 -
P02663 Ch YLQYLY - 110-116 1 0.51 0.00 -
P02663 Ch LYQGPIVL - 114-122 7 0.46 0.02 -
P02663 Ch LYQGPIVLNPW - 114-125 33 0.51 0.05 -
P02663 Ch YQGPIVLNPW - 115-125 2 0.55 0.00 -
P02663 Ch QGPIVLNPW - 116-125 14 0.48 0.01 -
P02663 Ch DQVKRNAVPITPTLNREQL - 125-144 2 0.92 0.00 S2_144
P02663 Ch NAVPITPTLNREQL - 130-144 6 0.96 0.06 S2_144
P02663 Ch NAVPITPTLNREQLSTSEENSKKTVDMESTEVF
 S15(Phospho);
S17(Phospho);
S21(Phospho);
M27(Oxidation)
130-163 7 0.32 0.07 S2_144
P02663 Ch NAVPITPTLNREQLSTSEENSKKTVDMESTEVF
 T8(Phospho);
T16(Phospho);
T24(Phospho)
130-163 3 0.30 0.07 S2_144
P02663 Ch AVPITPTLNREQL - 131-144 1 0.61 0.00 S2_144
P02663 Ch AVPITPTLNREQLSTSEENSKKTVDMESTEVF
 S16(Phospho);
S20(Phospho);
S28(Phospho)
131-163 5 0.30 0.03 S2_144
P02663 Ch AVPITPTLNREQLSTSEENSKKTVDMESTEVF
 S16(Phospho);
S20(Phospho);
S28(Phospho);
M26(Oxidation)
131-163 9 0.28 0.04 S2_144
P02663 Ch AVPITPTLNREQLSTSEENSKKTVDMESTEVF
 T15(Phospho);
T23(Phospho);
M26(Oxidation)
131-163 1 0.36 0.00 S2_144
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P02663 Ch LNREQLSTSEENSKKTVDMESTEVF
 S7(Phospho);
S9(Phospho);
S13(Phospho)
138-163 1 0.35 0.00 S2_144
P02663 Ch NREQLSTSEENSKKTVDMESTEVF
 S6(Phospho);
S8(Phospho);
S12(Phospho);
M18(Oxidation)
139-163 1 0.36 0.00 S2_144
P02663 Ch STSEENSKKTVDMESTEVF  M13(Oxidation) 144-163 2 0.93 0.08 S2_144
P02663 Ch TVDMESTEVF  S6(Phospho);M4(Oxidation) 153-163 2 0.37 0.01 S2_158
P02663 Ch LTEEEKNRLNF - 168-179 1 0.71 0.00 -
P02663 Ch TEEEKNRLNF - 169-179 6 0.45 0.01 -
P02663 Ch TEEEKNRLNFL - 169-180 4 0.52 0.04 -
P02663 Ch FLKKISQRY - 178-187 2 0.54 0.00 -
P02663 Ch LKKISQRY - 179-187 3 0.50 0.04 -
P02663 Ch YLKTVY - 194-200 2 0.56 0.01 -
P02663 Ch KAMKPW - 203-209 1 0.54 0.00 -
P02663 Ch IQPKTKVIPY - 209-219 8 0.48 0.01 -
P02663 El KNTMEHV - 16-23 4 0.94 0.04 S2_23
P02663 El KNTMEHVS - 16-24 6 0.95 0.05 S2_23
P02663 El KNTMEHVS  M4(Oxidation) 16-24 14 0.99 0.02 S2_23
P02663 El KNTMEHVSS  M4(Oxidation) 16-25 3 0.95 0.03 S2_23
P02663 El KNTMEHVSSSEESII  M4(Oxidation) 16-31 2 0.97 0.05 S2_23
P02663 El SSSEESII - 23-31 3 0.82 0.04 S2_23
P02663 El SSEESII - 24-31 1 0.89 0.00 S2_24
P02663 El SQETYKQEKNMAINPS  M11(Oxidation) 31-47 1 0.91 0.00 S2_31
P02663 El SQETYKQEKNMAINPSKENLCS
 S16(Phospho);
M11(Oxidation) 31-53 1 1.00 0.00 S2_31
P02663 El YKQEKNMAINPSKENLCS  M7(Oxidation) 35-53 1 0.89 0.00 S2_46
P02663 El NMAINPS  M2(Oxidation) 40-47 2 0.51 0.00 S2_46
P02663 El NMAINPSKENLCS  S7(Phospho) 40-53 1 0.63 0.00 S2_46
P02663 El NMAINPSKENLCS  S7(Phospho);M2(Oxidation) 40-53 2 0.48 0.02 S2_46
P02663 El MAINPSKENL - 41-51 1 0.91 0.00 S2_46
P02663 El MAINPSKENL  S6(Phospho);M1(Oxidation) 41-51 7 0.33 0.01 S2_46
P02663 El MAINPSKENL  S6(Phospho) 41-51 5 0.34 0.01 S2_46
P02663 El MAINPSKENLCS  M1(Oxidation) 41-53 5 0.41 0.03 S2_46
P02663 El MAINPSKENLCS  S6(Phospho);M1(Oxidation) 41-53 8 0.35 0.02 S2_46
P02663 El MAINPSKENLCS  S6(Phospho) 41-53 4 0.36 0.02 S2_46
P02663 El AINPSKENL  S5(Phospho) 42-51 3 0.37 0.02 S2_46
P02663 El AINPSKENLCS - 42-53 2 0.46 0.01 S2_46
P02663 El AINPSKENLCS  S5(Phospho) 42-53 10 0.42 0.01 S2_46
P02663 El INPSKENLCS  S4(Phospho) 43-53 4 0.40 0.01 S2_46
P02663 El KENLCS - 47-53 2 0.42 0.02 -
P02663 El STFCKEVV - 52-60 6 0.45 0.03 -
P02663 El TFCKEVV - 53-60 7 0.43 0.01 -
P02663 El FCKEVV - 54-60 2 0.46 0.00 -
P02663 El RNANEEEYSIG - 60-71 8 0.93 0.03 S2_71
P02663 El RNANEEEYSIG  S9(Phospho) 60-71 1 0.43 0.00 S2_71
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P02663 El RNANEEEYSIGS - 60-72 1 0.72 0.00 S2_71
P02663 El RNANEEEYSIGSSSEESAEVATEEV
 S12(Phospho);
S13(Phospho);
S14(Phospho);
S17(Phospho)
60-85 1 0.00 0.00 S2_71
P02663 El SIGSSSEESAEVATEEV
 S5(Phospho);
S6(Phospho);
S9(Phospho)
68-85 1 0.27 0.00 S2_71
P02663 El SSSEESAEVATEEV - 71-85 8 0.93 0.04 S2_71
P02663 El SSSEESAEVATEEVKI  T11(Phospho) 71-87 1 0.91 0.00 S2_71
P02663 El SSEESAEVATEEV - 72-85 1 0.66 0.00 S2_72
P02663 El SEESAEVATEEV - 73-85 4 0.86 0.01 S2_73
P02663 El KITVDDKHYQKA - 85-97 12 0.42 0.02 -
P02663 El TVDDKHYQKA - 87-97 7 0.43 0.05 -
P02663 El NQFYQKFPQYL - 101-112 27 0.46 0.01 -
P02663 El QYLYQGPI - 112-120 8 0.45 0.00 -
P02663 El QYLYQGPIVL - 112-122 13 0.46 0.03 -
P02663 El QYLYQGPIVLNPWDQV - 112-128 21 0.49 0.05 -
P02663 El YQGPIVL - 115-122 2 0.48 0.00 -
P02663 El YQGPIVLNPWDQV - 115-128 4 0.46 0.01 -
P02663 El VLNPWDQV - 120-128 7 0.47 0.01 -
P02663 El NPWDQV - 122-128 3 0.47 0.01 -
P02663 El KRNAVPI - 128-135 8 0.41 0.01 -
P02663 El TPTLNREQLSTSEENS  T11(Phospho) 135-151 1 0.50 0.00 S2_144
P02663 El LNREQLS - 138-145 7 0.91 0.01 S2_144
P02663 El LNREQLSTS - 138-147 4 0.71 0.10 S2_144
P02663 El LNREQLSTSEENS  S7(Phospho);S9(Phospho) 138-151 3 0.41 0.04 S2_144
P02663 El LNREQLSTSEENS  S9(Phospho) 138-151 1 0.47 0.00 S2_144
P02663 El KLTEEEKNRL - 167-177 3 0.45 0.02 -
P02663 El KLTEEEKNRLNFL - 167-180 4 0.46 0.04 -
P02663 El TEEEKNRL - 169-177 3 0.44 0.02 -
P02663 El SQRYQKFA - 183-191 3 0.50 0.01 -
P02663 El SQRYQKFALPQYL - 183-196 5 0.39 0.01 -
P02663 El VYQHQKA - 198-205 20 0.47 0.02 -
P02663 El YQHQKA - 199-205 10 0.75 0.01 -
P02663 El KVIPYV - 214-220 1 0.52 0.00 -
P02663 Gl KNTMEHVSSSEE - 16-28 4 0.95 0.02 S2_23
P02663 Gl KNTMEHVSSSEE  M4(Oxidation) 16-28 10 0.98 0.03 S2_23
P02663 Gl KNTMEHVSSSEESIISQE  M4(Oxidation) 16-34 1 0.84 0.00 S2_23
P02663 Gl KNTMEHVSSSEESIISQE
 S8(Phospho);
S9(Phospho);
S10(Phospho);
S13(Phospho);
M4(Oxidation)
16-34 13 0.23 0.02 S2_23
P02663 Gl KNTMEHVSSSEESIISQE
 S8(Phospho);
S9(Phospho);
S10(Phospho);
S13(Phospho)
16-34 4 0.24 0.03 S2_23
P02663 Gl KNTMEHVSSSEESIISQE
 S8(Phospho);
S9(Phospho);
S10(Phospho);
M4(Oxidation)
16-34 2 0.24 0.05 S2_23
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P02663 Gl KNTMEHVSSSEESIISQETYKQE
 S8(Phospho);
S9(Phospho);
S10(Phospho);
S13(Phospho);
M4(Oxidation)
16-39 2 0.19 0.07 S2_23
P02663 Gl HVSSSEE - 21-28 1 0.76 0.00 S2_23
P02663 Gl SIISQE - 28-34 1 0.77 0.00 S2_31
P02663 Gl TYKQEKNMAINPSKE  S13(Phospho);M8(Oxidation) 34-49 1 0.48 0.00 S2_46
P02663 Gl KNMAINPSKE  M3(Oxidation) 39-49 22 0.50 0.02 S2_46
P02663 Gl KNMAINPSKE - 39-49 1 0.52 0.00 S2_46
P02663 Gl KNMAINPSKE  S8(Phospho) 39-49 4 0.48 0.01 S2_46
P02663 Gl KNMAINPSKE  S8(Phospho);M3(Oxidation) 39-49 13 0.46 0.02 S2_46
P02663 Gl KNMAINPSKENLCSTFCKE  S8(Phospho);M3(Oxidation) 39-58 14 0.45 0.03 S2_46
P02663 Gl KNMAINPSKENLCSTFCKE  S8(Phospho) 39-58 1 0.47 0.00 S2_46
P02663 Gl NMAINPSKE  S7(Phospho) 40-49 2 0.46 0.00 S2_46
P02663 Gl NMAINPSKE  S7(Phospho);M2(Oxidation) 40-49 6 0.46 0.01 S2_46
P02663 Gl MAINPSKE  S6(Phospho);M1(Oxidation) 41-49 2 0.48 0.01 S2_46
P02663 Gl NLCSTFCKE - 49-58 22 0.52 0.01 -
P02663 Gl VVRNANEE - 58-66 4 0.70 0.01 -
P02663 Gl VVRNANEEE - 58-67 20 0.94 0.08 -
P02663 Gl VVRNANEEEYSIGSSSEE - 58-76 9 1.00 0.06 S2_71
P02663 Gl VVRNANEEEYSIGSSSEESAEVATEE
 S14(Phospho);
S15(Phospho);
S16(Phospho);
S19(Phospho)
58-84 13 0.30 0.17 S2_71
P02663 Gl VVRNANEEEYSIGSSSEESAEVATEE
 S15(Phospho);
S16(Phospho);
S19(Phospho)
58-84 1 0.38 0.00 S2_71
P02663 Gl YSIGSSSEE - 67-76 8 0.78 0.14 S2_71
P02663 Gl SAEVATEE - 76-84 5 0.96 0.03 S2_76
P02663 Gl SAEVATEE  T6(Phospho) 76-84 8 0.96 0.03 S2_76
P02663 Gl VKITVDDKHYQKALNE - 84-100 18 0.47 0.03 -
P02663 Gl QLSTSEE - 142-149 6 0.87 0.10 S2_144
P02663 Gl NSKKTVDMESTE  S10(Phospho);M8(Oxidation) 149-161 7 0.32 0.03 S2_158
P02663 Gl NSKKTVDMESTE  S10(Phospho) 149-161 1 0.34 0.00 S2_158
P02663 Tr KNTMEHVSSSEESIISQETYK  M4(Oxidation) 16-37 5 1.00 0.00 S2_23
P02663 Tr KNTMEHVSSSEESIISQETYK
 S8(Phospho);
S9(Phospho);
S10(Phospho);
S13(Phospho)
16-37 1 0.25 0.00 S2_23
P02663 Tr KNTMEHVSSSEESIISQETYK
 T3(Phospho);
S10(Phospho);
S13(Phospho);
S16(Phospho);
M4(Oxidation)
16-37 4 0.22 0.06 S2_23
P02663 Tr KNTMEHVSSSEESIISQETYKQEK  M4(Oxidation) 16-40 10 1.00 0.02 S2_23
P02663 Tr KNTMEHVSSSEESIISQETYKQEK
 S8(Phospho);
S9(Phospho);
S10(Phospho);
S13(Phospho);
M4(Oxidation)
16-40 8 0.21 0.04 S2_23
P02663 Tr KNTMEHVSSSEESIISQETYKQEK
 S9(Phospho);
S10(Phospho);
S13(Phospho);
S16(Phospho)
16-40 1 0.25 0.00 S2_23
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P02663 Tr NMAINPSK - 40-48 12 0.56 0.01 S2_46
P02663 Tr NMAINPSK  M2(Oxidation) 40-48 13 0.54 0.01 S2_46
P02663 Tr NMAINPSKENLCSTFCK  M2(Oxidation) 40-57 13 0.60 0.01 S2_46
P02663 Tr NMAINPSKENLCSTFCK - 40-57 6 0.60 0.02 S2_46
P02663 Tr NMAINPSKENLCSTFCK  S7(Phospho) 40-57 7 0.54 0.03 S2_46
P02663 Tr NMAINPSKENLCSTFCK  S7(Phospho);M2(Oxidation) 40-57 17 0.51 0.02 S2_46
P02663 Tr ENLCSTFCK - 48-57 19 0.56 0.01 -
P02663 Tr NANEEEYSIGSSSEESAEVATEEVK - 61-86 16 1.00 0.06 S2_71
P02663 Tr NANEEEYSIGSSSEESAEVATEEVK
 S11(Phospho);
S12(Phospho);
S13(Phospho);
S16(Phospho)
61-86 28 0.25 0.03 S2_71
P02663 Tr NANEEEYSIGSSSEESAEVATEEVK
 S12(Phospho);
S13(Phospho);
S16(Phospho)
61-86 2 0.31 0.02 S2_71
P02663 Tr NANEEEYSIGSSSEESAEVATEEVK  T21(Phospho) 61-86 1 0.95 0.00 S2_71
P02663 Tr EESAEVATEEVK  S3(Phospho) 74-86 1 0.33 0.00 S2_76
P02663 Tr SAEVATEEVK  S1(Phospho) 76-86 2 0.36 0.02 S2_76
P02663 Tr ITVDDK - 86-92 4 0.54 0.01 -
P02663 Tr ITVDDKHYQK - 86-96 12 0.55 0.02 -
P02663 Tr ALNEINQFYQK - 96-107 54 0.54 0.03 -
P02663 Tr FPQYLQYLYQGPIVLNPWDQVK - 107-129 7 0.79 0.03 -
P02663 Tr LYQGPIVLNPWDQVK - 114-129 11 0.53 0.03 -
P02663 Tr QGPIVLNPWDQVK - 116-129 1 0.49 0.00 -
P02663 Tr RNAVPITPTLNR - 129-141 5 0.57 0.02 -
P02663 Tr RNAVPITPTLNREQLSTSEENSKK
 T9(Phospho);
T17(Phospho) 129-153 2 0.40 0.04 S2_144
P02663 Tr NAVPITPTLNR - 130-141 27 0.57 0.02 -
P02663 Tr NAVPITPTLNREQLSTSEENSK  S15(Phospho);S17(Phospho) 130-152 2 0.32 0.01 S2_144
P02663 Tr NAVPITPTLNREQLSTSEENSKK
 S15(Phospho);
S17(Phospho) 130-153 11 0.32 0.04 S2_144
P02663 Tr AVPITPTLNR - 131-141 2 0.56 0.02 -
P02663 Tr REQLSTSEENSKK  S5(Phospho);S7(Phospho) 140-153 1 0.34 0.00 S2_144
P02663 Tr EQLSTSEENSK - 141-152 18 0.97 0.04 S2_144
P02663 Tr EQLSTSEENSK  S4(Phospho);S6(Phospho) 141-152 7 0.33 0.02 S2_144
P02663 Tr EQLSTSEENSK  S6(Phospho) 141-152 12 0.54 0.05 S2_144
P02663 Tr EQLSTSEENSKK - 141-153 31 0.98 0.01 S2_144
P02663 Tr EQLSTSEENSKK  S4(Phospho) 141-153 23 0.56 0.03 S2_144
P02663 Tr EQLSTSEENSKK  S4(Phospho);S6(Phospho) 141-153 26 0.33 0.02 S2_144
P02663 Tr EQLSTSEENSKKTVDMESTEVFTK
 T5(Phospho);
T13(Phospho);
S18(Phospho);
M16(Oxidation)
141-165 8 0.29 0.04 S2_144
P02663 Tr EQLSTSEENSKKTVDMESTEVFTK
 S4(Phospho);
S6(Phospho);
S10(Phospho)
141-165 2 0.30 0.00 S2_144
P02663 Tr TVDMESTEVFTK - 153-165 13 0.98 0.01 S2_158
P02663 Tr TVDMESTEVFTK  M4(Oxidation) 153-165 17 0.87 0.10 S2_158
P02663 Tr TVDMESTEVFTK  S6(Phospho) 153-165 24 0.33 0.03 S2_158
P02663 Tr TVDMESTEVFTK  T7(Phospho);M4(Oxidation) 153-165 38 0.32 0.03 S2_158
P02663 Tr TVDMESTEVFTKK  M4(Oxidation) 153-166 2 0.99 0.00 S2_158
P02663 Tr TVDMESTEVFTKK  S6(Phospho) 153-166 4 0.33 0.01 S2_158
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P02663 Tr LTEEEKNR - 168-176 22 0.57 0.01 -
P02663 Tr LNFLKK - 176-182 1 0.60 0.00 -
P02663 Tr FALPQYLK - 189-197 28 0.57 0.01 -
P02663 Tr TVYQHQK - 197-204 27 0.56 0.01 -
P02663 Tr AMKPWIQPK  M2(Oxidation) 204-213 8 0.56 0.02 -
P02663 Tr AMKPWIQPK - 204-213 9 0.59 0.03 -
Table 4-6: Overview of identified and quantified peptides obtained by proteolytic digestion of β-casein
Protein
Accession # Protease Sequence Modification* Position
# of q-
PSMs W-Ratio S.D.
Phosho-
Index
P02666 Ch KIEKFQSEEQQQTEDELQDKIHPF  S7(Phospho) 44-68 5 1.00 0.37 beta_50
P02666 Ch QSEEQQQTEDELQDKIHPF - 49-68 2 0.79 0.04 beta_50
P02666 Ch SLPQNIPPLTQTPVVVPPFLQPE - 84-107 1 0.49 0.00 -
P02666 Ch SLPQNIPPLTQTPVVVPPFLQPEVM  M25(Oxidation) 84-109 9 0.45 0.26 -
P02666 Ch SLPQNIPPLTQTPVVVPPFLQPEVM - 84-109 5 0.42 0.21 -
P02666 Ch NIPPLTQTPVVVPPFLQPEVM  M21(Oxidation) 88-109 9 0.45 0.09 -
P02666 Ch NIPPLTQTPVVVPPFLQPEVM - 88-109 7 0.46 0.22 -
P02666 Ch NIPPLTQTPVVVPPFLQPEVMGVS  M21(Oxidation) 88-112 1 0.62 0.00 -
P02666 Ch HKEMPFPKYPVEPFTESQSL - 121-141 1 0.82 0.00 -
P02666 Ch SQSLTLTDVE - 137-147 1 0.50 0.00 -
P02666 Ch TLTDVENL - 141-149 4 0.44 0.02 -
P02666 Ch TLTDVENLHLPLPL - 141-155 21 0.52 0.03 -
P02666 Ch KAVPYPQRDMPIQAF  M10(Oxidation) 191-206 23 0.42 0.02 -
P02666 Ch KAVPYPQRDMPIQAF - 191-206 13 0.41 0.04 -
P02666 Ch KAVPYPQRDMPIQAFL  M10(Oxidation) 191-207 8 0.41 0.02 -
P02666 Ch KAVPYPQRDMPIQAFL - 191-207 4 0.40 0.02 -
P02666 Ch PQRDMPIQAF  M5(Oxidation) 196-206 2 0.46 0.01 -
P02666 Ch LLYQEPVLGPVRGPFPI - 206-223 1 0.47 0.00 -
P02666 Ch LLYQEPVLGPVRGPFPIIV - 206-225 13 0.51 0.05 -
P02666 Ch LYQEPVLGPVRGPFPIIV - 207-225 7 0.45 0.03 -
P02666 Ch YQEPVLGPVRGPFPIIV - 208-225 3 0.46 0.02 -
P02666 Ch QEPVLGPVRGPFPIIV - 209-225 7 0.44 0.02 -
P02666 Ch RGPFPII - 217-224 2 0.23 0.02 -
P02666 El RELEELNVPGEIVESL - 16-32 2 0.84 0.22 beta_30
P02666 El NVPGEIVESL - 22-32 4 0.89 0.03 beta_30
P02666 El NVPGEIVESL  S9(Phospho) 22-32 1 0.38 0.00 beta_30
P02666 El NKKIEKFQSEEQQQTEDELQDKIHPF  S9(Phospho) 42-68 1 0.26 0.00 beta_50
P02666 El EKFQSEEQQQ  S5(Phospho) 46-56 2 0.34 0.00 beta_50
P02666 El EKFQSEEQQQTEDELQDKIHPF  S5(Phospho) 46-68 14 0.31 0.03 beta_50
P02666 El QSLVYPFPGPI - 71-82 10 0.38 0.01 -
P02666 El QSLVYPFPGPIPN - 71-84 14 0.39 0.04 -
P02666 El SLVYPFPGPI - 72-82 8 0.40 0.01 -
P02666 El LVYPFPGPI - 73-82 7 0.41 0.03 -
P02666 El LVYPFPGPIPN - 73-84 8 0.39 0.01 -
P02666 El VYPFPGPI - 74-82 11 0.40 0.02 -
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P02666 El VYPFPGPIPN - 74-84 9 0.38 0.01 -
P02666 El YPFPGPI - 75-82 7 0.41 0.02 -
P02666 El YPFPGPIPN - 75-84 8 0.39 0.01 -
P02666 El SLPQNIPPLTQTPV - 84-98 20 0.39 0.05 -
P02666 El SLPQNIPPLTQTPVVVPPFLQPEVMGV  M25(Oxidation) 84-111 2 0.79 0.30 -
P02666 El NIPPLTQTPV - 88-98 7 0.42 0.02 -
P02666 El NIPPLTQTPVVVPPFLQPEVMGV  M21(Oxidation) 88-111 7 0.52 0.05 -
P02666 El VVPPFLQPEVM - 98-109 11 0.38 0.02 -
P02666 El VVPPFLQPEVMGV  M11(Oxidation) 98-111 24 0.40 0.03 -
P02666 El VVPPFLQPEVMGV - 98-111 4 0.37 0.03 -
P02666 El FLQPEVM - 102-109 2 0.44 0.01 -
P02666 El FLQPEVMGV  M7(Oxidation) 102-111 3 0.42 0.00 -
P02666 El MAPKHKEMPFPKYPVEPF  M1(Oxidation);M8(Oxidation) 117-135 1 0.38 0.00 -
P02666 El TESQSLTLTDVENL - 135-149 2 0.42 0.03 -
P02666 El SLTLTDVENL - 139-149 4 0.39 0.01 -
P02666 El TLTDVENL - 141-149 5 0.46 0.03 -
P02666 El LTDVENL - 142-149 8 0.41 0.01 -
P02666 El DVENLHLPLPL - 144-155 5 0.42 0.04 -
P02666 El LQSWMHQPHQPLPPTV  M5(Oxidation) 155-171 11 0.43 0.05 -
P02666 El LQSWMHQPHQPLPPTV - 155-171 11 0.38 0.02 -
P02666 El LQSWMHQPHQPLPPTVMFPPQSV  M17(Oxidation) 155-178 1 0.42 0.00 -
P02666 El SWMHQPHQPLPPTV  M3(Oxidation) 157-171 1 0.53 0.00 -
P02666 El MFPPQSV  M1(Oxidation) 171-178 1 0.49 0.00 -
P02666 El MFPPQSV - 171-178 20 0.43 0.02 -
P02666 El MFPPQSVL  M1(Oxidation) 171-179 11 0.57 0.11 -
P02666 El MFPPQSVL - 171-179 15 0.42 0.02 -
P02666 El SQSKVLPVPQ - 181-191 9 0.38 0.05 -
P02666 El QSKVLPVPQ - 182-191 15 0.36 0.02 -
P02666 El KVLPVPQ - 184-191 3 0.38 0.01 -
P02666 El KAVPYPQ - 191-198 6 0.38 0.01 -
P02666 El KAVPYPQRDMPI  M10(Oxidation) 191-203 3 0.41 0.04 -
P02666 El KAVPYPQRDMPIQA  M10(Oxidation) 191-205 5 0.36 0.02 -
P02666 El KAVPYPQRDMPIQAF  M10(Oxidation) 191-206 1 0.45 0.00 -
P02666 El VPYPQRDMPI  M8(Oxidation) 193-203 5 0.40 0.03 -
P02666 El VPYPQRDMPI - 193-203 11 0.37 0.04 -
P02666 El VPYPQRDMPIQA  M8(Oxidation) 193-205 3 0.39 0.02 -
P02666 El VPYPQRDMPIQA - 193-205 3 0.36 0.01 -
P02666 El RDMPIQA  M3(Oxidation) 198-205 2 0.38 0.01 -
P02666 El DMPIQAFLL  M2(Oxidation) 199-208 1 0.46 0.00 -
P02666 El FLLYQEPV - 205-213 14 0.37 0.05 -
P02666 El FLLYQEPVLGPV - 205-217 27 0.38 0.03 -
P02666 El LLYQEPVLGPVR - 206-218 2 0.56 0.03 -
P02666 El LYQEPVLGPV - 207-217 4 0.40 0.01 -
P02666 El RGPFPI - 217-223 1 0.38 0.00 -
P02666 El RGPFPII - 217-224 1 0.46 0.00 -
P02666 El RGPFPIIV - 217-225 10 0.38 0.09 -
P02666 Gl RELEELNVPGEIVESLSSSEESITR - 16-41 1 0.42 0.00 beta_30
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P02666 Gl LNVPGEIVE - 21-30 8 0.92 0.00 beta_30
P02666 Gl KFQSEE  S4(Phospho) 47-53 3 0.32 0.01 beta_50
P02666 Gl KFQSEEQQQTE  S4(Phospho) 47-58 2 0.37 0.01 beta_50
P02666 Gl KFQSEEQQQTEDE - 47-60 4 0.91 0.01 beta_50
P02666 Gl KFQSEEQQQTEDE  S4(Phospho) 47-60 4 0.32 0.00 beta_50
P02666 Gl LQDKIHPFAQTQ - 60-72 16 0.44 0.01 -
P02666 Gl SLVYPFPGPIPNSLPQNIPPLTQTPVVVPPFLQPE - 72-107 2 1.00 0.00 -
P02666 Gl SLPQNIPPLTQTPVVVPPFLQPE - 84-107 6 0.43 0.02 -
P02666 Gl NIPPLTQTPVVVPPFLQPE - 88-107 1 0.42 0.00 -
P02666 Gl NIPPLTQTPVVVPPFLQPEVM - 88-109 1 1.00 0.00 -
P02666 Gl VMGVSKVKE  M2(Oxidation) 107-116 1 0.50 0.00 -
P02666 Gl VMGVSKVKE - 107-116 4 0.41 0.01 -
P02666 Gl AMAPKHKE - 116-124 4 0.41 0.01 -
P02666 Gl MPFPKYPVEPFTE  M1(Oxidation) 124-137 2 0.43 0.03 -
P02666 Gl MPFPKYPVEPFTE - 124-137 8 0.42 0.01 -
P02666 Gl SQSLTLTDVE - 137-147 12 0.45 0.02 -
P02666 Gl NLHLPLPLLQ - 147-157 13 0.41 0.03 -
P02666 Gl LQSWMHQPHQPLPPTV  M5(Oxidation) 155-171 3 0.44 0.01 -
P02666 Tr RELEELNVPGEIVESLSSSEESITR - 16-41 2 1.00 0.00 beta_30
P02666 Tr RELEELNVPGEIVESLSSSEESITR
 S17(Phospho);
S18(Phospho);
S19(Phospho);
S22(Phospho)
16-41 3 0.00 0.14 beta_30
P02666 Tr IEKFQSEEQQQTEDELQDK  S6(Phospho) 45-64 4 0.31 0.03 beta_50
P02666 Tr FQSEEQQQTEDELQDK - 48-64 4 0.92 0.10 beta_50
P02666 Tr FQSEEQQQTEDELQDK  S3(Phospho) 48-64 17 0.33 0.02 beta_50
P02666 Tr SLPQNIPPLTQTPVVVPPFLQPEVMGVSK  M25(Oxidation) 84-113 12 0.49 0.06 -
P02666 Tr SLPQNIPPLTQTPVVVPPFLQPEVMGVSK - 84-113 1 0.37 0.00 -
P02666 Tr VKEAMAPK  M5(Oxidation) 113-121 1 0.47 0.00 -
P02666 Tr EAMAPK  M3(Oxidation) 115-121 2 0.46 0.01 -
P02666 Tr EAMAPK - 115-121 2 0.43 0.01 -
P02666 Tr HKEMPFPK  M4(Oxidation) 121-129 2 0.45 0.00 -
P02666 Tr EMPFPK - 123-129 9 0.43 0.01 -
P02666 Tr VLPVPQK - 185-192 13 0.46 0.01 -
P02666 Tr AVPYPQR - 192-199 11 0.46 0.00 -
P02666 Tr DMPIQAFLLYQEPVLGPVR  M2(Oxidation) 199-218 23 0.52 0.08 -
P02666 Tr DMPIQAFLLYQEPVLGPVR - 199-218 6 0.52 0.11 -
P02666 Tr LLYQEPVLGPVR - 206-218 14 0.45 0.02 -
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Figure 1-1: Mass spectrometry workflow describing the principle steps to obtain an experimental (upper) and
theoretical (lower) spectrum. Both spectra are used for peptide identification by a search engine. Protein images
used were published under the CC-BY-SA-3.0 and GNU Free Documentation License, respectively (30,31).......2
Figure 1-2: Summary of absolute (yellow) and relative (orange) quantification methods commonly applied in
mass spectrometry based proteome research. Relative quantification can be further subdivided into MS (blue)
and MS/MS (green)  methods  depending  at  which  level  relative  quantification  is  performed.  Abbreviations:
AQUA (Absolute Quantification); SISCAPA (Stable Isotope Standard Capture with Anti-Peptide Antibodies);
QconCAT (Quantification Concatamer); IDi (Isotope Dilution); SILAC (Stable Isotope Labeling by/with Amino
Acids  in  Cell  Culture);  ICPL (Isotope-Coded  Protein  Label);  ICAT (Isotope-Coded  Affinity  Tag);  iTRAQ
(Isobaric Tags for Relative and Absolute Quantitation); TMT (Tandem Mass Tags)...............................................4
Figure 1-3: Chemical structure of iTRAQ-4Plex (upper), TMT-6Plex (middle) and iTRAQ-8Plex (lower) and
their corresponding isotopes being used and their resulting masses, respectively (right side). Cleavage sites after
MS/MS fragmentation are coded red and green for iTRAQ liberation and iTRAQ + balancer group dissociations
which are also observable, respectively. The blue line indicates the leaving group while iTRAQ labeling. The
exact structure for iTRAQ-8Plex is not published. Illustration is adapted by (63)...................................................6
Figure 1-4: Representative MS (left) and MS/MS (right) spectrum showing the combinatorial effect of iTRAQ-
4Plex multiplexing. The four samples are non-distinguishable in MS spectra (same precursor m/z due to iTRAQ
reporter ion and balancer group). Upon fragmentation, the four iTRAQ labelings liberate unique iTRAQ reporter
ions in the low m/z region (demonstrated by orange, blue, green and gray signals)................................................7
Figure  1-5:  From iTRAQ  labeled  samples  to  biological  pathways.  In  iTRAQ-4Plex  experiments,  the  four
samples are first reduced, alkylated and digested (usually trypsin), followed by iTRAQ labeling, each with a
unique iTRAQ labeling reagent. After labeling, samples are combined and analyzed by 1D- or 2D-LC ESI or
MALDI  MS.  Upon  precursor  ion  fragmentation,  reporter  ion  are  formed  together  with  sequence  specific
fragment ions.  Intensities (or areas) of the iTRAQ reporter ions are extracted from MS/MS spectra.  Protein
identification and  quantification results  from database  search  are  combined  to  calculate  the  significance  of
differentially  abundant  proteins.  For  visualization,  protein  networks  are  a  common  approach  to  highlight
differentially regulated pathways (string-db; (71)). Worflow was adapted by (69) and further modified, images
used were published under the CC-BY-SA-3.0 License (31)....................................................................................9
Figure 1-6:  Schematic diagram of the fundamental  parts  of  a  mass spectrometer  with the ion source,  mass
analyzer  and detector  being part  of  the instrument and the inlet  system and data storage system which are
attached by interfaces..............................................................................................................................................14
Figure 1-7: Ion formation during the ESI process. According to the polarity of the capillary, either positively or
negatively charged analyte ions are obtained. Typically, molecules > 1000 Da are observed as multiple charged
ions. Image is adapted by (158,159) and further modified.....................................................................................16
Figure 1-8: Schematic diagram of the LTQ Orbitrap Velos equipped with ETD. ©2009 Thermo Fisher Scientific
.................................................................................................................................................................................17
Figure 1-9: Nomenclature to describe peptide backbone fragmentation leading to a-, b-, c- and x-, y-, z-ions
depending on the charge remaining N- or C-terminal. Illustration is adapted by (84,169)....................................17
Figure 1-10: Structure of the commonly observed a-, b-, c- and x-, y- and z-ions after peptide fragmentation.....18
Figure 1-11: Cross section of the Orbitrap mass analyzer. ©2009 Thermo Fisher Scientific.................................22
Figure 1-12: Schematic overview of a dual fragmentation method utilizing CID-FT and HCD. After a prescan,
the five most intense precursor ions are being fragmented by CID and analyzed in the ion trap mass analyzer. In
parallel, the full scan is completed in the Orbitrap. After both processes have finished, the same precursor ions
are fragmented using HCD and subsequently analyzed in the Orbitrap mass analyzer..........................................23
Figure 2-1: Workflow utilized for database search in Proteome Discoverer. The default setting of each node (e.g.,
Spectrum Files) was used if not otherwise specified: (0) Spectrum Files to load in the .raw files; (1) Spectrum
Selector  (pre-slicing  and  filtering  of  MS  and  MS/MS  data);  (2)  MS2-Spectrum  Processor  (deisotope  and
deconvolute), (3) & (7) Scan Event Filter (to split into CID and HCD fragmentation data); (4) & (8) SEQUEST
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HT (search algorithm settings, see below); (5) phosphorRS 3.0 (an algorithm to assign phosphorylation sites); (9)
Reporter Ions Quantifier (iTRAQ-4Plex (Thermo Scientific Instruments; Integration Tolerance 20 ppm; Most
Confident  Centroid  as  Integration  Method;  Additional  Settings:  Show the  Raw Quan  Values;  Apply  Value
Corrections,  use  All  Peptides  enabled  and  deactivated  Experimental  Bias);  (10)  Event  Detector  (filter  for
precursor  ion  settings);  (11)  Precursor  Ions  Area  Detector  (reports  XICs  of  identified  peptides);  and  (12)
Percolator (for peptide validation and filtering)......................................................................................................43
Figure  2-2:  Offline  MS/MS  measurements  in  Orbitrap  of  the  iTRAQ  labeled  phosphopeptide  i115-
SpTFHAGQLR. (A) CID, 2+ charged precursor at  m/z 620.8; (B) CID, 3+-charged precursor at m/z 414.2.
Fragments labeled with an asterisk (*) have lost a charge. The fragment ion b92+-P shares the same mass as the
signal derived from the precursor including a neutral loss of the phospho-moiety [M-P] and a subsequent loss of
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Figure  2-3:  Offline  MS/MS  measurements  in  Orbitrap  of  the  iTRAQ  labeled  phosphopeptide  i115-
SpTFHAGQLR. (A) CID-MSA, 2+ charged precursor at m/z 620.8; (B) CID-MSA, 3+ charged precursor at m/z
414.2. Fragments labeled with an asterisk (*) have lost a charge...........................................................................48
Figure  2-4:  Offline  MS/MS  measurements  in  Orbitrap  of  the  iTRAQ  labeled  phosphopeptide  i115-
SpTFHAGQLR. (A) HCD, 2+ charged precursor at m/z 620.8; (B) HCD, 3+ charged precursor at m/z 414.2.
Fragments labeled with an asterisk (*) have lost a charge. The green labeled signal at m/z 110 (left to iTRAQ-
115 (B)) belongs to the histidine immonium ion.....................................................................................................50
Figure 2-5: Dependence of ion intensities and XCorrs of labeled phosphopeptide i115-SpTFHAGQLR acquired
in offline nano-ESI-Orbitrap MS on the NCE. (A) CID, 2+ charged precursor at m/z 620.8; (B) CID 3+ charged
precursor at m/z 414.2; (C) CID-MSA, 2+; (D) CID-MSA, 3+; (E) HCD, 2+; (F) HCD, 3+................................51
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number) and incorrect mapped phosphorylations sites (orange; upper number) at different NCE values. (A) CID-
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correct and the second number the incorrect identifications...................................................................................54
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Figure 2-9: Online LC-ESI MS measurements of the iTRAQ labeled phosphopeptide i114-117-SpTFHAGQLR
fragmented by HCD in dependence on the NCE. (A, B) relative intensities; (C, D) normalized intensities; for the
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Figure 2-10: Comparison of normalized iTRAQ reporter ion intensities, the protonated non-dissociated isobaric
tag  (iTRAQ  +  balancer  group)  at  m/z  145.10  and  the  corresponding  iTRAQ  ratios  (reporter  ion  114  as
denominator) depending on NCEs for HCD fragmentation for the 2+ charged precursors of peptides (A) i114-
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Figure  2-11:  Online  LC-ESI-MS/MS  measurements  of  the  iTRAQ  labeled  phosphopeptide  i114-117-
GHLpSEGLVTK fragmented  by HCD. (A,  B) relative intensities;  (C,  D)  normalized  intensities;  (E,  F)  the
corresponding iTRAQ ratios (reporter ion 114 as denominator), for the 2+ charged precursor at m/z 704.9 (A, C,
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Figure 2-12: Comparison and overlap of the number of peptide identifications of mix-2 at different NCE. Green
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peptide only identified by HCD. (A) 2+ charged precursors; (B) 3+ charged precursors......................................59
Figure 2-13: Comparison of online LC-ESI MS measurements of the iTRAQ labeled i114/i116-phosphopeptide
mix-2 fragmented  by HCD at  various NCE. Normalized intensities  are  shown,  averaged over  all  identified
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Figure 2-14: Comparison of SEQUESTs XCorr (Whiskers-Box-Plots) and the number of unique (x10) and total
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Figure 2-15: Averaged lengths of identified peptides for CID-IT and HCD in dependence of NCE applied for 2+,
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Figure 2-16: Whiskers-Box-Plots of iTRAQ reporter ion intensities after HCD fragmentation for the the protein-
mix in dependence of NCE applied for 2+ (A, D, G), 3+ (B, E, H) and 4+ (C, F, I) charged precursor ions. (A -
C) Normalized Intensities; (D - F) Relative Intensities; (G - I) Intensities (raw values)........................................65
Figure 2-17: Whiskers-Box-Plot for both technical replicates TR1 (gray, green) and TR2 (blue, orange) showing
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scans was related to the dynamic exclusion settings, as the number of repeating scans was lowered from 3 (TR1)
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(B, D, & F) (right sight (B))....................................................................................................................................80
Figure 2-24: The frequency of peptides identified within the bins of -10 to +10 ppm for the samples iTRAQ-114
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Figure 2-31: Structure and m/z value of the immonium ions generated after MS/MS fragmentation for the native
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Figure 2-32: Annotated MS/MS spectra after HCD fragmentation (LTQ Orbitrap Velos) shows the b- and y-ions
matched for the peptide VGINYWLAHK in its typical iTRAQ labeled form iVGINYWLAHiK (A) and with an
additional iTRAQ labeling at tyrosine iVGINiYWLAHiK (B). The additional iTRAQ modification is observable
by a mass increase of +144.10 Da for the b5+ and y6+ (and following) ions. At m/z 280.17, the Y-iTRAQ(-
4Plex) immonium ion is labeled and only present in the modified form (B). The peaks labeled with an asterisk
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Figure 2-33: Annotated MS/MS spectra after CID fragmentation (Synapt G2s, ESI mode) shows the b- and y-
ions matched for the peptide VGINYWLAHK in its common iTRAQ labeled form iVGINYWLAHiK (A) and
with an additional iTRAQ labeling on the tyrosine iVGINiYWLAHiK (B). The additional iTRAQ modification
is observable by a mass increase of +144.10 Da for the b5+ and y6+ (and following) ions. For the latter, the Y-
iTRAQ immonium is present at m/z 280.17, whereas the tyrosine immonium ion (m/z 136.07) shows a similar
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Figure 2-34: Annotated MS/MS spectra after CID fragmentation (AB SCIEX 5800 MALDI TOF/TOF) with
higher (A, B) and medium gas pressure (C, D) for the peptide VGINYWLAHK in its native iTRAQ labeled form
iVGINYWLAHiK (A,C) and with the additional iTRAQ labeling on tyrosine iVGINiYWLAHiK (B, D). The Y-
iTRAQ immonium at  m/z 280.17 is only present in the Y-iTRAQ modified form and more prominent after
fragmentation with higher gas pressure (B). Matrix used for MALDI measurements was CHCA........................98
Figure 2-35: Annotated MS/MS spectra after CID fragmentation (Orbitrap Velos, recorded in ion trap) shows the
b- and y-ions matched for the Peptide VGINYWLAHK in its typical iTRAQ labeled form iVGINYWLAHiK
(A) and with an additional  iTRAQ labeling on the tyrosine iVGINiYWLAHiK (B).  The additional  iTRAQ
modification is observable by a mass increase of +144.10 Da for the b5+ and y6+ (and following) ions...........100
Figure 2-36: Annotated MS/MS spectra after PQD fragmentation (LTQ Orbitrap Velos) shows the b and y-ions
matched for the Peptide VGINYWLAHK in its common iTRAQ labeled form iVGINYWLAHiK (A) and with
an additional iTRAQ labeling on the tyrosine iVGINiYWLAHiK (B)................................................................101
Figure  2-37:  The  annotated  MS/MS spectra  after  ETD  fragmentation  (Orbitrap  Velos,  spectra  recorded  in
Orbitrap mass analyzer) for the peptide VGINYWLAHK in its native iTRAQ labeled form iVGINYWLAHiK
(A) and with the additional iTRAQ labeling on tyrosine iVGINiYWLAHiK (B)...............................................102
Figure 2-38: The relative intensity (see Material and Methods for description) was calculated for the precursor
[M], the non-dissociated iTRAQ reporter ions (iTRAQ + balancer group),  iTRAQ reporter ions iTRAQ114-
iTRAQ117, tyrosine iTRAQ-4Plex immonium ion (iY-iTRAQ-4Plex) and the tyrosine immonium ion (iY) at
different collision energies (NCEs & CEs) for the peptide VGINYWLAHK. Ion properties were calculated for
the  common  iTRAQ  modified  (iVGINYWLAHiK,  (A,  C))  and  the  Y-iTRAQ  modified  form
(iVGINiYWLAHiK, (B, D)) for 2+ charged precursors. HCD data (LTQ Orbitrap Velos; A,B) and CID data
(Synapt G2S; C, D) were compared to demonstrate similar fragmentation pattern..............................................104
Figure 2-39: Annotated MS/MS spectra after HCD fragmentation (LTQ Orbitrap Velos) shows the b- and y-ions
matched for  the Staphylococcus aureus V-8 Protease (GluC) derived peptide LFRQFYQLD (A,  B) and the
tryptic  peptide  EPMIGVNQELAYFYPELFR  in  its  common  iTRAQ  labeled  form  iLFRQFYQLD  (A),
iEPMIGVNQELAiYFYPELFR (C) and with an additional iTRAQ labeling on the tyrosine, iLFRQFiYQLD (B),
iEPMIGVNQELAiYFYPELFR (D). The additional iTRAQ modification mass shift is obvious for the b6+ (and
following) ions. For the latter, the iY-iTRAQ immonium is present at m/z 440.28, which equals the mass of
tyrosine immonium ion (m/z 136.07) plus an iTRAQ-8Plex labeling (+304.20 Da for iTRAQ115, 118, 119 &
121 and +304.21 Da for iTRAQ113, 114, 116 & 117; according to UniMod Accession numbers 730 and 731).
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Figure 2-40: Overlay of Extracted Ion Chromatograms (XICs) for three tryptic peptides (iTRAQ-4Plex labeled)
being modified on the ε-amino and N-terminal amino group (upper row, unmodified) or carrying an additional
modification on tyrosine (lower row, Y-modified)................................................................................................108
Figure  2-41:  The  iTRAQ-4Plex  labeled  peptide  YSLTVAK  was  identified  to  be  present  in  three  forms:
iYSLTVAViK (A), with an additional phosphorylation at the N-terminus i,pYSLTVAViK (B) and in a N-terminal
doubly iTRAQ labeled form i,iYSLTVAViK (C). For iYSLTVAViK (A), the Y-iTRAQ specific immonium ion at
m/z 280.17 is equaling the a1+ ion. After phosphorylation (B), the pY-iTRAQ immonium ion (= a1+ ion) was
detected at m/z 360.14. Replacing the phospho-moiety with an iTRAQ group, the Y-2x(iTRAQ) immonium ion
XXIV
 4 Appendix
was detected at m/z 424.27. All MS/MS spectra were acquired after HCD fragmentation in the Orbitrap mass
analyzer. For the latter peptide (i,iYSLTVAViK), the additional iTRAQ modification had an influence on the b-
and a- ion series, which were predominantly present in the doubly charged form...............................................114
Figure 2-42: Peptide fragmentation of the iTRAQ-4Plex labeled peptide YSLTVAVK was shown before (Figure
2-41) for the three observed modification forms: iYSLTVAViK (A), with an additional phosphorylation at the N-
terminus  i,pYSLTVAViK  (B)  and  in  a  N-terminal  doubly  iTRAQ  labeled  form  i,iYSLTVAViK  (C).  To
demonstrate  the  impact/presence  of  the  observed  specific  immonium ions,  the  MS/MS  spectra  after  HCD
fragmentation at NCE = 75% are shown. For iYSLTVAVK, the Y-iTRAQ immonium ion was not detectable. For
the  phosphorylated  form,  the  tyrosine-  (iY,  m/z  136.07),  the  phosphotyrosine-  (pY,  m/z  216.04)  and  the
phosphotyrosine-iTRAQ  immonium ion  (pY-iTRAQ,  m/z  360.14)  were  detectable.  For  the  doubly  iTRAQ
labeled  N-terminal  tyrosine  (i,iYSLTVAViK),  the  tyrosine-  (iY,  m/z  136.07)  and  Y-iTRAQ  immonium  (Y-
iTRAQ, m/z 280.17) were present. The doubly iTRAQ labeled immonium ion (Y-2x(iTRAQ), m/z 424.27) was
not detectable.........................................................................................................................................................115
Figure 2-43: Schematic diagram of the multi-protease workflow for relative quantification using iTRAQ-8Plex.
The  control  sample  ("P"hosphorylated)  was  directly  used  for  iTRAQ labeling,  whereas  the  treated  sample
("D"ephosphorylated) was a 1:1 mixture of the phosphorylated and dephosphorylated sample. This simulated
two biologically differently phosphorylated samples. Afterwards, both samples are digested separately using four
enzymes  (chymotrypsin,  elastase,  Staphylococcus  aureus  V-8  Protease  (GluC)  and  trypsin).  Each  digest  is
labeled with a unique iTRAQ-8Plex channel. The pooled sample is then enriched for phosphopeptides in a batch
process using TiO2 (ratio 1:20). Samples labeled with gray dashes (“Single Protease Analysis”) are only used for
method development and not part of the workflow for analysis. All samples were subsequently analyzed by LC-
ESI MS..................................................................................................................................................................118
Figure  2-44:  For  the  two  workflows  using  a  small  FASTA file  (sF)  and  a  10x  bigger  FASTA file  (bF),
respectively,  the  protein  sequence  coverage  with  a  classical  FDR  approach  and  the  improvement  after
percolating the results are demonstrated for the protein coverage (A), the number of unique peptides (B), the
PSMs (C) and the protein area (D).  For data generation the casein sample after  iTRAQ-8Plex labeling and
enrichment  for  phosphorylated  peptides  was  used  (sample  CF,  see  workflow).  These  cover  the  non-
phosphorylated- (NP), wash- (WF) and phosphorylated fraction (PF) and were searched in MudPIT approach.
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Figure  2-45:  For  the  two  workflows  using  a  small  FASTA file  (sF)  and  a  10x  bigger  FASTA file  (bF),
respectively, (A) PSMs were split into CID-IT and HCD fragmentation and (B) for non- and phosphorylated
peptides. For data generation the casein sample after iTRAQ-8Plex labeling and enrichment for phosphorylated
peptides was used (sample CF, see workflow). These cover the non-phosphorylated- (NP),  wash- (WF) and
phosphorylated Fraction (PF) and were searched in MudPIT approach...............................................................128
Figure 2-46: To visualize the differences in protein coverage (A), the number of unique peptides (B) and the
number of PSMs, these values were plotted for the four singly used proteases (chymotrypsin (Ch), elastase (El),
GluC (Gl) and trypsin (Tr); each sample D + P in MudPIT approach), for the in-silico combination of the four
proteases and the phosphopeptide enrichment fractions (CF)...............................................................................129
Figure 2-47: Heat-Map in RGB style to visualize the frequency of each amino acid found within all unique
peptide groups identified by Proteome Discoverer for α-S1-casein using the reference workflow. The information
about the four singly used proteases chymotrypsin, elastase, GluC and trypsin, the in-silico combined sample
(CETG)  are  compared  to  the  enriched  sample  (CF).  The  enriched  fraction  covers  the  samples  non-
phosphorylated- (NP), wash- (WF) and phosphopeptide-fraction (PF). The same data sets (unique peptides) were
used. However, for (A) the highest number of amino acid occurrence was identified within each experiment,
whereas for (B), this was performed over all experiments. Especially for the phosphorylated amino acids pS56,
pS61, pS63 and pS130 the positive effect of phosphopeptide enrichment using TiO2 is clearly demonstrate able.
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Figure 2-48: Heat-Map in RGB style to visualize the frequency of each amino acid found within all unique
peptide groups identified by Proteome Discoverer for β-casein using the reference workflow. Here, the number
of  PSMs within a  peptide  groups  was  not  taken  into account.  The information about  the  four  singly  used
proteases chymotrypsin (Ch), elastase (El), GluC (Gl) and trypsin (Tr), the combination of all four (ME) as well
as the in-silico combined sample (CETG) are compared to the enriched sample (CF).  The enriched fraction
covers the samples non-phosphorylated- (NP), wash- (WF) and phosphopeptide-fraction (PF). The same data
sets (unique peptides) were used...........................................................................................................................132
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Figure 2-49: Heat-Map in RGB style to visualize the frequency of each amino acid found within all unique
peptide  groups  identified  by  Proteome Discoverer  for  α-S2-casein  using  the  reference  workflow.  Here,  the
number of PSMs within a peptide groups was not taken into account. The information about the four singly used
proteases chymotrypsin (Ch), elastase (El), GluC (Gl) and trypsin (Tr), the combination of all four (ME) as well
as the in-silico combined sample (CETG) are compared to the enriched sample (CF).  The enriched fraction
covers the samples non-phosphorylated- (NP), wash- (WF) and phosphopeptide-fraction (PF). The same data
sets (unique peptides) were used...........................................................................................................................133
Figure 2-50: Number of unique identified phosphopeptide sequences (A, C, E) and their total Peptide-Spectra-
Matches  (PSMs;  (B,  D,  F))  for  α-S1-casein  (A,  B),  β-casein  (C,  D)  and  α-S2-casein  (E,  F)  identified  by
Proteome Discoverer  1.4 using the reference workflow (see Material  and Methods for  further  details).  The
column diagrams contain the information about the four singly used proteases chymotrypsin (Ch), elastase (El),
GluC (Gl) and trypsin (Tr). Additionally, the in-silico combined sample (CETG) is compared to the enriched
sample  (CF).  The  enriched  fraction  covers  the  samples  non-phosphorylated-  (NP),  wash-  (WF)  and
phosphopeptide-fraction (PF)................................................................................................................................135
Figure 2-51: The identified phosphorylated peptides within the protein β-casein (A) and α-S2-casein (B) were
split into protease groups according to the C-terminal amino acid. Chymotrypsin and GluC (Ch-Gl) share two
P1' and chymotrypsin and elastase (Ch-El) one P1' cleavage sites, respectively, making them indistinguishable
without further bioinformatics tools (147). For the remaining cleavage sites (chymotrypsin, Ch; elastase,  El;
GluC, Gl; trypsin, Tr) only unique C-terminal cleavage sites are known. Other C-terminal amino acids were also
summed up and shown (unspecific, un). The amino acids threonine (un-T) and histidine (un-H) were highly
present and shown additionally. For the peptide group 130, all unspecific amino acids were also a part of the
Histidine group (un-H)..........................................................................................................................................137
Figure  2-52:  The  annotated  HCD MS/MS spectrum (filter:  max fragment  ion  deviation:  ±  20ppm,  signal-
intensity > 5% of most intense signal  in spectra)  for  the iTRAQ-8Plex labeled peptide iLEIVPNpSAEERL
showing an almost complete sequence coverage (b- and y-ion series combined).  Additionally,  fragment ions
formed by neutral  loss  events  similar  to  [M-P],  were observed (e.g.,  y6+-P).  Although this  peptide  can be
generated by elastase or chymotrypsin cleavage (I & L can be set to equal in database searches, e.g., MaxQuant
(300))  the iTRAQ reporter  ion intensities  (without  impurity correction) clearly shows its  origin by elastase
digestion (intense iTRAQ113 and iTRAQ119 signal)..........................................................................................138
Figure 2-53: All tryptic peptides identified and quantified for α-S1-casein. After re-grouping of unique peptides
the median and the standard deviation for each peptide group was calculated. For dephosphorylated peptides, a
w-Ratio towards 1 is expected, whereas for the phosphorylated counterpart a w-Ratio of 0.3 should be observed.
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Figure 2-54: α-S1-casein peptides covering a potential phosphorylation site were extracted from the identified
PSM list and further split into the related proteases according to their C-terminus and the iTRAQ reporter ion
signals for easier visualization (chymotrypsin in yellow, elastase in cyan, GluC in olive and trypsin in gray).
Finally, after re-grouping of unique peptides the median and the standard deviation for each peptide group was
calculated. For dephosphorylated peptides, a w-Ratio towards one is expected, whereas for the phosphorylated
counterpart a w-Ratio of 0.3 should be observed..................................................................................................141
Figure 2-55: β-casein peptides covering a potential phosphorylation site were extracted from the identified PSM
list and further split into the related proteases according to their C-terminus and the iTRAQ reporter ion signals
for easier visualization (chymotrypsin in yellow, elastase in cyan, GluC in olive and trypsin in gray). Finally,
after  re-grouping  of  unique  peptides  the  median  and  the  standard  deviation  for  each  peptide  group  was
calculated. For dephosphorylated peptides,  a w-Ratio towards 1 is expected, whereas for the phosphorylated
counterpart a w-Ratio of 0.3 should be observed..................................................................................................143
Figure 2-56: α-S2-casein chymotryptic peptides covering a potential phosphorylation site were extracted from
the identified PSM list and further split into the related proteases according to their C-terminus and the iTRAQ
reporter ion signals. Finally, after re-grouping of unique peptides the median and the standard deviation for each
peptide group was calculated. For dephosphorylated peptides, a w-Ratio towards 1 is expected, whereas for the
phosphorylated counterpart a w-Ratio of 0.3 should be observed........................................................................144
Figure 2-57: α-S2-casein elastase derived peptides covering a potential phosphorylation site were extracted from
the identified PSM list and further split into the related proteases according to their C-terminus and the iTRAQ
reporter ion signals. Finally, after re-grouping of unique peptides the median and the standard deviation for each
peptide group was calculated. For dephosphorylated peptides, a w-Ratio towards 1 is expected, whereas for the
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phosphorylated counterpart a w-Ratio of 0.3 should be observed........................................................................145
Figure 2-58: α-S2-casein GluC derived peptides covering a potential phosphorylation site were extracted from
the identified PSM list and further split into the related proteases according to their C-terminus and the iTRAQ
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